----- Citation 12368048 -----
12368048.ti.1 Strategies for preclinical evaluation of dendritic cell subsets for promotion of transplant tolerance in the nonhuman primate.

12368048.ti.1|relation|C0887936|Transplantation Tolerance|orgf|orgf|||PROCESS_OF|C0237798|Nonhuman Primates|mamm|mamm|||PREP|in|transplant tolerance|nonhuman primate|101|81|109|UMLS_CONC_REPLACE_SUBJ


----- Citation 12641497 -----
12641497.ab.1 AIM: To perform a systematic review of the efficacy of rabeprazole-based therapies in Helicobacter pylori eradication, and to conduct a meta-analysis comparing the efficacy of rabeprazole and other proton pump inhibitors when co-prescribed with antibiotics.


12641497.ab.1|relation|C0358591|Proton Pump Inhibitors|phsu|phsu|||compared_with|C0378482|rabeprazole|orch,phsu|phsu|||VERB|comparing|proton pump inhibitors|rabeprazole|150|198|176
12641497.ab.1|relation|C0087111|Therapeutic procedure|topp|topp|||USES|C0378482|rabeprazole|orch,phsu|phsu|||MOD/HEAD||therapies|rabeprazole||73|55

----- Citation 12868543 -----
12868543.ab.10 Comparison of data obtained in the follicular phase with those obtained in the luteal phase revealed differences in most pharmacokinetic parameters, which is seemingly indicative of the characteristic physiological changes associated with the luteal phase that largely affect the kinetics and availability of drugs such as ranitidine.


12868543.ab.10|relation|C0034665|Ranitidine|orch,phsu|phsu|||ISA|C0013227|Pharmaceutical Preparations|phsu|phsu|||SPEC|such as|ranitidine|drugs|315|323|309|APPOSITIVE



----- Citation 14534673 -----
14534673.ti.1 Clinical and epidemiological features of AIDS/tuberculosis comorbidity.


14534673.ti.1|relation|C0001175|Acquired Immunodeficiency Syndrome|dsyn|dsyn|||COEXISTS_WITH|C0041296|Tuberculosis|dsyn|dsyn|||NOM|comorbidity|AIDS|tuberculosis|59|41|46|NO_INDICATOR_RULE

----- Citation 14627806 -----
14627806.ab.9 The effect of mitomycin C was also evident in the normal size alleles in two cell lines with alleles of 13/13 and 12/69 repeats, where treated cultures showed new longer alleles.


14627806.ab.9|relation|C0002085|Alleles|gngm,aapp|gngm|||PART_OF|C0007600|Cell Line|cell|cell|||PREP|with|alleles|cell lines|87|93|77
14627806.ab.9|relation|C0002085|Alleles|gngm,aapp|gngm|||PART_OF|C0007600|Cell Line|cell|cell|||PREP|in|alleles|cell lines|69|62|77
14627806.ab.9|relation|C0002475|Mitomycin|antb,orch|antb|||AFFECTS|C0002085|Alleles|gngm|gngm|||NOM|effect|mitomycin C|alleles|4|14|62|NON_SEMNET_RELATION

----- Citation 15323262 -----
15323262.ti.1 [Vitamin D: synthesis, metabolism, regulation, and an assessment of its deficiency in patients with chronic renal disease].


15323262.ti.1|relation|C0022661|Kidney Failure, Chronic|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|chronic renal disease|patients|94|100|86

15323262.ab.9 These disorders are caused by secondary hyperparathyroidism which develops as a result of mineral metabolism impairment, especially of hypocalemia, 25(OH)D deficiency, and insufficient synthesis of 1,25(OH)2D.


15323262.ab.9|relation|C0020503|Hyperparathyroidism, Secondary|dsyn|dsyn|||CAUSES|C0012634|Disease|dsyn|dsyn|||VERB|caused|secondary hyperparathyroidism|disorders|20|30|6
15323262.ab.9|relation|C0154260|Disorder of mineral metabolism|patf|patf|||CAUSES|C0020503|Hyperparathyroidism, Secondary|dsyn|dsyn|||COMPLEX|develops as a result of|mineral metabolism impairment|secondary hyperparathyroidism|66|90|30|NEW_UMLS_CONC_SUBJ,NO_INDICATOR_RULE
15323262.ab.9|relation|C0020621|Hypokalemia|fndg|fndg|||ISA|C0687148|Disorder of mineral metabolism|patf|patf|||SPEC|especially|hypocalemia|mineral metabolism impairment|121|135|90|NOT_IN_HIERARCHY,NO_INDICATOR_RULE, NEW_UMLS_CONC_OBJ,APPOSITIVE
15323262.ab.9|relation|C0020621|Hypokalemia|fndg|fndg|||CAUSES(SPEC)|C0020503|Hyperparathyroidism, Secondary|dsyn|dsyn|||INFER||hypocalemia|secondary hyperparathyroidism||135|30

----- Citation 15473914 -----
15473914.ti.1 Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.


15473914.ti.1|relation|C0074710|pramipexol|orch,phsu|orch|||INHIBITS|C0114838|dopamine transporter|aapp,gngm,bacs|gngm|||VERB|downregulates|pramipexole|dopamine transporter|92|9|110
15473914.ti.1|relation|C0074710|pramipexol|orch,phsu|orch|||INTERACTS_WITH|C0082341|dopamine D3 receptor|aapp,rcpt,gngm|aapp|||PREP|via|pramipexole|D3 receptor|130|9|139|UMLS_CONC_REPLACE_OBJ
15473914.ti.1|relation|C0030567|Parkinson Disease|dsyn|dsyn|||PROCESS_OF|C0025929|Laboratory mice|mamm|mamm|||PREP|of|Parkinson's disease|mouse|63|67|52|UMLS_CONC_REPLACE_OBJ
15473914.ti.1|relation|C0000097|1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|hops,orch|orch|||ADMINISTERED_TO|C0025929|Laboratory mice|mamm|mamm|||MOD/HEAD||MPTP|mouse||47|52|UMLS_CONC_REPLACE_SUBJ,UMLS_CONC_REPLACE_OBJ,NO_INDICATOR_RULE
15473914.ti.1|relation|C0074710|pramipexol|orch,phsu|orch|||PREVENTS|C0030567|Parkinson Disease|dsyn|dsyn|||ADJ|neuroprotective|pramipexole|Parkinson's disease|24|9|67|NO_INDICATOR_RULE

----- Citation 15499431 -----
15499431.ab.7 Student's t test was used for detecting differences in susceptibility, with significance levels of alpha=0.05.



----- Citation 15499973 -----
15499973.ab.1 OBJECTIVE: To investigate the efficacy of intratympanic dexamethasone injections (IDI) for 15 patients with intractable Meniere's disease (MD).


15499973.ab.1|relation|C0025281|Meniere's Disease|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|Meniere's disease|patients|102|120|94
15499973.ab.1|relation|C0308803|DEXAMETHASONE INJECTION|clnd|clnd|||TREATS|C0030705|Patients|podg,humn|humn|||PREP|for|dexamethasone injection|patients|86|56|94|UMLS_CONC_REPLACE_SUBJ,DYSONYM
15499973.ab.1|relation|C0308803|DEXAMETHASONE INJECTION|clnd|clnd|||TREATS(INFER)|C0025281|Meniere's Disease|dsyn|dsyn|||INFER||dexamethasone injection|Meniere's disease||56|120

----- Citation 15526143 -----
15526143.ab.2 In recent studies, the BDNF expression was reduced by typical neuroleptics.


15526143.ab.2|relation|C0040615|Antipsychotic Agents|phsu|phsu|||INHIBITS|C0107103|Brain-Derived Neurotrophic Factor|aapp,bacs|aapp|||VERB|reduced|neuroleptics|BDNF|43|62|23

----- Citation 15534249 -----
15534249.ab.7 Based on these scans, subjects were classified as typical (leftward PT asymmetry) or atypical (rightward PT asymmetry).



----- Citation 15592935 -----
15592935.ti.1 Localisation of heme oxygenase isoforms in allergic human nasal mucosa.


15592935.ti.1|relation|C1305746|Entire mucous membrane of nose|tisu|tisu|||PART_OF|C0086418|Homo sapiens|humn|humn|||MOD/HEAD||nasal mucosa|human||58|52
15592935.ti.1|relation|C0020517|Hypersensitivity|patf|patf|||PROCESS_OF|C0086418|Homo sapiens|humn|humn|||MOD/HEAD||allergic|human||43|52|UMLS_CONC_REPLACE_SUBJ
15592935.ti.1|relation|C1305746|Entire mucous membrane of nose|tisu|tisu|||LOCATION_OF|C0018969|Heme Oxygenase (Decyclizing)|aapp,enzy|aapp|||NOM|Localisation|nasal mucosa|heme oxygenase|0|58|16

15592935.ab.10 In conclusion, unlike iNOS, HO-1 is minimally expressed in the nasal respiratory epithelium of either group.


15592935.ab.10|relation|C1282653|Entire respiratory epithelium|tisu|tisu|||LOCATION_OF|C0538674|Heme Oxygenase-1|aapp,enzy|aapp|||PREP|in|respiratory epithelium|HO-1|55|69|28
15592935.ab.10|relation|C1282653|Entire respiratory epithelium|tisu|tisu|||PART_OF|C0028429|Nose|bpoc|bpoc|||MOD/HEAD||respiratory epithelium|nasal||69|63
15592935.ab.10|relation|C1282653|Entire respiratory epithelium|tisu|tisu|||PART_OF|C1257890|Population Group|popg,humn|humn|||PREP|of|respiratory epithelium|group|91|69|102

----- Citation 15601558 -----
15601558.ab.6 Patients with single brain lesion received an extra 3 Gy x 5 radiotherapy on the limited field of brain lesion within 1 week after WBRT.


15601558.ab.6|relation|C0006104|Brain|bpoc|bpoc|||LOCATION_OF|C0577304|Single lesion|fndg|fndg|||MOD/HEAD||brain|single brain lesion||21|14
15601558.ab.6|relation|C0577304|Single lesion|fndg|fndg|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|single brain lesion|Patients|8|14|0
15601558.ab.6|relation|C0034618|Radiation therapy|topp|topp|||ADMINISTERED_TO|C0030705|Patients|podg,humn|humn|||VERB|received|radiotherapy|Patients|34|61|0
15601558.ab.6|relation|C0006104|Brain|bpoc|bpoc|||LOCATION_OF|C0221198|Lesion|fndg|fndg|||MOD/HEAD||brain|lesion||98|104
15601558.ab.6|relation|C1520143|Whole-Brain Radiotherapy|topp|topp|||PRECEDES|C0034618|Radiation therapy|topp|topp|||PREP|after|WBRT|radiotherapy|124|131|61

15601558.ab.8 RESULTS: Both sequential treatments relieved neurological symptoms of more than 80% of patients.


15601558.ab.8|relation|C1519252|Sequential Treatment|topp|topp|||TREATS|C0235031|Neurologic Symptoms|sosy|sosy|||VERB|relieved|sequential treatments|neurological symptoms|36|14|45
15601558.ab.8|relation|C0235031|Neurologic Symptoms|sosy|sosy|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|of|neurological symptoms|patients|66|45|87

15601558.ab.13 Myelosuppression was the main concentration-dependent toxicity.


15601558.ab.13|relation|C0854467|Myelosuppression|dsyn|dsyn|||ISA|C0600688|toxic effect|inpo|inpo|||SPEC|was|Myelosuppression|toxicity|17|0|54|NOT_IN_HIERARCHY

15601558.ab.16 CONCLUSION: Both sequential treatments can be safely performed for SCLC patients with brain metastases, may relieve neurological symptoms, and well control both primary and metastatic lesions.


15601558.ab.16|relation|C1519252|Sequential Treatment|topp|topp|||TREATS|C0030705|Patients|podg,humn|humn|||PREP|for|sequential treatments|patients|62|17|72
15601558.ab.16|relation|C0149925|Small cell carcinoma of lung|neop|neop|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||SCLC|patients||67|72
15601558.ab.16|relation|C0220650|Metastatic malignant neoplasm to brain|neop|neop|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|brain metastases|patients|80|86|72
15601558.ab.16|relation|C0220650|Metastatic malignant neoplasm to brain|neop|neop|||COEXISTS_WITH(INFER)|C0149925|Small cell carcinoma of lung|neop|neop|||INFER||brain metastases|SCLC||86|67
15601558.ab.16|relation|C1519252|Sequential Treatment|topp|topp|||TREATS(INFER)|C0149925|Small cell carcinoma of lung|neop|neop|||INFER||sequential treatment|SCLC||17|67
15601558.ab.16|relation|C1519252|Sequential Treatment|topp|topp|||TREATS(INFER)|C0220650|Metastatic malignant neoplasm to brain|neop|neop|||INFER||sequential treatment|brain metastases||17|86
15601558.ab.16|relation|C1519252|Sequential Treatment|topp|topp|||TREATS|C0235031|Neurologic Symptoms|sosy|sosy|||VERB|relieve|sequential treatment|neurological symptoms|108|17|116
15601558.ab.16|relation|C1519252|Sequential Treatment|topp|topp|||TREATS|C1513183|Metastatic Lesion|fndg|fndg|||VERB|control|sequential treatment|metastatic lesions|148|17|173

----- Citation 15623373 -----
15623373.ab.2 METHODS: Primary HCC patients who underwent tumor resection were retrospectively analyzed.


15623373.ab.2|relation|C0019204|Primary carcinoma of the liver cells|neop|neop|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||Primary HCC|patients||9|21
15623373.ab.2|relation|C0728940|Excision|topp|topp|||TREATS|C0030705|Patients|podg,humn|humn|||VERB|underwent|resection|patients|34|50|21
15623373.ab.2|relation|C0728940|Excision|topp|topp|||TREATS(INFER)|C0019204|Primary carcinoma of the liver cells|neop|neop|||INFER||resection|Primary HCC||50|9

15623373.ab.10 CONCLUSION: The expressions of c-Myc, Ki-67, MMP-2 and VEGF in cancer tissues of the patients are related to the recurrence of their HCC after tumor resection.


15623373.ab.10|relation|C0040300|Body tissue|tisu|tisu|||LOCATION_OF|C0006826|Malignant Neoplasms|neop|neop|||MOD/HEAD||tissues|cancer||70|63
15623373.ab.10|relation|C0040300|Body tissue|tisu|tisu|||PRODUCES|C2001898|MMP2 protein, human|aapp,enzy|aapp|||NOM|expression|tissues|MMP-2|16|70|45|NEWER_UMLS_CONC_OBJ
15623373.ab.10|relation|C0040300|Body tissue|tisu|tisu|||PRODUCES|C0208804|Ki-67 Antigen|aapp,irda,imft|aapp|||NOM|expression|tissues|Ki-67|16|70|38|NEW_UMLS_CONC_OBJ, DYSONYM
15623373.ab.10|relation|C0040300|Body tissue|tisu|tisu|||PRODUCES|C1171892|CCM2 protein, human|aapp,bacs|aapp|||NOM|expression|tissues|VEGF|16|70|55|NEWER_UMLS_CONC_OBJ
15623373.ab.10|relation|C0040300|Body tissue|tisu|tisu|||PRODUCES|C0080065|Proto-Oncogene Proteins c-myc|aapp,bacs|aapp|||NOM|expression|tissues|c-Myc|16|70|31
15623373.ab.10|relation|C0078058|Vascular Endothelial Growth Factor A|aapp,bacs|aapp|7422|VEGFA|PART_OF|C0040300|Body tissue|tisu|tisu|||NOM|expressions|VEGF|tissues|16|55|70|NEW_UMLS_CONC_SUBJ
15623373.ab.10|relation|C0728940|Excision|topp|topp|||TREATS|C0027651|Neoplasm|neop|neop|||MOD/HEAD||resection|tumor||149|143|NON_SEMNET_RELATION
15623373.ab.10|relation|C0728940|Excision|topp|topp|||PRECEDES|C0019204|Primary carcinoma of the liver cells|neop|neop|||PREP|after|resection|HCC|136|149|133
15623373.ab.10|relation|C0019204|Primary carcinoma of the liver cells|neop|neop|||PROCESS_OF|C0030705|Patients|humn|humn|||MOD/HEAD||HCC|their||133|127|ANAPHORA

----- Citation 15634358 -----
15634358.ti.1 The genetics of ray pattern variation in Caenorhabditis briggsae.


15634358.ti.1|relation|C0017399|genetic aspects|biof|biof|||PROCESS_OF|C0997972|Caenorhabditis briggsae|invt|invt|||PREP|in|genetics|Caenorhabditis briggsae|37|4|41

----- Citation 15653714 -----
15653714.ab.7 Even for substantial changes in P(a,CO2), the two methods resulted in similar results.



15653714.ab.10 Haemodilution influences the two methods differently causing relative overestimation of blood flow by the laser Doppler technique compared to the 1(33)xenon method.



----- Citation 15676161 -----
15676161.ab.2 Asymptomatic patients are discovered incidentally during cardiac surgery for an unrelated condition or postmortem.


15676161.ab.2|relation|C0231221|Asymptomatic|fndg|fndg|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||Asymptomatic|patients||0|13

15676161.ab.3 However, symptomatic patients may experience non-exertional paroxysmal stabbing chest pain.


15676161.ab.3|relation|C0008031|Chest Pain|sosy|sosy|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||VERB|experience|chest pain|patients|34|80|21|UMLS_CONC_REPLACE_SUBJ

----- Citation 15722357 -----
15722357.ab.3 Herein we describe the binding of three structurally diverse lipophilic drugs, bezafibrate, ibuprofen (both R- and S-isomers) and nitrazepam to I-FABP.


15722357.ab.3|relation|C0005330|Bezafibrate|orch,phsu|phsu|||INTERACTS_WITH|C1173118|FABP2 protein, human|aapp,gngm,bacs|aapp|||NOM|binding|bezafibrate|I-FABP|23|79|144|GERUND_INDICATOR,UMLS_CONC_REPLACE_OBJ
15722357.ab.3|relation|C0020740|Ibuprofen|orch,phsu|phsu|||INTERACTS_WITH|C1173118|FABP2 protein, human|aapp,gngm,bacs|aapp|||NOM|binding|ibuprofen|I-FABP|23|92|144|GERUND_INDICATOR,UMLS_CONC_REPLACE_OBJ
15722357.ab.3|relation|C0028126|Nitrazepam|orch,phsu|phsu|||INTERACTS_WITH|C1173118|FABP2 protein, human|aapp,gngm,bacs|aapp|||NOM|binding|nitrazepam|I-FABP|23|130|144|GERUND_INDICATOR,UMLS_CONC_REPLACE_OBJ
15722357.ab.3|relation|C0005330|Bezafibrate|orch,phsu|phsu|||ISA|C0013227|Pharmaceutical Preparations|phsu|phsu|||SPEC|,|bezafibrate|drugs|77|79|72|APPOSITIVE
15722357.ab.3|relation|C0020740|Ibuprofen|orch,phsu|phsu|||ISA|C0013227|Pharmaceutical Preparations|phsu|phsu|||SPEC|,|ibuprofen|drugs|77|92|72|APPOSITIVE
15722357.ab.3|relation|C0028126|Nitrazepam|orch,phsu|phsu|||ISA|C0013227|Pharmaceutical Preparations|phsu|phsu|||SPEC|,|nitrazepam|drugs|77|130|72|APPOSITIVE

----- Citation 15750263 -----
15750263.ab.1 To clarify the precise mechanisms involved in the reduced coronary flow reserve in hypertension, we compared the effects of the angiotensin II type 1 (AT1) receptor antagonist FK-739 with those of the angiotensin-converting enzyme (ACE) inhibitor enalapril for 6 weeks on the smooth muscle (SM) cell phenotype in intramyocardial arteries from male Wistar-Kyoto rats (WKY) and spontaneously hypertensive rats (SHR).


15750263.ab.1|relation|C0252010|FK 739|orch|orch|||ISA|C1449680|Angiotensin II Type 1 Receptor Blockers|phsu|phsu|||SPEC||FK-739|angiotensin II type 1 (AT1) receptor antagonist||176|128|NOT_IN_HIERARCHY
15750263.ab.1|relation|C0014025|Enalapril|aapp,phsu|phsu|||ISA|C0003015|Angiotensin-Converting Enzyme Inhibitors|phsu|phsu|||SPEC||enalapril|angiotensin-converting enzyme (ACE) inhibitor||247|201
15710263.ab.1|relation|C0252010|FK 739|orch|orch|||compared_with|C0014025|Enalapril|aapp,phsu|phsu|||VERB|compared|FK-739|enalapril|100|176|247
15710263.ab.1|relation|C0003842|Arteries|bpoc|bpoc|||PART_OF|C0034709|Rats, Inbred WKY|mamm|mamm|||PREP|from|arteries|Wistar-Kyoto rats|337|329|348
15710263.ab.1|relation|C0003842|Arteries|bpoc|bpoc|||PART_OF|C0034705|Rats, Inbred SHR|mamm|mamm|||PREP|from|arteries|spontaneously hypertensive rats|337|329|376
15710263.ab.1|relation|C0003842|Arteries|bpoc|bpoc|||LOCATION_OF|C1135918|Myocytes, Smooth Muscle|cell|cell|||PREP|in|arteries|smooth muscle (SM) cell|309|329|276
15750263.ab.1|relation|C0014025|Enalapril|aapp,phsu|phsu|||AFFECTS|C1135918|Myocytes, Smooth Muscle|cell|cell|||NOM|effects|enalapril|smooth muscle (SM) cell|113|247|276|ANAPHORA
15710263.ab.1|relation|C0252010|FK 739|orch|orch|||AFFECTS|C1135918|Myocytes, Smooth Muscle|cell|cell|||NOM|effects|FK-739|smooth muscle (SM) cell|113|176|276

----- Citation 15750284 -----
15750284.ab.5 Thus, a physiological concentration of GH stimulated the differentiation of B-lymphoid precursors from bone marrow stem cells.


15750284.ab.5|relation|C0037663|Somatotropin|aapp,horm,phsu|aapp|||AFFECTS|C1512631|Immature B-Lymphocyte|cell|cell|||COMPLEX|stimulated the differentiation|GH|B-lymphoid precursors|42|39|76|UMLS_CONC_REPLACE_OBJ,NO_INDICATOR_RULE
15750284.ab.5|relation|C1511246|Bone Marrow Stem Cell|cell|cell|||LOCATION_OF|C1512631|Immature B-Lymphocyte|cell|cell|||PREP|from|bone marrow stem cells|B-lymphoid precursors|97|103|76|UMLS_CONC_REPLACE_OBJ

15750284.ab.6 Since mRNAs of both GH and GH receptor were present in stem cells and B-cell precursors in bone marrow, GH may modulate B-lymphoid precursors development in an autocrine or paracrine manner in bone marrows.


15750284.ab.6|relation|C0038250|Stem cells|cell|cell|||LOCATION_OF|C0035696|RNA, Messenger|bacs,nnon|bacs|||PREP|in|stem cells|mRNAs|51|55|6
15750284.ab.6|relation|C0035696|RNA, Messenger|bacs,nnon|bacs|||PART_OF|C0037663|Somatotropin|aapp,horm,phsu|aapp|||PREP|of|mRNAs|GH|11|6|20
15750284.ab.6|relation|C0035696|RNA, Messenger|bacs,nnon|bacs|||PART_OF|C0034839|Growth Hormone Receptor|aapp,rcpt|aapp|||PREP|of|mRNAs|GH receptor|11|6|27
15750284.ab.6|relation|C0312738|Pre-B Lymphocytes|cell|cell|||LOCATION_OF|C0035696|RNA, Messenger|bacs,nnon|bacs|||PREP|in|stem cells|mRNAs|51|55|6|UMLS_CONC_REPLACE_SUBJ
15750284.ab.6|relation|C0312738|Pre-B Lymphocytes|cell|cell|||PART_OF|C0005953|Bone Marrow|bpoc|bpoc|||PREP|in|B-cell precursors|bone marrow|87|70|91|UMLS_CONC_REPLACE_SUBJ
15750284.ab.6|relation|C0038250|Stem cells|cell|cell|||PART_OF|C0005953|Bone Marrow|bpoc|bpoc|||PREP|in|stem cells|bone marrow|87|55|91
15750284.ab.6|relation|C0037663|Somatotropin|aapp,horm,phsu|aapp|||AFFECTS|C1512631|Immature B-Lymphocyte|cell|cell|||VERB|modulate|GH|B-lymphoid precursors|111|104|120|UMLS_CONC_REPLACE_OBJ
15750284.ab.6|relation|C0005953|Bone Marrow|bpoc|bpoc|||LOCATION_OF|C1512631|Immature B-Lymphocyte|cell|cell|||PREP|in|bone marrows|B-lymphoid precursors|189|193|120|UMLS_CONC_REPLACE_OBJ

----- Citation 15763007 -----
15763007.ti.1 Search and identification of spermatozoa and spermatids in the ejaculate of non-obstructive azoospermic patients.


15763007.ti.1|relation|C0004509|Azoospermia|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||azoospermic|patients||92|104

----- Citation 15765262 -----
15765262.ti.1 Nicotine induces conditioned place preferences over a large range of doses in rats.


15765262.ti.1|relation|C0028040|Nicotine|hops,orch,phsu|orch|||AUGMENTS|C0815102|place preference learning|menp|menp|||VERB|induces|Nicotine|conditioned place preferences|9|0|17
15765262.ti.1|relation|C0815102|place preference learning|menp|menp|||PROCESS_OF|C0034721|Rattus|mamm|mamm|||PREP|in|conditioned place preferences|rats|74|17|78

15765262.ab.5 In subsequent conditioning trials, the compartment paired with nicotine was the initially preferred side for half of the rats, and the initially non-preferred side for the other half.



----- Citation 15776283 -----
15776283.ab.2 In this report, by using an ideal mouse model that expresses IFN-gamma locally in muscle, we demonstrate that sustained low-level expression of IFN-gamma promotes the development of several types of tumor including H22 hepatoma, MA782/5S mammary adenocarcinoma and B16 melanoma.


15776283.ab.2|relation|C0026845|Muscle|tisu|tisu|||LOCATION_OF|C0021745|Interferon Type II|aapp,imft,phsu|aapp|||PREP|in|muscle|IFN-gamma|78|82|61
15776283.ab.2|relation|C0021745|Interferon Type II|aapp,imft,phsu|aapp|||PREDISPOSES|C0027651|Neoplasm|neop|neop|||VERB|promotes|IFN-gamma|tumor|154|144|199
15776283.ab.2|relation|C0019204|Primary carcinoma of the liver cells|neop|neop|||ISA|C0027651|Neoplasm|neop|neop|||SPEC|including|hepatoma|tumor|205|219|199|APPOSITIVE
15776283.ab.2|relation|C0858252|Breast adenocarcinoma|neop|neop|||ISA|C0027651|Neoplasm|neop|neop|||SPEC|including|mammary adenocarcinoma|tumor|205|238|199|APPOSITIVE
15776283.ab.2|relation|C0004565|Melanoma, B16|emod,neop|neop|||ISA|C0027651|Neoplasm|neop|neop|||SPEC|including|B16 melanoma|tumor|205|265|199|APPOSITIVE
15776283.ab.2|relation|C0021745|Interferon Type II|aapp,imft,phsu|aapp|||PREDISPOSES(SPEC)|C0019204|Primary carcinoma of the liver cells|neop|neop|||INFER||IFN-gamma|hepatoma||144|219
15776283.ab.2|relation|C0021745|Interferon Type II|aapp,imft,phsu|aapp|||PREDISPOSES(SPEC)|C0858252|Breast adenocarcinoma|neop|neop|||INFER||IFN-gamma|mammary adenocarcinoma||144|238
15776283.ab.2|relation|C0021745|Interferon Type II|aapp,imft,phsu|aapp|||PREDISPOSES(SPEC)|C0004565|Melanoma, B16|emod,neop|neop|||INFER||IFN-gamma|B16 melanoma||144|265

----- Citation 15781005 -----
15781005.ab.2 To assess the genetic and environmental determinants of BMD in southern Chinese women, we studied a community-based cohort of 531 pre- and postmenopausal southern Chinese women and assessed the influence of 12 candidate gene loci and lifestyle risk factors on spine and hip BMD.



15781005.ab.7 Using stepwise multiple linear regression analyses, body weight was the strongest predictor for BMD in premenopausal women (n = 262), which accounted for 15.9% of the variance at the spine, 20% at femoral neck, 17.1% at trochanter, 24.3% at total hip and 10.9% at the Ward's triangle.



15781005.ab.9 As for postmenopausal women (n = 269), body weight ( approximately 25% at various sites) and age (approximately 16% at femoral neck, trochanter, total hip and Ward's triangle sites) were the strongest predictors of BMD.



15781005.ab.10 Other significant predictors were age at menarche (4.4% at spine, 0.7% at femoral neck, 1.4% at trochanter, and 1.4% at Ward's triangle); weight bearing physical activity (2.1% at trochanter and 1% at total hip); calcium intake (1.1% at femoral neck, 0.9% at trochanter, and 1.7% at total hip) ; height (0.7% at trochanter); and ESR2 1082A/G genotype (0.8% at trochanter).



----- Citation 15790407 -----
15790407.ab.1 Good quality clinical trials are essential to inform the best cystic fibrosis (CF) management and care, by determining and comparing the effectiveness of new and existing therapies and drug delivery systems.



15790407.ab.9 The interventions investigated were: antibiotics (4); home versus hospital administration of antibiotics (1); steroids (1); mucolytic therapies (6); exercise (3) and pancreatic enzymes (1).


15790407.ab.9|relation|C0003232|Antibiotics|antb|antb|||ISA|C1273869|Intervention regimes|hlca|hlca|||SPEC|were|antibiotics|interventions|31|37|4|NOT_IN_HIERARCHY
15790407.ab.9|relation|C0038317|Steroids|strd|strd|||ISA|C1273869|Intervention regimes|hlca|hlca|||SPEC|were|steroids|interventions|31|110|4|NOT_IN_HIERARCHY
15790407.ab.9|relation|C1533734|Administration procedure|topp|topp|||ISA|C1273869|Intervention regimes|hlca|hlca|||SPEC|were|administration|interventions|31|75|4|NOT_IN_HIERARCHY,UMLS_CONC_REPLACE_SUBJ
15790407.ab.9|relation|C0087111|Therapeutic procedure|topp|topp|||ISA|C1273869|Intervention regimes|hlca|hlca|||SPEC|were|therapies|intervention|31|134|4|NOT_IN_HIERARCHY
15790407.ab.9|relation|C0087111|Therapeutic procedure|topp|topp|||USES|C0770152|MUCOLYTIC|orch,phsu|phsu|||MOD/HEAD||therapies|mucolytic||134|124
15790407.ab.9|relation|C0015259|Exercise|dora|dora|||ISA|C1273869|Intervention regimes|hlca|hlca|||SPEC|were|exercise|interventions|31|149|4|NOT_IN_HIERARCHY, NOT_IN_SEMGROUP
15790407.ab.9|relation|C0003232|Antibiotics|antb|antb|||ISA|C1273869|Intervention regimes|hlca|hlca|||SPEC|were|antibiotics|interventions|31|93|4|NOT_IN_HIERARCHY
15790407.ab.9|relation|C0920330|Pancreatic enzyme|aapp,enzy,phsu|phsu|||ISA|C1273869|Intervention regimes|hlca|hlca|||SPEC|were|pancreatic enzymes|interventions|31|166|4|NOT_IN_HIERARCHY

----- Citation 15797093 -----
15797093.ab.1 We report a case of primary cardiac epithelioid hemangioendothelioma arising from the right atrium of a 2-month-old infant.


15797093.ab.1|relation|C1269890|Entire right atrium|bpoc|bpoc|||PART_OF|C0021270|Infant|aggp,humn|humn|||PREP|of|right atrium|infant|98|86|116
15797093.ab.1|relation|C1269890|Entire right atrium|bpoc|bpoc|||LOCATION_OF|C0206732|Hemangioendothelioma, Epithelioid|neop|neop|||PREP|from|right atrium|epithelioid hemangioendothelioma|76|86|36

----- Citation 15802000 -----
15802000.ab.15 The cost increase associated with treating nine patients with glargine rather than NPH is less than the cost of treating one hypoglycemia event.
15802000.ab.15|relation|C0907402|Insulin, Glargine, Human|aapp,gngm,horm,phsu|aapp|||TREATS|C0030705|Patients|podg,humn|humn||


----- Citation 15808413 -----
15808413.ab.5 However, plasma nitrite is readily oxidized to nitrate within plasma, and thus its utility as a marker of NO production within the clinical setting may be limited.


15808413.ab.5|relation|C0032105|Plasma|bdsu|bdsu|||LOCATION_OF|C0699857|Nitrate|inch|inch|||PREP|within|plasma|nitrate|54|62|47|NON_SEMNET_RELATION
15808413.ab.5|relation|C0028137|Nitrites|chvs|chvs|||CONVERTS_TO|C0699857|Nitrate|inch|inch|||VERB|oxidized|nitrite|nitrate|35|16|47|NO_INDICATOR_RULE

15808413.ab.6 Alternatively, NOx (predominantly nitrate) is relatively stable in plasma (microM concentrations), but is produced by sources other than the vasculature and has been shown to be unsuitable as a measure of localized NO production.


15808413.ab.6|relation|C0032105|Plasma|bdsu|bdsu|||LOCATION_OF|C0028128|Nitric Oxide|bacs,inch|bacs|||PREP|in|plasma|NOx|63|67|15|NON_SEMNET_RELATION,NEW_UMLS_CONC_OBJ

----- Citation 15818416 -----
15818416.ti.1 tBid interaction with cardiolipin primarily orchestrates mitochondrial dysfunctions and subsequently activates Bax and Bak.


15818416.ti.1|relation|C1144558|tBid Protein|aapp,bacs|aapp|||INTERACTS_WITH|C0007188|Cardiolipins|lipd|lipd|||NOM|interaction|tBid|cardiolipin|5|0|22|UMLS_CONC_REPLACE_SUBJ
15818416.ti.1|relation|C0026237|Mitochondria|celc|celc|||LOCATION_OF|C0277785|Functional disorder|patf|patf|||MOD/HEAD||mitochondrial|dysfunction||57|71

15818416.ab.1 TNFR1/Fas engagement results in the cleavage of cytosolic Bid to truncated Bid (tBid), which translocates to mitochondria.


15818416.ab.1|relation|C0026237|Mitochondria|celc|celc|||LOCATION_OF|C1144558|tBid Protein|aapp|aapp|||VERB|translocates|mitochondria|tBid|93|109|80|NO_INDICATOR_RULE
15818416.ab.1|relation|C0531588|BID protein|aapp,bacs|aapp|||PART_OF|C0010854|Cytosol|celc|celc|||MOD/HEAD||Bid|cytosolic||58|48|UMLS_CONC_REPL_SUBJ
15818416.ab.1|relation|C0255808|tumor necrosis factor receptor 1A|aapp,rcpt|aapp|7132|TNFRSF1A|INTERACTS_WITH|C1539477|FAS gene|gngm|gngm|355|FAS|NOM|engagement|TNFR1|Fas|10|0|6|NO_INDICATOR_RULE[slash]

15818416.ab.6 Cardiolipin-deficient yeast mitochondria did not exhibit any respiratory inhibition by tBid, proving the absolute requirement for cardiolipin for tBid binding and activity.


15818416.ab.6|relation|C0026237|Mitochondria|celc|celc|||PART_OF|C0036025|Saccharomyces cerevisiae|fngs|fngs|||MOD/HEAD||mitochondria|yeast||28|22
15818416.ab.6|relation|C0007188|Cardiolipins|lipd|lipd|||INTERACTS_WITH|C1144558|tBid Protein|aapp|aapp|||NOM|binding|cardiolipin|tBid|151|130|146|NO_INDICATOR_RULE
15818416.ab.6|relation|C1144558|tBid Protein|aapp|aapp|||NEG_DISRUPTS|C0282636|Cell Respiration|celf|celf|||NOM|inhibition|tBid|respiratory|73|87|61|UMLS_CONC_REPLACE_SUBJ,UMLS_CONC_REPLACE_OBJ,NO_INDICATOR_RULE

15818416.ab.7 In contrast, the wild-type yeast mitochondria underwent a similar inhibition of ADP-stimulated respiration associated with reduced ATP synthesis.


15818416.ab.7|relation|C0026237|Mitochondria|celc|celc|||PART_OF|C0036025|Saccharomyces cerevisiae|fngs|fngs|||MOD/HEAD||mitochondria|yeast||33|27
15818416.ab.7|relation|C0001459|Adenosine Diphosphate|bacs,nnon|bacs|||AUGMENTS|C0035203|Respiration|phsf|phsf|||ADJ|stimulated|ADP|respiration|84|80|95|GOOD_SENTENCE

----- Citation 15836534 -----
15836534.ti.1 Racial and ethnic disparities in access to physicians with HIV-related expertise.

----- Citation 15840414 -----
15840414.ab.7 Catatonic patients showed significant deficits in the IGT characterized by an inability to shift from the initial preference for high-risk cards to a more advantageous strategy with low-risk cards.
15840414.ab.7|relation|C0007398|Catatonia|sosy|sosy|||PROCESS_OF|C0030705|Patients|podg,humn|humn||

----- Citation 15844163 -----
15844163.ab.9 In view of current efforts to develop and evaluate structure-modifying therapeutic approaches in osteoarthritis (OA), DTI may offer a tool to assess the structural properties of cartilage.



----- Citation 15853477 -----
15853477.ab.3 Executive dysfunction may vary as a function of the severity of depression.



15853477.ab.4 In addition, a subset of geriatric depression is also characterized by prominent deficits in executive functioning.
15853477.ab.4|relation|C0011581|Depressive disorder|mobd|mobd|||PROCESS_OF|C0001792|Elderly|aggp,humn|humn||

----- Citation 15862965 -----
15862965.ab.4 We found that the expression of PDGF receptors and PDGF-BB-mediated cell growth are regulated by calcitriol in prostate cells.


15862965.ab.4|relation|C0006674|Calcitriol|horm,phsu,strd,vita|horm|||INTERACTS_WITH|C0071253|Platelet-Derived Growth Factor Receptor|aapp,enzy,rcpt|aapp|||VERB|regulated|calcitriol|PDGF receptors|84|97|32
15862965.ab.4|relation|C0006674|Calcitriol|horm,phsu,strd,vita|horm|||AFFECTS|C0007595|Cell Growth|celf|celf|||VERB|regulated|calcitriol|cell growth|84|97|68
15862965.ab.4|relation|C0246681|platelet-derived growth factor BB|aapp,phsu|aapp|||AFFECTS|C0007595|Cell Growth|celf|celf|||ADJ|mediated|PDGF-BB|cell growth|59|51|68
15862965.ab.4|relation|C0007634|Cells|cell|cell|||PART_OF|C1278980|Entire prostate|bpoc|bpoc|||MOD/HEAD||cells|prostate||120|111
15862965.ab.4|relation|C0007634|Cells|cell|cell|||LOCATION_OF|C0006674|Calcitriol|horm,phsu,strd,vita|strd|||PREP|in|cells|calcitriol|107|120|97

----- Citation 15866565 -----
15866565.ab.14 CONCLUSION(S): In contrast to the effects of GnRH agonists to reduce chemotherapeutic destruction of primordial follicles, GnRH antagonists do not protect the ovary from the damaging effects of cyclophosphamide.


15866565.ab.14|relation|C0392920|Chemotherapy-Oncologic Procedure|topp|topp|||DISRUPTS|C1514441|Primordial Follicle|emst|emst|||NOM|destruction|chemotherapeutic|primordial follicles|86|69|101|NON_SEMNET_RELATION,NO_INDICATOR_RULE,UMLS_CONC_REPLACE_SUBJ
15866565.ab.14|relation|C2267073|Gonadotropin Releasing Hormone Receptor Agonist|phsu|phsu|||AFFECTS|C1514441|Primordial Follicle|emst|emst|||COMPLEX|reduce chemotherapeutic destruction|GnRH agonists|primordial follicles|62|45|101|NEWER_UMLS_CONC_SUBJ,NO_INDICATOR_RULE,NON_SEMNET_RELATION
15866565.ab.14|relation|C0010583|Cyclophosphamide|opco,phsu|phsu|||DISRUPTS|C0029939|Ovary|bpoc|bpoc|||COMPLEX|damaging effects|cyclophosphamide|ovary|174|194|159|NO_INDICATOR_RULE
15866565.ab.14|relation|C1268855|Gonadotropin releasing hormone antagonist|phsu,orch,horm|phsu|||NEG_AFFECTS|C0029939|Ovary|bpoc|bpoc|||VERB|protect|GnRH agonists|ovary|147|45|159|NO_INDICATOR_RULE

----- Citation 15872117 -----
15872117.ab.10 Kinetic studies on NF-kappaB-DNA interaction indicate that the diterpenoids decrease the B(max app) but have no effect on K(d app).


15872117.ab.10|relation|C0079904|NF-kappa B|aapp,imft|aapp|||INTERACTS_WITH|C0012854|DNA|bacs,nnon|bacs|||NOM|interaction|NF-kappaB|DNA|33|19|29|UMLS_CONC_REPLACE_SUBJ,UMLS_CONC_REPLACE_OBJ,HYPHEN

15872117.ab.11 This suggests that this class of compounds interacts with both p65 and p50 subunits at a site other than the DNA binding site and subsequently modulates the binding affinity of the transcription factor toward DNA with different NF-kappaB binding sequences.


15872117.ab.11|relation|C1706082|Compound (subtance)|chem|chem|||INTERACTS_WITH|C1367009|TNFRSF5 gene|gngm|gngm|||VERB|interacts|compounds|p50|43|33|71|NEWER_UMLS_CONC_SUBJ
15872117.ab.11|relation|C1706082|Compound (subtance)|chem|chem|||INTERACTS_WITH|C0040648|TRANSCRIPTION FACTOR|aapp,bacs|aapp|||VERB|modulates|compounds|transcription factor|143|33|181|NEWER_UMLS_CONC_SUBJ
15872117.ab.11|relation|C1706082|Compound (subtance)|chem|chem|||INTERACTS_WITH|C0599933|p65|aapp,bacs|bacs|||VERB|interacts|compounds|p65|43|33|63|NEWER_UMLS_CONC_SUBJ

----- Citation 15877828 -----
15877828.ti.1 Extracorporeal shock wave lithotripsy in the treatment of renal pelvicalyceal stones in morbidly obese patients.


15877828.ti.1|relation|C0015359|Extracorporeal Shockwave Lithotripsy|topp|topp|||TREATS|C0022650|Kidney Calculi|patf|patf|||NOM|treatment|Extracorporeal shock wave lithotripsy|renal pelvicalyceal stones|45|0|58
15877828.ti.1|relation|C0022650|Kidney Calculi|patf|patf|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|in|renal pelvicalyceal stones|patients|84|58|103
15877828.ti.1|relation|C0028754|Obesity|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||obese|patients||97|103
15877828.ti.1|relation|C0022650|Kidney Calculi|patf|patf|||COEXISTS_WITH(INFER)|C0028754|Obesity|dsyn|dsyn|||INFER||renal pelvicalyceal stones|obese||58|97

15877828.ab.2 In morbidly obese patients, since the kidney and stone are at a considerable distance from the skin (compared to non-obese patients) difficulty may be found in positioning the patient so that the stone is situated at the focal point of the lithotripter.


15877828.ab.2|relation|C0028754|Obesity|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||obese|patients||12|18
15877828.ab.2|relation|C0028754|Obesity|dsyn|dsyn|||NEG_PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||non-obese|patients||113|123

15877828.ab.11 The most effective (87% success rate) and cost-efficient treatment was in the patients with pelvic stones.


15877828.ab.11|relation|C0403716|Calculus in renal pelvis|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|pelvic stones|patients|86|92|78|UMLS_CONC_REPLACE_OBJ
15877828.ab.11|relation|C0087111|Therapeutic procedure|topp|topp|||TREATS|C0030705|Patients|podg,humn|humn|||PREP|in|treatment|patients|70|57|78
15877828.ab.11|relation|C0087111|Therapeutic procedure|topp|topp|||TREATS(INFER)|C0403716|Calculus in renal pelvis|dsyn|dsyn|||INFER||treatment|pelvic stones||57|92|UMLS_CONC_REPLACE_OBJ

15877828.ab.14 CONCLUSION: We conclude that ESWL with the Siemens Lithostar-plus is the most effective and cost-efficient in morbidly obese patients with pelvic stones sized between 6 and 20 mm.


15877828.ab.14|relation|C0028754|Obesity|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||obese|patients||119|125
15877828.ab.14|relation|C0403716|Calculus in renal pelvis|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|pelvic stones|patients|133|139|125
15877828.ab.14|relation|C0015359|Extracorporeal Shockwave Lithotripsy|topp|topp|||TREATS|C0030705|Patients|podg,humn|humn|||PREP|in|ESWL|patients|106|29|125
15877828.ab.14|relation|C0015359|Extracorporeal Shockwave Lithotripsy|topp|topp|||TREATS(INFER)|C0403716|Calculus in renal pelvis|dsyn|dsyn|||INFER||ESWL|pelvic stones||29|139
15877828.ab.14|relation|C0403716|Calculus in renal pelvis|dsyn|dsyn|||COEXISTS_WITH(INFER)|C0028754|Obesity|dsyn|dsyn|||INFER||pelvic stones|obese||58|97

15877828.ab.17 ESWL should not be considered as the first line of treatment in the morbidly obese patients with low caliceal stones where the stone was positioned more than 1 cm from the focal point on the extended shock pathway.

15877828.ab.17|relation|C0015359|Extracorporeal Shockwave Lithotripsy|topp|topp|||NEG_TREATS|C0030705|Patients|podg,humn|humn|||NOM|treatment|ESWL|patients|51|0|83
15877828.ab.17|relation|C0028754|Obesity|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||obese|patients||77|83
15877828.ab.17|relation|C0403714|Calyceal renal calculus|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|caliceal stones|patients|91|101|83
15877828.ab.17|relation|C0015359|Extracorporeal Shockwave Lithotripsy|topp|topp|||NEG_TREATS(INFER)|C0403714|Calyceal renal calculus|dsyn|dsyn|||INFER||ESWL|caliceal stones||0|101
15877828.ab.17|relation|C0403714|Calyceal renal calculus|dsyn|dsyn|||COEXISTS_WITH(INFER)|C0028754|Obesity|dsyn|dsyn|||INFER|||caliceal stones||obese

----- Citation 15885340 -----
15885340.ab.2 An unusual case of 4-year old girl presenting large tumor of the neck with massive calcification is described.


15885340.ab.2|relation|C0027530|Neck|blor|blor|||LOCATION_OF|C0027651|Neoplasms|neop|neop|||PREP|of|neck|tumor|57|65|52|UMLS_CONC_REPLACE_OBJ
15885340.ab.2|relation|C0027651|Neoplasms|neop|neop|||PROCESS_OF|C0870604|Girls|popg,humn|humn|||VERB|presenting|tumor|girl|35|52|30|UMLS_CONC_REPLACE_SUBJ,NO_INDICATOR_RULE
15885340.ab.2|relation|C0027533|Neck Neoplasms|neop|neop|||COEXISTS_WITH|C0175895|calcification|patf|patf|||PREP|with|tumor|calcification|69|52|83|UMLS_CONC_REPLACE_SUBJ

----- Citation 15896365 -----
15896365.ab.1 Apyrase/ATP-diphosphohydrolase hydrolyzes di- and triphosphorylated nucleosides in the presence of a bivalent ion with sequential release of orthophosphate.


15896365.ab.1|relation|C0003652|Apyrase|aapp,enzy|aapp|||INTERACTS_WITH|C0028621|Nucleosides|nnon|nnon|||VERB|hydrolyze|Apyrase|nucleosides|31|0|68|NO_INDICATOR_RULE
15896365.ab.1|relation|C0003652|Apyrase|aapp,enzy|aapp|||COEXISTS_WITH|C0022023|Ions|elii|elii|||NOM|presence|ATP-diphosphohydrolase|ion|87|8|110

15896365.ab.8 PLP-nucleotide derivatives were unable to produce inactivation of potato apyrase.


15896365.ab.8|relation|C0028630|Nucleotides|nnon|nnon|||NEG_CAUSES|C0544461|Inactivation|comd|comd|||VERB|produce|nucleotide|inactivation|42|4|50
15896365.ab.8|relation|C1145678|Solanum tuberosum|plnt|plnt|||LOCATION_OF|C0003652|Apyrase|aapp,enzy,gngm|aapp|||MOD/HEAD||potato|apyrase||66|73

----- Citation 15898907 -----
15898907.ti.1 Laparoscopic surgery for the management of obstruction of the gastric outlet and small bowel following previous laparotomy for major upper gastrointestinal resection or cancer palliation: a new concept.


15898907.ti.1|relation|C0751429|Surgical Procedures, Laparoscopic|topp|topp|||TREATS|C0162651|Gastric outlet obstruction|dsyn|dsyn|||NOM|management|Laparoscopic surgery|obstruction of the gastric outlet|29|0|43|NEWER_UMLS_CONC_OBJ
15898907.ti.1|relation|C0751429|Surgical Procedures, Laparoscopic|topp|topp|||TREATS|C0235329|Small bowel obstruction NOS|dsyn|dsyn|||NOM|management|Laparoscopic surgery|small bowel|29|0|81|NEWER_UMLS_CONC_OBJ,COORDINATION
15898907.ti.1|relation|C0023038|Laparotomy|topp|topp|||PRECEDES|C0751429|Surgical Procedures, Laparoscopic|topp|topp|||VERB|following|laparotomy|Laparoscopic surgery|93|112|0|GERUND_INDICATOR
15898907.ti.1|relation|C0023038|Laparotomy|topp|topp|||TREATS|C0679251|disease palliation|fndg|fndg|||PREP|for|laparotomy|palliation|122|112|176|NEWER_UMLS_CONC_OBJ
15898907.ti.1|relation|C0226874|Upper digestive tract structure|bdsy|bdsy|||LOCATION_OF|C0728940|Excision|topp|topp|||MOD/HEAD||upper gastrointestinal|resection||133|156|NON_SEMNET_RELATION
15898907.ti.1|relation|C0023038|Laparotomy|topp|topp|||METHOD_OF|C0728940|Excision|topp|topp|||PREP|for|laparotomy|resection|122|112|156

15898907.ab.1 BACKGROUND: Surgical relief of gastric outlet obstruction (GOO) or small bowel obstruction in patients who had undergone major resection or palliative bypass surgery for malignancy is conventionally achieved at a laparotomy.


15898907.ab.1|relation|C0543467|Operative Surgical Procedures|topp|topp|||TREATS|C0162651|Gastric outlet obstruction|dsyn|dsyn|||NOM|relief|Surgical|gastric outlet obstruction|21|12|31
15898907.ab.1|relation|C0543467|Operative Surgical Procedures|topp|topp|||TREATS|C0235329|Small bowel obstruction NOS|dsyn|dsyn|||NOM|relief|Surgical|small bowel obstruction|21|12|67
15898907.ab.1|relation|C0235329|Small bowel obstruction NOS|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|in|small bowel obstruction|patients|90|67|94
15898907.ab.1|relation|C0162651|Gastric outlet obstruction|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|in|gastric outlet obstruction|patients|90|31|94
15898907.ab.1|relation|C1536078|Bypass surgery|topp|topp|||TREATS|C0006826|Malignant Neoplasms|neop|neop|||PREP|for|bypass surgery|malignancy|165|151|170|UMLS_CONC_REPLACE_SUBJ
15898907.ab.1|relation|C0728940|Excision|topp|topp|||TREATS|C0006826|Malignant Neoplasms|neop|neop|||PREP|for|resection|malignancy|165|127|170
15898907.ab.1|relation|C1536078|Bypass surgery|topp|topp|||ADMINISTERED_TO|C0030705|Patients|podg,humn|humn|||VERB|undergone|bypass surgery|patients|111|151|94|UMLS_CONC_REPLACE_SUBJ
15898907.ab.1|relation|C0728940|Excision|topp|topp|||ADMINISTERED_TO|C0030705|Patients|podg,humn|humn|||VERB|undergone|resection|patients|111|127|94

15898907.ab.2 The potential role of minimally invasive surgery in the management of these complications has not been previously explored.


15898907.ab.2|relation|C0543467|Operative Surgical Procedures|topp|topp|||TREATS|C0009566|Complication|patf|patf|||NOM|management|surgery|complications|56|41|76

----- Citation 15912426 -----
15912426.ti.1 In vivo follow-up of rat tumor models with 2-deoxy-2-[F-18]fluoro-D-glucose/dual-head coincidence gamma camera imaging.


15912426.ti.1|relation|C0027651|Neoplasm|neop|neop|||PROCESS_OF|C0034721|Rattus|mamm|mamm|||MOD/HEAD||tumor|rat||25|21
15912426.ti.1|relation|C0034606|Radionuclide Imaging|diap|diap|||USES|C0046056|Fluorodeoxyglucose F18|orch,irda|irda|||MOD/HEAD||2-deoxy-2-[F-18]fluoro-D-glucose|gamma camera imaging||43|98|NEW_UMLS_CONC_SUBJ, NEW_UMLS_CONC_OBJ, COORDINATION
15912426.ti.1|relation|C1522577|follow-up|hlca|hlca|||USES|C0034606|Radionuclide Imaging|diap|diap|||PREP|with|follow-up|gamma camera imaging|37|8|98|NEW_UMLS_CONC_OBJ, NON_SEMNET_RELATION

15912426.ab.2 METHODS: Three different animal tumor models (osteosarcoma, melanoma, and breast cancer) were studied after FDG injection.


15912426.ab.2|relation|C1533685|Injection procedure|topp|topp|||USES|C0046056|Fluorodeoxyglucose F18|orch,irda|orch|||MOD/HEAD||injection|FDG||112|108|UMLS_CONC_REPLACE_OBJ
15912426.ab.2|relation|C0027651|Neoplasm|neop|neop|||PROCESS_OF|C0599779|Animal Model|anim|anim|||MOD/HEAD||tumor|animal tumor models||32|25
15912426.ab.2|relation|C0029463|osteosarcoma|neop|neop|||ISA|C0027651|Neoplasm|neop|neop|||SPEC|(|osteosarcoma|tumor|45|46|32|APPOSITIVE
15912426.ab.2|relation|C0025202|melanoma|neop|neop|||ISA|C0027651|Neoplasm|neop|neop|||SPEC|(|melanoma|tumor|45|60|32|APPOSITIVE
15912426.ab.2|relation|C0678222|Breast Carcinoma|neop|neop|||ISA|C0027651|Neoplasm|neop|neop|||SPEC|(|breast cancer|tumor|45|74|32|APPOSITIVE
15912426.ab.2|relation|C0029463|osteosarcoma|neop|neop|||PROCESS_OF(SPEC)|C0599779|Animal Model|anim|anim|||INFER||osteosarcoma|animal tumor models||46|25
15912426.ab.2|relation|C0025202|melanoma|neop|neop|||PROCESS_OF(SPEC)|C0599779|Animal Model|anim|anim|||INFER||melanoma|animal tumor models||60|25
15912426.ab.2|relation|C0678222|Breast Carcinoma|neop|neop|||PROCESS_OF(SPEC)|C0599779|Animal Model|anim|anim|||INFER||breast cancer|animal tumor models||74|25

----- Citation 15913690 -----
15913690.ab.4 Histological evaluation revealed dermal hemorrhage at 0.5 and 1 day.


15913690.ab.4|relation|C0344441|Histology Procedure|lbpr|lbpr|||DIAGNOSES|C0852361|Skin haemorrhage|dsyn|dsyn|||VERB|revealed|Histological evaluation|dermal hemorrhage|24|0|33|UMLS_CONC_REPLACE_SUBJ

----- Citation 15918623 -----
15918623.ti.1 Malignant smooth muscle tumours of soft tissue--a demographic and clinicopathological study at a tertiary care hospital.


15918623.ti.1|relation|C0225317|soft tissue|tisu|tisu|||LOCATION_OF|C1334620|Malignant Smooth Muscle Neoplasm|neop|neop|||PREP|of|soft tissue|Malignant smooth muscle tumours|31|35|0
15918623.ti.1|relation|C0337954|Tertiary care hospital|hcro,mnob|hcro|||LOCATION_OF|C0008972|Clinical Research|resa|resa|||PREP|at|tertiary care hospital|study|91|97|86

15918623.ab.23 LMS in the extremities was equally common in both genders, but trunk LMS was nearly twice as common in the females.


15918623.ab.23|relation|C0015385|Limb structure|bpoc|bpoc|||LOCATION_OF|C0023269|leiomyosarcoma|neop|neop|||PREP|in|extremities|LMS|3|11|0
15918623.ab.23|relation|C1280632|Entire trunk|bpoc|bpoc|||LOCATION_OF|C0023269|leiomyosarcoma|neop|neop|||MOD/HEAD||trunk|LMS||63|69
15918623.ab.23|relation|C0023269|leiomyosarcoma|neop|neop|||PROCESS_OF|C0086287|Females|popg,humn|humn|||PREP|in|LMS|females|99|69|107

----- Citation 15919385 -----
15919385.ab.8 The results on rheotactic behavior suggested a more complex regulatory mechanism, since TU but not T(4) treatment significantly affected rheotactic behavior.



----- Citation 15919667 -----
15919667.ab.3 Because UDP-Glc is required in the synthesis of proteoglycans, N-linked glycoproteins, and glycosphingolipids, the role of these gly-coconjugates in the cellular sensitivity to Cp-PLC was studied.


15919667.ab.3|relation|C0041988|Uridine Diphosphate Glucose|carb,nnon,bacs|bacs|||INTERACTS_WITH|C0033692|Proteoglycan|aapp,bacs|aapp|||NOM|synthesis|UDP-Glc|proteoglycans|35|8|48|NO_INDICATOR_RULE,NON_SEMNET_RELATION,UMLS_CONC_REPLACE_SUBJ
15919667.ab.3|relation|C0041988|Uridine Diphosphate Glucose|carb,nnon,bacs|bacs|||INTERACTS_WITH|C0017968|Glycoproteins|aapp,carb|aapp|||NOM|synthesis|UDP-Glc|glycoproteins|35|8|72|NO_INDICATOR_RULE,NON_SEMNET_RELATION,UMLS_CONC_REPLACE_SUBJ
15919667.ab.3|relation|C0041988|Uridine Diphosphate Glucose|carb,nnon,bacs|bacs|||INTERACTS_WITH|C0017978|Glycosphingolipids|lipd,phsu|lipd|||NOM|synthesis|UDP-Glc|glycosphingolipids|35|8|91|NO_INDICATOR_RULE,NON_SEMNET_RELATION,UMLS_CONC_REPLACE_SUBJ
15919667.ab.3|relation|C0017906|Glycoconjugates|carb|carb|||INTERACTS_WITH|C0031669|Phospholipase C|aapp,gngm,enzy|aapp|||NOM|role|gly-coconjugates|PLC|115|129|180|UMLS_CONC_REPLACE_SUBJ

15919667.ab.4 The cellular sensitivity to Cp-PLC was significantly enhanced by glycosphingolipid synthesis inhibitors, and a mutant cell line deficient in gangliosides was found to be hypersensitive to Cp-PLC.


15919667.ab.4|relation|C0009063|Clostridium perfringens|bact|bact|||LOCATION_OF|C0031669|Phospholipase C|aapp,enzy|aapp|||MOD/HEAD||PLC|Cp||31|28|ACRONYM
15919667.ab.4|relation|C0031669|Phospholipase C|aapp,enzy|aapp|||AFFECTS|C0007600|Cell Line|cell|cell|||ADJ|hypersensitive|Cp-PLC|cell line|170|188|118
15919667.ab.4|relation|C0017082|Gangliosides|bacs,lipd|bacs|||NEG_PART_OF|C0007600|Cell Line|cell|cell|||ADJ|deficient|gangliosides|cell line|128|141|118

15919667.ab.6 Removal of sialic acids by C. perfringens sialidase increases the sensitivity of cultured cells to Cp-PLC and intramuscular co-injection of C. perfringens sialidase, and Cp-PLC in mice potentiates the myotoxic effect of the latter.


15919667.ab.6|relation|C0009063|Clostridium perfringens|bact|bact|||LOCATION_OF|C0027803|Neuraminidase|aapp,enzy|aapp|||MOD/HEAD||C. perfringens|sialidase||27|42|NEW_UMLS_CONC_SUBJ
15919667.ab.6|relation|C0027803|Neuraminidase|aapp,enzy|aapp|||INHIBITS|C0037025|Sialic Acids|carb|carb|||NOM|Removal|sialidase|sialic acids|0|42|11|NO_INDICATOR_RULE
15919667.ab.6|relation|C0031669|Phospholipase C|aapp,enzy|aapp|||AFFECTS|C0007635|Cultured Cells|cell|cell|||NOM|sensitivity|PLC|cultured cells|66|102|81
15919667.ab.6|relation|C0027803|Neuraminidase|aapp,enzy|aapp|||AFFECTS|C0007635|Cultured Cells|cell|cell|||NOM|sensitivity|sialidase|cultured cells|66|42|81
15919667.ab.6|relation|C0009063|Clostridium perfringens|bact|bact|||LOCATION_OF|C0027803|Neuraminidase|aapp,enzy|aapp|||MOD/HEAD||C. perfringens|sialidase||140|155|NEW_UMLS_CONC_SUBJ
15919667.ab.6|relation|C0009063|Clostridium perfringens|bact|bact|||LOCATION_OF|C0031669|Phospholipase C|aapp,enzy|aapp|||MOD/HEAD||Cp|PLC||99|102|NEW_UMLS_CONC_SUBJ
15919667.ab.6|relation|C0009063|Clostridium perfringens|bact|bact|||LOCATION_OF|C0031669|Phospholipase C|aapp,enzy|aapp|||MOD/HEAD||Cp|PLC||170|173|NEW_UMLS_CONC_SUBJ
15919667.ab.6|relation|C0026809|Mus|mamm|mamm|||LOCATION_OF|C0031669|Phospholipase C|aapp,enzy|aapp|||PREP|in|mice|PLC|176|180|173

----- Citation 15919838 -----
15919838.ab.3 RESEARCH METHODS AND PROCEDURES: Clinical characteristics and serum VAP-1 levels in 20 morbidly obese subjects (mean BMI 38.84 kg/m(2)) were measured before and after vertical banded gastroplasty.


15919838.ab.3|relation|C0229671|Serum|bdsu|bdsu|||LOCATION_OF|C1455818|AOC3 protein, human|aapp,enzy|aapp|||MOD/HEAD||serum|VAP-1||62|68|UMLS_CONC_REPLACE_OBJ,NON_SEMNET_RELATION
15919838.ab.3|relation|C0028754|Obesity|dsyn|dsyn|||PROCESS_OF|C2349001|Human Study Subject|humn|humn|||MOD/HEAD||obese|subjects||96|102|NEWER_UMLS_CONC_OBJ
15919838.ab.3|relation|C1455818|AOC3 protein, human|aapp,enzy|aapp|||PART_OF|C2349001|Human Study Subject|humn|humn|||PREP|in|VAP-1|subjects|80|68|102|NEWER_UMLS_CONC_OBJ,UMLS_CONC_REPLACE_SUBJ

----- Citation 15925552 -----
15925552.ti.1 Liquid chromatography-tandem mass spectroscopy assay for quercetin and conjugated quercetin metabolites in human plasma and urine.


15925552.ti.1|relation|C0032105|Plasma|bdsu|bdsu|||LOCATION_OF|C0034392|Quercetin|orch,phsu,vita|orch|||PREP|in|plasma|quercetin|103|113|82|NON_SEMNET_RELATION,UMLS_CONC_REPLACE_SUBJ
15925552.ti.1|relation|C0042036|Urine|bdsu|bdsu|||LOCATION_OF|C0034392|Quercetin|orch,phsu,vita|orch|||PREP|in|urine|quercetin|103|124|82|NON_SEMNET_RELATION
15925552.ti.1|relation|C0032105|Plasma|bdsu|bdsu|||LOCATION_OF|C0870883|Metabolites|bacs|bacs|||PREP|in|plasma|metabolites|103|113|92|NON_SEMNET_RELATION,UMLS_CONC_REPLACE_SUBJ
15925552.ti.1|relation|C0042036|Urine|bdsu|bdsu|||LOCATION_OF|C0870883|Metabolites|bacs|bacs|||PREP|in|urine|metabolites|103|124|92|NON_SEMNET_RELATION
15925552.ti.1|relation|C0032105|Plasma|bdsu|bdsu|||PART_OF|C0086418|Homo sapiens|grup,humn|humn|||MOD/HEAD||plasma|human||113|107|UMLS_CONC_REPLACE_SUBJ,UMLS_CONC_REPLACE_OBJ
15925552.ti.1|relation|C0042036|Urine|bdsu|bdsu|||PART_OF|C0086418|Homo sapiens|grup,humn|humn|||MOD/HEAD||urine|human||124|107|COORDINATION,UMLS_CONC_REPLACE_OBJ

15925552.ab.3 Chromatographic separation was achieved on a C12 column using a mobile phase of acetonitrile/water with 0.2% formic acid (pH 2.4) (40/60, v/v).



----- Citation 15927218 -----
15927218.ab.1 Neurocysticercosis (NCC) is one of the major causes of neurological disease in China.

15927218.ab.1|relation|C0338437|Neurocysticercosis|dsyn|dsyn|||CAUSES|C0027765|nervous system disorder|dsyn|dsyn|||NOM|causes|Neurocysticercosis|neurological disease|45|0|55

15927218.ab.2 ELISA and immunoblotting using glycoproteins purified by preparative isoelectric focusing were used to detect human cysticercosis in Tongliao area, Inner Mongolia, China in 1998.

15927218.ab.2|relation|C0014441|Enzyme-Linked Immunosorbent Assay|lbpr|lbpr|||USES|C0017968|Glycoproteins|aapp,carb|aapp|||VERB|using|ELISA|glycoproteins|25|0|31|NON_SEMNET_RELATION
15927218.ab.2|relation|C0020985|Immunoblotting|lbpr|lbpr|||USES|C0017968|Glycoproteins|aapp,carb|aapp|||VERB|using|immunoblotting|glycoproteins|25|10|31|NON_SEMNET_RELATION
15927218.ab.2|relation|C0010678|Cysticercosis|dsyn|dsyn|||PROCESS_OF|C0086418|Homo sapiens|grup,humn|humn|||MOD/HEAD||cysticercosis|human||116|110
15927218.ab.2|relation|C0014441|Enzyme-Linked Immunosorbent Assay|lbpr|lbpr|||DIAGNOSES|C0010678|Cysticercosis|dsyn|dsyn|||VERB|detect|ELISA|cysticercosis|103|0|116
15927218.ab.2|relation|C0020985|Immunoblotting|lbpr|lbpr|||DIAGNOSES|C0010678|Cysticercosis|dsyn|dsyn|||VERB|detect|immunoblotting|cysticercosis|103|10|116
15927218.ab.2|relation|C0022169|Isoelectric Focusing|lbpr|lbpr|||METHOD_OF|C0020985|Immunoblotting|lbpr|lbpr|||PREP|by|isoelectric focusing|immunoblotting|53|69|10
15927218.ab.2|relation|C0022169|Isoelectric Focusing|lbpr|lbpr|||METHOD_OF|C0014441|Enzyme-Linked Immunosorbent Assay|lbpr|lbpr|||PREP|by|isoelectric focusing|ELISA|53|69|0

15927218.ab.3 Approximately 89% (39 of 44 inpatients and outpatients with suspected NCC at Tongliao City Hospital) were residents of Inner Mongolia.

15927218.ab.3|relation|C0338437|Neurocysticercosis|dsyn|dsyn|||PROCESS_OF|C0021562|inpatient|podg,humn|humn|||PREP|with|NCC|inpatients|54|70|28
15927218.ab.3|relation|C0338437|Neurocysticercosis|dsyn|dsyn|||PROCESS_OF|C0029921|Outpatients|podg|podg|||PREP|with|NCC|outpatients|54|70|43
15927218.ab.3|relation|C0020029|Hospitals, Urban|hcro|hcro|||LOCATION_OF|C0021562|inpatient|podg,humn|humn|||PREP|at|City Hospital|inpatients|73|86|28|NON_SEMNET_RELATION
15927218.ab.3|relation|C0020029|Hospitals, Urban|hcro|hcro|||LOCATION_OF|C0029921|Outpatients|podg|podg|||PREP|at|City Hospital|outpatients|73|86|43|NON_SEMNET_RELATION
15927218.ab.3|relation|C0021515|Inner Mongolia|geoa|geoa|||LOCATION_OF|C2347958|Resident(person)|popg|popg|||PREP|of|Inner Mongolia|residents|21,115|119|106|NEWER_UMLS_CONC_OBJ, NON_SEMNET_RELATION

15927218.ab.8 These findings confirm that both ELISA and immunoblotting assays are sufficiently sensitive to detect asymptomatic or symptomatic cysticercosis patients.


15927218.ab.8|relation|C0010678|Cysticercosis|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||cysticercosis|patients||130|144
15927218.ab.8|relation|C0014441|Enzyme-Linked Immunosorbent Assay|lbpr|lbpr|||DIAGNOSES(INFER)|C0010678|Cysticercosis|dsyn|dsyn|||INFER||ELISA|cysticercosis||33|130
15927218.ab.8|relation|C0201773|Immunoblot assay|lbpr|lbpr|||DIAGNOSES(INFER)|C0010678|Cysticercosis|dsyn|dsyn|||INFER||immunoblotting|cysticercosis||43|130

----- Citation 15927258 -----
15927258.ab.3 In the presence of iron(III) {NH, PhO(-), COO(-)}, {2NH, 2PhO(-), COO(-)} and {2NH, 2PhO(-), COO(-), OH(-)} coordinated complexes are dominant.



----- Citation 15935823 -----
15935823.ab.3 Median benzene exposure was 61, 22, 21, 9 and 6 microg/m3, respectively, with higher levels in workers than in referents.


15935823.ab.3|relation|C0238760|Benzene Exposure|fndg|fndg|||PROCESS_OF|C1527116|Workers|popg,humn|humn|||PREP|in|benzene exposure|workers|91|7|95

----- Citation 15943571 -----
15943571.ab.1 T cell immunity plays a critical role in controlling HIV-1 viremia, and encoding a limited set of HIV-1 genes within DNA and poxvirus vectors can, when used sequentially, induce high levels of T cell immunity in primates.


15943571.ab.1|relation|C0019704|HIV-1|virs|virs|||CAUSES|C0042749|Viremia|dsyn|dsyn|||MOD/HEAD||HIV-1|viremia||53,98|59
15943571.ab.1|relation|C1817907|T cell mediated immunity|orgf|orgf|||AFFECTS|C0042749|Viremia|dsyn|dsyn|||NOM|role|T cell immunity|viremia|33|0|59|NEWER_UMLS_CONC_SUBJ
15943571.ab.1|relation|C0206570|Chordopoxvirinae|virs|virs|||AUGMENTS|C1817907|T cell mediated immunity|orgf|orgf|||VERB|induce|poxvirus|T cell immunity|171|125|193|NEWER_UMLS_CONC_OBJ
15943571.ab.1|relation|C1817907|T cell mediated immunity|orgf|orgf|||PROCESS_OF|C0033147|Primates|mamm|mamm|||PREP|in|T cell immunity|primates|208|193|212|NEWER_UMLS_CONC_SUBJ
15943571.ab.1|relation|C0017337|Genes|gngm|gngm|||PART_OF|C0019704|HIV-1|virs|virs|||MOD/HEAD||genes|HIV-1||104|98
15943571.ab.1|relation|C0017337|Genes|gngm|gngm|||PART_OF|C0012854|DNA|bacs,nnon|bacs|||PREP|within|genes|DNA|109|104|117

----- Citation 15943707 -----
15943707.ab.2 In 18 donors, PMNs were mobilized using rHuG-CSF + dexamethasone.


15943707.ab.2|relation|C0011777|Dexamethasone|phsu,strd|phsu|||ADMINISTERED_TO|C0013018|Donor person|grup,humn|humn|||VERB|using|donors|dexamethasone|34|6|51
15943707.ab.2|relation|C1271481|Recombinant human granulocyte colony stimulating factor|aapp,phsu|phsu|||ADMINISTERED_TO|C0013018|Donor person|grup,humn|humn|||VERB|using|rHuG-CSF|donors|34|40|6|NEW_UMLS_CONC_SUBJ,GERUND_INDICATOR

----- Citation 15946936 -----
15946936.ti.1 BAP31 and its caspase cleavage product regulate cell surface expression of tetraspanins and integrin-mediated cell survival.


15946936.ti.1|relation|C1312720|PHEMX protein, human|aapp,bacs|aapp|||PART_OF|C0699040|Cell surface|celc|celc|||NOM|expression|tetraspanins|cell surface|61|75|48
15946936.ti.1|relation|C1424489|BCAP31 gene|gngm|gngm|10134|BCAP31|INTERACTS_WITH|C1312720|PHEMX protein, human|aapp,bacs|aapp|10077|TSPAN32|VERB|regulate|BAP31|tetraspanins|39|0|75|NEW_UMLS_CONC_SUBJ
15946936.ti.1|relation|C0021701|Integrins|aapp,gngm,imft,rcpt|aapp|||AFFECTS|C0007620|Cell Survival|celf|celf|||ADJ|mediated|integrin|cell survival|101|92|110
15946936.ti.1|relation|C1424489|BCAP31 gene|gngm|gngm|10134|BCAP31|AFFECTS|C0007620|Cell Survival|celf|celf|||VERB|regulate|BAP31|cell survival|39|0|110|NEW_UMLS_CONC_SUBJ
15946936.ti.1|relation|C0010656|caspase|aapp,enzy|aapp|||AFFECTS|C0007620|Cell Survival|celf|celf|||VERB|regulate|caspase cleavage product|cell survival|39|14|110|COORDINATION
15946936.ti.1|relation|C0010656|caspase|aapp,enzy|aapp|||INTERACTS_WITH|C1312720|PHEMX protein, human|aapp,bacs|aapp|||VERB|regulate|caspase cleavage product|tetraspanins|39|14|75

15946936.ab.2 Here we show that cell surface expression of the tetraspanins CD9 and CD81 is compromised in mouse cells from which the Bap31 gene has been deleted.


15946936.ab.2|relation|C1312720|PHEMX protein, human|aapp,bacs|aapp|10077|TSPAN32|PART_OF|C0699040|Cell surface|celc|celc|||NOM|expression|tetraspanins|cell surface|31|49|18
15946936.ab.2|relation|C0054970|CD9 antigen|aapp,imft|aapp|||ISA|C1312720|PHEMX protein, human|aapp,bacs|aapp|||SPEC||tetraspanins|CD9||49|62|UMLS_CONC_REPLACE_SUBJ, NOT_IN_HIERACHY
15946936.ab.2|relation|C0084715|CD81 antigen|aapp,imft|aapp|||ISA|C1312720|PHEMX protein, human|aapp,bacs|aapp|||SPEC||tetraspanins|CD81||49|70|UMLS_CONC_REPLACE_SUBJ, COORDINATION
15946936.ab.2|relation|C0007634|Cells|cell|cell|||PART_OF|C0026809|Mus|mamm|mamm|||MOD/HEAD||cells|mouse||99|93|UMLS_CONC_REPLACE_OBJ,WSD
15946936.ab.2|relation|C0007634|Cells|cell|cell|||LOCATION_OF|C1424489|BCAP31 gene|gngm|gngm|10134|BCAP31|PREP|from|cells|Bap31 gene|104|99|120|NEW_UMLS_CONC_OBJ
15946936.ab.2|relation|C1413246|CD9 gene|gngm|gngm|928|CD9|PART_OF(SPEC)|C0699040|Cell surface|celc|celc|||INFER||cell surface|CD9||18|62|UMLS_CONC_REPLACE_OBJ
15946936.ab.2|relation|C1413240|CD81 gene|gngm|gngm|975|CD81|PART_OF(SPEC)|C0699040|Cell surface|celc|celc|||INFER||cell surface|CD9||18|62|UMLS_CONC_REPLACE_OBJ

----- Citation 15948171 -----
15948171.ab.2 The current study assessed screening and preventive behaviors during 12 months after predictive genetic testing for hereditary nonpolyposis colorectal carcinoma (HNPCC) in an Australian clinical cohort.


15948171.ab.2|relation|C0600224|Testing, Genetic Predisposition|diap|diap|||DIAGNOSES|C0009405|Hereditary Nonpolyposis Colorectal Neoplasms|neop|neop|||PREP|for|predictive genetic testing|hereditary nonpolyposis colorectal carcinoma (HNPCC)|111|85|116|NO_INDICATOR_RULE, UMLS_CONC_REPLACE_OBJ, DYSONYM

15948171.ab.2|relation|C0009405|Hereditary Nonpolyposis Colorectal Neoplasms|neop|neop|||PROCESS_OF|C0599755|cohort|popg,humn|humn|||PREP|in|hereditary nonpolyposis colorectal carcinoma (HNPCC)|cohort|168|116|195|UMLS_CONC_REPLACE_SUBJ, DYSONYM

15948171.ab.2|relation|C0600224|Testing, Genetic Predisposition|diap|diap|||PRECEDES|C0220908|Screening procedure|hlca|hlca|||PREP|after|predictive genetic testing|screening|78|85|27|NON_SEMNET_RELATION, UMLS_CONC_REPLACE_SUBJ

----- Citation 15953327 -----
15953327.ab.13 CONCLUSIONS: Infective endocarditis is a rare illness in children and represents a diagnostic challenge.


15953327.ab.13|relation|C1541923|Infective endocarditis|dsyn|dsyn|||ISA|C0221423|Illness (finding)|fndg|fndg|||SPEC|is|Infective endocarditis|illness|36|13|46|NEWER_UMLS_CONC_OBJ,NOT_IN_HIERARCHY
15953327.ab.13|relation|C0221423|Illness (finding)|fndg|fndg|||PROCESS_OF|C0008059|Child|aggp,inpr,humn|humn|||PREP|in|illness|children|53|46|57|NEWER_UMLS_CONC_SUBJ
15953327.ab.13|relation|C1541923|Infective endocarditis|dsyn|dsyn|||PROCESS_OF(SPEC)|C0008059|Child|aggp,inpr,humn|humn|||INFER||Infective endocarditis|children||13|57

15953327.ab.15 Specific expertise in paediatric emergency care can assist in early diagnosis and management.



----- Citation 15953529 -----
15953529.ti.1 Disruption and restoration of cell-cell junctions in mouse vestibular epithelia following aminoglycoside treatment.


15953529.ti.1|relation|C0440438|Mouse epithelium|bdsu|bdsu|||PART_OF|C1321513|Entire vestibule|bpoc|bpoc|||MOD/HEAD||mouse vestibular epithelia|vestibular||53|59
15953529.ti.1|relation|C0021721|Intercellular Junctions|bsoj|bsoj|||PART_OF|C0440438|Mouse epithelium|bdsu|bdsu|||PREP|in|cell-cell junctions|mouse vestibular epithelia|49|30|53
15953529.ti.1|relation|C0087111|Therapeutic procedure|topp|topp|||USES|C0002556|Aminoglycosides|carb,phsu|phsu|||MOD/HEAD||treatment|aminoglycoside||105|90

15953529.ab.7 Transient disruption of cell-cell junctions and down-expression of E-cadherin is a rational response for the deletion of dying hair cells, and may be associated with a limited capacity for cell proliferations in mammalian vestibular epithelia following their rapid restoration.


15953529.ab.7|relation|C0014609|Epithelium|tisu|tisu|||PART_OF|C1321513|Entire vestibule|bpoc|bpoc|||MOD/HEAD||epithelia|vestibular||233|222
15953529.ab.7|relation|C1321513|Entire vestibule|bpoc|bpoc|||PART_OF|C0024660|Mammals|mamm|mamm|||MOD/HEAD||vestibular|mammalian||222|212|NEW_UMLS_CONC_OBJ
15953529.ab.7|relation|C0014609|Epithelium|tisu|tisu|||LOCATION_OF|C0596290|Cell Proliferation|celf|celf|||PREP|in|epithelia|cell proliferations|208|233|189

----- Citation 15956296 -----
15956296.ab.12 The difference in brine concentration had a very large impact on the salt in moisture content of the cheese.


15956296.ab.12|relation|C0054057|brine|inch|inch|||INTERACTS_WITH|C0206136|Sodium Chloride, Dietary|food,inch|inch|||NOM|impact|brine|salt|55|18|69

15956296.ab.13 The exterior of the cheese in 18% brine reached a salt in moisture content almost identical to that of the brine very quickly (17.3% at 4 d), whereas the salt in moisture content at the surface of the cheese block in saturated brine was only 11.9% at 4 d.



----- Citation 15958124 -----
15958124.ab.1 Guillain-Barre syndrome (GBS) and chronic inflammatory demyelinating poly-(radiculo)neuropathy (CIDP) are immune-mediated disorders with a variable duration of progression and a range in severity of weakness.


15958124.ab.1|relation|C0018378|Guillain-Barre Syndrome|dsyn|dsyn|||ISA|C0021053|Immune System Diseases|dsyn|dsyn|||SPEC|are|Guillain-Barre syndrome|immune-mediated disorders|102|0|106
15958124.ab.1|relation|C0393819|Polyradiculoneuropathy, Chronic Inflammatory Demyelinating|dsyn|dsyn|||ISA|C0021053|Immune System Diseases|dsyn|dsyn|||SPEC|are|CIDP|immune-mediated disorders|102|96|106

15958124.ab.2 Infections can trigger GBS and exacerbate CIDP.

15958124.ab.2|relation|C0021311|Infection|dsyn|dsyn|||CAUSES|C0018378|Guillain-Barre Syndrome|dsyn|dsyn|||VERB|trigger|Infections|GBS|15|0|23
15958124.ab.2|relation|C0021311|Infection|dsyn|dsyn|||AUGMENTS|C0393819|Polyradiculoneuropathy, Chronic Inflammatory Demyelinating|dsyn|dsyn|||VERB|exacerbate|Infections|CIDP|31|0|42|NO_INDICATOR_RULE, NO_SEMNET_RELATION

----- Citation 15958928 -----
15958928.ab.1 Fifteen employees became ill with headaches, nausea, and vomiting due to chemical poisoning at a Vermont community hospital on January 3, 1980.


15958928.ab.1|relation|C0018681|Headache|sosy|sosy|||PROCESS_OF|C0599987|Employee|prog,humn|humn|||PREP|with|headaches|employees|28|34|8
15958928.ab.1|relation|C0042963|Vomiting|sosy|sosy|||PROCESS_OF|C0599987|Employee|prog,humn|humn|||PREP|with|vomiting|employees|28|57|8
15958928.ab.1|relation|C0027497|Nausea|sosy|sosy|||PROCESS_OF|C0599987|Employee|prog,humn|humn|||PREP|with|nausea|employees|28|45|8
15958928.ab.1|relation|C0520761|Toxic effect of chemical|inpo|inpo|||CAUSES|C0018681|Headache|sosy|sosy|||COMPLEX|due to|chemical poisoning|headaches|66|73|34
15958928.ab.1|relation|C0520761|Toxic effect of chemical|inpo|inpo|||CAUSES|C0042963|Vomiting|sosy|sosy|||COMPLEX|due to|chemical poisoning|vomiting|66|73|57
15958928.ab.1|relation|C0520761|Toxic effect of chemical|inpo|inpo|||CAUSES|C0027497|Nausea|sosy|sosy|||COMPLEX|due to|chemical poisoning|nausea|66|73|45

----- Citation 15969273 -----
15969273.ab.4 CONCLUSION: Overarching patterns in the data suggested that the occupational performance of mothers of children with disabilities is constrained by time, overlaid by difficult emotions, and involves a desire for increased social contact.


15969273.ab.4|relation|C0231170|Disability NOS|patf|patf|||PROCESS_OF|C0008059|Child|aggp,humn,inpr|humn|||PREP|with|disabilities|children|111|117|103
15969273.ab.4|relation|C0597198|Performance|inbe|inbe|||PROCESS_OF|C0026591|Mothers|famg,humn|humn|||PREP|of|performance|mothers|88|77|92

----- Citation 15972039 -----
15972039.ab.1 BACKGROUND: Total thyroidectomy is increasingly being adopted for patients requiring surgical treatment for Graves' disease based on a comparable surgical risk and the lack of recurrence, as well as the questionable ability of subtotal thyroidectomy to maintain euthyroidism.


15972039.ab.1|relation|C0543467|Operative Surgical Procedures|topp|topp|||TREATS|C0018213|Graves' Disease|dsyn|dsyn|||PREP|for|surgical treatment|Graves' disease|103|85|108
15972039.ab.1|relation|C0193788|Total thyroidectomy|topp|topp|||TREATS|C0030705|Patients|podg,humn|humn|||PREP|for|Total thyroidectomy|patients|61|12|66

----- Citation 15972621 -----
15972621.ab.1 BACKGROUND: The conversion of mild cognitive impairment (MCI) to Alzheimer's disease is associated with substantial compromise of neocortical circuits subserving rapid cognitive functions such as working memory.


15972621.ab.1|relation|C0025265|Memory, Short-Term|menp|menp|||ISA|C0392335|Cognitive functions|menp|menp|||SPEC|such as|working memory|cognitive functions|188|196|168|APPOSITIVE

----- Citation 15974085 -----
15974085.ab.3 Also, carryover of longer chain primary amines, hexylamine and octylamine, was substantially reduced by cleaning the injection syringe with ammonia and water vapor between sample injections.


15974085.ab.3|relation|C0062685|hexylamine|orch|orch|||ISA|C0002508|Amines|orch|orch|||SPEC|,|hexylamine|amines|46|48|40|APPOSITIVE
15974085.ab.3|relation|C0069367|octylamine|orch|orch|||ISA|C0002508|Amines|orch|orch|||SPEC|,|octylamine|amines|46|63|40|APPOSITIVE


----- Citation 15975940 -----
15975940.ab.6 Surprisingly, dorsal signaling molecules such as Chordin, Noggin, Xnr6 and Cerberus were not re-expressed in these embryos.


15975940.ab.6|relation|C0055601|chordin|aapp,carb|aapp|8646|CHRD|ISA|C1519315|Signaling Molecule|bacs|bacs|||SPEC|such as|Chordin|signaling molecules|41|49|21|NOT_IN_HIERARCHY,APPOSITIVE
15975940.ab.6|relation|C1417753|NOG gene|gngm|gngm|9241|NOG|ISA|C1519315|Signaling Molecule|bacs|bacs|||SPEC|such as|Noggin|signaling molecules|41|58|21|NOT_IN_HIERARCHY,APPOSITIVE
15975940.ab.6|relation|C1447859|Xnr6 protein, Xenopus|aapp,bacs|aapp|||ISA|C1519315|Signaling Molecule|bacs|bacs|||SPEC|such as|Xnr6|signaling molecules|41|66|21|NEW_UMLS_CONC_SUBJ,NOT_IN_HIERARCHY,APPOSITIVE
15975940.ab.6|relation|C1742950|CER1 protein, human|aapp,bacs|aapp|||ISA|C1519315|Signaling Molecule|bacs|bacs|||SPEC|such as|Cerberus|signaling molecules|41|75|21|NEWER_UMLS_CONC_SUBJ,NOT_IN_HIERARCHY,APPOSITIVE

----- Citation 15980893 -----
15980893.ti.1 Underrepresentation of short palindromes in Selenomonas ruminantium DNA: evidence for horizontal gene transfer of restriction and modification systems?


15980893.ti.1|relation|C0012854|DNA|bacs,nnon|nnon|||PART_OF|C0318087|Selenomonas ruminantium|bact|bact|||MOD/HEAD||DNA|Selenomonas ruminantium||68|44

----- Citation 15982867 -----
15982867.ti.1 The emerging family of hepatoblastoma tumours: from ontogenesis to oncogenesis.


15982867.ti.1|relation|C0206624|Hepatoblastoma|neop|neop|||ISA|C0027651|Neoplasm|neop|neop|||SPEC||hepatoblastoma|tumours||23|38

15982867.ab.4 Furthermore, an impressive amount of molecular biological information on liver ontogenesis and growth regulation of hepatic tumours has recently accumulated, which will allow the development of a comprehensive classification system with particular emphasis on prognostics.


15982867.ab.4|relation|C0018270|Growth|orgf|orgf|||AFFECTS|C0023903|Liver neoplasms|neop|neop|||NOM|regulation|growth|hepatic tumours|102|95|116|NOTE:NEWER_UMLS_CONC_'regulation_of_growth'_orgf_C1160191

----- Citation 15988072 -----
15988072.ab.5 Although antibiotic prophylaxis can decrease the incidence of surgical side infection, the benefits should be weighed against the risks of toxic and allergic reactions, dysbacteriosis, and the emergence of bacterial resistance.


15988072.ab.5|relation|C0282638|Antibiotic Prophylaxis|topp|topp|||PREVENTS|C0009450|Communicable Diseases|dsyn|dsyn|||VERB|decrease|antibiotic prophylaxis|infection|36|9|76|WSD,UMLS_CONC_REPLACE_OBJ

----- Citation 15989002 -----
15989002.ab.6 CAPS patients had no differences by age, duration of the disease, its activity and symptoms from patients who had no CAPS.


15989002.ab.6|relation|C0085278|Antiphospholipid Syndrome|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||CAPS|patients||0|5
15989002.ab.6|relation|C0085278|Antiphospholipid Syndrome|dsyn|dsyn|||NEG_PROCESS_OF|C0030705|Patients|podg,humn|humn|||AUX|had|CAPS|patients|110|117|97

----- Citation 15990320 -----
15990320.ab.1 Polyamines and polyamine toxins are biologically important molecules, having modulatory effects on nucleotides and proteins.


15990320.ab.1|relation|C0032433|Polyamines|orch|orch|||INTERACTS_WITH|C0028630|Nucleotides|nnon|nnon|||NOM|effects|Polyamines|nucleotides|88|0|99
15990320.ab.1|relation|C0032433|Polyamines|orch|orch|||INTERACTS_WITH|C0033684|Proteins|aapp,bacs|aapp|||NOM|effects|Polyamines|proteins|88|0|115
15990320.ab.1|relation|C0040549|Toxin|bacs,hops|bacs|||INTERACTS_WITH|C0028630|Nucleotides|nnon|nnon|||NOM|effects|Polyamines|nucleotides|88|0|99
15990320.ab.1|relation|C0040549|Toxin|bacs,hops|bacs|||INTERACTS_WITH|C0033684|Proteins|aapp,bacs|aapp|||NOM|effects|Polyamines|proteins|88|0|115

----- Citation 15993885 -----
15993885.ti.1 Sex differences in the relation of body composition to markers of inflammation.



15993885.ab.7 In women, fat mass in % explained the highest percentage of the variability of circulating acute-phase proteins (18.2% for CRP, 7.2% for SAA, 6.1% for FIB, all p-values < 0.001), whereas in men, WHR explained the highest percentage of the variability (6.2% for CRP, 2.3% for SAA, 1.8% for FIB, all p-values < 0.001).


15993885.ab.7|relation|C0006560|C-reactive protein|aapp,imft|aapp|||ISA|C0001347|Acute-Phase Proteins|aapp,bacs|aapp|||SPEC|(|CRP|acute-phase proteins|112|123|91
15993885.ab.7|relation|C0002723|Serum amyloid A protein|aapp,imft|aapp|||ISA|C0001347|Acute-Phase Proteins|aapp,bacs|aapp|||SPEC|(|SAA|acute-phase proteins|112|137|91|COORDINATION,UMLS_CONC_REPLACE_SUBJ
15993885.ab.7|relation|C0016006|Fibrinogen|aapp,bacs|aapp|2091|FBL|ISA|C0001347|Acute-Phase Proteins|aapp,bacs|aapp|||SPEC|(|FIB|acute-phase proteins|112|151|91|COORDINATION

----- Citation 15993962 -----
15993962.ab.1 BACKGROUND: The factors associated with recurrent restenosis after SES implantation for in-stent restenosis are unknown.


15993962.ab.1|relation|C0021107|Implantation procedure|topp|topp|||PRECEDES|C0333186|Restenosis|acab|acab|||PREP|after|implantation|restenosis|60|71|50|NON_SEMNET_RELATION
15993962.ab.1|relation|C0021107|Implantation procedure|topp|topp|||USES|C2199093|sirolimus drug-eluting stent|phsu|phsu|||MOD/HEAD||SES|implantation||71|67|NEWER_UMLS_CONC_OBJ, OBJ_SEMTYPE_IS_QUESTIONABLE
15993962.ab.1|relation|C0021107|Implantation procedure|topp|topp|||TREATS|C0333186|Restenosis|acab|acab|||PREP|for|implantation|restenosis|83|71|50,97
15993962.ab.1|relation|C2199093|sirolimus drug-eluting stent|phsu|phsu|||TREATS(INFER)|C0333186|Restenosis|acab|acab|||INFER||SES|restenosis||67|50,97|NEWER_UMLS_CONC_OBJ, OBJ_SEMTYPE_IS_QUESTIONABLE

15993962.ab.6 A cardiac event related to the target vessel occurred in 24 (24%) patients, and was associated with dialysis status (p < 0.05), lower ejection fraction (p < 0.05) and revascularization without SES in another site (p < 0.0001).



15993962.ab.6|relation|C0741923|CARDIAC EVENT|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|in|cardiac event|patients|53|2|66
15993962.ab.6|relation|C1962926|Renal dialysis status|fndg|fndg|||AFFECTS|C0741923|CARDIAC EVENT|dsyn|dsyn|||VERB|associated|dialysis status|cardiac event|84|100|2|NEWER_UMLS_CONC_SUBJ
15993962.ab.6|relation|C0489482|Ejection fraction|fndg|fndg|||AFFECTS|C0741923|CARDIAC EVENT|dsyn|dsyn|||VERB|associated|ejection fraction|cardiac event|84|134|2|NEWER_UMLS_CONC_SUBJ
15993962.ab.6|relation|C0581603|Revascularization - action|topp|topp|||AFFECTS|C0741923|CARDIAC EVENT|dsyn|dsyn|||VERB|associated|revascularization|cardiac event|84|167|2
15993962.ab.6|relation|C0581603|Revascularization - action|topp|topp|||NEG_USES|C2199023|sirolimus drug-eluting stent|phsu|phsu|||PREP|without|revascularization|SES|184|167|193

----- Citation 15993989 -----
15993989.ab.14 Sera of the mice immunized with i.m.


15993989.ab.14|relation|C0026809|Mus|mamm|mamm|||LOCATION_OF|C0229671|Serum|bdsu|bdsu|||PREP|of|mice|Sera|4|12|0|NON_SEMNET_RELATION

----- Citation 15996060 -----
15996060.ti.1 Sex hormone concentrations in patients with rheumatoid arthritis are not normalized during 12 weeks of anti-tumor necrosis factor therapy.


15996060.ti.1|relation|C0003873|Rheumatoid Arthritis|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|rheumatoid arthritis|patients|38|44|30
15996060.ti.1|relation|C0036884|Gonadal Steroid Hormones|horm|horm|||PART_OF|C0030705|Patients|podg,humn|humn|||PREP|in|Sex hormone|patients|26|0|30

15996060.ab.2 In contrast, compared to controls, serum levels of estrogens are normal or elevated in women with RA.


15996060.ab.2|relation|C0003873|Rheumatoid Arthritis|dsyn|dsyn|||PROCESS_OF|C0043210|Woman|popg,humn|humn|||PREP|with|women|RA|92|87|98
15996060.ab.2|relation|C0014939|Estrogens|horm,phsu,strd|horm|||PART_OF|C0043210|Woman|popg,humn|humn|||PREP|in|estrogens|women|83|51|87

15996060.ab.7 Serum levels of DHEAS and free testosterone were markedly lower at baseline in patients compared to controls, but this did not change during anti-TNF therapy.


15996060.ab.7|relation|C0030705|Patients|podg,humn|humn|||LOCATION_OF|C0057277|Dehydroepiandrosterone Sulfate|bacs,phsu,strd|strd|||PREP|in|patients|DHEAS|75|79|16
15996060.ab.7|relation|C0030705|Patients|podg,humn|humn|||LOCATION_OF|C0443483|Free testosterone|horm,strd|strd|||PREP|in|patients|free testosterone|75|79|26
15996060.ab.7|relation|C0009932|Control Groups|grup,humn|humn|||LOCATION_OF|C0057277|Dehydroepiandrosterone Sulfate|bacs,phsu,strd|strd|||PREP|in|patients|DHEAS|75|79|16|COORDINATION
15996060.ab.7|relation|C0009932|Control Groups|grup,humn|humn|||LOCATION_OF|C0443483|Free testosterone|horm,strd|strd|||PREP|in|patients|free testosterone|75|79|26|COORDINATION

15996060.ab.10 CONCLUSION: Longterm therapy with anti-TNF did not change altered serum levels of typical sex hormones in patients with RA, although baseline values were largely different.


15996060.ab.10|relation|C0003873|Rheumatoid Arthritis|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|RA|patients|114|120|106
15996060.ab.10|relation|C1562242|Anti-tumor necrosis factor alpha drug|phsu|phsu|||NEG_INTERACTS_WITH|C0036884|Gonadal Steroid Hormones|horm|horm|||VERB|change|anti-TNF|sex hormones|51|34|90
15996060.ab.10|relation|C0030705|Patients|podg,humn|humn|||LOCATION_OF|C0036884|Gonadal Steroid Hormones|horm|horm|||PREP|in|sex hormones|patients|102|90|106|NON_SEMNET_RELATION

15996060.ab.11 In patients with RA, this indicates that alterations of sex hormones and altered activity of respective converting enzymes are imprinted for a long-lasting period over at least 12 weeks.


15996060.ab.11|relation|C0003873|Rheumatoid Arthritis|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|RA|patients|11|17|3

----- Citation 15998787 -----
15998787.ab.3 We show that disruption of the Nrf2 gene leads to severe allergen-driven airway inflammation and hyperresponsiveness in mice.


15998787.ab.3|relation|C0002092|Allergens|imft|imft|||CAUSES|C0021368|Inflammation|patf|patf|||ADJ|driven|allergen|inflammation|66|57|80|NO_INDICATOR_RULE
15998787.ab.3|relation|C0458827|Airway structure|bpoc|bpoc|||LOCATION_OF|C0021368|Inflammation|patf|patf|||MOD/HEAD||airway|inflammation||73|80|DYSONYM,NEW_UMLS_CONC_SUBJ
15998787.ab.3|relation|C0021368|Inflammation|patf|patf|||PROCESS_OF|C0026809|Mus|mamm|mamm|||PREP|in|inflammation|mice|116|80|120
15998787.ab.3|relation|C1414905|GABPA gene|gngm|gngm|2551,4780|GABPA,NFE2L2|AFFECTS|C0021368|Inflammation|patf|patf|||VERB|leads|Nrf2|inflammation|41|31|80


15998787.ab.4 Enhanced asthmatic response as a result of ovalbumin sensitization and challenge in Nrf2-disrupted mice was associated with more pronounced mucus cell hyperplasia and infiltration of eosinophils into the lungs than seen in wild-type littermates.

15998787.ab.4|relation|C0871261|response|clna|clna|||ASSOCIATED_WITH|C0521483|Mucous membrane hyperplasia|sosy|sosy|||VERB|associated|response|mucus cell hyperplasia|108|19|140
15998787.ab.4|relation|C0004096|Asthma|dsyn|dsyn|||PROCESS_OF|C0026809|Mus|mamm|mamm|||PREP|in|asthmatic|mice|80|9|99
15998787.ab.4|relation|C0871261|response|clna|clna|||PROCESS_OF|C0026809|Mus|mamm|mamm|||PREP|in|response|mice|80|19|99|NEWER_UMLS_CONC_SUBJ
15998787.ab.4|relation|C0024109|Lung|bpoc|bpoc|||LOCATION_OF|C0333390|Chronic eosinophilic inflammation|patf|patf|||PREP|into|lungs|infiltration of eosinophils|194|204|167|UMLS_CONC_REPLACE_OBJ
15998787.ab.4|relation|C0871261|response|clna|clna|||ASSOCIATED_WITH|C0333390|Chronic eosinophilic inflammation|patf|patf|||VERB|associated|response|infiltration of eosinophils|108|19|167|NEWER_UMLS_CONC_SUBJ,UMLS_CONC_REPLACE_OBJ,COORDINATION

15998787.ab.5 Nrf2 disruption resulted in an increased expression of the T helper type 2 cytokines interleukin (IL)-4 and IL-13 in bronchoalveolar lavage fluid and in splenocytes after allergen challenge.


15998787.ab.5|relation|C1519477|Splenocyte|cell|cell|||LOCATION_OF|C0214743|Interleukin-13|aapp,gngm,imft|aapp|||PREP|in|splenocytes|IL-13|149|153|108
15998787.ab.5|relation|C1519477|Splenocyte|cell|cell|||LOCATION_OF|C0021758|Interleukin-4|aapp,imft|aapp|||PREP|in|splenocytes|interleukin (IL)-4|149|153|85
15998787.ab.5|relation|C0006279|Bronchoalveolar Lavage Fluid|bdsu|bdsu|||LOCATION_OF|C0214743|Interleukin-13|aapp,gngm,imft|aapp|||PREP|in|bronchoalveolar lavage fluid|IL-13|113|117|108|NON_SEMNET_RELATION
15998787.ab.5|relation|C0006279|Bronchoalveolar Lavage Fluid|bdsu|bdsu|||LOCATION_OF|C0021758|Interleukin-4|aapp,imft|aapp|||PREP|in|bronchoalveolar lavage fluid|interleukin (IL)-4|113|117|85|NON_SEMNET_RELATION
15998787.ab.5|relation|C0021758|Interleukin-4|aapp,gngm,imft|aapp|||ISA|C0079189|cytokine|aapp,gngm,imft|aapp|||SPEC||interleukin (IL)-4|cytokine||85|75
15998787.ab.5|relation|C0214743|Interleukin-13|aapp,gngm,imft|aapp|||ISA|C0079189|cytokine|aapp,gngm,imft|aapp|||SPEC||IL-13|cytokine||108|75

----- Citation 16000282 -----
16000282.ab.10 The sensitivity of 18F-FDG PET for the identification of nodal metastases on a level-by-level basis was 22.1% higher than that of CT/MRI (74.7% vs. 52.6%, P < 0.001), whereas the specificity of 18F-FDG PET was 1.5% lower than that of CT/MRI (93.0% vs. 94.5%, P = 0.345).


16000282.ab.10|relation|C0872169|fluorodeoxyglucose positron emission tomography|diap|diap|||DIAGNOSES|C0027627|Neoplasm Metastasis|neop|neop|||NOM|identification|18F-FDG PET|metastases|39|19|63
16000282.ab.10|relation|C0024485|Magnetic Resonance Imaging|diap|diap|||DIAGNOSES|C0027627|Neoplasm Metastasis|neop|neop|||NOM|identification|CT/MRI|metastases|39|130|63

----- Citation 16003269 -----
16003269.ab.5 RESULTS: At 5 minutes after initiation of the pacing, giant pulmonary venous (PV) flow reversal (-76 cm/s) was observed in association with 1:1 ventriculoatrial conduction or complete atrioventricular dissociation.



----- Citation 16012316 -----
16012316.ab.8 RESULTS: The fraction of the range of ground-glass opacity and reticular opacity was greater in NSIP patients (32%, 12%) than in UIP patients (23%, 8%) (P < 0.001).


16012316.ab.8|relation|C1290344|Nonspecific interstitial pneumonia|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||NSIP|patients||96|101
16012316.ab.8|relation|C0085786|Hamman-Rich syndrome|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||UIP|patients||129|133

----- Citation 16015001 -----
16015001.ab.5 Patients with higher serum phosphorus (P) (group A: P > or = 7 mg/dl) were compared with those with lower serum P levels (group B: P < 7 mg/dl).


16015001.ab.5|relation|C0229671|Serum|bdsu|bdsu|||LOCATION_OF|C0031705|Phosphorus|elii,phsu|phsu|||MOD/HEAD||serum|phosphorus||21|27
16015001.ab.5|relation|C0030705|Patients|podg,humn|humn|||LOCATION_OF|C0031705|Phosphorus|elii,phsu|phsu|||PREP|with|Patients|phosphorus|8|0|27
16015001.ab.5|relation|C0030705|Patients|podg,humn|humn|||LOCATION_OF|C0031705|Phosphorus|elii,phsu|phsu|||PREP|with|Patients|P|94|0|112|ANAPHORA

16015001.ab.14 CONCLUSION: Although iPTH and bAP are frequently in agreement, it seems important to separate parathyroid activity given by iPTH, from bone remodelling reflected by bAP, in the presence of either a higher aluminum exposition or a well-controlled phosphatemia.



----- Citation 16020163 -----
16020163.ab.2 We surveyed a community sample of 423 adult men and women of African descent to determine acculturation's relationship to Black suicide.


16020163.ab.2|relation|C0038661|Suicide|inpo|inpo|||PROCESS_OF|C0085756|African American|popg,humn|humn|||MOD/HEAD||suicide|Black||128|122
16020163.ab.2|relation|C0025266|Male population group|popg,humn|humn|||ISA|C0001675|Adult|aggp,humn|humn|||SPEC||men|adult||44,54|38
16020163.ab.2|relation|C0043210|Woman|popg,humn|humn|||ISA|C0001675|Adult|aggp,humn|humn|||SPEC||women|adult||52|38|COORDINATION
16020163.ab.2|relation|C0000943|Acculturation|socb|socb|||AFFECTS|C0038661|Suicide|inpo|inpo|||NOM|relationship|acculturation|suicide|106|90|128|NON_SEMNET_RELATION,NO_INDICATOR_RULE

----- Citation 16024249 -----
16024249.ab.1 Fasciolosis is an uncommon disease in this region, as are parasitic infections of the breast.


16024249.ab.1|relation|C0015652|Fascioliasis|dsyn|dsyn|||ISA|C0012634|Disease|dsyn|dsyn|||SPEC|is|Fasciolosis|disease|12|0|27
16024249.ab.1|relation|C0006141|Breast|bpoc|bpoc|||LOCATION_OF|C0747256|Parasitic infection|dsyn|dsyn|||PREP|of|breast|parasitic infections|78|86|58

----- Citation 16025281 -----
16025281.ab.6 BAFF-R expression was found only in B-cell lymphoma (44/80, positive cases/examined cases): B-lymphoblastic lymphoma 0/3, B-chronic lymphocytic leukemia/small lymphocytic lymphoma 4/4, mantle cell lymphoma 9/11, follicular lymphoma 10/14, diffuse large B-cell lymphoma (DLBCL) 11/25, marginal zone B-cell lymphoma 8/10, lymphoplasmacytic lymphoma 2/2, plasma cell myeloma 0/2, and Burkitt lymphoma 0/9, but not in T/NK cell lymphomas (0/19) or Hodgkin lymphoma (0/10).


16025281.ab.6|relation|C1425064|TNFRSF13C gene|gngm|gngm|115650|TNFRSF13C|PART_OF|C0079731|B-Cell Lymphomas|neop|neop|||PREP|in|BAFF-R|B-cell lymphoma|32|0|36|GENE
16025281.ab.6|relation|C2853919|Lymphoblastic B-cell lymphoma|neop|neop|||ISA|C0079731|B-Cell Lymphomas|neop|neop|||SPEC|:|B-lymphoblastic lymphoma|B-cell lymphoma|90|92|36|NEWER_UMLS_CONC_SUBJ,NOT_IN_HIERARCHY,NO_INDICATOR_RULE(:),APPOSITIVE
16025281.ab.6|relation|C0861887|B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma|neop|neop|||ISA|C0079731|B-Cell Lymphomas|neop|neop|||SPEC|:|B-chronic lymphocytic leukemia/small lymphocytic lymphoma|B-cell lymphoma|90|122|36|UMLS_CONC_REPLACE_SUBJ,NOT_IN_HIERARCHY, NO_INDICATOR_RULE(:),APPOSITIVE
16025281.ab.6|relation|C0334634|Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse|neop|neop|||ISA|C0079731|B-Cell Lymphomas|neop|neop|||SPEC|:|mantle cell lymphoma|B-cell lymphoma|90|185|36|NO_INDICATOR_RULE(:),APPOSITIVE
16025281.ab.6|relation|C0024301|Lymphoma, Follicular|neop|neop|||ISA|C0079731|B-Cell Lymphomas|neop|neop|||SPEC|:|follicular lymphoma|B-cell lymphoma|90|212|36|NO_INDICATOR_RULE(:),APPOSITIVE
16025281.ab.6|relation|C0079744|Lymphoma, Large-Cell, Diffuse|neop|neop|||ISA|C0079731|B-Cell Lymphomas|neop|neop|||SPEC|:|diffuse large B-cell lymphoma|B-cell lymphoma|90|239|36|NO_INDICATOR_RULE(:),APPOSITIVE
16025281.ab.6|relation|C1367654|Marginal zone B-cell lymphoma|neop|neop|||ISA|C0079731|B-Cell Lymphomas|neop|neop|||SPEC|:|marginal zone B-cell lymphoma|B-cell lymphoma|90|284|36|NO_INDICATOR_RULE(:),APPOSITIVE
16025281.ab.6|relation|C0024419|Waldenstrom Macroglobulinemia|neop|neop|||ISA|C0079731|B-Cell Lymphomas|neop|neop|||SPEC|:|lymphoplasmacytic lymphoma|B-cell lymphoma|90|320|36|NO_INDICATOR_RULE(:),APPOSITIVE
16025281.ab.6|relation|C0026764|Multiple Myeloma|neop|neop|||ISA|C0079731|B-Cell Lymphomas|neop|neop|||SPEC|:|plasma cell myeloma|B-cell lymphoma|90|352|36|NOT_IN_HIERARCHY,NO_INDICATOR_RULE(:),APPOSITIVE
16025281.ab.6|relation|C0006413|Burkitt Lymphoma|neop|neop|||ISA|C0079731|B-Cell Lymphomas|neop|neop|||SPEC|:|Burkitt lymphoma|B-cell lymphoma|90|381|36|NOT_IN_HIERARCHY,NO_INDICATOR_RULE(:),APPOSITIVE
16025281.ab.6|relation|C0019829|Hodgkin Disease|neop|neop|||ISA|C0079731|B-Cell Lymphomas|neop|neop|||SPEC|:|Hodgkin lymphoma|B-cell lymphoma|90|444|36|NOT_IN_HIERARCHY,NO_INDICATOR_RULE(:),APPOSITIVE
16025281.ab.6|relation|C1425064|TNFRSF13C gene|gngm|gngm|||PART_OF(SPEC)|C2853919|Lymphoblastic B-cell lymphoma|neop|neop|||INFER||BAFF-R|B-lymphoblastic lymphoma||0|92|NEWER_UMLS_CONC_SUBJ
16025281.ab.6|relation|C1425064|TNFRSF13C gene|gngm|gngm|||PART_OF(SPEC)|C0861887|B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma|neop|neop|||INFER||BAFF-R|B-chronic lymphocytic leukemia/small lymphocytic lymphoma||0|122
16025281.ab.6|relation|C1425064|TNFRSF13C gene|gngm|gngm|115650|TNFRSF13C|PART_OF(SPEC)|C0334634|Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse|neop|neop|||INFER||BAFF-R|mantle cell lymphoma||0|185
16025281.ab.6|relation|C1425064|TNFRSF13C gene|gngm|gngm|115650|TNFRSF13C|PART_OF(SPEC)|C0024301|Lymphoma, Follicular|neop|neop|||INFER||BAFF-R|follicular lymphoma||0|212
16025281.ab.6|relation|C1425064|TNFRSF13C gene|gngm|gngm|115650|TNFRSF13C|PART_OF(SPEC)|C0079744|Lymphoma, Large-Cell, Diffuse|neop|neop|||INFER||BAFF-R|diffuse large B-cell lymphoma||0|239
16025281.ab.6|relation|C1425064|TNFRSF13C gene|gngm|gngm|115650|TNFRSF13C|PART_OF(SPEC)|C1367654|Marginal zone B-cell lymphoma|neop|neop|||INFER||BAFF-R|marginal zone B-cell lymphoma||0|284
16025281.ab.6|relation|C1425064|TNFRSF13C gene|gngm|gngm|115650|TNFRSF13C|PART_OF(SPEC)|C0024419|Waldenstrom Macroglobulinemia|neop|neop|||INFER||BAFF-R|lymphoplasmacytic lymphoma||0|320
16025281.ab.6|relation|C1425064|TNFRSF13C gene|gngm|gngm|115650|TNFRSF13C|PART_OF(SPEC)|C0026764|Multiple Myeloma|neop|neop|||INFER||BAFF-R|plasma cell myeloma||0|352
16025281.ab.6|relation|C1425064|TNFRSF13C gene|gngm|gngm|115650|TNFRSF13C|PART_OF(SPEC)|C0006413|Burkitt Lymphoma|neop|neop|||INFER||BAFF-R|Burkitt lymphoma||0|381
16025281.ab.6|relation|C1425064|TNFRSF13C gene|gngm|gngm|115650|TNFRSF13C|NEG_PART_OF(SPEC)|C0019829|Hodgkin Disease|neop|neop|||INFER||BAFF-R|Hodgkin lymphoma||0|444

16025281.ab.7 BAFF-R was expressed in most low-grade B-cell neoplasms and a small number of DLBCL, suggesting that BAFF-R may play an important role in the proliferation of neoplastic lymphoid cells.


16025281.ab.7|relation|||gngm|gngm|10673|TNFSF13B|PART_OF|C1332362|B-cell neoplasm|neop|neop|||VERB|expressed|BAFF-R|B-cell neoplasms|11|0|39
16025281.ab.7|relation|||gngm|gngm|10673|TNFSF13B|PART_OF|C0079744|Lymphoma, Large-Cell, Diffuse|neop|neop|||VERB|expressed|BAFF-R|DLBCL|11|0|78
16025281.ab.7|relation|||gngm|gngm|10673|TNFSF13B|AFFECTS|C0596290|Cell Proliferation|celf|celf|||NOM|role|BAFF-R|proliferation|130|101|142|UMLS_CONC_REPLACE_OBJ
16025281.ab.7|relation|C0596290|Cell Proliferation|celf|celf|||AFFECTS|C0086574|Lymphoid Cells|cell|cell|||PREP|of|proliferation|lymphoid cells|155|142|170|UMLS_CONC_REPLACE_SUBJ,UMLS_CONC_REPLACE_OBJ,NON_SEMNET_RELATION,NO_INDICATOR_RULE
16025281.ab.7|relation|C0086574|Lymphoid Cells|cell|cell|||LOCATION_OF|C0027651|Neoplasm|neop|neop|||MOD/HEAD||lymphoid cells|neoplastic||170|159|UMLS_CONC_REPLACE_SUBJ,UMLS_CONC_REPLACE_OBJ

----- Citation 16030174 -----
16030174.ab.5 PARTICIPANTS: We studied women with regular cycles (n = 36) and women with PCOS (n = 8).


16030174.ab.5|relation|C0032460|Polycystic Ovary Syndrome|dsyn|dsyn|||PROCESS_OF|C0043210|Woman|popg,humn|humn|||PREP|with|PCOS|women|69|75|64

16030174.ab.11 CONCLUSIONS: These data demonstrate that inhibin A and inhibin B concentrations are significantly reduced in the follicular fluid of women with PCOS compared with those in the follicular fluid of size-matched follicles from normal women, consistent with the decreased inhibin subunit mRNA expression in previous studies.


16030174.ab.11|relation|C0016431|Follicular Fluid|bdsu|bdsu|||PART_OF|C0043210|Woman|popg,humn|humn|||PREP|of|follicular fluid|women|129|113|133|NON_SEMNET_RELATION
16030174.ab.11|relation|C0032460|Polycystic Ovary Syndrome|dsyn|dsyn|||PROCESS_OF|C0043210|Woman|popg,humn|humn|||PREP|with|PCOS|women|138|144|133
16030174.ab.11|relation|C0016431|Follicular Fluid|bdsu|bdsu|||LOCATION_OF|C0971174|inhibin B|aapp,horm|aapp|||PREP|in|follicular fluid|inhibin B|105|113|55|NON_SEMNET_RELATION
16030174.ab.11|relation|C0016431|Follicular Fluid|bdsu|bdsu|||LOCATION_OF|C0883157|Inhibin A|aapp,horm|aapp|||PREP|in|follicular fluid|inhibin A|105|113|41|NON_SEMNET_RELATION,UMLS_CONC_REPLACE_OBJ

----- Citation 16038840 -----
16038840.ab.7 In patients with diverticular disease, NSAID use increases the risk of severe diverticular infection and perforation.


16038840.ab.7|relation|C1510475|Diverticulosis|anab,dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|diverticular disease|patients|11|17|3
16038840.ab.7|relation|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||PREDISPOSES|C0009450|Communicable Diseases|dsyn|dsyn|||COMPLEX|increases the risk|NSAID|diverticular infection|49|39|78
16038840.ab.7|relation|C0012817|diverticulum|anab|anab|||LOCATION_OF|C0009450|Communicable Diseases|dsyn|dsyn|||MOD/HEAD||diverticular|infection||78|91
16038840.ab.7|relation|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||PREDISPOSES|C0853013|Diverticular perforation|dsyn|dsyn|||COMPLEX|increases the risk|NSAID|diverticular infection and perforation|49|39|78|COORDINATION

----- Citation 16040903 -----
16040903.ab.2 MATERIALS AND METHODS: The study was approved by the institutional review board and, where appropriate, was compliant with the Health Insurance Portability and Accountability Act.



----- Citation 16044089 -----
16044089.ab.2 This study investigated the effect of peritoneal lavage with oxygenated PFC (O2-PFC) against hemorrhagic shock and resuscitation (HS/R).


16044089.ab.2|relation|C0031148|Peritoneal lavage|diap,topp|topp|||USES|C0359181|Perfluorochemical|orch,phsu|phsu|||PREP|with|peritoneal lavage|oxygenated PFC|55|38|61
16044089.ab.2|relation|C0031148|Peritoneal lavage|diap,topp|topp|||TREATS|C0036982|Shock, Hemorrhagic|patf|patf|||PREP|against|peritoneal lavage|hemorrhagic shock|84|38|93|NO_INDICATOR_RULE
16044089.ab.2|relation|C0359181|Perfluorochemical|orch,phsu|phsu|||TREATS(INFER)|C0036982|Shock, Hemorrhagic|patf|patf|||INFER||oxygenated PFC (O2-PFC)|hemorrhagic shock||61|93|NO_INDICATOR_RULE

16044089.ab.12 We conclude that treatment with O2-PFC lavage ameliorated HS/R-induced metabolic acidosis and intestinal damage, which was associated with better mortality, possibly by preserving microvascular perfusion and maintaining oxygen metabolism.


16044089.ab.12|relation|C0022100|Irrigation|topp|topp|||TREATS|C0220981|Metabolic acidosis|patf|patf|||VERB|ameliorated|lavage|metabolic acidosis|46|39|71
16044089.ab.12|relation|C0022100|Irrigation|topp|topp|||USES|C0359181|Perfluorochemical|orch,phsu|phsu|||MOD/HEAD||lavage|O2-PFC||39|32|UMLS_CONC_REPLACE_OBJ
16044089.ab.12|relation|C0359181|Perfluorochemical|orch,phsu|phsu|||TREATS(INFER)|C0220981|Metabolic acidosis|patf|patf|||INFER||O2-PFC|metabolic acidosis||32|71|INFERENCE
16044089.ab.12|relation|C0359181|Perfluorochemical|orch,phsu|phsu|||TREATS(INFER)|C0010957|Tissue damage|inpo|inpo|||INFER||O2-PFC|damage||32|105|INFERENCE
16044089.ab.12|relation|C0021853|Intestines|bpoc|bpoc|||LOCATION_OF|C0010957|Tissue damage|inpo|inpo|||MOD/HEAD||intestinal|damage||94|105
16044089.ab.12|relation|C0036982|Shock, Hemorrhagic|patf|patf|||CAUSES|C0220981|Metabolic acidosis|patf|patf|||ADJ|induced|HS/R|metabolic acidosis|63|58|71

----- Citation 16046858 -----
16046858.ab.4 We previously demonstrated that intracerebroventricular injection of the glutamate analog AMPA in rats at postnatal day 7 (P7) caused bilateral periventricular gray and white matter injury.


16046858.ab.4|relation|C1533685|Injection procedure|topp|topp|||USES|C0051318|alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid|irda,orch,phsu|phsu|||PREP|of|injection|AMPA|65|56|90
16046858.ab.4|relation|C1533685|Injection procedure|topp|topp|||TREATS|C0034721|Rattus|mamm|mamm|||PREP|in|injection|rats|94|56|98
16046858.ab.4|relation|C0051318|alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid|irda,orch,phsu|phsu|||ADMINISTERED_TO(INFER)|C0034721|Rattus|mamm|mamm|||INFER||AMPA|rats||90|98
16046858.ab.4|relation|C0682708|White Matter|tisu|tisu|||LOCATION_OF|C0175677|Injury|inpo|inpo|||MOD/HEAD||white matter|injury||169|182
16046858.ab.4|relation|C0018220|Gray Matter|tisu|tisu|||LOCATION_OF|C0175677|Injury|inpo|inpo|||MOD/HEAD||gray and white matter|injury||160|182|COORDINATION,NEW_UMLS_CONC_SUBJ
16046858.ab.4|relation|C1533685|Injection procedure|topp|topp|||CAUSES|C0175677|Injury|inpo|inpo|||VERB|caused|injection|injury|127|56|182
16046858.ab.4|relation|C0051318|alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid|irda,orch,phsu|phsu|||CAUSES(INFER)|C0175677|Injury|inpo|inpo|||INFER||AMPA|injury||90|182

----- Citation 16078061 -----
16078061.ab.2 METHODS: A questionnaire was used to assess the impact of FDG PET scan on diagnosis, management and clinical decision-making processes for epilepsy surgery from the managing clinician's perspective.


16078061.ab.2|relation|C0543467|Operative Surgical Procedures|topp|topp|||TREATS|C0014544|Epilepsy|dsyn|dsyn|||MOD/HEAD||surgery|epilepsy||148|139|WSD,NEW_UMLS_CONC_SUBJ
16078061.ab.2|relation|C0032743|Positron-Emission Tomography|diap|diap|||USES|C0046056|Fluorodeoxyglucose F18|irda,orch|irda|||MOD/HEAD||PET scan|FDG||62|58|UMLS_CONC_REPLACE_OBJ

16078061.ab.7 FDG PET had either a minor or a major impact on clinical management in 58 patients (51%), principally with regard to surgical candidacy.


16078061.ab.7|relation|C0872169|fluorodeoxyglucose positron emission tomography|diap|diap|||AFFECTS|C1516615|Clinical Management|hlca|hlca|||NOM|impact|FDG PET|clinical management|38|0|48|NON_SEMNET_RELATION
16078061.ab.7|relation|C1516615|Clinical Management|hlca|hlca|||TREATS|C0030705|Patients|humn|humn|||PREP|in|clinical management|patients|67|48|74

----- Citation 16079122 -----
16079122.ab.1 We report on febrile episodes occurring among 379 patients affected by chronic lymphocytic leukemia, observed from 1984 to 2002.


16079122.ab.1|relation|C0023434|Chronic Lymphocytic Leukemia|neop|neop|||AFFECTS|C0030705|Patients|podg,humn|humn|||VERB|affected|chronic lymphocytic leukemia|patients|59|71|50
16079122.ab.1|relation|C0015967|Fever|fndg|fndg|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||VERB|occurring|febrile|patients|30|13|50|GERUND_INDICATOR

16079122.ab.2 One hundred and twenty eight patients (33.7%) developed 341 febrile episodes, of which 251 were documented infections (82 severe and 169 moderate).


16079122.ab.2|relation|C0015967|Fever|fndg|fndg|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||VERB|developed|febrile|patients|46|60|29

----- Citation 16079931 -----
16079931.ab.3 Although no pathological changes could be identified by radiography of the chest, electrocardiography, or routine echocardiography, the assessment of diastolic function with Doppler echocardiography revealed left ventricular diastolic dysfunction.


16079931.ab.3|relation|C0013520|Echocardiography, Doppler|diap|diap|||DIAGNOSES|C1273070|Left ventricular diastolic dysfunction|dsyn|dsyn|||VERB|revealed|Doppler echocardiography|left ventricular diastolic dysfunction|199|174|208

----- Citation 16080004 -----
16080004.ab.8 Overnight incubation with 1 microM safrole did not alter cell proliferation, but incubation with 10-1000 microM safrole increased cell proliferation by 60+/-10%.


16080004.ab.8|relation|C0036049|Safrole|hops,orch|hops|||NEG_AFFECTS|C0596290|Cell Proliferation|celf|celf|||VERB|alter|safrole|cell proliferation|51|35|57
16080004.ab.8|relation|C0036049|Safrole|hops,orch|orch|||AUGMENTS|C0596290|Cell Proliferation|celf|celf|||VERB|increased|safrole|cell proliferation|120|112|130

----- Citation 16083305 -----
16083305.ti.1 Effects of human soluble BAFF synthesized in Escherichia coli on CD4+ and CD8+ T lymphocytes as well as NK cells in mice.


16083305.ti.1|relation|C0014834|Escherichia coli|bact|bact|||LOCATION_OF|C1682317|TNFSF13B protein, human|aapp,bacs|aapp|10673|TNFSF13B|PREP|in|Escherichia coli|BAFF|41|45|25|UMLS_CONC_REPLACE_OBJ
16083305.ti.1|relation|C0026809|Mus|mamm|mamm|||LOCATION_OF|C0022688|Natural Killer Cells|cell|cell|||PREP|in|mice|NK cells|112|116|104
16083305.ti.1|relation|C0026809|Mus|mamm|mamm|||LOCATION_OF|C0242629|CD8-Positive T-Lymphocytes|cell|cell|||PREP|in|mice|CD8+ T lymphocytes|112|116|74
16083305.ti.1|relation|C0026809|Mus|mamm|mamm|||LOCATION_OF|C0039215|CD4 Positive T Lymphocytes|cell|cell|||PREP|in|mice|CD4+|112|116|65
16083305.ti.1|relation|C1682317|TNFSF13B protein, human|aapp,bacs|aapp|10673|TNFSF13B|AFFECTS|C0242629|CD8-Positive T-Lymphocytes|cell|cell|||NOM|Effects|BAFF|CD8+ T lymphocytes|0|25|74|UMLS_CONC_REPLACE_SUBJ
16083305.ti.1|relation|C1682317|TNFSF13B protein, human|aapp,bacs|aapp|10673|TNFSF13B|AFFECTS|C0039215|CD4 Positive T Lymphocytes|cell|cell|||NOM|Effects|BAFF|CD4+|0|25|65|UMLS_CONC_REPLACE_SUBJ
16083305.ti.1|relation|C1682317|TNFSF13B protein, human|aapp,bacs|aapp|10673|TNFSF13B|AFFECTS|C0022688|Natural Killer Cells|cell|cell|||NOM|Effects|BAFF|NK cells|0|25|104|UMLS_CONC_REPLACE_SUBJ

16083305.ab.3 On the 8th day after injection, we investigated the effects of hsBAFF on immune functional activities of splenic B lymphocytes, CD4(+) and CD8(+) T lymphocytes and natural killer (NK) cells in mice.


16083305.ab.3|relation|C0026809|Mus|mamm|mamm|||LOCATION_OF|C0022688|Natural Killer Cells|cell|cell|||PREP|in|mice|natural killer (NK) cells|189|193|164
16083305.ab.3|relation|C0026809|Mus|mamm|mamm|||LOCATION_OF|C0242629|CD8-Positive T-Lymphocytes|cell|cell|||PREP|in|mice|CD8(+) T lymphocytes|189|193|139
16083305.ab.3|relation|C0026809|Mus|mamm|mamm|||LOCATION_OF|C0039215|CD4 Positive T Lymphocytes|cell|cell|||PREP|in|mice|CD4(+)|189|193|128
16083305.ab.3|relation|C0026809|Mus|mamm|mamm|||LOCATION_OF|C0004561|B-Lymphocytes|cell|cell|||PREP|in|mice|B lymphocytes|189|193|113
16083305.ab.3|relation|C0004561|B-Lymphocytes|cell|cell|||PART_OF|C0037993|Spleen|bpoc|bpoc|||MOD/HEAD||B lymphocytes|splenic||113|105
16083305.ab.3|relation|C1682317|TNFSF13B protein, human|aapp,bacs|aapp|10673|TNFSF13B|AFFECTS|C0004561|B-Lymphocytes|cell|cell|||NOM|effects|hsBAFF|B lymphocytes|52|63|113|UMLS_CONC_REPLACE_SUBJ
16083305.ab.3|relation|C1682317|TNFSF13B protein, human|aapp,bacs|aapp|10673|TNFSF13B|AFFECTS|C0039215|CD4 Positive T Lymphocytes|cell|cell|||NOM|effects|hsBAFF|CD4(+)|52|63|128|UMLS_CONC_REPLACE_SUBJ
16083305.ab.3|relation|C1682317|TNFSF13B protein, human|aapp,bacs|aapp|10673|TNFSF13B|AFFECTS|C0242629|CD8-Positive T-Lymphocytes|cell|cell|||NOM|effects|hsBAFF|CD8(+) T lymphocytes|52|63|139|UMLS_CONC_REPLACE_SUBJ
16083305.ab.3|relation|C1682317|TNFSF13B protein, human|aapp,bacs|aapp|10673|TNFSF13B|AFFECTS|C0022688|Natural Killer Cells|cell|cell|||NOM|effects|hsBAFF|natural killer (NK) cells|52|63|164|UMLS_CONC_REPLACE_SUBJ

----- Citation 16084063 -----
16084063.ti.1 Wnt/beta-catenin signaling inhibits death receptor-mediated apoptosis and promotes invasive growth of HNSCC.


16084063.ti.1|relation|C0105770|beta catenin|aapp,bacs|aapp|||DISRUPTS|C0162638|Apoptosis|celf|celf|||VERB|inhibits|beta-catenin|apoptosis|27|4|60
16084063.ti.1|relation|C0105770|beta catenin|aapp,bacs|aapp|||AUGMENTS|C1156244|invasive growth|patf|patf|||VERB|promotes|beta-catenin|invasive growth|74|4|83
16084063.ti.1|relation|C1156244|invasive growth|patf|patf|||COEXISTS_WITH|C0279671|Cervical Squamous Cell Carcinoma|neop|neop|||PREP|of|invasive growth|HNSCC|98|83|102

16084063.ab.1 The Wnt/beta-catenin signaling pathway plays a critical role in cell proliferation and oncogenesis.


16084063.ab.1|relation|C0105770|beta catenin|aapp,bacs|aapp|||AFFECTS|C0596290|Cell Proliferation|celf|celf|||NOM|role|Wnt/beta-catenin signaling pathway|cell proliferation|56|4|64
16084063.ab.1|relation|C0105770|beta catenin|aapp,bacs|aapp|||AFFECTS|C1326912|Tumorigenesis|neop|neop|||NOM|role|Wnt/beta-catenin signaling pathway|oncogenesis|56|4|87

----- Citation 16091875 -----
16091875.ab.14 CONCLUSIONS: Pre-emptive therapy with oral valganciclovir for CMV infections detected by PCR in either plasma or bronchoalveolar lavage after lung transplantation seems to be efficacious and safe.


16091875.ab.14|relation|C0087111|Therapeutic procedure|topp|topp|||USES|C0909381|valganciclovir|orch,phsu|phsu|||PREP|with|therapy|valganciclovir|32|25|43|UMLS_CONC_REPLACE_SUBJ
16091875.ab.14|relation|C0087111|Therapeutic procedure|topp|topp|||TREATS|C0010823|Cytomegalovirus Infections|dsyn|dsyn|||PREP|for|therapy|CMV infections|57|25|62|UMLS_CONC_REPLACE_SUBJ
16091875.ab.14|relation|C0909381|valganciclovir|orch,phsu|phsu|||TREATS(INFER)|C0010823|Cytomegalovirus Infections|dsyn|dsyn|||INFER||valganciclovir|CMV infections||43|62
16091875.ab.14|relation|C0032520|Polymerase Chain Reaction|lbpr,mbrt|lbpr|||DIAGNOSES|C0010823|Cytomegalovirus Infections|dsyn|dsyn|||PART|detected|PCR|CMV infections|77|89|62
16091875.ab.14|relation|C0024128|Lung Transplantation|topp|topp|||PRECEDES|C1535502|Bronchoalveolar Lavage|diap,topp|topp|||PREP|after|lung transplantation|bronchoalveolar lavage|135|142|113

----- Citation 16097204 -----
16097204.ab.6 Only 89% of the patients reported complete compliance with the prescription.



----- Citation 16100526 -----
16100526.ab.2 Veratridine depolarises neurons consequently causing epithelial anion secretion across mouse colon mucosa.


16100526.ab.2|relation|C0042525|Veratridine|bacs,orch,phsu|bacs|||CAUSES|C0036536|Process of secretion|biof|biof|||VERB|causing|Veratridine|secretion|45|0|70|DYSONYM,UMLS_CONC_REPLACE_OBJ,NON_SEMNET_RELATION,GERUND_INDICATOR
16100526.ab.2|relation|C0042525|Veratridine|bacs,orch,phsu|bacs|||AFFECTS|C0027882|Neurons|cell|cell|||VERB|depolarises|Veratridine|neurons|12|0|24|NO_INDICATOR_RULE
16100526.ab.2|relation|C0227349|Colonic mucous membrane|bpoc|bpoc|||LOCATION_OF|C0036536|Process of secretion|biof|biof|||PREP|across|colon mucosa|secretion|79|93|70|NON_SEMNET_RELATION,DYSONYM,UMLS_CONC_REPLACE_OBJ,NON_INDICATOR_RULE
16100526.ab.2|relation|C0227349|Colonic mucous membrane|bpoc|bpoc|||PART_OF|C0025929|Laboratory mice|mamm|mamm|||MOD/HEAD||colon mucosa|mouse||93|87|UMLS_CONC_REPLACE_OBJ 


16100526.ab.12 The enhanced veratridine response observed in +/+ tissue following BIIE0246, indicates that Y(2) receptors are located on submucosal neurons and that their activation by NPY will inhibit enteric noncholinergic secretory neurotransmission.


16100526.ab.12|relation|C0382066|neuropeptide Y2 receptor|aapp,rcpt|aapp|||DISRUPTS|C0678903|Neuronal Transmission|celf|celf|||VERB|inhibit|NPY|neurotransmission|179|170|220|UMLS_CONC_REPLACE_SUBJ
16100526.ab.12|relation|C0027893|neuropeptide Y|aapp,gngm,nsba|aapp|4852|NPY|STIMULATES|C0382066|neuropeptide Y2 receptor|aapp,rcpt|aapp|||NOM|activation|NPY|Y(2) receptors|156|170|92|UMLS_CONC_REPLACE_OBJ
16100526.ab.12|relation|C0027882|Neurons|cell|cell|||LOCATION_OF|C0382066|neuropeptide Y2 receptor|aapp,rcpt|aapp|||VERB|located|neurons|Y(2) receptors|111|133|92|UMLS_CONC_REPLACE_OBJ
16100526.ab.12|relation|C0027882|Neurons|cell|cell|||PART_OF|C0225344|Tunica submucosa|tisu|tisu|||MOD/HEAD||neurons|submucosal||133|122|DYSONYM,NEW_UMLS_CONC_OBJ
16100526.ab.12|relation|C0042525|Veratridine|bacs,orch,phsu|phsu|||AFFECTS|C0040300|Body tissue|tisu|tisu|||NOM|response|veratridine|tissue|25|13|50|DYSONYM,NEW_UMLS_CONC_OBJ

----- Citation 16101536 -----
16101536.ab.7 Although the medical management of SLE is not sufficient to warrant long-term survival of young patients, recent progress in anti-cytokine biologics therapy against rheumatoid arthritis (RA) has facilitated searching for the molecular targets of SLE.


16101536.ab.7|relation|C0281178|anti-cytokine therapy|topp|topp|||TREATS|C0003873|Rheumatoid Arthritis|dsyn|dsyn|||PREP|against|anti-cytokine biologics therapy|rheumatoid arthritis|156|125|165

16101536.ab.8 In this report, we briefly review the molecular basis of SLE pathogenesis, and discuss possible therapeutic targets in this disease, focusing particularly on signal transduction and adhesion molecules in T cells.


16101536.ab.8|relation|C0039194|T-Lymphocyte|cell|cell|||LOCATION_OF|C0007578|Cell Adhesion Molecules|aapp,gngm,bacs|aapp|||PREP|in|T cells|adhesion molecules|200|204|182

----- Citation 16102747 -----
16102747.ab.6 It is concluded that the mGlu5 receptor antagonist MPEP potently inhibits transient lower esophageal sphincter relaxations and that the mGlu5 receptor is a potential target for treatment of gastroesophageal reflux disease.


16102747.ab.6|relation|C0909109|2-methyl-6-(phenylethynyl)pyridine|orch,phsu|phsu|||ISA|C0242910|Excitatory Amino Acid Antagonists|phsu|phsu|||SPEC||MPEP|mGlu5 receptor antagonist||51|25|UMLS_CONC_REPLACE_SUBJ, UMLS_CONC_REPLACE_OBJ
16102747.ab.6|relation|C0242910|Excitatory Amino Acid Antagonists|phsu|phsu|||DISRUPTS|C0232482|Chalasia|ortf|ortf|||VERB|inhibits|mGlu5 receptor antagonist|sphincter relaxation|65|25|101|UMLS_CONC_REPLACE_SUBJ, UMLS_CONC_REPLACE_OBJ
16102747.ab.6|relation|C0014876|Esophagus|bpoc|bpoc|||LOCATION_OF|C0232482|Chalasia|ortf|ortf|||MOD/HEAD||esophageal|sphincter relaxation||90|101|UMLS_CONC_REPLACE_SUBJ, UMLS_CONC_REPLACE_OBJ
16102747.ab.6|relation|C0909109|2-methyl-6-(phenylethynyl)pyridine|orch,phsu|phsu|||DISRUPTS(SPEC)|C0232482|Chalasia|ortf|ortf|||INFER||MPEP|sphincter relaxation||51|101|UMLS_CONC_REPLACE_SUBJ, UMLS_CONC_REPLACE_OBJ

----- Citation 16105135 -----
16105135.ti.1 Elevated plasma homocysteine concentrations as a predictor of steatohepatitis in patients with non-alcoholic fatty liver disease.


16105135.ti.1|relation|C0400966|Non-alcoholic fatty liver|dsyn|dsyn|||ISA|C0012634|Disease|dsyn|dsyn|||SPEC||non-alcoholic fatty liver|disease||95|121
16105135.ti.1|relation|C2711227|Steatohepatitis|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|in|steatohepatitis|patients|77|62|81|NEWER_UMLS_CONC_SUBJ
16105135.ti.1|relation|C0012634|Disease|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|disease|patients|89|121|81
16105135.ti.1|relation|C0400966|Non-alcoholic fatty liver|dsyn|dsyn|||PROCESS_OF(SPEC)|C0030705|Patients|podg,humn|humn|||INFER||non-alcoholic fatty liver|patients||95|81
16105135.ti.1|relation|C0019879|Homocystine|aapp,bacs|aapp|||PREDISPOSES|C2711227|Steatohepatitis|dsyn|dsyn|||NOM|predictor|homocysteine|steatohepatitis|49|16|62|NEWER_UMLS_CONC_OBJ

16105135.ab.1 BACKGROUND: Although steatosis is common in patients with severe hyperhomocysteinemia due to deficiency of cystathionine beta-synthase, there are no satisfactory data on homocysteine concentrations in patients with non-alcoholic fatty liver disease.


16105135.ab.1|relation|C0400966|Non-alcoholic fatty liver|dsyn|dsyn|||ISA|C0012634|Disease|dsyn|dsyn|||SPEC||non-alcoholic fatty liver|disease||215|241
16105135.ab.1|relation|C0012634|Disease|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|disease|patients|209|241|201
16105135.ab.1|relation|C0400966|Non-alcoholic fatty liver|dsyn|dsyn|||PROCESS_OF(SPEC)|C0030705|Patients|podg,humn|humn|||INFER||non-alcoholic fatty liver|patients||215|201
16105135.ab.1|relation|C0152254|Fatty degeneration|patf|patf|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|in|steatosis|patients|40|21|44
16105135.ab.1|relation|C0598608|Hyperhomocysteinemia|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|hyperhomocysteinemia|patients|52|65|44
16105135.ab.1|relation|C0010641|Cystathionine beta-Synthase|aapp,enzy|aapp|||CAUSES|C0598608|Hyperhomocysteinemia|dsyn|dsyn|||COMPLEX|due to|cystathionine beta-synthase|hyperhomocysteinemia|86|107|65
16105135.ab.1|relation|C0019879|Homocystine|aapp,bacs|aapp|||PART_OF|C0030705|Patients|podg,humn|humn|||PREP|in|homocysteine|patients|197|170|201

16105135.ab.4 Homocysteine levels were measured by high-performance liquid chromatography.



16105135.ab.5 Insulin, folate, vitamin B(12) and lipoprotein levels were also determined in all groups.



16105135.ab.11 CONCLUSIONS: The plasma homocysteine concentrations were significantly higher in patients with non-alcoholic fatty liver disease, while the concentrations were not affected by chronic viral hepatitis.


16105135.ab.11|relation|C0400966|Non-alcoholic fatty liver|dsyn|dsyn|||ISA|C0012634|Disease|dsyn|dsyn|||SPEC||non-alcoholic fatty liver|disease||95|121
16105135.ab.11|relation|C0030705|Patients|podg,humn|humn|||LOCATION_OF|C0019879|Homocystine|aapp,gngm,bacs|aapp|||PREP|in|patients|homocysteine|77|81|24
16105135.ab.11|relation|C0012634|Disease|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|disease|patients|89|121|81
16105135.ab.11|relation|C0400966|Non-alcoholic fatty liver|dsyn|dsyn|||PROCESS_OF(SPEC)|C0030705|Patients|podg,humn|humn|||INFER||non-alcoholic fatty liver|patients||95|81

----- Citation 16109053 -----
16109053.ti.1 An introduction to the basic principles of health economics for those involved in the development and delivery of headache care.



----- Citation 16109976 -----
16109976.ab.2 In preterm lambs, intraamniotic endotoxin and interleukin 1 (IL-1) induce lung inflammation followed by lung maturation.


16109976.ab.2|relation|C0021755|Interleukin-1|aapp,gngm,imft|aapp|||CAUSES|C0032285|Pneumonia|dsyn|dsyn|||VERB|induce|interleukin 1|lung inflammation|67|46|74
16109976.ab.2|relation|C0014264|Endotoxins|carb,hops,lipd|carb|||CAUSES|C0032285|Pneumonia|dsyn|dsyn|||VERB|induce|endotoxin|lung inflammation|67|32|74
16109976.ab.2|relation|C0032285|Pneumonia|dsyn|dsyn|||PROCESS_OF|C1123019|Domestic Sheep|mamm|mamm|||PREP|In|lung inflammation|lambs|0|74|11
16109976.ab.2|relation|C1254042|Anatomical maturation|phsf|phsf|||PROCESS_OF|C1123019|Domestic Sheep|mamm|mamm|||PREP|In|maturation|lambs|0|109|11|DYSONYM,NEW_UMLS_CONC_SUBJ
16109976.ab.2|relation|C1254042|Anatomical maturation|phsf|phsf|||AFFECTS|C0024109|Lung|bpoc|bpoc|||MOD/HEAD||maturation|lung||109|104|NO_INDICATOR_RULE,NON_SEMNET_RELATION,DYSONYM,NEW_UMLS_CONC_SUBJ
16109976.ab.2|relation|C0032285|Pneumonia|dsyn|dsyn|||PRECEDES|C1254042|Anatomical maturation|phsf|phsf|||PART|followed|lung inflammation|maturation|92|74|109|NON_SEMNET_RELATION,DYSONYM,NEW_UMLS_CONC_OBJ

16109976.ab.4 METHODS: Lung inflammation was induced by intraamniotic injection of endotoxin or IL-1.


16109976.ab.4|relation|C1533685|Injection procedure|topp|topp|||CAUSES|C0032285|Pneumonia|dsyn|dsyn|||VERB|induced|injection|Lung inflammation|31|56|9
16109976.ab.4|relation|C1533685|Injection procedure|topp|topp|||USES|C0014264|Endotoxins|carb,hops,lipd|carb|||PREP|of|injection|endotoxin|65|56|69|NON_SEMNET_RELATION
16109976.ab.4|relation|C1533685|Injection procedure|topp|topp|||USES|C0021755|Interleukin-1|aapp,imft|aapp|||PREP|of|injection|IL-1|65|56|82|NON_SEMNET_RELATION

----- Citation 16111865 -----
16111865.ab.1 Spam emails are considered as a serious privacy-related violation, besides being a costly, unsolicited communication.



----- Citation 16119618 -----
16119618.ab.2 MATERIAL AND METHODS: Twenty-one channel EEG of 21 patients with Down syndrome and 21 normal children, with ages ranging from 1 to 8 years, were submitted to quantitative analysis EEG of discharge-free epochs.


16119618.ab.2|relation|C0013080|Down Syndrome|cgab,dsyn|cgab|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|Down syndrome|patients|59|65|51
16119618.ab.2|relation|C1527380|Electroencephalogram|diap|diap|||ADMINISTERED_TO|C0030705|Patients|podg,humn|humn|||PREP|of|EEG|patients|44|41|51|NO_INDICATOR_RULE
16119618.ab.2|relation|C1527380|Electroencephalogram|diap|diap|||ADMINISTERED_TO|C0008059|Child|aggp,inpr,humn|humn|||PREP|of|EEG|children|44|41|93|NO_INDICATOR_RULE

----- Citation 16121636 -----
16121636.ab.3 The various variables analyzed were number of megakaryocytes and micromegakaryocytes, area, perimeter and diameter of the megakaryocytic elements.



----- Citation 16126188 -----
16126188.ab.2 In earlier studies, detection of circulating DNA has been investigated for the detection of various forms of cancer.


16126188.ab.4 In the case of pregnancies, detection of fetal DNA in maternal plasma is a useful tool for detecting and monitoring certain fetal diseases and pregnancy-associated complications.


16126188.ab.4|relation|C0032105|Plasma|bdsu|bdsu|||PART_OF|C0026591|Mothers|famg,humn|humn|||MOD/HEAD||plasma|maternal||63|54|NON_SEMNET_RELATION
16126188.ab.4|relation|C0032105|Plasma|bdsu|bdsu|||LOCATION_OF|C0012854|DNA|bacs,nnon|bacs|||PREP|in|plasma|DNA|50|63|47|NON_SEMNET_RELATION
16126188.ab.4|relation|C1511790|Detection|topp|topp|||DIAGNOSES|C0015929|Fetal Diseases|dsyn|dsyn|||VERB|detecting|detection|fetal diseases|91|28|124|GERUND_INDICATOR
16126188.ab.4|relation|C1511790|Detection|topp|topp|||DIAGNOSES|C0032962|Pregnancy Complications|dsyn|dsyn|||VERB|detecting|detection|pregnancy-associated complications|91|28|143|GERUND_INDICATOR
16126188.ab.4|relation|C0012854|DNA|bacs,nnon|bacs|||PART_OF|C0015965|Fetus|emst|emst|||MOD/HEAD||DNA|fetal||47|41|UMLS_CONC_REPLACE_OBJ

----- Citation 16138263 -----
16138263.ab.5 Male Wistar rats were treated with L-thyroxin (25 microg/100 g, sc, od) for fourteen days, while normal rats served as controls.


16138263.ab.5|relation|C0040165|Thyroxine|aapp,horm,phsu|aapp|||TREATS|C0034716|Rats, Wistar|mamm|mamm|||VERB|treated|L-thyroxin|Wistar rats|22|35|5

----- Citation 16141404 -----
16141404.ab.6 As shown by real-time quantitative reverse-transcription polymerase chain reaction (RT-PCR), EPC stimulation by SFLLRN significantly enhanced the mRNA expression of SDF-1 and its receptor CXCR-4.


16141404.ab.6|relation|C0219419|thrombin receptor peptide (42-47)|aapp|aapp|||AUGMENTS|C0038250|Stem cells|cell|cell|||NOM|stimulation|SFLLRN|EPC|97|112|93
16141404.ab.6|relation|C0219419|thrombin receptor peptide (42-47)|aapp|aapp|||STIMULATES|C0250501|CXCR4 Receptors|rcpt,aapp,imft|rcpt|||VERB|enhanced|SFLLRN|receptor CXCR-4|133|112|179|NEWER_UMLS_CONC_OBJ, COORDINATION
16141404.ab.6|relation|C0219419|thrombin receptor peptide (42-47)|aapp|aapp|||STIMULATES|C0218504|Stromal Cell-Derived Factor 1|aapp,imft|aapp|||VERB|enhanced|SFLLRN|SDF-1|133|112|165


16141404.ab.8 PAR-1 stimulation by SFLLRN also increased the formation of capillary-like structures by EPC in Matrigel, and this effect was abrogated by anti-CXCR-4, anti-SDF-1, and MEK inhibitor pretreatment.


16141404.ab.8|relation|C0219419|thrombin receptor peptide (42-47)|aapp|aapp|||STIMULATES|C1366449|F2R gene|gngm|gngm|2149|F2R|NOM|stimulation|SFLLRN|PAR-1|6|21|0|NEW_UMLS_CONC_OBJ

16141404.ab.9 CONCLUSIONS: Human EPCs express functional PAR-1.


16141404.ab.9|relation|C0038250|Stem cells|cell|cell|||PRODUCES|C0668084|Receptor, PAR-1|aapp,rcpt|aapp|||VERB|express|EPCs|PAR-1|24|19|43|UMLS_CONC_REPLACE_OBJ
16141404.ab.9|relation|C0038250|Stem cells|cell|cell|||PART_OF|C0086418|Homo sapiens|humn|humn|||MOD/HEAD||EPCs|Human||19|13
16141404.ab.9|relation|C0014257|Endothelium|tisu|tisu|||LOCATION_OF|C0038250|Stem cells|cell|cell|||MOD/HEAD||EPCs|EPCs||19|19|NEW_UMLS_CONC_SUBJ

----- Citation 16144778 -----
16144778.ab.8 Results indicate that the cardio-respiratory depression evoked by anandamide administered via the peripheral circulation requires intact supranodose vagi.


16144778.ab.8|relation|C0211726|anandamide|bacs,eico|bacs|||CAUSES|C0235063|Respiratory Depression|patf|patf|||VERB|evoked|anandamide|respiratory depression|56|66|33

----- Citation 16146326 -----
16146326.ab.1 BACKGROUND AND PURPOSE: To describe the timings and ranges of linear displacements of the pelvis and feet occurring in a healthy older population when stepping up onto a step, and to describe variations noted in a small sample of subjects with hemiplegia.


16146326.ab.1|relation|C0018991|Hemiplegia|sosy|sosy|||PROCESS_OF|C0681850|Study Subject|grup,humn|humn|||PREP|with|hemiplegia|subjects|238|244|230|NEWER_UMLS_CONC_OBJ


----- Citation 16149149 -----
16149149.ti.1 Effect of Gui Zhi decoction on enteric mucosal immune in mice with collagen-induced arthritis.


16149149.ti.1|relation|C0971858|Arthritis, Collagen-Induced|emod|emod|||PROCESS_OF|C0026809|Mus|mamm|mamm|||PREP|with|collagen-induced arthritis|mice|61|67|57
16149149.ti.1|relation|C0282557|Immune Response, Mucosal|ortf|ortf|||PROCESS_OF|C0026809|Mus|mamm|mamm|||PREP|in|enteric mucosal immune|mice|53|31|57|NEED_TO_ALLOW_PROCESS_OF_FOR_FUNCTIONS
16149149.ti.1|relation|C2353543|guizhi decoction|bacs|bacs|||AFFECTS|C0282557|Immune Response, Mucosal|ortf|ortf|||NOM|Effect|Gui Zhi decoction|enteric mucosal immune|0|10|31|NEW_UMLS_CONC_SUBJ, UMLS_CONC_REPLACE_OBJ, DYSONYM

----- Citation 16154523 -----
16154523.ti.1 Simultaneous enantioselective determination of amphetamine and congeners in hair specimens by negative chemical ionization gas chromatography-mass spectrometry.


16154523.ti.1|relation|C0444095|Hair Specimen|bpoc|bpoc|||LOCATION_OF|C0002658|Amphetamine|nsba,orch,phsu|orch|||PREP|in|hair specimens|amphetamine|72|76|47
16154523.ti.1|relation|C0444095|Hair Specimen|bpoc|bpoc|||LOCATION_OF|C0678518|congener|chvs|chvs|||PREP|in|hair specimens|congeners|72|76|63

16154523.ab.6 Intra- and inter-assay precision and respective accuracy were acceptable.



16154523.ab.7 The enantiomeric ratios (R versus S) of AM, MA, MDA, MDMA and MDEA were determined in hair from suspected amphetamine abusers.


16154523.ab.7|relation|C0018494|hair|bpoc|bpoc|||LOCATION_OF|C0946224|METHYLENEDIOXYETHYLAMPHETAMINE|orch|orch|||PREP|in|hair|MDEA|82|86|62
16154523.ab.7|relation|C0018494|hair|bpoc|bpoc|||LOCATION_OF|C0115471|Ecstasy - drug|hops,orch,phsu|orch|||PREP|in|hair|MDMA|82|86|53
16154523.ab.7|relation|C0018494|hair|bpoc|bpoc|||LOCATION_OF|C0002658|Amphetamine|nsba,orch,phsu|orch|||PREP|in|hair|AM|82|86|40
16154523.ab.7|relation|C0018494|hair|bpoc|bpoc|||LOCATION_OF|C0025611|Methamphetamine|hops,orch,phsu|orch|||PREP|in|hair|MA|82|86|44
16154523.ab.7|relation|C0018494|hair|bpoc|bpoc|||LOCATION_OF|C0000379|3,4-Methylenedioxyamphetamine|orch,phsu|orch|||PREP|in|hair|MDA|82|86|48
16154523.ab.7|relation|C0018494|hair|bpoc|bpoc|||PART_OF|C0338666|Drug abuser|podg,humn|humn|||PREP|from|hair|abusers|90|86|118|NEWER_UMLS_CONC_OBJ

----- Citation 16160007 -----
16160007.ti.1 Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation.


16160007.ti.1|relation|C0599155|Mutation, Missense|genf|genf|||AFFECTS|C1413036|ADAMTS13 gene|gngm,aapp|gngm|11093|ADAMTS13|NOM|Modulation|missense mutation|ADAMTS13|0|113|14|NEW_UMLS_CONC_OBJ
16160007.ti.1|relation|C0032529|Polymorphism, Genetic|genf|genf|||AFFECTS|C1413036|ADAMTS13 gene|gngm,aapp|gngm|11093|ADAMTS13|NOM|Modulation|polymorphisms|ADAMTS13|0|93|14|NEW_UMLS_CONC_OBJ
16160007.ti.1|relation|C0032529|Polymorphism, Genetic|genf|genf|||AFFECTS|C0002520|Amino Acids|aapp,bacs,phsu|aapp|||MOD/HEAD||polymorphisms|amino acid||93|82|NO_INDICATOR_RULE,NON_SEMNET_RELATION

16160007.ab.1 Sequence analysis of the ADAMTS13 locus of 2 patients with hereditary thrombotic thrombocytopenic purpura (TTP) revealed the homozygous presence of 4 single nucleotide polymorphisms (SNPs) (R7W, Q448E, P618A, A732V) and a rare missense mutation (R1336W).


16160007.ab.1|relation|C0034155|Purpura, Thrombotic Thrombocytopenic|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|thrombotic thrombocytopenic purpura|patients|53|70|45
16160007.ab.1|relation|C1413036|ADAMTS13 gene|gngm,aapp|gngm|11093|ADAMTS13|PART_OF|C0030705|Patients|podg,humn|humn|||PREP|of|ADAMTS13|patients|39|25|45|NEW_UMLS_CONC_SUBJ
16160007.ab.1|relation|C0162801|Sequence Analysis|lbpr,mbrt|lbpr|||DIAGNOSES|C1705737|Missense Mutation Abnormality|comd|comd|||VERB|revealed|Sequence analysis|rare missense mutation (R1336W)|112|0|222|NON_SEMNET_RELATION_WITH_mbrt, NEWER_UMLS_CONC_OBJ

----- Citation 16160855 -----
16160855.ab.2 Denervation was performed by cutting the sciatic nerve.


16160855.ab.2|relation|C0152060|Transection (procedure)|topp|topp|||METHOD_OF|C0011307|Denervation|topp|topp|||PREP|by|cutting|Denervation|25|29|0

----- Citation 16167756 -----
16167756.ab.8 CONCLUSIONS: Manifestations of SS disease differ in malarial areas and it is questionable whether interventions developed in non-malarial areas apply.


16167756.ab.8|relation|C0086981|C0002895|Sickle Cell Anemia|dsyn|dsyn|||ISA|C0012634|Disease|dsyn|dsyn|||SPEC||SS|disease||31|34

----- Citation 16167981 -----
16167981.ab.2 Grey shows an autosomal dominant inheritance and the locus has previously been mapped to horse chromosome 25 (ECA25), around the TXN gene.

16167981.ab.2|relation|C0008633|Chromosomes|celc|celc|||PART_OF|C0242616|Equidae|mamm|mamm|||MOD/HEAD||chromosome 25 (ECA25)|horse||95|89
16167981.ab.2|relation|C1708726|Locus|gngm|gngm|||PART_OF|C0008633|Chromosomes|celc|celc|||VERB|mapped|locus|horse chromosome 25 (ECA25)|79|53|89|NEWER_UMLS_CONC_SUBJ

----- Citation 16172203 -----
16172203.ab.1 BACKGROUND: The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agents has been incompletely addressed, though newer agents are currently used far more commonly.


16172203.ab.1|relation|C0040615|Antipsychotic Agents|phsu|phsu|||compared_with|C0450442|Agent|chvf|chvf|||PART|compared|antipsychotic drugs|agents|94|71|122

16172203.ab.8 The times to discontinuation because of intolerable side effects were similar among the groups, but the rates differed (P=0.04); olanzapine was associated with more discontinuation for weight gain or metabolic effects, and perphenazine was associated with more discontinuation for extrapyramidal effects.



----- Citation 16172797 -----
16172797.ti.1 High grade primary breast lymphoma: is it a different clinical entity?


16172797.ti.1|relation|C0024299|Lymphoma|neop|neop|||PART_OF|C0006141|Breast|bpoc|bpoc|||MOD/HEAD||High grade primary breast lymphoma|breast||0|19

16172797.ab.1 Primary lymphoma of the breast (PBL) is a rare neoplasm, its outcome remains unclear compared to other lymphomas.


16172797.ab.1|relation|C0024299|Lymphoma|neop|neop|||ISA|C0027651|Neoplasm|neop|neop|||SPEC|is|lymphoma|neoplasm|37|8|47
16172797.ab.1|relation|C0024299|Lymphoma|neop|neop|||PART_OF|C0006141|Breast|bpoc|bpoc|||PREP|of|lymphoma|breast|16|8|24


----- Citation 16173158 -----
16173158.ab.1 This issue contains peer-reviewed papers from a workshop on Closed Ecological Systems: Earth and Space Applications at the 35th COSPAR General Assembly in Paris, France, convened in July 2004.


----- Citation 16176149 -----
16176149.ab.9 In conclusion, the AM extract produced a very weak effect on the prevention of bone loss induced by OVX and Ca deficiency in rats, but was similar to the results observed with alendronate.


16176149.ab.9|relation|C0392519|Calcium deficiency|dsyn|dsyn|||CAUSES|C0599877|loss; bone|patf|patf|||PART|induced|Ca deficiency|bone loss|89|108|79
16176149.ab.9|relation|C0029936|Ovariectomy|topp|topp|||CAUSES|C0599877|loss; bone|patf|patf|||PART|induced|OVX|bone loss|89|100|79|NON_SEMNET_RELATION
16176149.ab.9|relation|C0392519|Calcium deficiency|dsyn|dsyn|||PROCESS_OF|C0034721|Rattus|mamm|mamm|||PREP|in|Ca deficiency|rats|121|108|125
16176149.ab.9|relation|C0029936|Ovariectomy|topp|topp|||ADMINISTERED_TO|C0034721|Rattus|mamm|mamm|||PREP|in|OVX|rats|121|100|125|NON_SEMNET_RELATION
16176149.ab.9|relation|C2828366|Extract (substance)|sbst|sbst|||PREVENTS|C0599877|loss; bone|patf|patf|||NOM|prevention|extract|bone loss|65|22|79|NEWER_UMLS_CONC_SUBJ

----- Citation 16177843 -----
16177843.ti.1 Prevalence and diagnosis of schizophrenia based on register, case record and interview data in an isolated Finnish birth cohort born 1940-1969.


16177843.ti.1|relation|C0036341|Schizophrenia|mobd|mobd|||OCCURS_IN|C0599755|cohort|popg,humn|humn|||PREP|in|schizophrenia|cohort|91|28|121

16177843.ab.5 The corresponding birth cohort of 14,817 persons and 12,368 alive in 1998 was identified from the National Population Register.



16177843.ab.6 We validated 69% of the register diagnosis by making DSM-IV consensus diagnoses, and interviewed 131 (55%) of the 237 patients with SCID-I and SCID-II.



16177843.ab.7 RESULTS: The register-based lifetime prevalence was 1.5% for schizophrenia and 1.9% for schizophrenia spectrum psychotic disorders: in birth cohorts born 1945 to 1959, the latter prevalence was especially high (2.4%).


16177843.ab.7|relation|C0036341|Schizophrenia|mobd|mobd|||ISA|C0033975|Psychotic Disorders|mobd|mobd|||SPEC||schizophrenia|psychotic disorders||88|111
16177843.ab.7|relation|C0033975|Psychotic Disorders|mobd|mobd|||OCCURS_IN|C0599755|cohort|popg,humn|humn|||NOM|prevalence|psychotic disorders|cohort|179|111|141|ANAPHORA

----- Citation 16181881 -----
16181881.ab.1 BACKGROUND: Off-pump, closed, beating heart, minimally-invasive surgery in patients with lone atrial fibrillation (AF) must be effective to become the preferred alternative to catheter ablation.


16181881.ab.1|relation|C0340489|Lone atrial fibrillation|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|lone atrial fibrillation|patients|83|89|75
16181881.ab.1|relation|C0543467|Operative Surgical Procedures|topp|topp|||TREATS|C0030705|Patients|podg,humn|humn|||PREP|in|surgery|patients|71|64|75|UMLS_CONC_REPLACE_SUBJ
16181881.ab.1|relation|C0543467|Operative Surgical Procedures|topp|topp|||TREATS(INFER)|C0340489|Lone atrial fibrillation|dsyn|dsyn|||INFER||surgery|lone atrial fibrillation||64|89|UMLS_CONC_REPLACE_SUBJ

----- Citation 16182253 -----
16182253.ab.1 Several nuclear and cytoplasmic proteins in metazoans are modified by O-linked N-acetylglucosamine (O-GlcNAc).


16182253.ab.1|relation|C1333198|Cytoplasmic Protein|aapp,bacs|aapp|||PART_OF|C0320223|Metazoa|invt|invt|||PREP|in|cytoplasmic protein|metazoans|40|20|44|NEW_UMLS_CONC_OBJ
16182253.ab.1|relation|C0949374|Nuclear Protein|aapp,bacs|aapp|||PART_OF|C0320223|Metazoa|invt|invt|||PREP|in|nuclear|metazoans|40|8|44|UMLS_CONC_REPLACE_SUBJ,NEW_UMLS_CONC_OBJ,COORDINATION
16182253.ab.1|relation|C0001056|Acetylglucosamine|bacs,carb|bacs|||INTERACTS_WITH|C1333198|Cytoplasmic Protein|aapp,gngm,bacs|aapp|||VERB|modified|acetylglucosamine|cytoplasmic proteins|58|81|20
16182253.ab.1|relation|C0001056|Acetylglucosamine|bacs,carb|bacs|||INTERACTS_WITH|C0028589|Nuclear Proteins|aapp,bacs|aapp|||VERB|modified|acetylglucosamine|nuclear and cytoplasmic proteins|58|81|8|COORDINATION,ELLIPSIS, NEWER_UMLS_CONC_OBJ

16182253.ab.6 Mutations in the SCA10 gene cause progressive cerebellar ataxias and seizures.


16182253.ab.6|relation|C0026882|Mutation|genf|genf|||CAUSES|C0393525|Progressive cerebellar ataxia|dsyn|dsyn|||VERB|cause|Mutations|progressive cerebellar ataxias|28|0|34|NON_SEMNET_RELATION
16182253.ab.6|relation|C0026882|Mutation|genf|genf|||CAUSES|C0036572|Seizures|sosy|sosy|||VERB|cause|Mutations|seizures|28|0|69|NON_SEMNET_RELATION
16182253.ab.6|relation|C1419829|SCA10 gene|gngm|gngm|||LOCATION_OF|C0026882|Mutation|genf|genf|||PREP|in|SCA10 gene|Mutations|9|17|0|RELATION_BLOCKED_IN_EXCEPTIONS.PL_FILE
16182253.ab.6|relation|C1419829|SCA10 gene|gngm|gngm|25814|ATXN10|CAUSES|C0393525|Progressive cerebellar ataxia|dsyn|dsyn|||VERB|cause|SCA10 gene|progressive cerebellar ataxias|28|17|34|INFERENCE
16182253.ab.6|relation|C1419829|SCA10 gene|gngm|gngm|25814|ATXN10|CAUSES|C0036572|Seizures|sosy|sosy|||VERB|cause|SCA10 gene|seizures|28|17|69|INFERENCE

16182253.ab.7 We demonstrate that SCA10 interacts with OGT in vivo and is modified by O-linked glycosylation in MIN6 cells, suggesting a novel role for the Ataxin-10 protein in pancreatic beta cells.


16182253.ab.7|relation|C0007634|Cells|cell|cell|||LOCATION_OF|C1621325|protein amino acid O-linked glycosylation|moft|moft|||PREP|in|cells|O-linked glycosylation|94|103|72|NEWER_UMLS_CONC_OBJ
16182253.ab.7|relation|C1621325|protein amino acid O-linked glycosylation|moft|moft|||AFFECTS|C1419829|SCA10 gene|gngm|gngm|25814|ATXN10|VERB|modified|O-linked glycosylation|SCA10|60|72|20|NEWER_UMLS_CONC_SUBJ,NON_SEMNET_RELATION
16182253.ab.7|relation|C0030281|Structure of beta Cell of islet|cell|cell|||LOCATION_OF|C1609855|ATXN10 protein, human|aapp,bacs|aapp|25814|ATXN10|PREP|in|pancreatic beta cells|Ataxin-10 protein|159|163|142|UMLS_CONC_REPLACE_SUBJ
16182253.ab.7|relation|C1538308|ATXN10 gene|gngm|gngm|||INTERACTS_WITH|C1121142|O-GlcNAc transferase|aapp,enzy|aapp|||VERB|interacts|SCA10|OGT|26|20|41

----- Citation 16185180 -----
16185180.ab.8 Patients with severe MDRPA infections should be treated with combination therapy, consisting of an antipseudomonal beta-lactam with an aminoglycoside or fluoroquinolone rather than aminoglycoside and fluoroquinolone combinations, to provide adequate therapy and improve patient outcomes.


16185180.ab.8|relation|C0009429|Combined Modality Therapy|topp|topp|||TREATS|C0030705|Patients|podg,humn|humn|||VERB|treated|combination therapy|Patients|48|61|0|NEW_UMLS_CONC_SUBJ,WSD
16185180.ab.8|relation|C0854135|Pseudomonas aeruginosa infection NOS|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|MDRPA|Patients|8|21|0
16185180.ab.8|relation|C0009429|Combined Modality Therapy|topp|topp|||TREATS(INFER)|C0854135|Pseudomonas aeruginosa infection NOS|dsyn|dsyn|||INFER||combination therapy|MDRPA||61|21|NEW_UMLS_CONC_SUBJ,WSD
16185180.ab.8|relation|C0009429|Combined Modality Therapy|topp|topp|||USES|C0282215|beta-Lactams|antb,orch|antb|||VERB|consisting|combination therapy|beta-lactam|82|61|115|NO_INDICATOR_RULE,GERUND_INDICATOR,NEW_UMLS_CONC_SUBJ,WSD
16185180.ab.8|relation|C0009429|Combined Modality Therapy|topp|topp|||USES|C0002556|Aminoglycosides|carb,phsu|phsu|||VERB|consisting|combination therapy|aminoglycoside|82|61|135|NO_INDICATOR_RULE,GERUND_INDICATOR,NEW_UMLS_CONC_SUBJ,WSD
16185180.ab.8|relation|C0009429|Combined Modality Therapy|topp|topp|||USES|C0949665|Fluoroquinolones|orch,phsu|phsu|||VERB|consisting|combination therapy|fluoroquinolone|82|61|153|NO_INDICATOR_RULE,GERUND_INDICATOR,NEW_UMLS_CONC_SUBJ,WSD

16185180.ab.9 Synergy has been observed when resistant antipseudomonal drugs were combined in vitro against MDRPA with successful clinical application reported in two centers.



----- Citation 16185321 -----
16185321.ab.1 Killer cell immunoglobulin-like receptors (KIRs) belong to a diverse family of natural killer (NK) cell receptors recognizing human leukocyte antigen (HLA) class I molecules.


16185321.ab.1|relation|C0665952|killer inhibitory receptor|aapp,rcpt|aapp|||INTERACTS_WITH|C0019721|HLA Antigens|aapp,imft|aapp|||INFER||Killer cell immunoglobulin-like receptors|human leukocyte antigen||0|126|UMLS_CONC_REPLACE_SUBJ

----- Citation 16194167 -----
16194167.ti.1 Can transthoracic echocardiography with subcostal view predict abdominal aortic atherosclerosis?


16194167.ti.1|relation|C0430462|Transthoracic echocardiography|diap|diap|||DIAGNOSES|C0398356|Abdominal aortic atherosclerosis|dsyn|dsyn|||VERB|predict|transthoracic echocardiography|abdominal aortic atherosclerosis|55|4|63

16194167.ab.2 During transthoracic echocardiography (TTE), subcostal views may suggest abdominal (ABD) aortic (AO) ATH, but this diagnosis may be inaccurate due to suboptimal images, which may in part relate to use of nonlinear probes.



16194167.ab.10 TTE correlated with TEE grading with an r = 0.42 (P = 0.0001) for patients (n = 75) with adequate TTE and r = 0.32 (P = 0.001) for all patients (n = 100), including those with suboptimal TTE images.


16194167.ab.10|relation|C0430462|Transthoracic echocardiography|diap|diap|||ADMINISTERED_TO|C0030705|Patients|podg,humn|humn|||PREP|with|TTE|patients|83|98|66
16194167.ab.10|relation|C0430462|Transthoracic echocardiography|diap|diap|||ADMINISTERED_TO|C0030705|Patients|podg,humn|humn|||PREP|with|TTE|patients|170|187|135|ANAPHORA
16194167.ab.10|relation|C0430462|Transthoracic echocardiography|diap|diap|||ISA|C0025086|Medical Imaging|diap|diap|||SPEC||TTE|images||187|191

----- Citation 16194666 -----
16194666.ab.6 These findings suggest that, in this study area, arsenic concentrations in most wells remain stable over time and a limited number of measurements per well can be used to predict arsenic exposures over a period of many years.



----- Citation 16197815 -----
16197815.ab.4 METHODS: Nine patients with ALS were randomly assigned to receive either a high dose (3 microg/kg of body weight) or low dose (0.5 microg/kg of body weight) of IGF-1 every 2 weeks for 40 weeks.


16197815.ab.4|relation|C0002736|Amyotrophic Lateral Sclerosis|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|ALS|patients|22|28|14
16197815.ab.4|relation|C0021665|Insulin-Like Growth Factor I|aapp,bacs|aapp|||ADMINISTERED_TO|C0030705|Patients|podg,humn|humn|||VERB|receive|IGF-1|patients|58|160|14

16197815.ab.6 RESULTS: The high-dose treatment slowed a decline of motor functions of the ALS patients in total Norris and limb Norris scales, but not in bulbar Norris or vital capacity.


16197815.ab.6|relation|C0002736|Amyotrophic Lateral Sclerosis|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||ALS|patients||76|80
16197815.ab.6|relation|C0087111|Therapeutic procedure|topp|topp|||AFFECTS|C0234130|Motor function|ftcn|ftcn|||COMPLEX|slowed a decline|treatment|motor functions|33|23|53|WSD,NON_SEMNET_RELATION

----- Citation 16204062 -----
16204062.ab.3 We recently showed that the atypical PKC (aPKC) isozyme PKCiota is overexpressed in human non-small cell lung cancer (NSCLC) cells and that PKCiota plays a critical role in the transformed growth of the human lung adenocarcinoma A549 cell line in vitro and tumorigenicity in vivo.


16204061.ab.3|relation|C0667917|protein kinase C iota|aapp,enzy|aapp|5584|PRKCI|ISA|C0022173|Isoenzymes|aapp,enzy|aapp|||SPEC||PKCiota|isozyme||56|48
16204061.ab.3|relation|C0667917|protein kinase C iota|aapp,enzy|aapp|5584|PRKCI|AFFECTS|C1519697|Tumorigenicity|patf|patf|||NOM|role|PKCiota|tumorigenicity|165|140|257
16204061.ab.3|relation|C0667917|protein kinase C iota|aapp,enzy|aapp|5584|PRKCI|AFFECTS|C0682523|Human Cell Line|cell|cell|||NOM|role|PKCiota|human lung adenocarcinoma A549 cell line|165|140|203
16204061.ab.3|relation|C0682523|Human Cell Line|cell|cell|||LOCATION_OF|C0152013|Adenocarcinoma of lung|neop|neop|||MOD/HEAD||human lung adenocarcinoma A549 cell line|lung adenocarcinoma||203|209|UMLS_CONC_REPLACE_OBJ
16204061.ab.3|relation|C0007634|Cells|cell|cell|||LOCATION_OF|C0007131|Carcinoma, Non-Small-Cell Lung|neop|neop|||MOD/HEAD||cells|non-small cell lung cancer (NSCLC)||125|90|UMLS_CONC_REPLACE_SUBJ,UMLS_CONC_REPLACE_OBJ
16204061.ab.3|relation|C0007634|Cells|cell|cell|||PART_OF|C0086418|Homo sapiens|humn|humn|||MOD/HEAD||cells|human||125|84|UMLS_CONC_REPLACE_SUBJ
16204061.ab.3|relation|C0007131|Carcinoma, Non-Small-Cell Lung|neop|neop|||PROCESS_OF(INFER)|C0086418|Homo sapiens|humn|humn|||INFER||non-small cell lung cancer (NSCLC)|human||90|84|INFERENCE,UMLS_CONC_REPLACE_SUBJ
16204062.ab.3|relation|C0758621|atypical protein kinase C|aapp,enzy|aapp|||ISA|C0022173|Isoenzymes|aapp,enzy|aapp|||SPEC||atypical PKC (aPKC)|isozyme||28|48

16204062.ab.4 Here we provide compelling evidence that PKCiota is an oncogene in NSCLC based on the following criteria: (a) aPKCiota is overexpressed in the vast majority of primary NSCLC tumors; (b) tumor PKCiota expression levels predict poor survival in patients with NSCLC; (c) the PKCiota gene is frequently amplified in established NSCLC cell lines and primary NSCLC tumors; (d) gene amplification drives PKCiota expression in NSCLC cell lines and primary NSCLC tumors; and (e) disruption of PKCiota signaling with a dominant negative PKCiota allele blocks the transformed growth of human NSCLC cells harboring PKCiota gene amplification.


16204062.ab.4|relation|C0667917|protein kinase C iota|aapp,enzy|aapp|5584|PRKCI|ISA|C0029016|Oncogenes|gngm|gngm|||SPEC|is|PKCiota|oncogene|49|41|55
16204062.ab.4|relation|C0029016|Oncogenes|gngm|gngm|||ASSOCIATED_WITH|C0007131|Carcinoma, Non-Small-Cell Lung|neop|neop|||PREP|in|oncogene|NSCLC|63|55|67
16204062.ab.4|relation|C0667917|protein kinase C iota|aapp,enzy|aapp|5584|PRKCI|ASSOCIATED_WITH(SPEC)|C0007131|Carcinoma, Non-Small-Cell Lung|neop|neop|||INFER||PKCiota|NSCLC||41|67
16204062.ab.4|relation|C0027651|Neoplasm|neop|neop|||PRODUCES|C0758621|atypical protein kinase C|aapp,enzy|aapp|||VERB|overexpressed|tumors|aPKCiota|122|174|110|NO_INDICATOR_RULE, NON_SEMNET_RELATION, NEW_UMLS_CONC_OBJ
16204062.ab.4|relation|C0007131|Carcinoma, Non-Small-Cell|neop|neop|||PRODUCES(SPEC)|C0758621|atypical protein kinase C|aapp,enzy|aapp|||INFER||NSCLC|aPKCiota||168|110|NO_INDICATOR_RULE, NON_SEMNET_RELATION, NEW_UMLS_CONC_OBJ
16204062.ab.4|relation|C0007131|Carcinoma, Non-Small-Cell|neop|neop|||ISA|C0027651|Neoplasm|neop|neop|||SPEC||NSCLC|tumors||168|174
16204062.ab.4|relation|C0027651|Neoplasm|neop|neop|||PRODUCES|C0667917|protein kinase C  iota|aapp,enzy|aapp|||NOM|expression|tumor|PKCiota|200|186|192|NEWER_UMLS_CONC_OBJ
16204062.ab.4|relation|C0007131|Carcinoma, Non-Small-Cell Lung|neop|neop|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|NSCLC|patients|251|257|243
16204062.ab.4|relation|C0667917|protein kinase C iota|aapp,enzy|aapp|5584|PRKCI|PART_OF|C0007600|Cell Line|cell|cell|||PREP|in|PKCiota|cell line|308|272|330|UMLS_CONC_REPLACE_OBJ
16204062.ab.4|relation|C0007131|Carcinoma, Non-Small-Cell|neop|neop|||PART_OF|C0007600|Cell Line|cell|cell|||MOD/HEAD||NSCLC|cell lines||324|330|NEW_UMLS_CONC_OBJ
16204062.ab.4|relation|C0007131|Carcinoma, Non-Small-Cell Lung|neop|neop|||ISA|C0027651|Neoplasm|neop|neop|||SPEC||NSCLC|tumors||353|359
16204062.ab.4|relation|C0007600|Cell Line|cell|cell|||LOCATION_OF|C0007131|Carcinoma, Non-Small-Cell Lung|neop|neop|||MOD/HEAD||cell lines|NSCLC||425|419|UMLS_CONC_REPLACE_SUBJ
16204062.ab.4|relation|C0667917|protein kinase C iota|aapp,enzy|aapp|5584|PRKCI|PART_OF|C0027651|Neoplasm|neop|neop|||PREP|in|PKCiota|tumor|415|397|454
16204062.ab.4|relation|C0667917|protein kinase C iota|aapp,enzy|aapp|5584|PRKCI|PART_OF(SPEC)|C0007131|Carcinoma, Non-Small-Cell Lung|neop|neop|||INFER||PKCiota|NSCLC||397|448
16204062.ab.4|relation|C0667917|protein kinase C iota|aapp,enzy|aapp|5584|PRKCI|PART_OF|C0007600|Cell Line|cell|cell|||PREP|in|PKCiota|cell line|415|397|425|UMLS_CONC_REPLACE_OBJ
16204062.ab.4|relation|C0667917|protein kinase C iota|aapp,enzy|aapp|5584|PRKCI|PART_OF|C0027651|Neoplasm|neop|neop|||PREP|in|PKCiota|tumor|415|397|454
16204062.ab.4|relation|C0007131|Carcinoma, Non-Small-Cell Lung|neop|neop|||ISA|C0027651|Neoplasm|neop|neop|||SPEC||NSCLC|tumors||448|454
16204062.ab.4|relation|C0667917|protein kinase C iota|aapp,enzy|aapp|5584|PRKCI|PART_OF(SPEC)|C0007131|Carcinoma, Non-Small-Cell Lung|neop|neop|||INFER||PKCiota|NSCLC||397|448
16204062.ab.4|relation|C0017256|Gene Amplification|genf|genf|||STIMULATES|C0667917|protein kinase C iota|aapp,enzy|aapp|5584|PRKCI|VERB|drives|gene amplification|PKCiota|390|371|397|NON_SEMNET_RELATION,NO_INDICATOR_RULE
16204062.ab.4|relation|C0002085|Alleles|gngm|gngm|||INHIBITS|C0667917|protein kinase C iota|aapp,enzy|aapp|5584|PRKCI|NOM|disruption|allele|PKCiota|470|535|484|NO_INDICATOR_RULE
16204062.ab.4|relation|C0007634|Cells|cell|cell|||LOCATION_OF|C0007131|Carcinoma, Non-Small-Cell Lung|neop|neop|||MOD/HEAD||cells|NSCLC||587|581|UMLS_CONC_REPLACE_SUBJ
16204062.ab.4|relation|C0007634|Cells|cell|cell|||LOCATION_OF|C0017256|Gene Amplification|genf|genf|||VERB|harboring|cells|gene amplification|593|587|611|GERUND_INDICATOR,UMLS_CONC_REPLACE_SUBJ,NON_SEMNET_RELATION,NO_INDICATOR_RULE

----- Citation 16205318 -----
16205318.ti.1 Ipsapirone and ketanserin protects against circulatory shock, intracranial hypertension, and cerebral ischemia during heatstroke.


16205318.ti.1|relation|C0123905|ipsapirone|orch,phsu|phsu|||PREVENTS|C0036974|Shock|patf|patf|||VERB|protects|Ipsapirone|circulatory shock|26|0|43
16205318.ti.1|relation|C0022616|Ketanserin|orch,phsu|phsu|||PREVENTS|C0036974|Shock|patf|patf|||VERB|protects|ketanserin|circulatory shock|26|15|43
16205318.ti.1|relation|C0123905|ipsapirone|orch,phsu|phsu|||PREVENTS|C0151740|Intracranial Hypertension|dsyn|dsyn|||VERB|protects|Ipsapirone|intracranial hypertension|26|0|62
16205318.ti.1|relation|C0022616|Ketanserin|orch,phsu|phsu|||PREVENTS|C0151740|Intracranial Hypertension|dsyn|dsyn|||VERB|protects|ketanserin|intracranial hypertension|26|15|62
16205318.ti.1|relation|C0123905|ipsapirone|orch,phsu|phsu|||PREVENTS|C0917798|Cerebral Ischemia|dsyn|dsyn|||VERB|protects|Ipsapirone|cerebral ischemia|26|0|93
16205318.ti.1|relation|C0022616|Ketanserin|orch,phsu|phsu|||PREVENTS|C0917798|Cerebral Ischemia|dsyn|dsyn|||VERB|protects|ketanserin|cerebral ischemia|26|15|93

----- Citation 16207633 -----
16207633.ab.5 In the cells of CHO and bone marrow treated with aloe, glutathione (GSH) levels were shown to be higher and extracellular discharge rate increased as incubation time with aloe rose.


16207633.ab.5|relation|C1278992|Entire ovary|bpoc|bpoc|||PART_OF|C0018555|Hamsters, Chinese|mamm|mamm|||MOD/HEAD||CHO|CHO||16|16
16207633.ab.5|relation|C0007634|Cells|cell|cell|||PART_OF|C1278992|Entire ovary|bpoc|bpoc|||PREP|of|cells|CHO|12|7|16
16207633.ab.5|relation|C0007634|Cells|cell|cell|||PART_OF|C0005953|Bone Marrow|bpoc|bpoc|||PREP|of|cells|bone marrow|12|7|24

16207633.ab.6 MDR1 and MRP2 gene were more expressed in Hepa c cells than in NTCC cells, but there was no change in BCRP gene expression.


16207633.ab.6|relation|C0007634|Cells|cell|cell|||LOCATION_OF|C0376622|ABCB1 gene|aapp,gngm|gngm|5243|ABCB1|VERB|expressed|cells|MDR1|29|49|0|UMLS_CONC_REPLACE_SUBJ
16207633.ab.6|relation|C0007634|Cells|cell|cell|||LOCATION_OF|C1412077|ABCC2 gene|aapp,gngm|gngm|1244|ABCC2|VERB|expressed|cells|MRP2|29|49|9|UMLS_CONC_REPLACE_SUBJ
16207633.ab.6|relation|C1412077|ABCC2 gene|gngm|gngm|||PART_OF|C0677626|hepatoma cell|cell|cell|||VERB|expressed|MRP2 gene|Hepa c cells|29|9|42|UMLS_CONC_REPLACE_OBJ, NEW_UMLS_CONC_SUBJ
16207633.ab.6|relation|C0376622|ABCB1 gene|gngm|gngm|||PART_OF|C0677626|hepatoma cell|cell|cell|||VERB|expressed|MDR1|Hepa c cells|29|0|42|UMLS_CONC_REPLACE_OBJ

----- Citation 16216070 -----
16216070.ab.1 Cytochrome b5 reductase (cb5r), a member of the ferredoxin:NADP+ reductase family of flavoprotein transhydrogenases, catalyzes the NADH-dependent reduction of cytochrome b5.


16216070.ab.1|relation|C0056921|CYTOCHROME B5 REDUCTASE|aapp,enzy|aapp|||INTERACTS_WITH|C0010746|Cytochromes b5|aapp,enzy|aapp|||VERB|catalyzes|Cytochrome b5 reductase|cytochrome b5|117|0|159
16216070.ab.1|relation|C0027289|NADH|bacs,nnon,phsu|bacs|||INHIBITS|C0010746|Cytochromes b5|aapp,enzy|aapp|||NOM|reduction|NADH|cytochrome b5|146|131|159

----- Citation 16225901 -----
16225901.ab.2 Biological systems used in Europe are based on the process of double rapid biofiltration during which dissolved oxygen and pH need to be strictly controlled in order to limit abiotic iron oxidation.



16225901.ab.7 This system combines simple, low-cost operation and maintenance with high iron and manganese removal efficiencies, thus constituting a technology which is particularly suited to small waterworks.



----- Citation 16228202 -----
16228202.ab.2 The presence of glucosylceramide has been confirmed in some yeast; however, the extent of the role of glucosylceramide in yeast is unknown.


16228202.ab.2|relation|C0036025|Saccharomyces cerevisiae|fngs|fngs|||LOCATION_OF|C0017770|Glucosylceramides|bacs,lipd|bacs|||NOM|presence|yeast|glucosylceramide|4|60|16
16228202.ab.2|relation|C0017770|Glucosylceramides|bacs,lipd|bacs|||AFFECTS|C0036025|Saccharomyces cerevisiae|fngs|fngs|||NOM|role|glucosylceramide|yeast|94|102|122

16228202.ab.3 Thus, the extent of presence of glucosylceramide in yeast was surveyed using 90 strains of 24 genera.


16228202.ab.3|relation|C0036025|Saccharomyces cerevisiae|fngs|fngs|||LOCATION_OF|C0017770|Glucosylceramides|bacs,lipd|bacs|||PREP|in|yeast|glucosylceramide|48|52|32

----- Citation 16230392 -----
16230392.ab.2 It has been shown that EP2 plays a critical role in tumorigenesis in mouse mammary gland and colon.


16230392.ab.2|relation|C1419062|PTGER2 gene|gngm|gngm|||ASSOCIATED_WITH|C1326912|Tumorigenesis|neop|neop|||NOM|role|EP2|tumorigenesis|44|23|52|NEWER_UMLS_CONC_SUBJ
16230392.ab.2|relation|C0929301|Mammary gland|bpoc|bpoc|||LOCATION_OF|C1326912|Tumorigenesis|neop|neop|||PREP|in|mammary gland|tumorigenesis|65|75|52
16230392.ab.2|relation|C0009368|Colon|bpoc|bpoc|||LOCATION_OF|C1326912|Tumorigenesis|neop|neop|||PREP|in|colon|tumorigenesis|65|93|52
16230392.ab.2|relation|C0929301|Mammary gland|bpoc|bpoc|||PART_OF|C0026809|Mus|mamm|mamm|||MOD/HEAD||mammary gland|mouse||75|69
16230392.ab.2|relation|C0009368|Colon|bpoc|bpoc|||PART_OF|C0026809|Mus|mamm|mamm|||MOD/HEAD||colon|mouse||93|69

----- Citation 16232237 -----
16232237.ab.13 This cancer presents in younger patients and at a more advanced stage.


16232237.ab.13|relation|C0006826|Malignant Neoplasms|neop|neop|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||VERB|presents|cancer|patients|12|5|32

----- Citation 16243512 -----
16243512.ab.3 Their mechanisms of action include nucleophilic catalysis, induction of conformational strain, coordination with metal ions, and stabilization of transition states.



16243512.ab.4 Recent applications of CAbs with clinical significance include the conversion of cocaine to a non-psychoactive form, the degradation of nicotine, activation of prodrugs for targeted chemotherapy, protection from ultraviolet radiation, inhibition of HIV infectivity, and the destruction of aggregates of beta-amyloid implicated in Alzheimer's disease.


16243512.ab.4|relation|C0078939|Amyloid beta-Protein|aapp,gngm|aapp|||AFFECTS|C0002395|Alzheimer's Disease|dsyn|dsyn|||VERB|implicated|beta-amyloid|Alzheimer's disease|316|303|330|UMLS_CONC_REPLACE_SUBJ,NO_INDICATOR_RULE

----- Citation 16246439 -----
16246439.ab.6 Compared with placebo, candesartan therapy significantly lowered plasma hsCRP levels relative to baseline measurements from 1.10 to 0.70 mg/l (P=0.024) and soluble CD40 ligand levels by 30+/-11% (P<0.001).


16246439.ab.6|relation|C0032042|Placebos|medd,topp|medd|||compared_with|C0717550|candesartan|orch,phsu|phsu|||VERB|Compared|placebo|candesartan|0|14|23
16246439.ab.6|relation|C0717550|candesartan|orch,phsu|phsu|||INHIBITS|C0167627|CD40 Ligand|aapp,imft|aapp|||VERB|lowered|candesartan|CD40 ligand|57|23|164|COORDINATION

16246439.ab.10 There were significant correlations between percent changes in adiponectin levels and percent changes in insulin (r=-0.340, P=0.022) or QUICKI (r=0.325, P=0.029).



16246439.ab.11 CONCLUSIONS: Candesartan therapy significantly reduced inflammation and increased adiponectin levels and improved insulin sensitivity in hypertensive patients.


16246439.ab.11|relation|C0717550|candesartan|orch,phsu|phsu|||TREATS|C0021368|Inflammation|patf|patf|||VERB|reduced|Candesartan|inflammation|47|13|55|NO_INDICATOR_RULE
16246439.ab.11|relation|C0717550|candesartan|orch,phsu|phsu|||STIMULATES|C0389071|Adiponectin|aapp,bacs|aapp|9370|ADIPOQ|VERB|increased|Candesartan|adiponectin|72|13|82|VERBAL_COORDINATION
16246439.ab.11|relation|C0717550|candesartan|orch,phsu|phsu|||TREATS|C0920563|insulin sensitivity|patf|patf|||VERB|improved|Candesartan|insulin sensitivity|105|13|114|VERBAL_COORDINATION
16246439.ab.11|relation|C0857121|Hypertensive|fndg|fndg|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||hypertensive|patients||137|150
16246439.ab.11|relation|C0920563|insulin sensitivity|patf|patf|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|in|insulin sensitivity|patients|133|114|150
16246439.ab.11|relation|C0021368|Inflammation|patf|patf|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|in|inflammation|patients|133|55|150

----- Citation 16251535 -----
16251535.ab.8 Germ-line or somatic mutations were found in 5 of 42 sequenced microRNAs in 11 of 75 patients with CLL, but no such mutations were found in 160 subjects without cancer (P<0.001).


16251535.ab.8|relation|C1101610|MicroRNAs|bacs,nnon|nnon|||LOCATION_OF|C0544886|Somatic mutation|comd|comd|||PREP|in|microRNAs|somatic mutations|41|63|13
16251535.ab.8|relation|C1101610|MicroRNAs|bacs,nnon|nnon|||LOCATION_OF|C0206530|Germ-Line Mutation|genf|genf|||PREP|in|microRNAs|Germ-line|41|63|0|COORDINATION,UMLS_CONC_REPLACE_OBJ
16251535.ab.8|relation|C0023434|Chronic Lymphocytic Leukemia|neop|neop|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|CLL|patients|93|99|85
16251535.ab.8|relation|C0544886|Somatic mutation|comd|comd|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|in|somatic mutation|patients|72|13|85
16251535.ab.8|relation|C0206530|Germ-Line Mutation|genf|genf|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|in|Germ-line|patients|72|0|85|COORDINATION,UMLS_CONC_REPLACE_SUBJ
16251535.ab.8|relation|C0026882|Mutation|genf|genf|||NEG_PROCESS_OF|C2349001|Human Study Subject|humn|humn|||PREP|in|mutations|subjects|136|116|144|NEWER_UMLS_CONC_OBJ
16251535.ab.8|relation|C0006826|Malignant Neoplasms|neop|neop|||NEG_PROCESS_OF|C2349001|Human Study Subject|humn|humn|||PREP|without|cancer|subjects|152|161|144|NEWER_UMLS_CONC_OBJ

----- Citation 16256984 -----
16256984.ab.1 Adherens junctions and more specifically cadherins play an important role in endothelial cell integrity and growth and, in general, in vascular morphogenesis.


16256984.ab.1|relation|C0887872|Adherens Junction|celc|celc|||AFFECTS|C1123009|vasculogenesis|ortf|ortf|||NOM|role|Adherens junctions|vascular morphogenesis|69|0|135
16256984.ab.1|relation|C0006631|Cadherins|aapp,bacs|aapp|||AFFECTS|C1123009|vasculogenesis|ortf|ortf|||NOM|role|cadherins|vascular morphogenesis|69|41|135
16256984.ab.1|relation|C0887872|Adherens Junction|celc|celc|||AFFECTS|C0225336|Endothelial Cells|cell|cell|||NOM|role|Adherens junctions|endothelial cell|69|0|77
16256984.ab.1|relation|C0006631|Cadherins|aapp,bacs|aapp|||AFFECTS|C0225336|Endothelial Cells|cell|cell|||NOM|role|cadherins|endothelial cell|69|41|77
16256984.ab.1|relation|C0006631|Cadherins|aapp,bacs|aapp|||AFFECTS|C0007595|Cell Growth|celf|celf|||NOM|role|cadherins|endothelial cell integrity and growth|69|41|77|UMLS_CONC_REPLACE_OBJ
16256984.ab.1|relation|C0887872|Adherens Junction|celc|celc|||AFFECTS|C0007595|Cell Growth|celf|celf|||NOM|role|Adherens junctions|endothelial cell integrity and growth|69|0|77|UMLS_CONC_REPLACE_OBJ

16256984.ab.7 N-cadherin is also abundantly expressed in the endothelium and may be important in modulating VE-cadherin expression.


16256984.ab.7|relation|C0014257|Endothelium|tisu|tisu|||LOCATION_OF|C0027215|N-Cadherins|aapp,bacs|aapp|||VERB|expressed|endothelium|N-cadherin|30|47|0|UMLS_CONC_REPLACE_OBJ
16256984.ab.7|relation|C0027215|N-Cadherins|aapp,bacs|aapp|||INTERACTS_WITH|C0300423|cadherin 5|aapp,imft|aapp|||VERB|modulating|N-cadherin|VE-cadherin|83|0|94|UMLS_CONC_REPLACE_SUBJ,GERUND_INDICATOR

----- Citation 16260902 -----
16260902.ab.3 RESULTS: Subjects seronegative to hepatitis A were vaccinated with hepatitis A antigen.


16260902.ab.3|relation|C0062523|Hepatitis A Antigens|imft|imft|||ADMINISTERED_TO|C0681850|Study Subject|podg,humn|humn|||VERB|vaccinated|hepatitis A antigen|Subjects|51|67|9|NEWER_UMLS_CONC_OBJ, NO_INDICATOR_RULE


----- Citation 16260962 -----
16260962.ab.3 METHODS: After venous blood sampling, subjects (16 CFS patients) performed a maximal exercise stress test on a bicycle ergometer with continuous monitoring of cardiorespiratory variables.


16260962.ab.3|relation|C0015674|Chronic Fatigue Syndrome|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||CFS|patients||51|55
16260962.ab.3|relation|C0015260|Exercise stress test|diap|diap|||ADMINISTERED_TO|C0030705|Patients|podg,humn|humn|||VERB|performed|exercise stress test|patients|65|85|55
16260962.ab.3|relation|C0015260|Exercise stress test|diap|diap|||USES|C0180749|Bicycle ergometer|medd|medd|||PREP|on|exercise stress test|bicycle ergometer|105|85|111|NO_INDICATOR_RULE

16260962.ab.6 CONCLUSION: These data provide evidence for an association between intracellular immune deregulation and exercise performance in patients with CFS.


16260962.ab.6|relation|C0015674|Chronic Fatigue Syndrome|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|CFS|patients|137|143|129
16260962.ab.6|relation|C0597198|Performance|inbe|inbe|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|in|performance|patients|125|114|129

----- Citation 16261927 -----
16261927.ab.2 Whether the change in behaviour is related to opioid-induced sedation or to insufficient pain relief remains to be investigated.


16261927.ab.2|relation|C0242402|Opioids|hops,phsu|hops|||CAUSES|C0600097|Sedation|sosy|sosy|||ADJ|induced|opioid|sedation|53|46|61
16261927.ab.2|relation|C0600097|Sedation|sosy|sosy|||AFFECTS|C0542299|Behavioral change|inbe|inbe|||VERB|related|sedation|change in behaviour|35|61|12|NON_SEMNET_RELATION,UMLS_CONC_REPLACE_OBJ


----- Citation 16266740 -----
16266740.ti.1 Cadmium and lead contamination in japonica rice grains and its variation among the different locations in southeast China.


16266740.ti.1|relation|C0086369|Grains|plnt|plnt|||LOCATION_OF|C0023175|Lead|elii,hops|hops|||PREP|in|lead|rice grains|30|12|43|NEW_UMLS_CONC_OBJ,NEWER_UMLS_SEMTYPE_OBJ
16266740.ti.1|relation|C0086369|Grains|plnt|plnt|||LOCATION_OF|C0006632|Cadmium|elii,hops|hops|||PREP|in|Cadmium|rice grains|30|0|43
16266740.ti.1|relation|C1140671|Oryza sativa|plnt|plnt|||ISA|C0086369|Grains|plnt|plnt|||SPEC||rice|grains||43|48|NOT_IN_HIERARCHY

16266740.ab.1 On the basis of a large-scale survey with 269 sampling sites and a field experiment with 12 cultivars grown at 3 ecologically different locations, Cadmium (Cd) and lead (Pb) contamination in milled rice grains and its variation among different locations were investigated in the area of southeast China.


16266740.ab.1|relation|C0086369|Grains|plnt|plnt|||LOCATION_OF|C0006632|Cadmium|elii,hops|hops|||PREP|in|Cadmium (Cd)|rice|187|147|198
16266740.ab.1|relation|C0086369|Grains|plnt|plnt|||LOCATION_OF|C0023175|Lead|elii,hops|hops|||PREP|in|lead (Pb)|rice|187|164|198|NEW_UMLS_CONC_OBJ, NEWER_UMLS_SEMTYPE_OBJ
16266740.ab.1|relation|C0449705|Site of sampling|spco|spco|||LOCATION_OF|C0038951|Surveys|resa|resa|||PREP|with|sampling site|survey|36|46|30|UMLS_CONC_REPLACE_SUBJ,NEWER_UMLS_SEMTYPE_SUBJ
16266740.ab.1|relation|C1140671|Oryza sativa|plnt|plnt|||ISA|C0086369|Grains|plnt|plnt|||SPEC||rice|grains||198|203|NOT_IN_HIERARCHY

----- Citation 16272203 -----
16272203.ab.8 Regional wall motion assessed by circumferential shortening velocity suggested enhanced circumferential fiber contractility in the Ren-2 rats (P = 0.02), but tissue Doppler imaging, used to assess longitudinal function, was not different between groups.


16272203.ab.8|relation|C1258017|Heart Contractility|ortf|ortf|||PROCESS_OF|C0034721|Rattus|mamm|mamm|||PREP|in|contractility|rats|123|110|137|UMLS_CONC_REPLACE_SUBJ

----- Citation 16272824 -----
16272824.ab.7 Secretion of tumor necrosis factor-alpha (TNF-alpha), interleukin-8 (IL-8) and IL-6 in supernatants from HMC-1 cells was measured by a sandwich enzyme-linked immunosorbent assay.


16272824.ab.7|relation|C1550101|Supernatant|bdsu|bdsu|||PART_OF|C0007634|Cells|cell|cell|||PREP|from|supernatants|cells|99|87|111|NON_SEMNET_RELATION
16272824.ab.7|relation|C1550101|Supernatant|bdsu|bdsu|||LOCATION_OF|C1456820|Tumor Necrosis Factor-alpha|aapp,imft|aapp|||PREP|in|supernatants|tumor necrosis factor-alpha|83|87|13|NON_SEMNET_RELATION
16272824.ab.7|relation|C1550101|Supernatant|bdsu|bdsu|||LOCATION_OF|C0079633|Interleukin-8|aapp,imft|aapp|||PREP|in|supernatants|interleukin-8|83|87|54|NON_SEMNET_RELATION
16272824.ab.7|relation|C1550101|Supernatant|bdsu|bdsu|||LOCATION_OF|C0021760|Interleukin-6|aapp,imft|aapp|||PREP|in|supernatants|IL-6|83|87|79|NON_SEMNET_RELATION

16272824.ab.12 Significantly reduced levels (p < 0.05) of TNF-alpha, IL-8 and IL-6 were observed in the human mast cell line with SPS and SPS components.


16272824.ab.12|relation|C0682523|Human Cell Line|cell|cell|||LOCATION_OF|C0021760|Interleukin-6|aapp,gngm,imft|aapp|||PREP|in|human mast cell line|IL-6|81|89|63
16272824.ab.12|relation|C0682523|Human Cell Line|cell|cell|||LOCATION_OF|C1456820|Tumor Necrosis Factor-alpha|aapp,gngm,imft|aapp|||PREP|in|human mast cell line|TNF-alpha|81|89|43
16272824.ab.12|relation|C0682523|Human Cell Line|cell|cell|||LOCATION_OF|C0079633|Interleukin-8|aapp,imft|aapp|||PREP|in|human mast cell line|IL-8|81|89|54

16272824.ab.14 CONCLUSIONS: These findings suggest that SPS has an inhibitory effect on atopic allergic reaction and this might be useful for the clinical application to treat allergic diseases such as AD.


16272824.ab.14|relation|C1701972|sopoongsan|orch,phsu,bacs|orch|||DISRUPTS|C1527304|Allergic Reaction|patf|patf|||COMPLEX|inhibitory effect|SPS|allergic reaction|52|41|80|NEWER_UMLS_CONC_SUBJ,NO_INDICATOR_RULE
16272824.ab.14|relation|C0011615|Dermatitis, Atopic|dsyn|dsyn|||ISA|C0012634|Disease|dsyn|dsyn|||SPEC|such as|AD|disease|179|187|170|APPOSITIVE
16272824.ab.14|relation|C1701972|sopoongsan|orch,phsu,bacs|orch|||TREATS|C0012634|Disease|dsyn|dsyn|||VERB|treat|SPS|disease|155|41|170|NEWER_UMLS_CONC_SUBJ
16272824.ab.14|relation|C1701972|sopoongsan|orch,phsu,bacs|orch|||TREATS(SPEC)|C0011615|Dermatitis, Atopic|dsyn|dsyn|||INFER||SPS|AD||41|187|NEWER_UMLS_CONC_SUBJ

----- Citation 16280382 -----
16280382.ab.1 The present study was designed to evaluate the effects of long-term use of aqueous extract of gutkha (a form of smokeless tobacco) on the antioxidant defense status and histopathological changes in liver, lung, and kidney of male Wistar rats.


16280382.ab.1|relation|C0023884|Liver|bpoc|bpoc|||PART_OF|C0034716|Rats, Wistar|mamm|mamm|||PREP|of|liver|Wistar rats|221|198|230
16280382.ab.1|relation|C0024109|Lung|bpoc|bpoc|||PART_OF|C0034716|Rats, Wistar|mamm|mamm|||PREP|of|lung|Wistar rats|221|205|230
16280382.ab.1|relation|C0022646|Kidney|bpoc|bpoc|||PART_OF|C0034716|Rats, Wistar|mamm|mamm|||PREP|of|kidney|Wistar rats|221|215|230

16280382.ab.9 Histopathological findings suggest that administration of AEST at the high dose for 2 weeks or at the low dose for 32 weeks could cause mild to moderate inflammation in liver and lungs.


16280382.ab.9|relation|C0040338|Smokeless Tobacco|sbst|sbst|||CAUSES|C0021368|Inflammation|patf|patf|||VERB|cause|AEST|inflammation|130|58|153
16280382.ab.9|relation|C0023884|Liver|bpoc|bpoc|||LOCATION_OF|C0021368|Inflammation|patf|patf|||PREP|in|liver|inflammation|165|169|153
16280382.ab.9|relation|C0024109|Lung|bpoc|bpoc|||LOCATION_OF|C0021368|Inflammation|patf|patf|||PREP|in|lung|inflammation|165|179|153

----- Citation 16281706 -----
16281706.ab.1 PURPOSE: This paper describes the accomplishments of the Pacific Islander Cancer Control Network (PICCN).



----- Citation 16284436 -----
16284436.ab.4 In Turkey, a country with high incidence rates of goiter due to iodine deficiency, the frequency of mutations in the thyrotropin receptor signal transduction pathway has not been evaluated up to now.


16284436.ab.4|relation|C0342199|Iodine deficiency syndrome|dsyn|dsyn|||CAUSES|C0018021|Goiter|dsyn|dsyn|||PREP|due to|iodine deficiency|goiter|56|64|50|DYSONYM,UMLS_CONC_REPLACE_SUBJ

16284436.ab.12 In conclusion, the frequency of mutations in the cAMP signal transduction pathway was found to be lower than expected in the Turkish population most likely because of the use of SSCP as a screening method and sequencing only a part of TSHR exon 10.


16284436.ab.12|relation|C0026882|Mutation|genf|genf|||COEXISTS_WITH|C0086982|Signal Transduction Pathways|celf,moft|celf|||PREP|in|mutations|signal transduction pathway|41|32|54
16284436.ab.12|relation|C0243031|Single-Stranded Conformational Polymorphism|lbtr|lbtr|||METHOD_OF|C0220908|Screening procedure|hlca|hlca|||NOM|method|SSCP|screening|198|178|188
16284436.ab.12|relation|C0015295|Exons|bacs,nnon|nnon|||PART_OF|C0034844|Thyrotropin Receptor|aapp,rcpt|aapp|7253|TSHR|MOD/HEAD||exon|TSHR||240|235

----- Citation 16284524 -----
16284524.ab.9 It was suggested that individuals seroconverting later in calendar time were more likely to have TDR (relative risk 3.89 and 95% CI: 0.84 to 18.02, and relative risk 4.69 and 95% CI: 1.03 to 21.31, for 1996-1999 and 2000-2003, respectively, compared with pre-1996; P trend = 0.08).


16284524.ab.9|relation|C0013203|Drug resistance|biof|biof|||PROCESS_OF|C0237401|Individual|grup,humn|humn|||AUX|have|TDR|individuals|92|97|22

16284524.ab.11 The total estimated proportion of individuals with TDR varied between 10.3% and 15.5% according to which definition was used.


16284524.ab.11|relation|C0013203|Drug resistance|biof|biof|||PROCESS_OF|C0237401|Individual|humn|humn|||PREP|with|TDR|individuals|45|51|34

----- Citation 16285448 -----
16285448.ab.3 A commercial stent, nominally 4.4 mm in diameter and 12 mm in length, was used for a phantom study and placed along the length of the integrated balloon ultrasound catheter.


16285448.ab.3|relation|C0008972|Clinical Research|resa|resa|||USES|C0282611|Phantoms, Imaging|medd|medd|||MOD/HEAD||study|phantom||93|85
16285448.ab.3|relation|C0008972|Clinical Research|resa|resa|||USES|C0038257|Stents|medd|medd|||PREP|for||study|stent||93|13

----- Citation 16288225 -----
16288225.ab.7 The U2 subgroup was associated with overexpression of genes involved in T-cell activation and apoptosis, including NFKB1 and BCL-2.


16288225.ab.7|relation|C0017337|Genes|gngm|gngm|||AFFECTS|C1155065|T-Cell Activation|celf|celf|||PART|involved|genes|T-cell activation|60|54|72
16288225.ab.7|relation|C0017337|Genes|gngm|gngm|||AFFECTS|C0162638|Apoptosis|celf|celf|||PART|involved|genes|apoptosis|60|54|94
16288225.ab.7|relation|C1417708|NFKB1 gene|gngm|gngm|4790|NFKB1|ISA|C0017337|Genes|gngm|gngm|||SPEC|including|NFKB1|genes|105|115|54|UMLS_CONC_REPLACE_SUBJ
16288225.ab.7|relation|C0376515|BCL2 gene|gngm|gngm|||ISA|C0017337|Genes|gngm|gngm|||SPEC|including|BCL-2|genes|105|125|54|UMLS_CONC_REPLACE_SUBJ
16288225.ab.7|relation|C1417708|NFKB1 gene|gngm|gngm|4790|NFKB1|AFFECTS(SPEC)|C1155065|T-Cell Activation|celf|celf|||INFER||NFKB1|T-cell activation||115|72|UMLS_CONC_REPLACE_SUBJ
16288225.ab.7|relation|C0376515|BCL2 gene|gngm|gngm|||AFFECTS(SPEC)|C1155065|T-Cell Activation|celf|celf|||INFER||BCL-2|T-cell activation||125|72|UMLS_CONC_REPLACE_SUBJ
16288225.ab.7|relation|C1417708|NFKB1 gene|gngm|gngm|4790|NFKB1|AFFECTS(SPEC)|C0162638|Apoptosis|celf|celf|||INFER||NFKB1|apoptosis||115|94|UMLS_CONC_REPLACE_SUBJ
16288225.ab.7|relation|C0376515|BCL2 gene|gngm|gngm|||AFFECTS(SPEC)|C0162638|Apoptosis|celf|celf|||INFER||BCL-2|apoptosis||125|94|UMLS_CONC_REPLACE_SUBJ

----- Citation 16290001 -----
16290001.ab.2 METHODS: This study initially surveyed 163 patients with clinical stage Ib or IIa cervical adenocarcinoma treated with radical hysterectomy and pelvic lymphadenectomy.


16290001.ab.2|relation|C0279672|Cervical Adenocarcinoma|neop|neop|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|cervical adenocarcinoma|patients|51|82|43
16290001.ab.2|relation|C0677962|Radical hysterectomy|topp|topp|||TREATS|C0279672|Cervical Adenocarcinoma|neop|neop|||PART|treated|radical hysterectomy|cervical adenocarcinoma|106|119|82
16290001.ab.2|relation|C0193883|Pelvic lymphadenectomy|topp|topp|||TREATS|C0279672|Cervical Adenocarcinoma|neop|neop|||PART|treated|pelvic lymphadenectomy|cervical adenocarcinoma|106|144|82

16290001.ab.3 Of the 163 patients, 116 had preoperative serum CA125 levels, and 14 had pelvic lymph node metastasis.


16290001.ab.3|relation|C0030797|Pelvis|blor|blor|||LOCATION_OF|C0686619|Secondary malignant neoplasm of lymph node|neop|neop|||MOD/HEAD||pelvic|lymph node metastasis||73|80
16290001.ab.3|relation|C0686619|Secondary malignant neoplasm of lymph node|neop|neop|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||VERB|had|lymph node metastasis|patients|69|80|11

----- Citation 16291723 -----
16291723.ab.2 Coincident with actomyosin ring constriction, primary and secondary septa are deposited and then the primary septum is degraded to release daughter cells from one another.



16291723.ab.9 Our data suggest that the three closely related fission yeast Rho-GEF molecules perform two distinct essential functions.


16291723.ab.9|relation|C0606872|rho guanine nucleotide exchange factor p115|aapp,bacs|aapp|9181,56731|ARHGEF2,SLC2A4RG|PART_OF|C0178453|Schizosaccharomyces pombe|fngs|fngs|||MOD/HEAD||Rho-GEF|fission yeast||62|48

----- Citation 16291815 -----
16291815.ab.1 ATP-activated currents were studied in Leydig cells of mice with the patch-clamp technique.


16291815.ab.1|relation|C0023602|Structure of interstitial cell of Leydig|cell|cell|||PART_OF|C0026809|Mus|mamm|mamm|||PREP|of|Leydig cells|mice|51|39|55
16291815.ab.1|relation|C0023602|Structure of interstitial cell of Leydig|cell|cell|||LOCATION_OF|C0001480|Adenosine Triphosphate|phsu,nnon,bacs|bacs|||PREP|in|Leydig cells|ATP|35|39|0|UMLS_CONC_REPLACE_OBJ

----- Citation 16296031 -----
16296031.ab.17 This can be concluded from their precipitation with the sera against the bovine serum proteins in the immunoelectrophoresis test.


16296031.ab.17|relation|C0036825|Serum Proteins|aapp,bacs|aapp|||PART_OF|C1140701|Bos taurus|mamm|mamm|||MOD/HEAD||serum proteins|bovine||80|73

----- Citation 16303761 -----
16303761.ab.2 The interaction of HGF with c-met, a receptor tyrosine kinase expressed by many cells, is important in cell growth, migration, and formation of endothelial and epithelial tubes.


16303761.ab.2|relation|C0072453|Proto-Oncogene Protein c-met|rcpt,aapp,enzy|aapp|||INTERACTS_WITH|C0062534|Hepatocyte Growth Factor|aapp,gngm,bacs|gngm|||NOM|interaction|c-met|HGF|4|28|19|NEW_UMLS_CONJ_SUBJ
16303761.ab.2|relation|C0007634|Cells|cell|cell|||PRODUCES|C0206364|Receptor Protein-Tyrosine Kinases|aapp,gngm,enzy,rcpt|aapp|||PART|expressed|cells|receptor tyrosine kinase|62|80|37
16303761.ab.2|relation|C0072453|Proto-Oncogene Protein c-met|rcpt,aapp,enzy|aapp|||ISA|C0206364|Receptor Protein-Tyrosine Kinases|aapp,gngm,enzy,rcpt|aapp|||SPEC|,|c-met|receptor tyrosine kinase|33|28|37|NEW_UMLS_CONC_SUBJ,APPOSITIVE
16303761.ab.2|relation|C0007634|Cells|cell|cell|||PRODUCES(SPEC)|C0072453|Proto-Oncogene Protein c-met|rcpt,aapp,enzy|aapp|||INFER||cells|c-met||80|28|UMLS_CONC_REPLACE_OBJ

16303761.ab.6 Here we show that chymases, which are chymotryptic peptidases secreted by mast cells, hydrolyze HGF, thereby abolishing scatter factor activity while generating an NK4-like antagonist of HGF scatter factor activity.


16303761.ab.6|relation|C0055673|Chymase|aapp,gngm,enzy|aapp|||ISA|C0030940|Peptide Hydrolases|aapp,gngm,enzy|aapp|||SPEC|are|chymases|peptidases|34|18|51
16303761.ab.6|relation|C0024880|mast cell|cell|cell|||PRODUCES|C0055673|Chymase|aapp,gngm,enzy|aapp|||PART|secreted|mast cell|chymases|62|74|18
16303761.ab.6|relation|C0055673|Chymase|aapp,gngm,enzy|aapp|||INTERACTS_WITH|C0062534|Hepatocyte Growth Factor|aapp,gngm,bacs|gngm|||VERB|hydrolyze|chymases|HGF|86|18|96|NO_INDICATOR_RULE
16303761.ab.6|relation|C0055673|Chymase|aapp,gngm,enzy|aapp|||INHIBITS|C0062534|Hepatocyte Growth Factor|aapp,bacs|aapp|||VERB|abolishing|chymases|scatter factor|109|18|120|GERUND_INDICATOR
16303761.ab.6|relation|C0055673|Chymase|aapp,gngm,enzy|aapp|||PRODUCES|C0243076|antagonists|chvf|chvf|||VERB|generating|chymases|antagonist|150|18|173|GERUND_INDICATOR,NON_SEMNET_RELATION
16303761.ab.6|relation|C1537404|IL32 gene|gngm|gngm|9235|IL32|DISRUPTS|C1149472|growth factor activity|moft|moft|||NOM|antagonist|NK4|scatter factor activity|173|164|191|NEW_UMLS_CONC_SUBJ

16303761.ab.10 Mast cell/neutrophil cathepsin G and neutrophil elastase generate similar fragments of HGF by cleaving near the chymase site.


16303761.ab.10|relation|C0054868|Cathepsin G|aapp,gngm,enzy|aapp|1511|CTSG|PART_OF|C0027950|neutrophil|cell|cell|||MOD/HEAD||cathepsin G|neutrophil||21|10
16303761.ab.10|relation|C0054868|Cathepsin G|aapp,gngm,enzy|aapp|1511|CTSG|PART_OF|C0024880|mast cell|cell|cell|||MOD/HEAD||cathepsin G|Mast cell||21|0
16303761.ab.10|relation|C0064833|Leukocyte Elastase|aapp,gngm,enzy|gngm|||PRODUCES|C0062534|Hepatocyte Growth Factor|aapp,bacs|aapp|||VERB|generate|neutrophil elastase|HGF|57|37|87
16303761.ab.10|relation|C0054868|Cathepsin G|aapp,gngm,enzy|aapp|1511|CTSG|PRODUCES|C0062534|Hepatocyte Growth Factor|aapp,bacs|aapp|||VERB|generate|neutrophil elastase|HGF|57|37|87
16303761.ab.10|relation|C0699918|Elastases|aapp,enzy|aapp|||PART_OF|C0027950|neutrophil|cell|cell|||MOD/HEAD||elastase|neutrophil||48|37|NEW_UMLS_CONC_SUBJ

----- Citation 16304222 -----
16304222.ti.1 Low-dose anticoagulation in Chinese patients with mechanical heart valves.


16304222.ti.1|relation|C0003281|anticoagulation|topp|topp|||TREATS|C0030705|Patients|podg,humn|podg|||PREP|in|anticoagulation|patients|24|9|36
16304222.ti.1|relation|C0030705|Patients|podg,humn|humn|||USES|C0493527|HEART-VALVE, MECHANICAL|medd|medd|||PREP|with|patients|mechanical heart valves|44|36|50

----- Citation 16310382 -----
16310382.ab.1 Cystitis, urethritis and pyelonephritis in cattle most commonly result from ascending urinary tract infection with Corynebacterium renale, Corynebacterium cystidis, Corynebacterium pilosum or Escherichia coli.


16310382.ab.1|relation|C0010692|Cystitis|dsyn|dsyn|||PROCESS_OF|C0007452|Cattle|mamm|mamm|||PREP|in|Cystitis|cattle|39|0|43
16310382.ab.1|relation|C0041976|Urethritis|dsyn|dsyn|||PROCESS_OF|C0007452|Cattle|mamm|mamm|||PREP|in|urethritis|cattle|39|10|43
16310382.ab.1|relation|C0034186|Pyelonephritis|dsyn|dsyn|||PROCESS_OF|C0007452|Cattle|mamm|mamm|||PREP|in|pyelonephritis|cattle|39|25|43
16310382.ab.1|relation|C0042029|Urinary tract infection|dsyn|dsyn|||CAUSES|C0010692|Cystitis|dsyn|dsyn|||VERB|result|urinary tract infection|Cystitis|64|86|0
16310382.ab.1|relation|C0042029|Urinary tract infection|dsyn|dsyn|||CAUSES|C0041976|Urethritis|dsyn|dsyn|||VERB|result|urinary tract infection|urethritis|64|86|10
16310382.ab.1|relation|C0042029|Urinary tract infection|dsyn|dsyn|||CAUSES|C0034186|Pyelonephritis|dsyn|dsyn|||VERB|result|urinary tract infection|pyelonephritis|64|86|25
16310382.ab.1|relation|C0315176|Corynebacterium renale|bact|bact|||CAUSES|C0042029|Urinary tract infection|dsyn|dsyn|||PREP|with|Corynebacterium renale|urinary tract infection|109|115|86
16310382.ab.1|relation|C0315188|Corynebacterium pilosum|bact|bact|||CAUSES|C0042029|Urinary tract infection|dsyn|dsyn|||PREP|with|Corynebacterium pilosum|urinary tract infection|109|165|86
16310382.ab.1|relation|C0014834|Escherichia coli|bact|bact|||CAUSES|C0042029|Urinary tract infection|dsyn|dsyn|||PREP|with|Escherichia coli|urinary tract infection|109|192|86
16310382.ab.1|relation|C0010148|Corynebacterium|bact|bact|||CAUSES|C0042029|Urinary tract infection|dsyn|dsyn|||PREP|with|Corynebacterium|urinary tract infection

16310382.ab.2 We describe the clinical, bacteriological, clinical-pathological and epidemiological findings in a dairy cattle herd with urinary tract infection (UTI).


16310382.ab.2|relation|C0042029|Urinary tract infection|dsyn|dsyn|||PROCESS_OF|C0175925|Dairy cattle|mamm|mamm|||PREP|with|urinary tract infection|dairy cattle|116|122|99
16310382.ab.2|relation|C0037088|Signs and Symptoms|sosy|sosy|||PROCESS_OF|C0175925|Dairy cattle|mamm|mamm|||PREP|in|findings|dairy cattle|93|85|99|UMLS_CONC_REPLACE_SUBJ,WSD

----- Citation 16311763 -----
16311763.ab.4 Transcript levels for factors involved in mitochondrial biogenesis (PGC-1alpha, Tfam), mitochondrial function (COX-1, COX-4), control of contractile phenotype (MyHC I, IIa, IIx) as well as mechanical stress marker (IGF-I) were quantified using an reverse-transcriptase polymerase chain reaction approach.


16311763.ab.4|relation|C1418779|PPARGC1A gene|gngm|gngm|5225|PGC|AFFECTS|C0005495|Biogenesis|npop|npop|||PART|involved|PGC-1alpha|biogenesis|30|68|56|NON_SEMNET_RELATION
16311763.ab.4|relation|C1420696|TFAM gene|gngm|gngm|7019|TFAM|AFFECTS|C0005495|Biogenesis|npop|npop|||PART|involved|Tfam|biogenesis|30|80|56|NON_SEMNET_RELATION
16311763.ab.4|relation|C0026237|Mitochondria|celc|celc|||LOCATION_OF|C0005495|Biogenesis|npop|npop|||MOD/HEAD||mitochondrial|biogenesis||42|56|NON_SEMNET_RELATION,UMLS_CONC_REPLACE_SUBJ
16311763.ab.4|relation|C0389003|cyclooxygenase 1|aapp,enzy|aapp|||AFFECTS|C0026237|Mitochondria|celc|celc|||PART|involved|COX-1|mitochondrial|30|111|87|UMLS_CONC_REPLACE_OBJ
16311763.ab.4|relation|C1413634|COX4I1 gene|gngm|gngm|||AFFECTS|C0026237|Mitochondria|celc|celc|||PART|involved|COX-4|mitochondrial|30|118|87|UMLS_CONC_REPLACE_SUBJ,UMLS_CONC_REPLACE_OBJ
16311763.ab.4|relation|C0021665|Insulin-Like Growth Factor I|aapp,bacs|aapp|||AFFECTS|C0038442|Stress, Mechanical|npop|npop|||NOM|marker|IGF-I|mechanical stress|207|215|189|NO_INDICATOR_RULE

----- Citation 16316352 -----
16316352.ab.1 BACKGROUND: An association between renal hemodynamic dysfunction and coronary artery disease (CAD) has been documented in chronic renal failure; however, no information is available in CAD patients with normal glomerular filtration rate (GFR).


16316352.ab.1|relation|C0010054|Coronary Arteriosclerosis|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||CAD|patients||185|189
16316352.ab.1|relation|C0017654|Glomerular Filtration Rate|diap,ortf|ortf|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|glomerular filtration rate|patients||210|189
16316352.ab.1|relation|C0010054|Coronary Arteriosclerosis|dsyn|dsyn|||COEXISTS_WITH|C0022661|Kidney Failure, Chronic|dsyn|dsyn|||PREP|in|coronary artery disease|chronic renal failure|118|69|122
16316352.ab.1|relation|C0151746|Abnormal renal function|patf|patf|||COEXISTS_WITH|C0022661|Kidney Failure, Chronic|dsyn|dsyn|||PREP|in|renal hemodynamic dysfunction|chronic renal failure|118|35|122
16316352.ab.1|relation|C0151746|Abnormal renal function|patf|patf|||COEXISTS_WITH|C0010054|Coronary Arteriosclerosis|dsyn|dsyn|||NOM|association|renal hemodynamic dysfunction|coronary artery disease (CAD)|15|35|69

16316352.ab.13 CONCLUSION: In CAD patients with normal GFR, reduction in renal perfusion and absence of renal functional reserve likely represent early markers of progressive renal dysfunction.


16316352.ab.13|relation|C0010054|Coronary Arteriosclerosis|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||CAD|patients||15|19
16316352.ab.13|relation|C0017654|Glomerular Filtration Rate|diap,ortf|ortf|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|GFR|patients|27|40|19

----- Citation 16317035 -----
16317035.ab.1 Cytochrome c6 has long been known as a redox carrier of the thylakoid lumen of cyanobacteria and some eukaryotic algae that can substitute for plastocyanin in electron transfer.


16317035.ab.1|relation|C1622729|thylakoid lumen|celc|celc|||PART_OF|C1047211|Cyanobacterium|bact|bact|||PREP|of|thylakoid lumen|cyanobacteria|75|60|79|NEWER_UMLS_CONC_SUBJ
16317035.ab.1|relation|C1622729|thylakoid lumen|celc|celc|||PART_OF|C0002028|Algae|alga|alga|||PREP|of|thylakoid lumen|algae|75|60|113|NEWER_UMLS_CONC_SUBJ
16317035.ab.1|relation|C0002028|Algae|alga|alga|||ISA|C0684063|Eukaryota|orgm|orgm|||SPEC||algae|eukaryotic||113|102
16317035.ab.1|relation|C0111798|Cytochromes c6|aapp,bacs|aapp|||PART_OF|C1622729|thylakoid lumen|celc|celc|||NOM|carrier|Cytochrome c6|thylakoid lumen|45|0|60|NEWER_UMLS_CONC_OBJ

----- Citation 16328214 -----
16328214.ab.7 Findings were confirmed by histological results of a biopsy if rejection, tumor, or acute tubular necrosis were suspected.


16328214.ab.7|relation|C0005558|Biopsy|diap|diap|||DIAGNOSES|C0243095|Finding|fndg|fndg|||VERB|confirmed|biopsy|Findings|14|53|0|NEWER_UMLS_SEMTYPE_OBJ

----- Citation 16328359 -----
16328359.ti.1 Features of the clear zone of odontoclasts in the Chinook salmon (Oncorhynchus tshawytscha).


16328359.ti.1|relation|C0028876|Odontoclasts|cell|cell|||PART_OF|C0205943|Oncorhynchus tshawytscha|fish|fish|||PREP|in|odontoclasts|Chinook salmon|42|30|50

16328359.ab.1 This study aims to clarify the features of the clear zone of odontoclasts on shedding teeth of a teleost fish, Chinook salmon, Oncorhynchus tshawytscha (Walbaum), using a light microscope to determine the orientation between a cell body and a resorptive lacuna, followed by transmission electron microscopy.


16328359.ab.1|relation|C0028876|Odontoclasts|cell|cell|||PART_OF|C0040426|Tooth structure|bpoc|bpoc|||PREP|on|odontoclasts|teeth|73|61|86
16328359.ab.1|relation|C0040426|Tooth structure|bpoc|bpoc|||PART_OF|C1028265|teleost fish|fish|fish|||PREP|of|teeth|teleost fish|91|86|97
16328359.ab.1|relation|C0205943|Oncorhynchus tshawytscha|fish|fish|||ISA|C1028265|teleost fish|fish|fish|||SPEC|,|Chinook salmon|teleost fish|109|111|97|NOT_IN_HIERARCHY
16328359.ab.1|relation|C0947630|Scientific Study|lbpr|lbpr|||USES|C0491970|Microscopes, Light|medd|medd|||VERB|using|study|light microscope|163|5|171|GERUND_INDICATOR,UMLS_CONC_REPLACE_SUBJ,NON_SEMNET_RELATION
16328359.ab.1|relation|C0491970|Microscopes, Light|medd|medd|||PRECEDES|C0678118|Transmission Electron Microscopy|lbpr|lbpr|||PART|followed|light microscope|transmission electron microscopy|262|171|274|NON_SEMNET_RELATION,INFERENCE

----- Citation 16330201 -----
16330201.ab.3 30-40% epoxy resin adhesive and 50-70% polyurethane, has been developed and used for the first time as the outer protective membrane of the sensor.



----- Citation 16330236 -----
16330236.ti.1 [Ovarian hyperstimulation induced by a GnRH agonist. About one case].


16330236.ti.1|relation|C0243192|agonists|phsu|phsu|||CAUSES|C0549383|Ovarian hyperstimulation|patf|patf|||VERB|induced|agonist|Ovarian hyperstimulation|26|44|1

----- Citation 16332537 -----
16332537.ab.2 After eyelid closure in young animals (monocular deprivation, MD), visual cortical neurons become dominated by the open eye, a phenomenon known as ocular dominance (OD) plasticity . 

16332537.ab.2|relation|C0027882|Neurons|cell|cell|||PART_OF|C0042817|Visual Cortex|bpoc|bpoc|||MOD/HEAD||neurons|visual cortical||83|67

----- Citation 16332961 -----
16332961.ab.2 The main site for ROS production is the respiratory chain inside the mitochondria and accumulation of mtDNA mutations, and impaired respiratory chain function have been associated with degenerative diseases and aging.


16332961.ab.2|relation|C0026237|Mitochondria|celc|celc|||LOCATION_OF|C0162362|Respiratory Chain|moft|moft|||||PREP|inside|mitochondria|respiratory chain|57|69|40|
16332961.ab.2|relation|C0162362|Respiratory Chain|moft|moft|||LOCATION_OF|C0162772|Reactive Oxygen Species|bacs,elii|bacs|||NOM|site|respiratory chain|ROS|9|40|18
16332961.ab.2|relation|C0162362|Respiratory Chain|moft|moft|||AFFECTS|C1285162|Degenerative disorder|dsyn|dsyn|||VERB|associated|respiratory chain|degenerative diseases|169|132|185|NON_SEMNET_RELATION
16332961.ab.2|relation|C0162362|Respiratory Chain|moft|moft|||AFFECTS|C0001811|Aging|orgf|orgf|||VERB|associated|respiratory chain|aging|169|132|211|NON_SEMNET_RELATION
16332961.ab.2|relation|C0026237|Mitochondria|celc|celc|||LOCATION_OF|C0162362|Respiratory Chain|moft|moft|||PREP|inside|mitochondria|respiratory chain|57|69|40|NO_INDICATOR_RULE

----- Citation 16338777 -----
16338777.ab.1 OBJECTIVE: To study the microbial characteristics of patients with pelvic inflammatory disease (PID) and the possible impact of an intrauterine device (IUD) on the microbial environment in women presenting with PID.


16338777.ab.1|relation|C0242172|Pelvic Inflammatory Disease|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|pelvic inflammatory disease|patients|61|67|53
16338777.ab.1|relation|C0242172|Pelvic Inflammatory Disease|dsyn|dsyn|||PROCESS_OF|C0043210|Woman|popg,humn|humn|||VERB|presenting|PID|women|195|211|189|GERUND_INDICATOR,NO_INDICATOR_RULE

----- Citation 16338878 -----
16338878.ab.3 Additional findings included paraesophageal hiatus hernia containing squames, urethral atresia, absence of vulva, lung hypoplasia, mild hypoplasia of the corpus callosum, and short umbilical cord with single umbilical artery (SUA).


16338878.ab.3|relation|C0010090|Corpus Callosum|bpoc|bpoc|||LOCATION_OF|C0243069|Hypoplasia|patf|patf|||PREP|of|corpus callosum|hypoplasia|146|154|136
16338878.ab.3|relation|C0266786|Short cord unspecified|anab|anab|||COEXISTS_WITH|C1384670|Single umbilical artery|cgab|cgab|||PREP|with|short umbilical cord|single umbilical artery|195|175|201

----- Citation 16339800 -----
16339800.ab.7 We demonstrate in vitro and in vivo that the ahg3-1 missense mutation causes the loss of PP2C activity, providing concrete confirmation that this PP2C functions as a negative regulator in ABA signaling.


16339800.ab.7|relation|C0599155|Mutation, Missense|genf|genf|||DISRUPTS|C1149927|protein phosphatase activity|moft|moft|||COMPLEX|causes the loss|missense mutation|PP2C activity|70|52|89|NO_INDICATOR_RULE,NON_SEMNET_RELATION
16339800.ab.7|relation|C1142755|AHG3 protein, Arabidopsis|aapp,enzy|aapp|||LOCATION_OF|C0599155|Mutation, Missense|genf|genf|||MOD/HEAD||ahg3-1|missense mutation||45|52|NON_SEMNET_RELATION,NO_INDICATOR_RULE,NEWER_UMLS_CONC_OBJ
16339800.ab.7|relation|C0247248|protein phosphatase 2C|aapp,enzy|aapp|||DISRUPTS|C0037083|Signal Transduction|celf|celf|||NOM|negative regulator|PP2C|signaling|166|146|192
16339800.ab.7|relation|C0037083|Signal Transduction|celf|celf|||AFFECTS|C0000843|Abscisic Acid|bacs,orch|bacs|||MOD/HEAD||signaling|ABA||192|188|NON_SEMNET_RELATION,NO_INDICATOR_RULE

----- Citation 16340726 -----
16340726.ab.2 METHODS: Dynamic 133Xe SPECT was performed in 34 patients with emphysema and 15 patients with other forms of COPD.


16340726.ab.2|relation|C0040399|Tomography, Emission-Computed, Single-Photon|diap|diap|||ADMINISTERED_TO|C0030705|Patients|podg,humn|humn|||VERB|performed|SPECT|patients|33|23|49
16340726.ab.2|relation|C0040399|Tomography, Emission-Computed, Single-Photon|diap|diap|||ADMINISTERED_TO|C0030705|Patients|podg,humn|humn|||VERB|performed|SPECT|patients|33|23|80
16340726.ab.2|relation|C0013990|Pathological accumulation of air in tissues|patf|patf|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|emphysema|patients|57|63|49
16340726.ab.2|relation|C0024117|Chronic Obstructive Airway Disease|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|COPD|patients|88|109|80

----- Citation 16352184 -----
16352184.ab.9 We used this procedure concomitantly with valve surgery in 84 patients.


16352184.ab.9|relation|C0184661|Procedures|hlca|hlca|||TREATS|C0030705|Patients|podg,humn|humn|||PREP|in|procedure|patients|55|13|62
16352184.ab.9|relation|C0543467|Operative Surgical Procedures|topp|topp|||TREATS|C0030705|Patients|podg,humn|humn|||PREP|in|surgery|patients|55|48|62|WSD,UMLS_CONC_REPLACE_SUBJ
16352184.ab.9|relation|C0543467|Operative Surgical Procedures|topp|topp|||COEXISTS_WITH|C0184661|Procedures|hlca|hlca|||PREP|with|surgery|procedure|36|48|13|WSD,UMLS_CONC_REPLACE_SUBJ,NON_SEMNET_RELATION

16352184.ab.12 The technique is easily reproducible and the tools involved are inexpensive and readily available.



----- Citation 16361909 -----
16361909.ab.9 Anteroposterior pelvic radiographs were obtained before and after PCCD application, and after definitive stabilization.


16361909.ab.9|relation|C0030797|Pelvis|blor|blor|||LOCATION_OF|C1306645|Plain x-ray|diap|diap|||MOD/HEAD||pelvic|radiographs||16|23
16361909.ab.9|relation|C1306645|Plain x-ray|diap|diap|||PRECEDES|C0185125|Application procedure|hlca|hlca|||PREP|before|radiographs|application|48|23|71
16361909.ab.9|relation|C0185125|Application procedure|hlca|hlca|||PRECEDES|C1306645|Plain x-ray|diap|diap|||PREP|after|application|radiographs|59|71|23
16361909.ab.9|relation|C1293130|Stabilization|topp|topp|||PRECEDES|C1306645|Plain x-ray|diap|diap|||PREP|after|stabilization|radiographs|87|105|23|NON_SEMNET_RELATION

----- Citation 16362132 -----
16362132.ab.11 CONCLUSION: Factors associated with breast density in older, post-menopausal women differ from traditional breast cancer risk factors and from factors associated with breast density in pre-menopausal and younger post-menopausal women.


16362132.ab.11|relation|C0206159|Postmenopause|orgf|orgf|||PROCESS_OF|C0043210|Woman|popg,humn|humn|||MOD/HEAD||post-menopausal|women||61|77
16362132.ab.11|relation|C0206158|Premenopause|phsf|phsf|||PROCESS_OF|C0043210|Woman|popg,humn|humn|||MOD/HEAD||pre-menopausal|women||185|228
16362132.ab.11|relation|C0206159|Postmenopause|orgf|orgf|||PROCESS_OF|C0043210|Woman|popg,humn|humn|||MOD/HEAD||post-menopausal|women||212|228

----- Citation 16362541 -----
16362541.ab.7 Intraclass correlations coefficients (R) were used as an index of day-to-day reproducibility, and analyses were conducted on all participants and only those with tetraplegia.


16362541.ab.7|relation|C0034372|Quadriplegia|dsyn|dsyn|||PROCESS_OF|C0679646|Participant|popg,humn|humn|||PREP|with|tetraplegia|participants|156|162|129|ANAPHORA

----- Citation 16371595 -----
16371595.ab.3 The fertilization calcium wave is then set into the context of cell cycle control, and the mechanism of repetitive calcium spiking in mammalian eggs is investigated.


16371595.ab.3|relation|C0029974|Ovum|cell|cell|||LOCATION_OF|C0600429|Calcium Spikes|celf|celf|||PREP|in|eggs|calcium spiking|130|144|115|NON_SEMNET_RELATION
16371595.ab.3|relation|C0029974|Ovum|cell|cell|||PART_OF|C0024660|Mammals|mamm|mamm|||MOD/HEAD||eggs|mammalian||144|134|NEW_UMLS_CONC_OBJ

16371595.ab.11 Evidence that the Wingless/calcium signaling pathway is a strong ventralizing signal in Xenopus, mediated by phosphoinositide signaling, is adumbrated.

16371595.ab.11|relation|C0031621|Phosphatidylinositols|bacs,lipd|lipd|||AFFECTS|C0037083|Signal Transduction|celf|celf|||PART|mediated|phosphoinositide signaling|ventralizing signal|97|109|65
16371595.ab.11|relation|C0037083|Signal Transduction|celf|celf|||PROCESS_OF|C0043342|Xenopus|amph|amph|||PREP|in|strong ventralizing signal|Xenopus|84|58|88

----- Citation 16372122 -----
16372122.ab.9 A total of 19.6% of patients were not aware of their penile deformities in the diabetic group.


16372122.ab.9|relation|C0030851|penis|bpoc|bpoc|||LOCATION_OF|C0000768|Congenital Abnormality|cgab|cgab|||MOD/HEAD||penile|deformities||53|60
16372122.ab.9|relation|C0000768|Congenital Abnormality|cgab|cgab|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||deformities|patients||60|20|ANAPHORA
16372122.ab.9|relation|C0000768|Congenital Abnormality|cgab|cgab|||PROCESS_OF|C1257890|Population Group|popg,humn|humn|||PREP|in|deformities|group|71|60|88|UMLS_CONC_REPLACE_OBJ,WSD,DYSONYM
16372122.ab.9|relation|C0011847|Diabetes|dsyn|dsyn|||PROCESS_OF|C1257890|Population Group|popg,humn|humn|||MOD/HEAD||diabetic|group||79|88|UMLS_CONC_REPLACE_SUBJ,UMLS_CONC_REPLACE_OBJ

16372122.ab.10 Erectile function, provided by history and in response to intracavernosal injection and a stimulation test, was significantly diminished in patients with PD and DM (P < 0.05).


16372122.ab.10|relation|C0030848|Peyronie Disease|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|PD|patients|148|154|140
16372122.ab.10|relation|C0011849|Diabetes Mellitus|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|DM|patients|148|161|140

16372122.ab.13 PD seems to be a silent consequence of DM and should be actively sought in diabetic men.

16372122.ab.13|relation|C0011849|Diabetes Mellitus|dsyn|dsyn|||CAUSES|C0030848|Peyronie Disease|dsyn|dsyn|||NOM|consequence|DM|PD|24|39|0|NO_INDICATOR_RULE
16372122.ab.13|relation|C0241863|Diabetic|fndg|fndg|||PROCESS_OF|C0025266|Male population group|popg,humn|humn|||MOD/HEAD||diabetic|men||75|84
16372122.ab.13|relation|16372122.ab.13|relation|C0030848|Peyronie Disease|dsyn|dsyn|||PROCESS_OF(INFER)|C0025266|Male population group|popg,humn|humn|||PREP|in|PD|men|71|39|84

----- Citation 16372914 -----
16372914.ab.2 The placental isozyme (PLAP) is an oncofetal antigen expressed in several malignancies including choriocarcinoma, seminoma and ovarian carcinoma.


16372914.ab.2|relation|C0008497|Choriocarcinoma|neop|neop|||ISA|C0006826|Malignant Neoplasms|neop|neop|||SPEC|including|choriocarcinoma|malignancies|87|97|74|APPOSITIVE
16372914.ab.2|relation|C0036631|Seminoma|neop|neop|||ISA|C0006826|Malignant Neoplasms|neop|neop|||SPEC|including|seminoma|malignancies|87|114|74|APPOSITIVE
16372914.ab.2|relation|C0029925|Ovarian Carcinoma|neop|neop|||ISA|C0006826|Malignant Neoplasms|neop|neop|||SPEC|including|ovarian carcinoma|malignancies|87|127|74|APPOSITIVE
16372914.ab.2|relation|C0301811|Alkaline phosphatase isoenzyme, placental fraction|aapp,enzy|aapp|||ISA|C0069494|oncofetal antigen|aapp,imft|aapp|||SPEC|is|placental isozyme|oncofetal antigen|29|4|35|NOT_IN_HIERARCHY,UMLS_CONC_REPLACE_SUBJ
16372914.ab.2|relation|C0069494|oncofetal antigens|aapp,imft|aapp|||PART_OF|C0006826|Malignant Neoplasms|neop|neop|||PART|expressed|oncofetal antigen|malignancies|53|35|74
16372914.ab.2|relation|C0301811|Alkaline phosphatase isoenzyme, placental fraction|aapp,enzy|aapp|||PART_OF(SPEC)|C0006826|Malignant Neoplasms|neop|neop|||INFER||placental isozyme|malignancies||4|74|UMLS_CONC_REPLACE_SUBJ
16372914.ab.2|relation|C0069494|oncofetal antigens|aapp,imft|aapp|||PART_OF(SPEC)|C0008497|Choriocarcinoma|neop|neop|||INFER||oncofetal antigen|choriocarcinoma||35|97
16372914.ab.2|relation|C0069494|oncofetal antigens|aapp,imft|aapp|||PART_OF(SPEC)|C0036631|Seminoma|neop|neop|||INFER||oncofetal antigen|seminoma||35|114
16372914.ab.2|relation|C0069494|oncofetal antigens|aapp,imft|aapp|||PART_OF(SPEC)|C0029925|Ovarian Carcinoma|neop|neop|||INFER||oncofetal antigen|ovarian carcinoma||35|127
16372914.ab.2|relation|C0301811|Alkaline phosphatase isoenzyme, placental fraction|aapp,enzy|aapp|||PART_OF(SPEC)|C0008497|Choriocarcinoma|neop|neop|||INFER||placental isozyme|choriocarcinoma||4|97
16372914.ab.2|relation|C0301811|Alkaline phosphatase isoenzyme, placental fraction|aapp,enzy|aapp|||PART_OF(SPEC)|C0036631|Seminoma|neop|neop|||INFER||placental isozyme|seminoma||4|114
16372914.ab.2|relation|C0301811|Alkaline phosphatase isoenzyme, placental fraction|aapp,enzy|aapp|||PART_OF(SPEC)|C0029925|Ovarian Carcinoma|neop|neop|||INFER||placental isozyme|ovarian carcinoma||4|127

16372914.ab.9 In this work, the library was first incubated with PLAP and the bound clones then eluted by incubation with L-Phe-Gly-Gly along with the substrate, para-nitro phenyl phosphate (pNPP).



----- Citation 16373645 -----
16373645.ab.3 METHODS: We analyzed the mRNA expression of Ccm1 and Ccm2 in the embryonic and postnatal mouse brain by in situ hybridization.


16373645.ab.3|relation|C0035696|RNA, Messenger|nnon,bacs|bacs|||PART_OF|C1619867|CCM2 protein, human|aapp,bacs,gngm|aapp|83605|CCM2|NOM|expression|mRNA expression|Ccm2|30|25|53|NON_SEMNET_RELATION,NEW_UMLS_CONC_OBJ
16373645.ab.3|relation|C0035696|RNA, Messenger|nnon,bacs|bacs|||PART_OF|C1366433|CCM1 gene|gngm,aapp|aapp|889|KRIT1|NOM|expression|mRNA expression|Ccm1|30|25|44|NON_SEMNET_RELATION
16373645.ab.3|relation|C0006104|Brain|bpoc|bpoc|||LOCATION_OF|C1619867|CCM2 protein, human|aapp,bacs,gngm|aapp|83605|CCM2|PREP|in|brain|Ccm2|57|95|53|NEW_UMLS_CONC_OBJ
16373645.ab.3|relation|C0006104|Brain|bpoc|bpoc|||LOCATION_OF|C1366433|CCM1 gene|gngm,aapp|aapp|889|KRIT1|PREP|in|brain|Ccm1|57|95|44
16373645.ab.3|relation|C0006104|Brain|bpoc|bpoc|||PART_OF|C0026809|Mus|mamm|mamm|||MOD/HEAD||brain|mouse||95|89|UMLS_CONC_REPLACE_OBJ


16373645.ab.4 Subsequently, we generated CCM2-specific polyclonal antibodies and tested their specificity using transient transfection experiments in various cell lines.


16373645.ab.4|relation|C0007600|Cell Line|cell|cell|||LOCATION_OF|C0040669|Transfection|genf,mbrt|genf|||PREP|in|cell lines|transfection|132|144|108

16373645.ab.5 We then investigated CCM2 protein expression in cerebral and extracerebral tissues by Western blot analysis as well as immunohistochemistry and compared these results with CCM1 (KRIT1) protein expression.


16373645.ab.5|relation|C0006104|Brain|bpoc|bpoc|||LOCATION_OF|C1619867|CCM2 protein, human|aapp,bacs,gngm|aapp|83605|CCM2|PREP|in|cerebral|CCM2|44|48|21|NEW_UMLS_CONC_OBJ
16373645.ab.5|relation|C0006104|Brain|bpoc|bpoc|||LOCATION_OF|C1366433|CCM1 gene|gngm,aapp|aapp|889|KRIT1|PREP|in|cerebral|CCM1|44|48|172|COORDINATION
16373645.ab.5|relation|C1619867|CCM2 protein, human|aapp,bacs,gngm|aapp|83605|CCM2|compared_with|C1366433|CCM1 gene|gngm,aapp|gngm|889|KRIT1|VERB|compared|CCM2|CCM1|144|21|172
16373645.ab.5|relation|C0040300|Body tissue|tisu|tisu|||LOCATION_OF|C1619867|CCM2 protein, human|aapp,bacs,gngm|aapp|83605|CCM2|PREP|in|tissues|CCM2 |44|75|21
16373645.ab.5|relation|C0040300|Body tissue|tisu|tisu|||LOCATION_OF|C1366433|CCM1 gene|gngm,aapp|aapp|889|KRIT1|PREP|in|tissues|CCM1|44|75|172|COORDINATION 

----- Citation 16376188 -----
16376188.ab.5 Thus, the findings indicated that it would be safe for a patient with these implants to undergo MRI at 3 T or lower.


16376188.ab.5|relation|C0024485|Magnetic Resonance Imaging|diap|diap|||ADMINISTERED_TO|C0030705|Patients|podg,humn|humn|||VERB|undergo|MRI|patient|88|96|57
16376188.ab.5|relation|C0030705|Patients|podg,humn|humn|||USES|C0021102|Implants|medd|medd|||PREP|with|patient|implants|64|57|76

----- Citation 16376670 -----
16376670.ti.1 Anterior uveitis and iris nodules that are associated with Langerhans cell histiocytosis.


16376670.ti.1|relation|C0042165|Anterior uveitis|dsyn|dsyn|||COEXISTS_WITH|C0019621|Histiocytosis, Langerhans-Cell|dsyn|dsyn|||VERB|associated|Anterior uveitis|Langerhans cell histiocytosis|43|0|59
16376670.ti.1|relation|C0424839|Iris nodule|fndg|fndg|||COEXISTS_WITH|C0019621|Histiocytosis, Langerhans-Cell|dsyn|dsyn|||VERB|associated|Anterior uveitis|Langerhans cell histiocytosis|43|0|59

16376670.ab.5 RESULTS: An 18-year-old male patient with unilateral anterior segment inflammation and iris nodules experienced visual improvement from 20/200 to 20/25 after treatment with a 5-day course of topical corticosteroids.


16376670.ab.5|relation|C0021368|Inflammation|patf|patf|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|inflammation|patient|36|70|29
16376670.ab.5|relation|C0424839|Iris nodule|fndg|fndg|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|iris nodules|patient|36|87|29
16376670.ab.5|relation|C0304604|Topical form corticosteroids|phsu|phsu|||TREATS|C0030705|Patients|podg,humn|humn|||NOM|improvement|topical corticosteroids|patient|119|191|29
16376670.ab.5|relation|C0304604|Topical form corticosteroids|phsu|phsu|||TREATS(INFER)|C0021368|Inflammation|patf|patf|||INFER||topical corticosteroids|inflammation||191|70
16376670.ab.5|relation|C0304604|Topical form corticosteroids|phsu|phsu|||TREATS(INFER)|C0424839|Iris nodule|fndg|fndg|||INFER||topical corticosteroids|iris nodules||191|87

----- Citation 16380233 -----
16380233.ab.8 In pure cultures, the phospholipid fatty acid (PLFA) composition was strongly influenced by both the carbon source and the growth phase.


16380233.ab.8|relation|C0031676|Phospholipids|bacs,lipd|bacs|||ISA|C0015684|Fatty Acids|bacs,lipd|bacs|||SPEC||phospholipid|fatty acid||22|35
16380233.ab.8|relation|C0015684|Fatty Acids|bacs,lipd|lipd|||INTERACTS_WITH|C0007009|Carbon|elii|elii|||VERB|influence|fatty acid|carbon|78|35|101
16380233.ab.8|relation|C0031676|Phospholipids|bacs,lipd|bacs|||INTERACTS_WITH(SPEC)|C0007009|Carbon|elii|elii|||INFER||phospholipid|fatty acid||22|35

----- Citation 16387100 -----
16387100.ab.12 Recurrence of glomerulopathy underlying ESRD was frequent for IgAN, FSG, and MCGN, but this was rarely seen in membranous GN.


16387100.ab.12|relation|C1261469|End stage renal failure|dsyn|dsyn|||MANIFESTATION_OF|C1398810|glomerulopathy|dsyn|dsyn|||VERB|underlying|ESRD|glomerulopathy|29|40|14|GERUND_INDICATOR,NO_INDICATOR_RULE
16387100.ab.12|relation|C1398810|glomerulopathy|dsyn|dsyn|||COEXISTS_WITH|C0017661|IGA Glomerulonephritis|dsyn|dsyn|||PREP|for|glomerulopathy|IgAN|57|14|62|NO_INDICATOR_RULE
16387100.ab.12|relation|C1398810|glomerulopathy|dsyn|dsyn|||COEXISTS_WITH|C0403425|Focal segmental glomerulosclerosis|dsyn|dsyn|||PREP|for|glomerulopathy|FSG|57|14|68|NO_INDICATOR_RULE
16387100.ab.12|relation|C1398810|glomerulopathy|dsyn|dsyn|||COEXISTS_WITH|C0017662|Glomerulonephritis, Membranoproliferative|dsyn|dsyn|||PREP|for|glomerulopathy|MCGN|57|14|77|NO_INDICATOR_RULE
16387100.ab.12|relation|C1398810|glomerulopathy|dsyn|dsyn|||COEXISTS_WITH|C0017665|Glomerulonephritis, Membranous|dsyn|dsyn|||PREP|in|glomerulopathy|membranous GN|107|14|111|ANAPHORA

----- Citation 16391093 -----
16391093.ab.7 For compost and pack treatments, this manure was amended with sawdust or straw to provide an optimal moisture content (60%) for composting for 56 days.



----- Citation 16394795 -----
16394795.ab.10 Manometry showed a higher anal sphincter resting pressure and a lower critical volume in food intolerance patients than in the others suffering from constipation unrelated to food intolerance.


16394795.ab.10|relation|C0024751|Manometry|lbpr|lbpr|||DIAGNOSES|C0429217|Anal sphincter pressure|fndg|fndg|||VERB|showed|Manometry|anal sphincter resting pressure|10|0|26
16394795.ab.10|relation|C0149696|Food intolerance|sosy|sosy|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||food intolerance|patients||89|106
16394795.ab.10|relation|C0009806|Constipation|sosy|sosy|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||VERB|suffering|constipation|patients|134|149|106|ANAPHORA
16394795.ab.10|relation|C0009806|Constipation|sosy|sosy|||NEG_COEXISTS_WITH|C0149696|Food intolerance|sosy|sosy|||PART|unrelated|constipation|food intolerance|162|149|175|NO_INDICATOR_RULE, NEGATION_COMPLEX

16394795.ab.12 CONCLUSIONS: Food intolerance-related constipation is characterized by proctitis.


16394795.ab.12|relation|C0149696|Food intolerance|sosy|sosy|||AFFECTS|C0009806|Constipation|sosy|sosy|||ADJ|related|Food intolerance|constipation|30|13|38
16394795.ab.12|relation|C0033246|Proctitis|dsyn|dsyn|||MANIFESTATION_OF|C0009806|Constipation|sosy|sosy|||VERB|characterized|proctitis|constipation|54|71|38|NO_INDICATOR_RULE

----- Citation 16395331 -----
16395331.ab.1 Cell cycle progression in Caulobacter is driven by the master transcriptional regulators CtrA and GcrA.


16395331.ab.1|relation|C1516334|Cell Cycle Progression|celf|celf|||PROCESS_OF|C0085448|Caulobacter|bact|bact|||PREP|in|Cell cycle progression|Caulobacter|22|0|26
16395331.ab.1|relation|C0385936|CtrA protein, bacteria|aapp,bacs|aapp|||ISA|C1336788|Transcription Regulatory Protein|aapp,bacs|aapp|||SPEC||CtrA|transcriptional regulators||89|62|UMLS_CONC_REPLACE_OBJ
16395331.ab.1|relation|C1336788|Transcription Regulatory Protein|aapp,bacs|aapp|||AFFECTS|C1516334|Cell Cycle Progression|celf|celf|||VERB|driven|transcriptional regulators|Cell cycle progression|41|62|0|UMLS_CONS_REPLACE_SUBJ,NO_INDICATOR_RULE
16395331.ab.1|relation|C0385936|CtrA protein, bacteria|aapp,bacs|aapp|||AFFECTS(SPEC)|C1516334|Cell Cycle Progression|celf|celf|||INFER||CtrA|Cell cycle progression||89|0

----- Citation 16402182 -----
16402182.ab.5 Splenic lymphocytes or purified B-cells obtained from BALB/c mice were cultured with various combinations of IL-4, anti-CD40 antibody, and PAM-extract for 7 days.


16402182.ab.5|relation|C0024264|Lymphocyte|cell|cell|||PART_OF|C0037993|Spleen|bpoc|bpoc|||MOD/HEAD||lymphocytes|Splenic||8|0
16402182.ab.5|relation|C0004561|B-Lymphocytes|cell|cell|||PART_OF|C0025919|Mice, Inbred BALB C|mamm|mamm|||PREP|from|B-cells|BALB/c mice|48|32|54|UMLS_CONC_REPLACE_OBJ

16402182.ab.6 IgE and IgG concentrations of culture supernatants were measured by ELISA.



----- Citation 16407061 -----
16407061.ab.5 These reveal the viral morphology with unprecedented clarity and suggest the following mechanism for core formation inside the extracellular virion: core growth initiates at the narrow end of the cone and proceeds toward the distal side of the virion until limited by the viral membrane.


16407061.ab.5|relation|C0521119|Extracellular|celc|celc|||LOCATION_OF|C0042760|Virion|celc|celc|||MOD/HEAD||extracellular|virion||127|141
16407061.ab.5|relation|C0042760|Virion|celc|celc|||LOCATION_OF|C0598995|virus core|aapp,nnon|aapp|||PREP|inside|virion|core|115|141|101|UMLS_CONC_REPLACE_OBJ
16407061.ab.5|relation|C1167398|Viral envelope|celc|celc|||DISRUPTS|C0018270|Growth|orgf|orgf|||PART|limited|viral membrane|growth|257|272|154

----- Citation 16411510 -----
16411510.ab.3 Our research explored risk factors for participation restrictions experienced by people affected by leprosy.


16411510.ab.3|relation|C0023343|Leprosy|dsyn|dsyn|||AFFECTS|C0027361|Persons|popg,humn|humn|||PART|affected|leprosy|people|88|100|81

----- Citation 16411522 -----
16411522.ti.1 Treatment of refractory pseudomonas aeruginosa exit-site infection by simultaneous removal and reinsertion of peritoneal dialysis catheter.


16411522.ti.1|relation|C0204835|Removal of peritoneal dialysis catheter|topp|topp|||TREATS|C0854135|Pseudomonas aeruginosa infection NOS|dsyn|dsyn|||NOM|Treatment|removal and reinsertion of peritoneal dialysis catheter|pseudomonas aeruginosa exit-site infection|0|83|24|UMLS_CONC_REPLACE_SUBJ
16411522.ti.1|relation|C0405873|Insertion of temporary peritoneal dialysis catheter|topp|topp|||TREATS|C0854135|Pseudomonas aeruginosa infection NOS|dsyn|dsyn|||NOM|Treatment|reinsertion of peritoneal dialysis catheter|pseudomonas aeruginosa exit-site infection|0|95|24|UMLS_CONC_REPLACE_SUBJ

16411522.ab.8 RESULTS: Over a 10-year period, 37 CAPD patients underwent the operation.


16411522.ab.8|relation|C0031140|Peritoneal Dialysis, Continuous Ambulatory|topp|topp|||ADMINISTERED_TO|C0030705|Patients|podg,humn|humn|||MOD/HEAD||CAPD|patients||35|40
16411522.ab.8|relation|C0543467|Operative Surgical Procedures|topp|topp|||ADMINISTERED_TO|C0030705|Patients|podg,humn|podg|||VERB|underwent|operation|patients|49|63|40

----- Citation 16412044 -----
16412044.ti.1 Phenotype of early cardiomyopathic changes induced by active immunization of rats with a synthetic peptide corresponding to the second extracellular loop of the human beta-adrenergic receptor.


16412044.ti.1|relation|C0205991|Immunization, Active|topp|topp|||CAUSES|C0878544|Cardiomyopathies|dsyn|dsyn|||PART|induced|active immunization|cardiomyopathic|43|54|19
16412044.ti.1|relation|C0597551|synthetic peptide|aapp|aapp|||ADMINISTERED_TO|C0034721|Rattus|mamm|mamm|||NOM|immunization|synthetic peptide|rats|61|89|77|NO_INDICATOR_RULE
16412044.ti.1|relation|C0597551|synthetic peptide|aapp|aapp|||PART_OF|C0001643|beta-2 Adrenergic Receptors|aapp,rcpt|aapp|||PREP|of|synthetic peptide|beta-adrenergic receptor|153|89|167
16412044.ti.1|relation|C0001643|beta-2 Adrenergic Receptors|aapp,rcpt|aapp|||PART_OF|C0086418|Homo sapiens|humn|humn|||MOD/HEAD||beta-adrenergic receptor|human||167|161

16412044.ab.1 In the failing human heart, due to idiopathic dilated cardiomyopathy, it has been suggested that the beta1-adrenergic receptor (beta1AR) is a potential pathogenic autoantigen.


16412044.ab.1|relation|C1281570|Entire heart|bpoc|bpoc|||PART_OF|C0086418|Homo sapiens|grup,humn|humn|||MOD/HEAD||heart|human||21|15

----- Citation 16415554 -----
16415554.ab.2 One patient was successfully cured by steroid therapy, while the other did not respond to steroid but oral mesalazine was effective.


16415554.ab.2|relation|C0149783|Steroid therapy|topp|topp|||TREATS|C0030705|Patients|podg,humn|humn|||VERB|cured|steroid therapy|patient|29|38|4

16415554.ab.3 Systemic lupus erythematosus is frequently accompanied by gastrointestinal symptoms, but colonic lesions are quite rare, and the regular treatment is not fixed yet.


16415554.ab.3|relation|C0024141|Lupus Erythematosus, Systemic|dsyn|dsyn|||COEXISTS_WITH|C0426576|Gastrointestinal symptoms NOS|sosy|sosy|||VERB|accompanied|Systemic lupus erythematosus|gastrointestinal symptoms|43|0|58
16415554.ab.3|relation|C0009368|Colon|bpoc|bpoc|||LOCATION_OF|C0221198|Lesion|fndg|fndg|||MOD/HEAD||colonic|lesions||89|97

----- Citation 16418362 -----
16418362.ti.1 Direct visualization of the human subthalamic nucleus with 3T MR imaging.


16418362.ti.1|relation|C1281060|Entire subthalamic nucleus|bpoc|bpoc|||PART_OF|C0086418|Homo sapiens|humn|humn|||MOD/HEAD||subthalamic nucleus|human||34|28

16418362.ab.6 METHODS: We performed preoperative stereotactic MR imaging at 3T to visualize the STN in 13 patients undergoing deep-brain stimulation for PD.


16418362.ab.6|relation|C0394162|Deep Brain Stimulation|topp|topp|||TREATS|C0030567|Parkinson Disease|dsyn|dsyn|||PREP|for|deep-brain stimulation|PD|134|112|139
16418362.ab.6|relation|C0394162|Deep Brain Stimulation|topp|topp|||ADMINISTERED_TO|C0030705|Patients|podg,humn|humn|||VERB|undergoing|deep-brain stimulation|patients|101|112|92|GERUND_INDICATOR
16418362.ab.6|relation|C1281060|Entire subthalamic nucleus|bpoc|bpoc|||PART_OF|C0030705|Patients|podg,humn|humn|||PREP|in|STN|patients|85|82|92

16418362.ab.12 CONCLUSION: 3T MR imaging appears to be an excellent tool for reliable and accurate direct visualization of the human STN, necessary for precise surgical targeting.


16418362.ab.12|relation|C1281060|Entire subthalamic nucleus|bpoc|bpoc|||PART_OF|C0086418|Homo sapients|humn|humn|||MOD/HEAD||STN|human||118|112

----- Citation 16424791 -----
16424791.ab.8 Treatment with amlodipine, independently of blood pressure lowering, reduced atherosclerosis development in E3L/CRP mice.


16424791.ab.8|relation|C0004153|Atherosclerosis|dsyn|dsyn|||PROCESS_OF|C0026809|Mus|mamm|mamm|||PREP|in|atherosclerosis|mice|104|77|116
16424791.ab.8|relation|C0087111|Therapeutic procedure|topp|topp|||PREVENTS|C0004153|Atherosclerosis|dsyn|dsyn|||VERB|reduced|Treatment|atherosclerosis|69|0|77|UMLS_CONC_REPLACE_SUBJ
16424791.ab.8|relation|C0087111|Therapeutic procedure|topp|topp|||USES|C0051696|Amlodipine|orch,phsu|phsu|||PREP|with|Treatment|amlodipine|9|0|15
16424791.ab.8|relation|C0051696|Amlodipine|orch,phsu|phsu|||PREVENTS(INFER)|C0004153|Atherosclerosis|dsyn|dsyn|||INFER||amlodipine|atherosclerosis||15|77|NOT_SURE_ABOUT INFERENCE
16424791.ab.8|relation|C0006560|C-reactive protein|aapp,gngm,imft|imft|||ADMINISTERED_TO|C0026809|Mus|mamm|mamm|||MOD/HEAD||CRP|mice||112|116
16424791.ab.8|relation|C0052200|apolipoprotein E3 (Leidein)|aapp|aapp|||ADMINISTERED_TO|C0026809|Mus|mamm|mamm|||MOD/HEAD||CRP|mice||112|116

----- Citation 16425104 -----
16425104.ab.4 To test this hypothesis, we investigated the combined effects of environmental conditions and inbreeding on fitness in the self-fertile snail Lymnaea stagnalis, using a stress gradient (0-2) applied to a 100 isolated and paired lineages: laboratory control (0), outdoor microcosm control (1) and pesticide exposure under outdoor microcosm conditions (2).


16425104.ab.4|relation|C0323913|Lymnaea stagnalis|invt|invt|||ISA|C0037378|Snails|invt|invt|||SPEC||Lymnaea stagnalis|snail||142|136

----- Citation 16430036 -----
16430036.ab.3 Two cycles of freezing--hawing were employed, with apex backward movement when necessary.



16430036.ab.8 58% of the patients had unilateral prostate cancer, 42% bilateral.


16430036.ab.8|relation|C0376358|Malignant neoplasm of prostate|neop|neop|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||AUX|had|prostate cancer|patients|20|35|11
16430036.ab.8|relation|C0376358|Malignant neoplasm of prostate|neop|neop|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||AUX|had|prostate cancer|patients|20|35|11|ELLIPSIS

16430036.ab.17 1 patient suffered injury of the mucosa at the prostatic urethra, which did not result in rectal fistula and was treated with bladder catheter for 3 months.


16430036.ab.17|relation|C0026724|Mucous Membrane|tisu|tisu|||LOCATION_OF|C0175677|Injury|inpo|inpo|||PREP|of|mucosa|injury|25|33|19
16430036.ab.17|relation|C0458450|Prostatic Urethra|bpoc|bpoc|||LOCATION_OF|C0175677|Injury|inpo|inpo|||PREP|at|prostatic urethra|injury|39|47|19
16430036.ab.17|relation|C0175677|Injury|inpo|inpo|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||VERB|suffered|injury|patient|10|19|2
16430036.ab.17|relation|C0179802|Urinary catheter|medd|medd|||TREATS|C0175677|Injury|inpo|inpo|||VERB|treated|bladder catheter|injury|113|126|19
16430036.ab.17|relation|C0175677|Injury|inpo|inpo|||NEG_CAUSES|C0034884|Rectal Fistula|anab|anab|||VERB|result|injury|rectal fistula|80|19|90|NON_SEMNET_RELATION

----- Citation 16430741 -----
16430741.ab.4 The aim of this study was to isolate and characterize synovial cells from the human temporomandibular joint (TMJ).


16430741.ab.4|relation|C1269048|Entire temporomandibular joint|bpoc|bpoc|||PART_OF|C0086418|Homo sapiens|grup,humn|humn|||MOD/HEAD||temporomandibular joint|human||84|78
16430741.ab.4|relation|C0224522|Synoviocytes|cell|cell|||PART_OF|C1269048|Entire temporomandibular joint|bpoc|bpoc|||PREP|from|synovial cells|temporomandibular joint|68|54|84|NO_INDICATOR_RULE

----- Citation 16431130 -----
16431130.ab.5 We here report the implementation of a new, telemetric, infrared-video gaze-tracker to measure visual orienting in freely moving, socially housed prosimian primates (Lemur catta).


16431130.ab.5|relation|C0086861|Prosimii|mamm|mamm|||ISA|C0033147|Primates|mamm|mamm|||SPEC||prosimian|primates||146|156
16431130.ab.5|relation|C0324779|Lemur catta|mamm|mamm|||ISA|C0033147|Primates|mamm|mamm|||SPEC|(|Lemur catta|primates|165|166|156

----- Citation 16436670 -----
16436670.ab.4 IFN-alpha profoundly alters cytoskeletal organization of hairy cells and causes reversion of the hairy appearance into a rounded morphology.


16436670.ab.4|relation|C1610033|Interferon Alpha, Human|aapp,gngm,imft|aapp|||AFFECTS|C1511632|Cytoskeletal Modeling|celf|celf|||VERB|alters|IFN-alpha|cytoskeletal organization|21|0|28
16436670.ab.4|relation|C0333850|Hairy cell|cell|cell|||LOCATION_OF|C1511632|Cytoskeletal Modeling|celf|celf|||PREP|of|hairy cells|cytoskeletal organization|53|57|28

16436670.ab.5 Because cytoskeletal rearrangements are controlled by the Rho family of GTPases, we investigated the GTPase activation status in hairy cells and their regulation by IFN-alpha.

16436670.ab.5|relation|C1610033|Interferon Alpha, Human|aapp,imft|aapp|||INTERACTS_WITH|C0018296|Guanosine Triphosphate Phosphohydrolases|aapp,enzy|aapp|||NOM|regulation|IFN-alpha|GTPase|151|165|101|ANAPHORA
16436670.ab.5|relation|C0333850|Hairy cell|cell|cell|||LOCATION_OF|C0018296|Guanosine Triphosphate Phosphohydrolases|aapp,enzy|aapp|||PREP|in|hairy cells|GTPase|125|129|101

16436670.ab.7 In sharp contrast, RhoA activity was low in hairy cells but was increased by IFN-alpha treatment.


16436670.ab.7|relation|C0333850|Hairy cell|cell|cell|||LOCATION_OF|C0812234|RHOA gene|gngm|gngm|387|RHOA|PREP|in|hairy cells|RhoA|40|44|19
16436670.ab.7|relation|C1610033|Interferon Alpha, Human|aapp,imft|aapp|||STIMULATES|C0812234|RHOA gene|gngm|gngm|387|RHOA|VERB|increased|IFN-alpha|RhoA|64|77|19

----- Citation 16440178 -----
16440178.ab.1 The secretion of uterine luminal fluid initially provides a transport and support medium for spermatozoa and unimplanted embryos, while the absorption of uterine luminal fluid in early pregnancy results in the closure of the lumen and allows blastocysts to establish intimate contact with the uterine epithelium.


16440178.ab.1|relation|C0014609|Epithelium|tisu|tisu|||PART_OF|C0042149|Uterus|bpoc|bpoc|||MOD/HEAD||epithelium|uterine||301|293
16440178.ab.1|relation|C0042149|Uterus|bpoc|bpoc|||LOCATION_OF|C0005889|Body Fluids|bdsu|bdsu|||MOD/HEAD||uterine|fluid||17|33|NON_SEMNET_RELATION, UMLS_CONC_REPLACE_OBJ, DYSONYM


----- Citation 16441715 -----
16441715.ti.1 Is a dual-sensor pacemaker appropriate in patients with sino-atrial disease?


16441715.ti.1|relation|C0037188|Sinoatrial Block|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|sino-atrial disease|patients|50|56|42|UMLS_CONC_REPLACE_SUBJ
16441715.ti.1|relation|C0810633|pacemakers|medd|medd|||TREATS|C0030705|Patients|podg,humn|podg|||PREP|in|pacemaker|patients|38|17|42
16441715.ti.1|relation|C0810633|pacemakers|medd|medd|||TREATS(INFER)|C0037188|Sinoatrial Block|dsyn|dsyn|||INFER||pacemaker|sino-atrial disease||17|56

----- Citation 16445747 -----
16445747.ti.1 Promoters and their regulation in Ustilago maydis and other phytopathogenic fungi.


16445747.ti.1|relation|C0446013|Ustilago maydis|fngs|fngs|||LOCATION_OF|C0086860|Promoter (Genetics)|bacs,nnon|bacs|||PREP|in|Ustilago maydis|Promoters|30|34|0
16445747.ti.1|relation|C0016832|fungus|fngs|fngs|||LOCATION_OF|C0086860|Promoter (Genetics)|bacs,nnon|bacs|||PREP|in|fungi|Promoters|30|76|0

16445747.ab.3 In Ustilago maydis, central players of pathogenic development are the high mobility group box protein Prf1 that binds to the pheromone response element and the homeodomain transcription factor b, which recognizes an hsg-like consensus motif known from yeast Mata1-Matalpha2 DNA binding.


16445747.ab.3|relation|||gngm,aapp|aapp|5551|PRF1|INTERACTS_WITH|C0600508|Response Elements|bacs,nnon|bacs|||VERB|binds|Prf1|response element|112|102|135
16445747.ab.3|relation|||gngm,aapp|aapp|5551|PRF1|ISA|C0949597|HMGB Proteins|aapp,bacs|aapp|||SPEC||Prf1|high mobility group box protein||102|70|NOT_IN_HIERARCHY
16445747.ab.3|relation|C0904168|MAT alpha 2 protein|aapp|aapp|||INTERACTS_WITH|||gngm,aapp|aapp|4143|MAT1A|NOM|binding|Matalpha2|Mata1|278|264|258
16445747.ab.3|relation|C1148673|DNA Binding|genf|genf|||PROCESS_OF|C0036025|Saccharomyces cerevisiae|fngs|fngs|||MOD/HEAD||DNA binding|yeast||274|252|SN_RELATION_DISALLOWED
16445747.ab.3|relation|C0904168|MAT alpha 2 protein|aapp|aapp|||PART_OF|C0036025|Saccharomyces cerevisiae|fngs|fngs|||MOD/HEAD||Matalpha2|yeast||264|252

----- Citation 16455026 -----
16455026.ti.1 Selection of optimal adjuvant endocrine therapy for early-stage breast cancer.


16455026.ti.1|relation|C0279025|Endocrine therapy|topp|topp|||TREATS|C0678222|Breast Carcinoma|neop|neop|||PREP|for|endocrine therapy|breast cancer|47|30|64

16455026.ab.2 Decades later, the discovery that estrogen plays a central role in this process eventually led to two important consequences: first, different modalities were developed to suppress or antagonize estrogen; and second, the ability to detect estrogen receptor in breast cancer tissue became a predictor of response to treatment--probably the best marker for response among all solid tumors.


16455026.ab.2|relation|C1521747|Mammary Gland Parenchyma|tisu|tisu|||LOCATION_OF|C0034804|Estrogen Receptors|aapp,rcpt|aapp|2099|ESR1|PREP|in|breast cancer tissue|estrogen receptor|256|260|239
16455026.ab.2|relation|C1521747|Mammary Gland Parenchyma|tisu|tisu|||PART_OF|C0006826|Malignant Neoplasms|neop|neop|||MOD/HEAD||tissue|breast cancer||274|260

16455026.ab.3 Tamoxifen, which works by competitively antagonizing hormonal receptors in breast cancer cells, has been for the past three decades the standard of care for adjuvant therapy for any woman with hormone receptor-positive early breast cancer, regardless of nodal status or menopausal setting.


16455026.ab.3|relation|C0039286|Tamoxifen|orch,phsu|phsu|||INHIBITS|C0019929|Hormone Receptor|aapp,rcpt|aapp|||VERB|antagonizing|Tamoxifen|hormonal receptors|40|0|53|GERUND_INDICATOR,NO_INDICATOR_RULE
16455026.ab.3|relation|C1512505|Breast Cancer Cell|cell|cell|||LOCATION_OF|C0019929|Hormone Receptor|aapp,rcpt|aapp|||PREP|in|breast cancer cells|hormonal receptors|71|75|53
16455026.ab.3|relation|C0678222|Breast Carcinoma|neop|neop|||PROCESS_OF|C0043210|Woman|popg,humn|humn|||PREP|with|breast cancer|woman|187|225|182
16455026.ab.3|relation|C0677850|adjuvant therapy|topp|topp|||USES|C0039286|Tamoxifen|orch,phsu|phsu|||PREP|for|adjuvant therapy|Tamoxifen|152|157|0
16455026.ab.3|relation|C0677850|adjuvant therapy|topp|topp|||TREATS|C0043210|Woman|popg,humn|humn|||PREP|for|adjuvant therapy|woman|173|157|182
16455026.ab.3|relation|C0677850|adjuvant therapy|topp|topp|||TREATS(INFER)|C0678222|Breast Carcinoma|neop|neop|||INFER||adjuvant therapy|breast cancer||157|225
16455026.ab.3|relation|C0039286|Tamoxifen|orch,phsu|phsu|||TREATS(INFER)|C0043210|Woman|popg,humn|humn|||INFER||Tamoxifen|woman||0|182|INFERENCE
16455026.ab.3|relation|C0039286|Tamoxifen|orch,phsu|phsu|||TREATS(INFER)|C0678222|Breast Carcinoma|neop|neop|||INFER||Tamoxifen|breast cancer||0|225|INFERENCE

----- Citation 16460640 -----
16460640.ab.15 There were 54 trauma and 83 non-trauma patients.


16460640.ab.15|relation|C0175677|Injury|inpo|inpo|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||trauma|patients||14|39
16460640.ab.15|relation|C0175677|Injury|inpo|inpo|||NEG_PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||non-trauma|patients||28|39

16460640.ab.20 In HIV-positive surgical patients, CD4 counts have no relation to in-hospital outcome in a heterogeneous group of surgical patients.


16460640.ab.20|relation|C0019699|HIV Seropositivity|fndg|fndg|||PROCESS_OF|C0871463|Surgical Patients|podg,humn|humn|||MOD/HEAD||HIV-positive|surgical patients||3|16

----- Citation 16461476 -----
16461476.ab.1 BACKGROUND AND AIMS: Butyrate enemas have been shown to be effective in treatment of ulcerative colitis, but the mechanism of the effects of butyrate is not totally known.


16461476.ab.1|relation|C0014268|Administration of enema|topp|topp|||TREATS|C0009324|Ulcerative Colitis|dsyn|dsyn|||NOM|treatment|enema|ulcerative colitis|72|30|85
16461476.ab.1|relation|C0014268|Administration of enema|topp|topp|||USES|C0006521|Butyrates|lipd|lipd|||MOD/HEAD||enema|Butyrate||30|21|NON_SEMNET_RELATION
16461476.ab.1|relation|C0006521|Butyrates|lipd|lipd|||TREATS(INFER)|C0009324|Ulcerative Colitis|dsyn|dsyn|||INFER||Butyrate|ulcerative colitis||21|85|NON_SEMNET_RELATION

----- Citation 16462770 -----
16462770.ab.4 In analysing surgical tissue samples of NSCLC, we found that expression of MKP1/CL100, a negative regulator of JNK, showed a strong nuclear staining for tumor cells, whereas, in normal bronchial epithelia, MKP1 was localized in the cytoplasm as well as in nuclei.


16462770.ab.4|relation|C1333257|DUSP1 gene|gngm|gngm|1843|DUSP1|INTERACTS_WITH|C0872053|JUN kinase|aapp,enzy|aapp|3725|JUN|NOM|regulator|MKP1/CL100|JNK|98|75|111|NO_INDICATOR_RULE, UMLS_CONC_REPLACE_SUBJ, UMLS_CONC_REPLACE_OBJ
16462770.ab.4|relation|C0599333|Epithelium of bronchus|bpoc|bpoc|||LOCATION_OF|C1333257|DUSP1 gene|gngm|gngm|1843|DUSP1|PREP|in|bronchial epithelia|MKP1|174|185|206
16462770.ab.4|relation|C1292533|Tissue specimen|tisu|tisu|||PART_OF|C0007131|Carcinoma, Non-Small-Cell Lung|neop|neop|||PREP|of|tissue samples|NSCLC|36|22|40
16462770.ab.4|relation|C0010834|Cytoplasm|celc|celc|||LOCATION_OF|C1333257|DUSP1 gene|gngm|gngm|1843|DUSP1|VERB|localized|cytoplasm|MKP1|215|232|206|NEW_UMLS_CONC_OBJ
16462770.ab.4|relation|C0007610|Cell Nucleus|celc|celc|||LOCATION_OF|C1333257|DUSP1 gene|gngm|gngm|1843|DUSP1|VERB|localized|nuclei|MKP1|215|256|206|NEW_UMLS_CONC_OBJ

16462770.ab.6 Expressing a small-interfering RNA (siRNA) vector for MKP1 in H-460 cells resulted in a more efficient activation by cisplatin of JNK and p38 than in the parental cells, and this correlated with a 10-fold increase in sensitivity to cisplatin.

16462770.ab.6|relation|C0008838|Cisplatin|inch,phsu|inch|||STIMULATES|C0872053|JUN kinase|aapp,enzy|aapp|3725|JUN|NOM|activation|cisplatin|JNK|103|117|130
16462770.ab.6|relation|C0008838|Cisplatin|inch,phsu|inch|||STIMULATES|C1366876|MAPK14 gene|gngm|gngm|||NOM|activation|cisplatin|p38|103|117|138


16462770.ab.6|relation|C0007634|Cells|cell|cell|||LOCATION_OF|C1333257|DUSP1 gene|gngm|gngm|1843|DUSP1|PREP|in|cells|MKP1|58|68|54|NEW_UMLS_CONC_OBJ
16462770.ab.6|relation|C1099354|RNA, Small Interfering|bacs,nnon|bacs|||INTERACTS_WITH|C1333257|DUSP1 gene|gngm|gngm|1843|DUSP1|NOM|Expressing|small-interfering RNA|MKP1|0|13|54|NEW_UMLS_CONC_OBJ,GERUND_INDICATOR

16462770.ab.11 Overall, the results showed that inhibition of MKP1 expression contributes to a slow down in cell growth in mice and an increase of cisplatin-induced cell death in NSCLC.


16462770.ab.11|relation|C0008838|Cisplatin|inch,phsu|inch|||CAUSES|C0007587|Cell Death|celf|celf|||ADJ|induced|cisplatin|cell death|142|132|150
16462770.ab.11|relation|C0007587|Cell Death|celf|celf|||COEXISTS_WITH|C0007131|Carcinoma, Non-Small-Cell Lung|neop|neop|||PREP|in|cell death|NSCLC|160|150|164|NON_SEMNET_RELATION
16462770.ab.11|relation|C1333257|DUSP1 gene|gngm|gngm|1843|DUSP1|AFFECTS|C0007595|Cell Growth|celf|celf|||VERB|contributes|MKP1|cell growth|63|47|93|NEW_UMLS_CONC_OBJ
16462770.ab.11|relation|C0007595|Cell Growth|celf|celf|||PROCESS_OF|C0026809|Mus|mamm|mamm|||PREP|in|cell growth|mice|104|93|108

----- Citation 16470169 -----
16470169.ab.5 Rho signaling via ROCK has been previously shown either to activate or to downregulate PI3K/Akt.


16470169.ab.5|relation|C0073185|rho|aapp,imft|aapp|6010,29984|RHO,RHOD|STIMULATES|C0044602|1-Phosphatidylinositol 3-Kinase|aapp,enzy|aapp|||VERB|activate|Rho|PI3K|59|0|87
16470169.ab.5|relation|C0073185|rho|aapp,imft|aapp|6010,29984|RHO,RHOD|STIMULATES|C0164786|Proto-Oncogene Proteins c-akt|aapp,enzy|aapp|||VERB|activate|Rho|Akt|59|0|92
16470169.ab.5|relation|C0073185|rho|aapp,imft|aapp|6010,29984|RHO,RHOD|INHIBITS|C0044602|1-Phosphatidylinositol 3-Kinase|aapp,enzy|aapp|||VERB|downregulate|Rho|PI3K|74|0|87
16470169.ab.5|relation|C0073185|rho|aapp,imft|aapp|6010,29984|RHO,RHOD|INHIBITS|C0164786|Proto-Oncogene Proteins c-akt|aapp,enzy|aapp|||VERB|downregulate|Rho|Akt|74|0|92

16470169.ab.9 In addition, inhibition of PI3K, Akt, or ROCK partially decreased invasion.



----- Citation 16470989 -----
16470989.ab.7 DISCUSSION: Hierarchic severity levels, sum score of disability, and preceding changes in disability status are risk factors for depressive symptoms.


16470989.ab.7|relation|C0231170|Disability NOS|patf|patf|||PREDISPOSES|C0086132|Depressive Symptoms|sosy|sosy|||NOM|risk factor|disability|depressive symptoms|112|90|129|NON_SEMNET_RELATION

----- Citation 16479855 -----
16479855.ab.9 Balloon dilatation resulted in complete elimination of the stricture in 44/82 (54%) and a reduction in the stricture in 32/82 (39%) and no improvement in 6/82 (7%).


16479855.ab.9|relation|C0004704|Balloon Dilatation|topp|topp|||TREATS|C0333187|Stricture|anab|anab|||NOM|elimination|Balloon dilatation|stricture|40|0|59|NO_INDICATOR_RULE
16479855.ab.9|relation|C0004704|Balloon Dilatation|topp|topp|||TREATS|C0333187|Stricture|anab|anab|||NOM|reduction|Balloon dilatation|stricture|90|0|107|NO_INDICATOR_RULE,COORDINATION
16479855.ab.9|relation|C0004704|Balloon Dilatation|topp|topp|||NEG_TREATS|C0333187|Stricture|anab|anab|||NOM|improvement|Balloon dilatation|stricture|139|0|107|COORDINATION,ELLIPSIS

----- Citation 16480563 -----
16480563.ab.2 DESIGN: Participants with Down's syndrome (N=26) were compared with non-Down syndrome learning disabled participants (N=26).


16480563.ab.2|relation|C0013080|Down Syndrome|cgab,dsyn|dsyn|||PROCESS_OF|C0679646|Participant|popg,humn|humn|||PREP|with|Down's syndrome|Participants|20|26|8
16480563.ab.2|relation|C0013080|Down Syndrome|cgab,dsyn|dsyn|||NEG_PROCESS_OF|C0679646|Participant|popg,humn|humn|||MOD/HEAD||non-Down syndrome|participants||68|104
16480563.ab.2|relation|C0751265|Learning Disabilities|mobd|mobd|||PROCESS_OF|C0679646|Participant|popg,humn|humn|||MOD/HEAD||learning disabled|participants||86|104|UMLS_CONC_REPLACE_SUBJ

----- Citation 16483645 -----
16483645.ti.1 Immunohistochemical determination of estrogen receptor-alpha in vaginal and tumor tissues of healthy and TVT-affected bitches and their relation to serum concentrations of estradiol-17beta and progesterone.


16483645.ti.1|relation|C0042232|Vagina|bpoc|bpoc|||LOCATION_OF|C0665341|Estrogen Receptor alpha|aapp,rcpt|aapp|||PREP|in|vaginal|estrogen receptor-alpha|60|64|37
16483645.ti.1|relation|C0040300|Body tissue|tisu|tisu|||LOCATION_OF|C0665341|Estrogen Receptor alpha|aapp,gngm,rcpt|aapp|||PREP|in|tissues|estrogen receptor-alpha|60|82|37|COORDINATION
16483645.ti.1|relation|C0040300|Body tissue|tisu|tisu|||PART_OF|C0027651|Neoplasm|neop|neop|||MOD/HEAD||tissues|tumor||82|76
16483645.ti.1|relation|C0042465|Venereal Tumors, Veterinary|neop|neop|||PROCESS_OF|C0939793|Bitch|mamm|mamm|||ADJ|affected|TVT|bitches|109|105|118|NEW_UMLS_CONC_SUBJ
16483645.ti.1|relation|C0040300|Body tissue|tisu|tisu|||PART_OF|C0939793|Bitch|mamm|mamm|||PREP|of|tissues|bitches|89|82|118

16483645.ab.1 One of the most frequent canine neoplasms is the transmissible venereal tumor (TVT), which affects the male and the female genital tract.


16483645.ab.1|relation|C0027651|Neoplasm|neop|neop|||PROCESS_OF|C0012984|Canis familiaris|mamm|mamm|||MOD/HEAD||neoplasms|canine||32|25
16483645.ab.1|relation|C0042465|Venereal Tumors, Veterinary|neop|neop|||ISA|C0027651|Neoplasm|neop|neop|||SPEC|is|transmissible venereal tumor|neoplasms|42|49|32
16483645.ab.1|relation|C0042465|Venereal Tumors, Veterinary|neop|neop|||PROCESS_OF(SPEC)|C0012984|Canis familiaris|mamm|mamm|||INFER||transmissible venereal tumor|canine||49|25
16483645.ab.1|relation|C0042465|Venereal Tumors, Veterinary|neop|neop|||AFFECTS|C0017421|Female genitalia|bpoc|bpoc|||VERB|affects|transmissible venereal tumor|female genital tract|91|49|116|NON_SEMNET_RELATION

16483645.ab.8 Although some samples had expression in the endothelium of blood vessels, no ER-alpha expression was observed in neoplastic tissues.


16483645.ab.8|relation|C0014257|Endothelium|tisu|tisu|||PART_OF|C0005847|Blood Vessels|bpoc|bpoc|||PREP|of|endothelium|blood vessels|55|44|59
16483645.ab.8|relation|C0040300|Body tissue|tisu|tisu|||NEG_LOCATION_OF|C1521863|ESR1 protein, human|aapp,rcpt|aapp|2099|ESR1|PREP|in|tissues|ER-alpha|109|124|77
16483645.ab.8|relation|C0027651|Neoplasm|neop|neop|||LOCATION_OF|C0040300|Body tissue|tisu|tisu|||MOD/HEAD||neoplastic|tissues||113|124

----- Citation 16496259 -----
16496259.ab.13 Five eyes (7%) had transient increase of IOP controlled by topical antiglaucomatous medications.


16496259.ab.13|relation|C0013227|Pharmaceutical Preparations|phsu|phsu|||TREATS|C0595921|Intraocular pressure disorder|dsyn|dsyn|||VERB|controlled|antiglaucomatous medications|IOP|45|67|41
16496259.ab.13|relation|C0013227|Pharmaceutical Preparations|phsu|phsu|||TREATS|C0017601|Glaucoma|dsyn|dsyn|||MOD/HEAD||medications|antiglaucomatous||84|67
16496259.ab.13|relation|C0015392|Eye|bpoc|bpoc|||LOCATION_OF|C0595921|Intraocular pressure disorder|dsyn|dsyn|||VERB|had|eyes|IOP|15|5|41|NON_SEMNET_RELATION

----- Citation 16496495 -----
16496495.ab.9 Organophosphates were implicated in 70.9% of all fatalities, with over 20% resulting from oral exposure to rat poison (RP).

16496495.ab.9|relation|C1452958|Organophosphates|orch|orch|||AFFECTS|C0011065|Cessation of life|orgf|orgf|||VERB|implicated|Organophosphates|fatalities|22|0|49|NO_SYNONYM

16496495.ab.10 CONCLUSION: Organophosphates and rat poison (RP) are the leading causes of APP admissions to major referral hospitals in Zimbabwe, with most of the admissions being the result of deliberate self-poisoning.


16496495.ab.10|relation|C1452958|Organophosphates|orch|orch|||CAUSES|C0275009|Pesticide poisoning|inpo|inpo|||NOM|causes|Organophosphates|APP|65|12|75
16496495.ab.10|relation|C0032346|Poisons|hops|hops|||CAUSES|C0275009|Pesticide poisoning|inpo|inpo|||NOM|causes|poison|APP|65|37|75

----- Citation 16498946 -----
16498946.ab.3 In Gilbert's syndrome, genetic alterations are located at the promoter of the gene and accompanied by the nucleotide insert of thymine adenine (TA).


16498946.ab.3|relation|C0086860|Promoter (Genetics)|bacs,nnon|bacs|||PART_OF|C0017337|Genes|aapp,gngm|gngm|||PREP|of|promoter|gene|70|62|78|NEW_UMLS_CONC_SUBJ,DYSONYM
16498946.ab.3|relation|C0086860|Promoter (Genetics)|bacs,nnon|bacs|||LOCATION_OF|C0026882|Mutation|genf|genf|||VERB|located|promoter|genetic alterations|47|62|23|DYSONYM

----- Citation 16503396 -----
16503396.ab.11 Combined treatment improves overall and disease-free survival in patients with stage II, III and IVA oral tongue cancer.


16503396.ab.11|relation|C0009429|Combined Modality Therapy|topp|topp|||TREATS|C0030705|Patients|podg,humn|humn|||PREP|in|Combined treatment|patients|61|0|65
16503396.ab.11|relation|C0153349|Malignant neoplasm of tongue|neop|neop|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|tongue cancer|patients|73|106|65
16503396.ab.11|relation|C0009429|Combined Modality Therapy|topp|topp|||TREATS(INFER)|C0153349|Malignant neoplasm of tongue|neop|neop|||INFER||Combined treatment|tongue cancer||0|106

----- Citation 16503761 -----
16503761.ab.1 Thiazolidinediones (TZDs) are peroxisomal proliferator-activated receptor (PPAR)-gamma agonists.

16503761.ab.1|relation|C1257987|Thiazolidinediones|orch,phsu|orch|||ISA|C2917405|Peroxisome Proliferator Receptor gamma Agonist [EPC]|phsu|phsu|||SPEC|are|Thiazolidinediones (TZDs)|peroxisomal proliferator-activated receptor (PPAR)-gamma agonists|26|0|30|NEWER_UMLS_CONC_OBJ
16503761.ab.1|relation|C1257987|Thiazolidinediones|orch,phsu|orch|||STIMULATES|C0166417|PPAR gamma|aapp,gngm,rcpt|gngm|||NOM|agonists|Thiazolidinediones|peroxisomal proliferator-activated receptor (PPAR)-gamma|87|0|30

16503761.ab.7 Other, as yet, unapproved uses of TZDs include: non-alcoholic fatty liver disease, in which TZDs reduced hepatic fat accumulation and improved liver function tests; polycystic ovary syndrome, where TZDs improved ovulation, hirsutism and endothelial dysfunction; and lipodystrophies, where TZDs increased body fat (marginally) and decrease liver size.


16503761.ab.7|relation|C1257987|Thiazolidinediones|orch,phsu|phsu|||TREATS|C0012634|Disease|dsyn|dsyn|||NOM|uses|TZDs|disease|26|34|74
16503761.ab.7|relation|C0400966|Non-alcoholic fatty liver|dsyn|dsyn|||ISA|C0012634|Disease|dsyn|dsyn|||SPEC||non-alcoholic fatty liver|disease||48|74
16503761.ab.7|relation|C1257987|Thiazolidinediones|orch,phsu|phsu|||TREATS(SPEC)|C0400966|Non-alcoholic fatty liver|dsyn|dsyn|||INFER||TZDs|non-alcoholic fatty liver||34|48
16503761.ab.7|relation|C1257987|Thiazolidinediones|orch,phsu|phsu|||DISRUPTS|C0151765|Liver fatty deposition|fndg|fndg|||VERB|reduced|TZDs|hepatic fat accumulation|97|92|105|UMLS_CONC_REPLACE_OBJ,NON_SEMNET_RELATION
16503761.ab.7|relation|C1257987|Thiazolidinediones|orch,phsu|phsu|||TREATS|C0032460|Polycystic Ovary Syndrome|dsyn|dsyn|||NOM|uses|TZDs|polycystic ovary syndrome|26|34|165
16503761.ab.7|relation|C1257987|Thiazolidinediones|orch,phsu|phsu|||AUGMENTS|C0029965|Ovulation|ortf|ortf|||VERB|improved|TZDs|ovulation|203|198|212|NO_INDICATOR_RULE
16503761.ab.7|relation|C1257987|Thiazolidinediones|orch,phsu|phsu|||TREATS|C0019572|Hirsutism|fndg|fndg|||VERB|improved|TZDs|hirsutism|203|198|223
16503761.ab.7|relation|C1257987|Thiazolidinediones|orch,phsu|phsu|||TREATS|C0856169|Endothelial dysfunction|dsyn|dsyn|||VERB|improved|TZDs|endothelial dysfunction|203|198|237
16503761.ab.7|relation|C1257987|Thiazolidinediones|orch,phsu|phsu|||TREATS|C0023787|Lipodystrophy|dsyn|dsyn|||NOM|uses|TZDs|lipodystrophies|26|34|266
16503761.ab.7|relation|C1257987|Thiazolidinediones|orch,phsu|phsu|||AFFECTS|C0426688|Liver size|fndg|fndg|||VERB|decrease|TZDs|liver size|330|289|339
16503761.ab.7|relation|C1257987|Thiazolidinediones|orch,phsu|phsu|||AFFECTS|C0023901|Liver Function Tests|lbpr|lbpr|||VERB|improved|TZD|liver function tests||

----- Citation 16504132 -----
16504132.ab.10 CONCLUSION: Cu2+ is a significant inducer for lysogenic cyanobacterial cells and consequently would be a potential control agent in the cyanobacteria population in fresh water ecosystems.


16504132.ab.10|relation|C0009968|Copper|bacs,elii,phsu|bacs|||AUGMENTS|C0007634|Cells|cell|cell|||NOM|inducer|Cu2+|cells|34|12|71|NON_SEMNET_RELATION,NO_INDICATOR_RULE
16504132.ab.10|relation|C0007634|Cells|cell|cell|||PART_OF|C1047211|Cyanobacterium|bact|bact|||MOD/HEAD||cells|cyanobacterial||71|56
16504132.ab.10|relation|C0024352|Lysogeny|biof|biof|||PROCESS_OF|C1047211|Cyanobacterium|bact|bact|||MOD/HEAD||lysogenic|cyanobacterial||46|56

----- Citation 16507901 -----
16507901.ab.6 In the present study, we examined the expression of the alpha5(IV)/alpha6(IV) chains and the methylation profiles of the bidirectional promoter region of COL4A5/COL4A6 in colon cancer cell lines and colorectal tumor tissues.


16507901.ab.6|relation|C0040300|Body tissue|tisu|tisu|||PART_OF|C0009404|Colorectal Neoplasms|neop|neop|||MOD/HEAD||tissue|colorectal tumor||216|199
16507901.ab.6|relation|C0007600|Cell Line|cell|cell|||PART_OF|C0699790|Colon Carcinoma|neop|neop|||MOD/HEAD||cell line|colon cancer||184|171
16507901.ab.6|relation|C1413586|COL4A5 gene|gngm|gngm|||ASSOCIATED_WITH|C0699790|Colon Carcinoma|neop|neop|||PREP|in|COL4A5|colon cancer|167|154|171|UMLS_CONC_REPLACE_SUBJ, UMLS_CONC_REPLACE_OBJ, COORDINATION
16507901.ab.6|relation|C1332775|COL4A6 gene|gngm|gngm|||ASSOCIATED_WITH|C0699790|Colon Carcinoma|neop|neop|||PREP|in|COL4A6|colon cancer|167|161|171|UMLS_CONC_REPLACE_SUBJ, UMLS_CONC_REPLACE_OBJ, COORDINATION
16507901.ab.6|relation|C1413586|COL4A5 gene|gngm|gngm|||ASSOCIATED_WITH|C0009404|Colorectal Neoplasms|neop|neop|||PREP|in|COL4A5|colorectal tumor|167|154|199|UMLS_CONC_REPLACE_SUBJ, COORDINATION
16507901.ab.6|relation|C1332775|COL4A6 gene|gngm|gngm|||ASSOCIATED_WITH|C0009404|Colorectal Neoplasms|neop|neop|||PREP|in|COL4A6|colorectal tumor|167|161|199|UMLS_CONC_REPLACE_SUBJ, COORDINATION
16507901.ab.6|relation|C0033413|Promoter Regions (Genetics)|bacs,nnon|bacs|||PART_OF|C1332775|COL4A6 gene|gngm|gngm|||PREP|of|promoter region|COL4A6|150|135|161|UMLS_CONC_REPLACE_OBJ, COORDINATION
16507901.ab.6|relation|C0033413|Promoter Regions (Genetics)|bacs,nnon|bacs|||PART_OF|C1413586|COL4A5 gene|gngm|gngm|||PREP|of|promoter region|COL4A5|150|135|154|UMLS_CONC_REPLACE_OBJ, COORDINATION

----- Citation 16510729 -----
16510729.ab.1 The dopamine D3 receptor, which is highly enriched in nucleus accumbens (NAc), has been suggested to play an important role in reinforcement and reward.


16510729.ab.1|relation|C0028633|Nucleus Accumbens|bpoc|bpoc|||LOCATION_OF|C0082341|dopamine D3 receptor|aapp,rcpt|aapp|||PREP|in|nucleus accumbens|dopamine D3 receptor|50|54|4
16510729.ab.1|relation|C0082341|dopamine D3 receptor|aapp,rcpt|aapp|||AFFECTS|C0035397|Rewards|menp|menp|||COMPLEX|play an important role|dopamine D3 receptor|reward|101|4|145|NO_INDICATOR_RULE,NON_SEMNET_RELATION
16510729.ab.1|relation|C0082341|dopamine D3 receptor|aapp,rcpt|aapp|||AFFECTS|C0035007|Psychological reinforcement|menp,topp|menp|||COMPLEX|play an important role|dopamine D3 receptor|reinforcement|101|4|127|NO_INDICATOR_RULE,NON_SEMNET_RELATION,NEW_UMLS_CONC_OBJ
 
----- Citation 15561572 -----
15561572.ab.7 The molar relaxivity of PTIR267 in saline is 26 mM(-1)s(-1).



----- Citation 16513142 -----
16513142.ab.2 Some of these sequences are implicated in various specific cellular events, including meiotic recombination, chromosomal breaks and transcriptional regulation, and also in several human disorders.


16513142.ab.2|relation|C0012634|Disease|dsyn|dsyn|||PROCESS_OF|C0086418|Homo sapiens|grup,humn|humn|||MOD/HEAD||disorders|human||186|180
16513142.ab.2|relation|C0162326|DNA Sequence|nnon,nusq|nusq|||ASSOCIATED_WITH|C0012634|Disease|dsyn|dsyn|||VERB|implicated|sequences|disorders|28|14|186
16513142.ab.2|relation|C0162326|DNA Sequence|nnon,nusq|nnon|||AFFECTS|C1155792|Meiotic Recombination|celf|celf|||VERB|implicated|sequences|meiotic recombination|28|14|86
16513142.ab.2|relation|C0162326|DNA Sequence|nnon,nusq|nnon|||AFFECTS|C0333704|Chromosome Breaks|comd|comd|||VERB|implicated|sequences|chromosomal breaks|28|14|109
16513142.ab.2|relation|C0162326|DNA Sequence|nnon,nusq|nnon|||AFFECTS|C1158770|Transcriptional Regulation|celf|celf|||VERB|implicated|sequences|transcriptional regulation|28|14|132

16513142.ab.3 In this review, we document the formation of DNA secondary structures by the G-rich repetitive sequences that have been found in several minisatellites, telomeres and in various triplet repeats, and report their effects on in vitro DNA synthesis.


16513142.ab.3|relation|C1511699|DNA Structure|nnon|nnon|||AFFECTS|C0598312|DNA biosynthesis|genf|genf|||NOM|effects|DNA secondary structures|DNA synthesis|212|45|232|ANAPHORA
16513142.ab.3|relation|C0086908|Repetitive Region|nusq|nusq|||PART_OF|C0242827|Minisatellite Repeats|bacs,nnon|nnon|||PREP|in|repetitive sequences|minisatellites|125|84|137|NON_SEMNET_RELATION
16513142.ab.3|relation|C0086908|Repetitive Region|nusq|nusq|||PART_OF|C0282537|Trinucleotide Repeats|bacs,nnon|nnon|||PREP|in|repetitive sequences|triplet repeats|125|84|178|NON_SEMNET_RELATION
16513142.ab.3|relation|C0086908|Repetitive Region|nusq|nusq|||PART_OF|C0085187|telomere|celc|celc|||PREP|in|repetitive sequences|telomeres|125|84|153

----- Citation 16519885 -----
16519885.ab.4 Inhibitors for the Rho target, ROCK, which regulates myosin II activity, and for myosin II ATPase prevented the accumulation of AJ components, indicating that myosin II activity is more directly involved than Rho activity.

16519885.ab.4|relation|C0073185|rho|aapp,imft|aapp|||INTERACTS_WITH|C0027103|Myosin Type II|aapp,enzy|aapp|||VERB|regulates|Rho target|myosin II|43|19|53
16519885.ab.4|relation|C0243077|inhibitors|chvf|chvf|||Inhibitors||||1000|0|10|VERB|DISRUPTS|C0230613|Zonula Adherens|celc|||adherens junction||
C0243077|inhibitors|chvf|chvf|||Inhibitors||||1000|0|10|INHIBITS|C0027096|Myosin ATPase|aapp,enzy|aapp|||PREP|for|inhibitors|myosin II ATPase|| NO INDICATOR RULE, ALLOWED RELATION?

----- Citation 16531862 -----
16531862.ti.1 Concomitant fractures of the acetabulum and spine: a retrospective review of over 300 patients.


16531862.ti.1|relation|C1279100|Entire acetabulum|bpoc|bpoc|||LOCATION_OF|C0016658|Fracture|inpo|inpo|||PREP|of|acetabulum|fractures|21|29|12
16531862.ti.1|relation|C1280065|Entire spine|bpoc|bpoc|||LOCATION_OF|C0016658|Fracture|inpo|inpo|||PREP|of|spine|fractures|21|44|12

16531862.ab.7 An average 8.6-day delay in diagnosis occurred in three spine fracture patients.


16531862.ab.7|relation|C0080179|Spinal Fractures|inpo|inpo|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||spine fracture|patients||56|71

16531862.ab.9 CONCLUSIONS: It is essential that the traumatologists have a high index of suspicion for spine injury, particularly thoracolumbar injury in patients who sustain fractures of the acetabulum.


16531862.ab.9|relation|C1279100|Entire acetabulum|bpoc|bpoc|||LOCATION_OF|C0016658|Fracture|inpo|inpo|||PREP|of|acetabulum|fractures|170|178|161
16531862.ab.9|relation|C0016658|Fracture|inpo|inpo|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||VERB|sustain|fractures|patients|153|161|140|NO_INDICATOR_RULE
16531862.ab.9|relation|C0450219|Thoracolumbar|spco|spco|||LOCATION_OF|C0175677|Injury|inpo|inpo|||MOD/HEAD||thoracolumbar|injury||116|130
16531862.ab.9|relation|C0175677|Injury|inpo|inpo|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|in|injury|patients|136|130|140
16531862.ab.9|relation|C0037937|Spinal Injuries|inpo|inpo|||PROCESS_OF(SPEC)|C0030705|Patients|podg,humn|humn|||INFER||spine injury|patients||89|140
16531862.ab.9|relation|C0037937|Spinal Injuries|inpo|inpo|||ISA|C0175677|Injury|inpo|inpo|||SPEC|particularly|spine injury|injury|103|89|130|APPOSITIVE

----- Citation 16531984 -----
16531984.ab.1 Reactive oxygen species formation and release of pro-inflammatory/pro-atherogenic cytokines, that is, interleukin 1-beta and tumor necrosis factor-alpha, need the activation of the arachidonic acid cascade via the enzyme 5-lipoxygenase (5-Lox).


16531984.ab.1|relation|C0021753|Interleukin-1 beta|aapp,imft|aapp|||ISA|C0079189|cytokine|aapp,imft|aapp|||SPEC|is|interleukin 1-beta|cytokines|98|102|82
16531984.ab.1|relation|C1448177|TNF protein, human|aapp,bacs|aapp|7124|TNF|ISA|C0079189|cytokine|aapp,imft|aapp|||SPEC|is|tumor necrosis factor-alpha|cytokines|98|125|82
16531984.ab.1|relation|C0003693|Arachidonate 5-Lipoxygenase|aapp,bacs,gngm|aapp|||ISA|C0014442|Enzymes|enzy,orch|enzy|||SPEC||5-lipoxygenase|enzyme||221|214|UMLS_CONC_REPLACE_SUBJ,GOOD_SENTENCE
16531984.ab.1|relation|C0003693|Arachidonate 5-Lipoxygenase|aapp,bacs,gngm|aapp|||STIMULATES|C0003695|Arachidonic Acid|eico|eico|||NOM|activation|5-lipoxygenase|arachidonic acid|163|221|181|UMLS_CONC_REPLACE_SUBJ

16531984.ab.11 Omega-3 may thus protect PBMCs of ESRD patients against oxidative stress.


16531984.ab.11|relation|C1261469|End stage renal failure|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||ESRD|patients||34|39
16531984.ab.11|relation|C1321301|Peripheral blood mononuclear cell|cell|cell|||PART_OF|C0030705|Patients|podg,humn|humn|||PREP|of|PBMCs|ESRD|30|25|34
16531984.ab.11|relation|C0015689|Fatty Acids, Omega-3|bacs,lipd,phsu|phsu|||PREVENTS|C0242606|Oxidative Stress|comd|comd|||VERB|protect|Omega-3|oxidative stress|17|0|56|DYSONYM

----- Citation 16540467 -----
16540467.ab.4 APL patients carrying these mutations display resistance to retinoic acid (RA) and very poor prognosis.


16540467.ab.4|relation|C0023487|Acute Promyelocytic Leukemia|neop|neop|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||APL|patients||0|4

16540467.ab.6 Mut PML interacts with PML-RARalpha in PML-CB and potentiates PML-RARalpha-mediated inhibition of RA-dependent transcription.


16540467.ab.6|relation|C1366903|PML gene|gngm|gngm|5371|PML|INTERACTS_WITH|C1709412|PML-RARA Fusion Protein|aapp|aapp|||VERB|interacts|PML|PML-RARalpha|8|4|23|NEWER_UMLS_CONC_OBJ
16540467.ab.6|relation|C1366903|PML gene|gngm|gngm|5371|PML|AUGMENTS|C0040649|Transcription, Genetic|genf|genf|||VERB|potentiates|PML|transcription|50|4|111
16540467.ab.6|relation|C0040845|Tretinoin|orch,phsu|orch|||AFFECTS|C0040649|Transcription, Genetic|genf|genf|||ADJ|dependent|RA|transcription|101|98|111|NO_INDICATOR_RULE
16540467.ab.6|relation|C1709412|PML-RARA Fusion Protein|aapp|aapp|||DISRUPTS|C0040649|Transcription, Genetic|genf|genf|||NOM|inhibition|PML-RARalpha|transcription|84|62|111|NEWER_UMLS_CONC_SUBJ

----- Citation 16540643 -----
16540643.ab.1 There is an increasing interest in complementing conventional histopathologic evaluation with molecular tools that could increase the sensitivity and specificity of cancer staging for diagnostic and prognostic purposes.



----- Citation 16543714 -----
16543714.ti.1 A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4.


16543714.ti.1|relation|C0040808|Treatment Protocols|resa,topp|topp|||USES|C0249582|paricalcitol|orch,phsu,vita|phsu|||PREP|of|regimens|paricalcitol|31|23|35
16543714.ti.1|relation|C0040808|Treatment Protocols|resa,topp|topp|||TREATS|C0020503|Hyperparathyroidism, Secondary|dsyn|dsyn|||NOM|treatment|regimens|secondary hyperparathyroidism|64|23|77
16543714.ti.1|relation|C0249582|paricalcitol|orch,phsu,vita|phsu|||TREATS(INFER)|C0020503|Hyperparathyroidism, Secondary|dsyn|dsyn|||INFER||paricalcitol|secondary hyperparathyroidism||35|77
16543714.ti.1|relation|C0020503|Hyperparathyroidism, Secondary|dsyn|dsyn|||COEXISTS_WITH|C0022661|Kidney Failure, Chronic|dsyn|dsyn|||PREP|in|secondary hyperparathyroidism|CKD|106|77|110

16543714.ab.1 BACKGROUND: Intermittent dosing of calcitriol for secondary hyperparathyroidism (SHPT) has been associated with greater parathyroid hormone (PTH) reduction with fewer calcemic and phosphatemic effects than daily (QD) dosing.


16543714.ab.1|relation|C0006674|Calcitriol|horm,phsu,strd,vita|phsu|||TREATS|C0020503|Hyperparathyroidism, Secondary|dsyn|dsyn|||PREP|for|calcitriol|secondary hyperparathyroidism|45|35|50
16543714.ab.1|relation|C0006674|Calcitriol|horm,phsu,strd,vita|phsu|||INHIBITS|C0030520|Parathyroid Hormones|aapp,horm,phsu|horm|||NOM|reduction|calcitriol|parathyroid hormone|146|35|120|COMPLEX_INDICATOR

16543714.ab.9 CONCLUSIONS: QD dosing of paricalcitol capsules is as efficacious as TIW dosing in achieving the primary end point (2 consecutive > or = 30% reductions in PTH) in stage 3 and 4 CKD patients with SHPT.


16543714.ab.9|relation|C0022661|Kidney Failure, Chronic|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||CKD|patients||177|181
16543714.ab.9|relation|C0020503|Hyperparathyroidism, Secondary|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|SHPT|patients|189|195|181
16543714.ab.9|relation|C0249582|paricalcitol|orch,phsu,vita|phsu|||TREATS|C0030705|Patients|humn|humn|||PREP|in|paricalcitol|patients|79,151,159|26|181
16543714.ab.9|relation|C0249582|paricalcitol|orch,phsu,vita|phsu|||TREATS(INFER)|C0231178|Chronic failure|patf|patf|||INFER||paricalcitol|CKD||26|177
16543714.ab.9|relation|C0249582|paricalcitol|orch,phsu,vita|phsu|||TREATS(INFER)|C0020503|Hyperparathyroidism, Secondary|dsyn|dsyn|||INFER||paricalcitol|SHPT||26|195

16543714.ab.10 Moreover, the QD regimen had no significant effect on hypercalcemia, hyperphosphatemia or Ca x P product as compared with placebo or intermittent dosing.


16543714.ab.10|relation|C0040808|Treatment Protocols|resa,topp|resa|||compared_with|C0032042|Placebos|medd,topp|medd|||PART|compared|regimen|placebo|108|17|122
16543714.ab.10|relation|C0040808|Treatment Protocols|resa,topp|resa|||NEG_AFFECTS|C0085681|Hyperphosphatemia|dsyn|dsyn|||NOM|effect|regimen|hyperphosphatemia|44|17|69|COORDINATION
16543714.ab.10|relation|C0040808|Treatment Protocols|resa,topp|resa|||NEG_AFFECTS|C0020437|Hypercalcemia|dsyn|dsyn|||NOM|effect|regimen|hypercalcemia|44|17|54|COORDINATION

----- Citation 16549534 -----
16549534.ab.8 Reviewing previously reported cases, all patients diagnosed as DJS before 10 y of age have mutations involving one of the two ATP-binding cassettes (ABC) of the MRP2.


16549534.ab.8|relation|C0026882|Mutation|genf|genf|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||AUX|have|mutations|patients|86|91|41
16549534.ab.8|relation|C0022350|Jaundice, Chronic Idiopathic|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PART|diagnosed|DJS|patients|50|63|41
16549534.ab.8|relation|C0026882|Mutation|genf|genf|||LOCATION_OF|C0525410|multidrug resistance-associated protein 2|aapp,gngm,bacs|gngm|||VERB|involving|mutations|MRP2|101|91|161|NON_SEMNET_RELATION
16549534.ab.8|relation|C0242738|ATP-Binding Cassette Transporters|aapp,bacs|bacs|||PART_OF|C0525410|multidrug resistance-associated protein 2|aapp,bacs|bacs|||PREP|of|ATP-binding cassettes (ABC)|MRP2|153|126|161|UMLS_CONC_REPLACE_SUBJ, DYSONYM

16549534.ab.9 This study suggests that long-term follow-up is indicated for neonatal DJS because of possible recurrence and/or second attacks of jaundice in later life, and that disruption of functionally important ABC domains in MRP2 may be related to the earlier onset of the disease.

16549534.ab.9|relation|C0022350|Jaundice, Chronic Idiopathic|dsyn|dsyn|||PROCESS_OF|C0021289|Infant, Newborn|aggp,humn|humn|||MOD/HEAD||DJS|neonatal||71|62
16549534.ab.9|relation|C1522577|follow-up|hlca|hlca|||TREATS|C0022350|Jaundice, Chronic Idiopathic|dsyn|dsyn|||PREP|for|follow-up|DJS|57|35|71|PREP_IS_SUBCATEGORIZED_FOR_BY_INDICATED
16549534.ab.9|relation|C0525410|multidrug resistance-associated protein 2|aapp,gngm,bacs|gngm|||ASSOCIATED_WITH|C0012634|Disease|dsyn|dsyn|||VERB|related|MRP2|disease|228|216|264

----- Citation 16551631 -----
16551631.ab.5 CDC2 activity was also found to be higher in siPTHrP-treated cells.


16551631.ab.5|relation|C1332721|CDC2 gene|gngm,gngm|gngm|983|CDC2|PART_OF|C0007634|Cells|cell|cell|||PREP|in|CDC2|cells|41|0|61

----- Citation 16554223 -----
16554223.ti.1 CT pulmonary angiography is the first-line imaging test for acute pulmonary embolism: a survey of US clinicians.


16554223.ti.1|relation|C0677490|Pulmonary angiogram|diap|diap|||ISA|C0011923|Diagnostic Imaging|diap|diap|||SPEC|is|pulmonary angiography|imaging test|25|3|43|UMLS_CONC_REPLACE_OBJ
16554223.ti.1|relation|C0011923|Diagnostic Imaging|diap|diap|||DIAGNOSES|C2882221|Acute pulmonary embolism NOS|patf|patf|||PREP|for|imaging|acute pulmonary embolism|55|43|60


16554223.ab.1 RATIONALE AND OBJECTIVES: Our aim is to document current imaging practices for diagnosing acute pulmonary embolism (PE) among physicians practicing in the United States and explore factors associated with these practices.

16554223.ab.1|relation|C0079595|Imaging Techniques|diap|diap|||DIAGNOSES|C0034065|Pulmonary Embolism|dsyn|dsyn|||VERB|diagnosing|imaging|acute pulmonary embolism|79|57|90|GERUND_INDICATOR,DYSONYM PROCESSING?

----- Citation 16555656 -----
16555656.ab.2 METHODS: Flat dentin surfaces were obtained at the facial surface of extracted bovine incisors.


16555656.ab.2|relation|C0021156|Incisor|bpoc|bpoc|||PART_OF|C1140701|Bos taurus|mamm|mamm|||MOD/HEAD||incisors|bovine||86|79

----- Citation 16556753 -----
16556753.ab.1 BACKGROUND: Poor outcome in anterior cruciate ligament reconstruction is often related to tunnel position.


16556753.ab.1|relation|C0078960|Anterior Cruciate Ligament|bpoc|bpoc|||LOCATION_OF|C0524865|Reconstructive Surgical Procedures|topp|topp|||MOD/HEAD||anterior cruciate ligament|reconstruction||28|55

----- Citation 16569841 -----
16569841.ti.1 In vitro analysis of ISEcp1B-mediated mobilization of naturally occurring beta-lactamase gene blaCTX-M of Kluyvera ascorbata.


16569841.ti.1|relation|C0597979|beta-Lactamase|aapp,enzy,gngm|aapp|||PART_OF|C0315267|Kluyvera ascorbata|bact|bact|||PREP|of|beta-lactamase|Kluyvera ascorbata|102|74|106

16569841.ab.3 Insertions of ISEcp1B upstream of the blaCTX-M-2 gene in K. ascorbata reference strain CIP7953 were first selected with cefotaxime (0.5 and 2 microg/ml).



----- Citation 16584203 -----
16584203.ti.1 Relationship of stopped flow to steady state parameters in the dimeric copper amine oxidase from Hansenula polymorpha and the role of zinc in inhibiting activity at alternate copper-containing subunits.


16584203.ti.1|relation|C0319605|Hansenula polymorpha|fngs|fngs|||LOCATION_OF|C0019587|Amine Oxidase (Copper-Containing)|aapp,gngm,enzy|aapp|||PREP|from|Hansenula polymorpha|copper amine oxidase|91|97|71

----- Citation 16594738 -----
16594738.ab.8 For conventional slides, participant sensitivity on pure HSIL cases was greatest (98.0%) and on pure LSIL cases was least (95.2%), while participant performance on cases with mixed features was intermediate (97.0% for mixed HSIL and 96.7% for mixed LSIL).


16594738.ab.8|relation|C0597198|Performance|inbe|inbe|||PROCESS_OF|C0679646|Participant|popg,humn|humn|||MOD/HEAD||performance|participant||149|137

16594738.ab.9 In contrast, participant performance on ThinPrep slides showed the greatest sensitivity for mixed LSIL slides (97.9%), while performance on mixed HSIL slides showed the lowest sensitivity (95.7%); slides with pure features had intermediate sensitivity levels (96.3% for both HSIL and LSIL).


16594738.ab.9|relation|C0597198|Performance|inbe|inbe|||PROCESS_OF|C0679646|Participant|popg,humn|humn|||MOD/HEAD||performance|participant||25|13

16594738.ab.13 Participant performance on conventional mixed cases is distinctly different from performance on ThinPrep mixed cases.


16594738.ab.13|relation|C0597198|Performance|inbe|inbe|||PROCESS_OF|C0679646|Participant|popg,humn|humn|||MOD/HEAD||performance|Participant||12|0

----- Citation 16597919 -----
16597919.ti.1 Calcitonin gene-related peptide inhibits interleukin-1beta-induced endogenous monocyte chemoattractant protein-1 secretion in type II alveolar epithelial cells.


16597919.ti.1|relation|C0006669|Calcitonin Gene-Related Peptide|aapp,horm,nsba|aapp|||INHIBITS|C0128897|Monocyte Chemoattractant Protein-1|aapp,imft|aapp|||VERB|inhibits|Calcitonin gene-related peptide|monocyte chemoattractant protein-1|32|0|78
16597919.ti.1|relation|C0225700|Pneumocyte, type 2|cell|cell|||LOCATION_OF|C0128897|Monocyte Chemoattractant Protein-1|aapp,gngm,imft|aapp|||PREP|in|type II alveolar epithelial cells|monocyte chemoattractant protein-1|122|126|78
16597919.ti.1|relation|C0021753|Interleukin-1 beta|aapp,imft|aapp|||STIMULATES|C0128897|Monocyte Chemoattractant Protein-1|aapp,gngm,imft|aapp|||ADJ|induced|interleukin-1beta|monocyte chemoattractant protein-1|59|41|78

16597919.ab.8 Moreover, CGRP attenuated IL-1beta-induced reactive oxygen species (ROS) formation, the early event in proinflammatory factor signaling.


16597919.ab.8|relation|C0006669|Calcitonin Gene-Related Peptide|aapp,gngm,horm,nsba|aapp|||INHIBITS|C0162772|Reactive Oxygen Species|bacs,elii|bacs|||VERB|attenuated|CGRP|reactive oxygen species|15|10|43
16597919.ab.8|relation|C0021753|Interleukin-1 beta|aapp,gngm,imft|aapp|||STIMULATES|C0162772|Reactive Oxygen Species|bacs,elii|bacs|||ADJ|induced|IL-1beta|reactive oxygen species|35|26|43

16597919.ab.9 We previously showed that the CGRP inhibitory effect was mediated by elevated intracellular cAMP and show here that analogs of cAMP, 8-bromoadenosine 3',5'-cyclic monophosphothioate and the Sp isomer of adenosine 3',5'-cyclic monophosphothioate, mimicked the CGRP suppressive effect on IL-1beta-induced ROS formation, NF-kappaB activation, and MCP-1 secretion.


16597919.ab.9|relation|C0021753|Interleukin-1 beta|aapp,gngm,imft|aapp|||STIMULATES|C0162772|Reactive Oxygen Species|bacs,elii|bacs|||ADJ|induced|IL-1beta|ROS|295|286|303
16597919.ab.9|relation|C0175996|Protoplasm|celc|celc|||LOCATION_OF|C0001455|Cyclic AMP|nnon,bacs|nnon|||MOD/HEAD||intracellular|cAMP||78|92
16597919.ab.9|relation|C0001455|Cyclic AMP|nnon,bacs|nnon|||INTERACTS_WITH|C0006669|Calcitonin Gene-Related Peptide|aapp,horm,nsba|aapp|||VERB|mediated|cAMP|CGRP|57|92|30
16597919.ab.9|relation|C0006669|Calcitonin Gene-Related Peptide|aapp,gngm,horm,nsba|aapp|||INHIBITS|C0128897|Monocyte Chemoattractant Protein-1|aapp,imft|aapp|||ADJ|suppressive|CGRP|MCP-1|264|259|344|NO_INDICATOR_RULE, COORDINATION
16597919.ab.9|relation|C0006669|Calcitonin Gene-Related Peptide|aapp,gngm,horm,nsba|aapp|||INHIBITS|C0079904|NF-kappa B|aapp,imft|aapp|||ADJ|suppressive|CGRP|NF-kappaB|264|259|318|NO_INDICATOR_RULE, NEW_UMLS_CONC_OBJ, COORDINATION
16597919.ab.9|relation|C0006669|Calcitonin Gene-Related Peptide|aapp,gngm,horm,nsba|aapp|||INHIBITS|C0162772|Reactive Oxygen Species|bacs,elii|bacs|||ADJ|suppressive|CGRP|ROS |264|259|303

----- Citation 16604563 -----
16604563.ab.4 Both children and parents reported on the child's HRQL using parallel forms of the Children's Health Questionnaire.



----- Citation 16606611 -----
16606611.ab.5 Trimethylation of histone H3K4 and H3K27 at the embryonic/fetal and adult globin gene promoters is equivalent in definitive cells; therefore, the differential binding of EKLF to these promoters does not appear to result from changes in chromatin configuration.


16606611.ab.5|relation|C0215398|erythroid Kruppel-like factor|aapp,bacs|aapp|||INTERACTS_WITH|C0086860|Promoter (Genetics)|bacs,nnon|bacs|||NOM|binding|EKLF|promoters|159|170|184|UMLS_CONC_REPLACE_SUBJ,GERUND_INDICATOR
16606611.ab.5|relation|C0086860|Promoter (Genetics)|bacs,nnon|bacs|||PART_OF|C0017645|Globin|aapp,bacs|aapp|||MOD/HEAD||promoters|globin||86|74
16606611.ab.5|relation|C0017645|Globin|aapp,gngm,bacs|aapp|||PART_OF|C0001675|Adult|aggp,humn|humn|||MOD/HEAD||globin|adult||74|68

----- Citation 16608828 -----
16608828.ab.1 Cohort studies have consistently shown underground miners exposed to high levels of radon to be at excess risk of lung cancer, and extrapolations based on those results indicate that residential radon may be responsible for nearly 10-15% of all lung cancer deaths per year in the United States.


16608828.ab.1|relation|C0034629|Radon|elii,hops|elii|||PREDISPOSES|C0684249|Carcinoma of lung|neop|neop|||NOM|risk|radon|lung cancer|106|84|114
16608828.ab.1|relation|C0034629|Radon|elii,hops|elii|||CAUSES|C1306577|Death (finding)|fndg|fndg|||ADJ|responsible|radon|deaths|208|195|257
16608828.ab.1|relation|C0684249|Carcinoma of lung|neop|neop|||CAUSES|C1306577|Death (finding)|fndg|fndg|||MOD/HEAD||lung cancer|deaths||245|257|NO_INDICATOR_RULE

16608828.ab.4 The possibility that a demonstrated lung carcinogen may be present in large numbers of homes raises a serious public health concern.


----- Citation 16617173 -----
16617173.ab.5 Findings suggest the value of meditation as an intervention strategy with survivors and demonstrate the need for further research in this area.


16617173.ab.5|relation|C0814263|Meditation Therapy|topp|topp|||ISA|C1273869|Intervention regimes|hlca|hlca|||SPEC|as|meditation|intervention|41|30|47|APPOSITIVE

----- Citation 16625528 -----
16625528.ti.1 Replacement arthroplasty versus internal fixation for extracapsular hip fractures in adults.


16625528.ti.1|relation|C0185317|Arthroplasty, Replacement|topp|topp|||compared_with|C0016642|Fracture Fixation, Internal|topp|topp|||PREP|versus|Replacement arthroplasty|internal fixation|24|0|32
16625528.ti.1|relation|C0016642|Fracture Fixation, Internal|topp|topp|||TREATS|C0019557|Hip Fractures|inpo|inpo|||PREP|for|internal fixation|hip fractures|49|32|68|UMLS_CONC_REPLACE_OBJ,DYSONYM
16625528.ti.1|relation|C0019557|Hip Fractures|inpo|inpo|||PROCESS_OF|C0001675|Adult|aggp,humn|aggp|||PREP|in|hip fractures|adults|81|68|85|UMLS_CONC_REPLACE_SUBJ,DYSONYM
16625528.ti.1|relation|C0185317|Arthroplasty, Replacement|topp|topp|||TREATS|C0019557|Hip Fractures|inpo|inpo|||PREP|for|Replacement arthroplasty|hip fractures|49|0|68|UMLS_CONC_REPLACE_OBJ,DYSONYM

16625528.ab.1 BACKGROUND: Internal fixation, commonly used for extracapsular hip fractures, may fail particularly in unstable fractures.


16625528.ab.1|relation|C0016642|Fracture Fixation, Internal|topp|topp|||TREATS|C0019557|Hip Fractures|inpo|inpo|||PREP|for|Internal fixation|hip fractures|44|12|63
16625528.ab.1|relation|C0016642|Fracture Fixation, Internal|topp|topp|||NEG_TREATS|C0559876|Unstable fracture|inpo|inpo|||PREP|in|Internal fixation|unstable fractures|99|12|103

16625528.ab.5 SELECTION CRITERIA: Randomised and quasi-randomised trials comparing replacement arthroplasty with an internal fixation implant for adults with an extracapsular hip fracture.


16625528.ab.5|relation|C0019557|Hip Fractures|inpo|inpo|||PROCESS_OF|C0001675|Adult|aggp,humn|humn|||PREP|with|hip fracture|adults|138|161|132
16625528.ab.5|relation|C0185317|Arthroplasty, Replacement|topp|topp|||compared_with|C0021102|Implants|medd|medd|||VERB|comparing|replacement arthroplasty|implant|59|69|120|GERUND_INDICATOR
16625528.ab.5|relation|C0016642|Fracture Fixation, Internal|topp|topp|||USES|C0021102|Implants|medd|medd|||MOD/HEAD||internal fixation|implant||102|120
16625528.ab.5|relation|C0185317|Arthroplasty, Replacement|topp|topp|||TREATS|C0001675|Adult|aggp,humn|humn|||PREP|for|replacement arthroplasty|adults|127|69|132
16625528.ab.5|relation|C0021102|Implants|medd|medd|||TREATS|C0001675|Adult|aggp,humn|humn|||PREP|for|implant|adults|127|120|132
16625528.ab.5|relation|C0021102|Implants|medd|medd|||TREATS(INFER)|C0019557|Hip Fractures|inpo|inpo|||INFER||implant|hip fracture||120|161
16625528.ab.5|relation|C0185317|Arthroplasty, Replacement|topp|topp|||TREATS(INFER)|C0019557|Hip Fractures|inpo|inpo|||INFER||replacement arthroplasty|hip fracture||69|161
16625528.ab.5|relation|C0016642|Fracture Fixation, Internal|topp|topp|||TREATS|C0001675|Adult|aggp,humn|humn|||PREP|for|Internal fixation|adults
16625528.ab.5|relation|C0016642|Fracture Fixation, Internal|topp|topp|||TREATS(INFER)|C0019557|Hip Fractures|inpo|inpo||||Internal fixation|hip fracture

16625528.ab.7 We requested additional information from trial investigators.



----- Citation 16628891 -----
16628891.ab.2 In these crops, and particularly in covered tomatoes, bumble-bees are used for cross-pollination as an alternative to labour intensive manual techniques.



16628891.ab.5 The count of dead adults and larvae did not show any differences between the treatments, whereas the measurement of sugar water consumption was shown to correlate well with pollination.

16628891.ab.5|relation|C1875789|SUGAR/WATER|orch,phsu|orch|||AFFECTS|C1522786|pollination|orgf|orgf|||VERB|correlate|sugar water consumption|pollination|153|116|173|NEWER_UMLS_CONC_SUBJ
16628891.ab.5|relation|C1306577|Death (finding)|fndg|fndg|||PROCESS_OF|C0001675|Adult|aggp,humn|humn|||MOD/HEAD||dead|adults||13|18
16628891.ab.5|relation|C1306577|Death (finding)|fndg|fndg|||PROCESS_OF|C0023047|Larva|invt|invt|||MOD/HEAD||dead|larvae||13|29|COORDINATION

----- Citation 16630952 -----
16630952.ab.2 Extrapulmonary tuberculosis is presumably a marker of immunodeficiency, but cytokine responses have not been well studied in such patients.


16610952.ab.2|relation|C0679362|Extrapulmonary tuberculosis|dsyn|dsyn|||PREDISPOSES|C0021051|Immunologic Deficiency Syndromes|dsyn|dsyn|||NOM|marker|Extrapulmonary tuberculosis|immunodeficiency|44|0|54

16630952.ab.3 OBJECTIVE: Assess immune defects in persons with previous extrapulmonary tuberculosis.


16630952.ab.3|relation|C0301889|Immune defect|patf|patf|||PROCESS_OF|C0027361|Persons|popg,humn|humn|||PREP|in|immune defects|persons|32|18|36
16630952.ab.3|relation|C0679362|Extrapulmonary tuberculosis|dsyn|dsyn|||PROCESS_OF|C0027361|Persons|popg,humn|humn|||PREP|with|extrapulmonary tuberculosis|persons|32|58|36

----- Citation 16641628 -----
16641628.ab.4 In this report, we describe the use of customized parascapular free flaps, after standard reconstructive surgeries, for the correction of defects of facial contour in Treacher Collins patients.


16641628.ab.4|relation|C0242387|Mandibulofacial Dysostosis|cgab|cgab|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||Treacher Collins|patients||167|184
16641628.ab.4|relation|C0524865|Reconstructive Surgical Procedures|topp|topp|||PRECEDES|C0456999|Parascapular flap|bpoc|bpoc|||PREP|after|standard reconstructive surgeries|customized parascapular free flaps|74|81|39|NON_SEMNET_RELATION
16641628.ab.4|relation|C0524865|Reconstructive Surgical Procedures|topp|topp|||TREATS|C0030705|Patients|podg,humn|podg|||PREP|in|reconstructive surgeries|patients|163|90|184
16641628.ab.4|relation|C0524865|Reconstructive Surgical Procedures|topp|topp|||TREATS(INFER)|C0242387|Mandibulofacial Dysostosis|cgab|cgab|||INFER||reconstructive surgeries|Treacher Collins||90|167

16641628.ab.6 METHODS: From June 1995 to December 2003, 8 patients with Treacher Collins syndrome underwent microsurgical correction of facial contour using 16 free flaps.


16641628.ab.6|relation|C0242387|Mandibulofacial Dysostosis|cgab|cgab|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|Treacher Collins syndrome|patients|52|58|44|NON_SEMNET_RELATION
16641628.ab.6|relation|C0026035|Microsurgery|topp|topp|||ADMINISTERED_TO|C0030705|Patients|podg,humn|humn|||VERB|underwent|microsurgical|patients|84|94|44|NEW_UMLS_CONC_SUBJ
16641628.ab.6|relation|C0026035|Microsurgery|topp|topp|||USES|C0441031|Free flap|tisu|tisu|||VERB|using|microsurgical|free flaps|137|94|146|GERUND_INDICATOR,NEW_UMLS_CONC_SUBJ

16641628.ab.20 Customized soft-tissue free flaps can be employed to differentially resurface these defects and achieve optimal esthetic results in these challenging patients.



----- Citation 16643848 -----
16643848.ab.1 In the present study, we have shown that KCl known as an inducer for differentiation of neuronal cells increases the human Sia-alpha2,3-Gal-beta1,4-GlcNAc-R:alpha2,8-sialyltransferase (hST8Sia III) gene transcription via phosphoinositide 3 kinase (PI-3K) in glioblastoma U-87MG cells.


16643848.ab.1|relation|C0032825|Potassium Chloride|inch,phsu|phsu|||AUGMENTS|C0007589|Cell Differentiation process|celf|celf|||NOM|inducer|KCl|differentiation|57|41|69|NEW_UMLS_CONC_SUBJ,NEW_UMLS_CONC_OBJ
16643848.ab.1|relation|C1539875|ST8SIA3 gene|gngm|gngm|||LOCATION_OF|C0040649|Transcription, Genetic|genf|genf|||MOD/HEAD||hST8Sia III|gene transcription||185|198|NEW_UMLS_CONC_SUBJ, SEMNET_RELATION_BLOCKED_IN_LOCSEMNET
16643848.ab.1|relation|C0007634|Cells|cell|cell|||LOCATION_OF|C2936824|Phosphatidylinositol 3-Kinases|aapp,enzy|aapp|||PREP|in|U-87MG cells|phosphoinositide 3 kinase (PI-3K)|254|271|221|UMLS_CONC_REPLACE_OBJ
16643848.ab.1|relation|C0007589|Cell Differentiation process|celf|celf|||PROCESS_OF|C0007634|Cells|cell|cell|||PREP|of|differentiation|neuronal cells|84|88|69|UMLS_CONC_REPLACE_OBJ
16643848.ab.1|relation|C0007634|Cells|cell|cell|||LOCATION_OF|C0176363|Glioblastoma|neop|neop|||MOD/HEAD||U-87MG cells|glioblastoma||271|258|PART_OF_RELATION_BLOCKED_BETWEEN_NEOP_AND_CELL
16643848.ab.1|relation|C0032825|Potassium Chloride|inch,phsu|phsu|||AUGMENTS|C0040649|Transcription, Genetic|genf|genf|||VERB|increases|KCl|gene transcription|103|41|198|NEW_UMLS_CONC_SUBJ
16643848.ab.1|relation|C0032825|Potassium Chloride|inch,phsu|phsu|||INTERACTS_WITH|C2936824|Phosphatidylinositol 3-Kinases|aapp,enzy|aapp|||PREP|via|KCl|phosphoinositide 3 kinase (PI-3K)|216|41|221|NEW_UMLS_CONC_SUBJ,NEW_UMLS_CONC_OBJ,NO_INDICATOR_RULE
16643848.ab.1|relation|C1539875|ST8SIA3 gene|gngm|gngm|||LOCATION_OF|C0040649|Transcription, Genetic|genf|genf|||MOD/HEAD||hST8Sia III|gene transcription||185|198|NEW_UMLS_CONC_SUBJ, SEMNET_RELATION_BLOCKED_IN_LOCSEMNET

----- Citation 16644456 -----
16644456.ab.6 The clinical significance of these findings remains undefined, however, especially in view of the fact that small bowel lesions also have been found in about 10% of patients with arthritis not taking nonsteroidal anti-inflammatory drugs and in 13.8% of healthy subjects [41,42].


16644456.ab.6|relation|C0021852|Intestines, Small|bpoc|bpoc|||LOCATION_OF|C0221198|Lesion|fndg|fndg|||MOD/HEAD||small bowel|lesions||108|120
16644456.ab.6|relation|C0221198|Lesion|fndg|fndg|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|in|lesions|patients|148|120|165
16644456.ab.6|relation|C0003864|Arthritis|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|arthritis|patients|174|179|165
16644456.ab.6|relation|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NEG_ADMINISTERED_TO|C0030705|Patients|podg,humn|humn|||VERB|taking|nonsteroidal anti-inflammatory drugs|patients|193|200|165
16644456.ab.6|relation|C0221198|Lesion|fndg|fndg|||PROCESS_OF|C2349001|Human Study Subject|humn|humn|||PREP|in|lesions|subjects|240|120|261|NEWER_UMLS_CONC_OBJ

----- Citation 16649886 -----
16649886.ab.13 Moreover, there are indications that, in this relationship, repeated FAC appraisals are not only based on steady walking speeds, but that the walking speeds related to a specific FAC appraisal also change and, over time, may shift gradually from higher to lower speeds.



----- Citation 16673312 -----
16673312.ab.8 Making these assumptions, we calculated that the diagnosis of either intestinal tuberculosis or Crohn's disease would have been made made correctly in 77 of our 88 patients (87.5 %), incorrectly in seven patients (8.0 %), and would not have been made in four patients (4.5 %).


16673312.ab.8|relation|C0275911|Tuberculosis of intestines|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|in|intestinal tuberculosis|patients|147|69|164|COORDINATION
16673312.ab.8|relation|C0010346|Crohn's disease|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|in|Crohn's disease|patients|147|96|164

----- Citation 16687138 -----
16687138.ab.1 The sympathetic neurotransmitter norepinephrine has been found to increase mucosal adherence of enterohemorrhagic Escherichia coli O157:H7 in explants of murine cecum and porcine distal colon.


16687138.ab.1|relation|C0028351|Norepinephrine|nsba,orch,phsu|nsba|||ISA|C0027908|Neurotransmitters|nsba|nsba|||SPEC||norepinephrine|neurotransmitter||33|16
16687138.ab.1|relation|C0007531|Cecum|bpoc|bpoc|||PART_OF|C0026809|Mus|mamm|mamm|||MOD/HEAD||cecum|murine||161|154
16687138.ab.1|relation|C0009368|Colon|bpoc|bpoc|||PART_OF|C0039005|Family suidae|mamm|mamm|||MOD/HEAD||colon|porcine||186|171

----- Citation 16688036 -----
16688036.ab.2 OBJECTIVES: To determine significant correlations between kyphosis and lordosis in Scheuermann kyphosis, determine predictability of spontaneous sagittal lordosis correction after thoracic correction and fusion, and understand better the biomechanics of the spine.


16688036.ab.2|relation|C0022821|Kyphosis deformity of spine|anab,dsyn|anab|||COEXISTS_WITH|C0024003|Lordosis|anab|anab|||NOM|correlations|kyphosis|lordosis|37|58|71|UMLS_CONC_SUBJ_REPLACE, DYSONYM
16688036.ab.2|relation|C0022821|Kyphosis deformity of spine|anab,dsyn|anab|||COEXISTS_WITH|C0036310|Scheuermann's Disease|dsyn|dsyn|||PREP|in|kyphosis|Scheuermann kyphosis|79|58|83|UMLS_CONC_SUBJ_REPLACE, DYSONYM
16688036.ab.2|relation|C0024003|Lordosis|anab|anab|||COEXISTS_WITH|C0036310|Scheuermann's Disease|dsyn|dsyn|||PREP|in|lordosis|Scheuermann kyphosis|79|71|83

----- Citation 16689926 -----
16689926.ti.2 (1)H-NMR structures and photoaffinity labeling of the Torpedo californica nicotinic acetylcholine receptor.


16689926.ti.2|relation|C0034830|Nicotinic Receptors|aapp,gngm,rcpt|gngm|||PART_OF|C0327698|Torpedo californica|fish|fish|||MOD/HEAD||nicotinic acetylcholine receptor|Torpedo californica||74|54

----- Citation 16696376 -----
16696376.ab.3 AIM: The aim of this study was to analyse chromosomal alterations in patients with azoospermia.


16696376.ab.3|relation|C0004509|Azoospermia|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|azoospermia|patients|77|83|69
16696376.ab.3|relation|C0008625|Chromosome abnormality|comd|comd|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|in|chromosomal alterations|patients|65|42|69

----- Citation 16702302 -----
16702302.ab.4 Older populations are more prone to bone loss with weight loss; in women, this is due at least in part to a reduced dietary Ca intake and/or efficiency of absorption.


16702302.ab.4|relation|C0043096|Body Weight decreased|fndg|fndg|||COEXISTS_WITH|C0599877|loss; bone|patf|patf|||PREP|with|weight loss|bone loss|45|51|36
16702302.ab.4|relation|C0599877|loss; bone|patf|patf|||OCCURS_IN|C1518563|Older Population|popg,humn|humn|||ADJ|prone|bone loss|Older populations|27|36|0
16702302.ab.4|relation|C0043096|Body Weight decreased|fndg|fndg|||OCCURS_IN|C1518563|Older Population|popg,humn|humn|||ADJ|prone|weight loss|Older populations|27|51|0

16702302.ab.5 Potential hormonal mechanisms regulating bone loss during weight loss are discussed, including decreases in estrogen, leptin, glucagon-like peptide-2, growth hormone, and insulin-like growth factor-1, or an increase in cortisol.


16702302.ab.5|relation|C0599877|loss; bone|patf|patf|||COEXISTS_WITH|C0043096|Body Weight decreased|fndg|fndg|||PREP|during|bone loss|weight loss|50|41|58|NO_INDICATOR_RULE
16702302.ab.5|relation|C0019932|Hormones|horm|horm|||AFFECTS|C0599877|loss; bone|patf|patf|||VERB|regulating|hormonal|bone loss|30|10|41|GERUND_INDICATOR,UMLS_CONC_REPLACE_SUBJ

----- Citation 16709260 -----
16709260.ab.9 CONCLUSION: This high-confidence characterization of seminal plasma content provides an inventory of proteins with potential roles in fertilization.


16709260.ab.9|relation|C0033684|Proteins|aapp,gngm,bacs|aapp|||AFFECTS|C0015914|Fertilization|orgf|orgf|||NOM|role|proteins|fertilization|125|101|134

----- Citation 16710995 -----
16710995.ab.5 The rat glioma cells were transfected with constructed pGenesil-1-shRNA plasmid and scrambled plasmid.


16710995.ab.5|relation|C0017638|Glioma|neop|neop|||PROCESS_OF|C0034721|Rattus|mamm|mamm|||MOD/HEAD||rat|glioma cells||4|8
16710995.ab.5|relation|C0007634|Cells|cell|cell|||LOCATION_OF|C0017638|Glioma|neop|neop|||MOD/HEAD||cells|glioma||15|8
16710995.ab.5|relation|C0032136|Plasmids|bacs,nnon|bacs|||ADMINISTERED_TO|C0007634|Cells|cell|cell|||VERB|transfected|cells|plasmid|26|15|72|NON_SEMNET_RELATION,NO_INDICATOR_RULE

----- Citation 16719197 -----
16719197.ab.7 The mean tumor size was 2.18 cm, smaller than the proposed for malignant criteria, and none of the eight patients (0%) had any symptoms of hypercalcemia at the time of diagnosis.


16719197.ab.7|relation|C1457887|Symptoms|sosy|sosy|||NEG_PROCESS_OF|C0030705|Patients|podg,humn|humn|||AUX|had|symptoms|patients|119|127|105
16719197.ab.7|relation|C1457887|Symptoms|sosy|sosy|||MANIFESTATION_OF|C0020437|Hypercalcemia|dsyn|dsyn|||PREP|of|symptoms|hypercalcemia|135|127|139|NO_INDICATOR_RULE

16719197.ab.8 Seven of eight patients (87.5%) had frank signs of invasion together with other histological features, and two patients had associated papillary carcinoma of the thyroid.

16719197.ab.8|relation|C0311392|Physical findings|sosy|sosy|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||VERB|had|signs|patients|32|42|15
16719197.ab.8|relation|C0007133|Carcinoma, Papillary|neop|neop|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||VERB|had|papillary carcinoma|patients|120|135|111
16719197.ab.8|relation|C0040132|Thyroid Gland|bpoc|bpoc|||LOCATION_OF|C0007133|Carcinoma, Papillary|neop|neop|||PREP|of|thyroid|papillary carcinoma|154|162|135|NEW_UMLS_CONC_OBJ, DYSONYM


16719197.ab.10 On the other hand, 17 patients with benign histology had tumors greater than 3 cm, and an additional 18 had palpable masses on physical examination.


16719197.ab.10|relation|C0027651|Neoplasm|neop|neop|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||AUX|had|tumors|patients|53|57|22
16719197.ab.10|relation|C0746412|MASS PALPABLE|fndg|fndg|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||AUX|had|palpable masses|patients|104|108|22|ELLIPSIS,UMLS_CON_REPLACE_SUBJ

----- Citation 16724072 -----
16724072.ab.2 Our study includes 711 systemic lupus erythematosus (SLE) patients and 755 healthy controls.


16724072.ab.2|relation|C0024141|Lupus Erythematosus, Systemic|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||systemic lupus erythematosus|patients||23|58

----- Citation 16732098 -----
16732098.ti.1 Parturition in the rat: a physiological pain model.


16732098.ti.1|relation|C0005615|Birth|orgf|orgf|||PROCESS_OF|C0034721|Rattus|mamm|mamm|||PREP|in|Parturition|rat|11|0|19

16732098.ab.7 Finally, epidural morphine (30 microg/10 microl) in oxytocin-treated rats, although resulting in no change of labor duration, significantly decreased the number of stretches (8 +/- 2 vs. 57 +/- 12 for epidural saline) and the number of c-Fos-positive neurons in the lumbosacral spinal segments (80 +/- 25 vs. 165 +/- 17 for epidural saline).


16732098.ab.7|relation|C0030095|Oxytocin|aapp,horm,phsu|aapp|||TREATS|C0034721|Rattus|mamm|mamm|||ADJ|treated|oxytocin|rats|61|52|69|NO_INDICATOR_RULE
16732098.ab.7|relation|C0026549|Morphine|orch,phsu|orch|||TREATS|C0034721|Rattus|mamm|mamm|||PREP|in|morphine|rats|48|18|69|NO_INDICATOR_RULE
16732098.ab.7|relation|C0026549|Morphine|orch,phsu|orch|||NEG_AFFECTS|C0566679|Duration of labor|clna|clna|||NOM|change|morphine|labor duration|100|18|110|NON_SEMNET_RELATION,NO_INDICATOR_RULE
16732098.ab.7|relation|C0223603|Lumbosacral spine|bpoc|bpoc|||LOCATION_OF|C0027882|Neurons|cell|cell|||PREP|in|lumbosacral spinal|neurons|258|266|251
16732098.ab.7|relation|C0027882|Neurons|cell|cell|||LOCATION_OF|C0085940|FOS gene|gngm|gngm|2353|FOS|ADJ|positive|neurons|c-Fos|242|251|236
16732098.ab.7|relation|C0026549|Morphine|orch,phsu|orch|||DISRUPTS|C0027882|Neurons|cell|cell|||VERB|decreased|morphine|neurons|140|18|251

----- Citation 16732879 -----
16732879.ab.4 Two applications of moxidectin completely prevented pre-natal and lactogenic infections in the puppies.


16732879.ab.4|relation|C0021311|Infection|dsyn|dsyn|||PROCESS_OF|C0869010|Puppies|mamm|mamm|||PREP|in|infections|puppies|87|77|95
16732879.ab.4|relation|C0163557|milbemycin B|antb,orch|antb|||PREVENTS|C0021311|Infection|dsyn|dsyn|||VERB|prevented|moxidectin|infections|42|20|77|COORDINATION

16732879.ab.7 The administration of moxidectin did not show any side effects in the dams.



----- Citation 16733164 -----
16733164.ab.3 METHODS: Tirofiban (0-100 ng x mL(-1)) and heparin (0 or 1 U x mL(-1)) were added to blood samples obtained from 20 healthy volunteers.



16733164.ab.9 After additional administration of heparin, platelet inhibition was only comparable for the glass bead test with heparinase and aggregometry, and the correlation coefficient remained unchanged for the glass bead test with heparinase versus aggregometry (rho = 0.878, P < .001).


16733164.ab.9|relation|C0200472|Platelet adhesiveness test|lbpr|lbpr|||USES|C0062507|Heparin Lyase|aapp,enzy|aapp|||PREP|with|glass bead test|heparinase|107|92|113|NEWER_UMLS_CONC_SUBJ,NON_SEMNET_RELATION
16733164.ab.9|relation|C0200472|Platelet adhesiveness test|lbpr|lbpr|||USES|C0062507|Heparin Lyase|aapp,enzy|aapp|||PREP|with|glass bead test|heparinase|216|201|222|NEWER_UMLS_CONC_SUBJ,NON_SEMNET_RELATION

16733164.ab.13 However, in heparinized blood the glass bead test with heparinase is essential to accurately assess platelet function.


16733164.ab.13|relation|C0200472|Platelet adhesiveness test|lbpr|lbpr|||USES|C0062507|Heparin Lyase|aapp,enzy|aapp|||PREP|with|glass bead test|heparinase|49|34|55|NEWER_UMLS_CONC_SUBJ,NON_SEMNET_RELATION

----- Citation 16733895 -----
16733895.ab.1 OBJECTIVE: To explore the impact of hydrogen sulfide (H2S) donor, sodium hydrosulfide (NaHS), on pulmonary vascular structure and vasoactive peptides in rats with pulmonary hypertension induced by high pulmonary blood flow.


16733895.ab.1|relation|C0074725|sodium bisulfide|inch|inch|||AFFECTS|C0459963|Pulmonary vascular structure|bpoc|bpoc|||NOM|impact|hydrogen sulfide|pulmonary vascular structure|26|36|97
16733895.ab.1|relation|C0074725|sodium bisulfide|inch|inch|||INTERACTS_WITH|C0030956|Peptides|aapp|aapp|||NOM|impact|hydrogen sulfide|peptides|26|36|141
16733895.ab.1|relation|C0459963|Pulmonary vascular structure|bpoc|bpoc|||PART_OF|C0034721|Rattus|mamm|mamm|||PREP|in|pulmonary vascular structure|rats|149|97|153
16733895.ab.1|relation|C0030956|Peptides|aapp|aapp|||PART_OF|C0034721|Rattus|mamm|mamm|||PREP|in|peptides|rats|149|141|153
16733895.ab.1|relation|C0020542|Hypertension, Pulmonary|dsyn|dsyn|||PROCESS_OF|C0034721|Rattus|mamm|mamm|||PREP|with|pulmonary hypertension|rats|157|163|153
16733895.ab.1|relation|C0232338|Blood flow|orgf|orgf|||CAUSES|C0020542|Hypertension, Pulmonary|dsyn|dsyn|||PART|induced|blood flow|pulmonary hypertension|186|212|163

16733895.ab.9 The morphologic changes including micro-and ultra-structural changes of pulmonary arteries of rats were observed under optical microscope and electro-microscope, respectively.


16733895.ab.9|relation|C0034052|Pulmonary artery structure|bpoc|bpoc|||PART_OF|C0034721|Rattus|mamm|mamm|||PREP|of|pulmonary arteries|rats|90|72|94

----- Citation 16736257 -----
16736257.ab.5 The probasal bodies and microtubules within the blepharoplast cavities are labeled with antibodies specific to acetylated tubulin.


16736257.ab.5|relation|C0026046|Microtubules|celc|celc|||PART_OF|C0230744|Basal body of cilium or flagellum, not bacterial|celc|celc|||PREP|within|microtubules|blepharoplast|36|24|48
16736257.ab.5|relation|C0003241|Antibodies|aapp,imft|aapp|||INTERACTS_WITH|C0041348|Tubulin|aapp,bacs|aapp|||ADJ|specific|antibodies|acetylated tubulin|99|88|111|NO_INDICATOR_RULE, ONLY_NOUN_SPECIFICITY

16736257.ab.6 Positive but weak reactions of the blepharoplast core occur with the centrosomereactive antibodies MPM-2 and C-9.


16736257.ab.6|relation|C1167518|nucleocapsid location|celc|celc|||PART_OF|C0230744|Basal body of cilium or flagellum, not bacterial|celc|celc|||MOD/HEAD||core|blepharoplast||49|35
16736257.ab.6|relation|C0242608|Centrosome|celc|celc|||LOCATION_OF|C0003241|Antibodies|aapp,imft|aapp|||MOD/HEAD||centrosome|antibodies||69|88|RUN_IN_WORDS

----- Citation 16739239 -----
16739239.ab.2 The effect of ligand concentration, the length of spacer arm and the nature of metal ion were investigated on immobilized metal ion affinity chromatography (IMAC).



----- Citation 16750542 -----
16750542.ab.1 X-linked adrenoleukodystrophy (X-ALD) is a peroxisomal disorder biochemically characterized by the accumulation of very long chain fatty acids (VLCFA), particularly hexacosanoic acid (C(26:0)) and tetracosanoic acid (C(24:0)), in tissues and biological fluids.


16750542.ab.1|relation|C0162309|Adrenoleukodystrophy|dsyn|dsyn|||ISA|C0282528|Peroxisomal Disorders|dsyn|dsyn|||SPEC|is|adrenoleukodystrophy|peroxisomal disorder|38|9|43
16750542.ab.1|relation|C0040300|Body tissue|tisu|tisu|||LOCATION_OF|C0064975|lignoceric acid|bacs,lipd|lipd|||PREP|in|tissue|tetracosanoic acid|226|230|197
16750542.ab.1|relation|C0040300|Body tissue|tisu|tisu|||LOCATION_OF|C0062609|hexacosanoic acid|bacs,lipd|lipd|||PREP|in|tissue|hexacosanoic acid|226|230|165
16750542.ab.1|relation|C0062609|hexacosanoic acid|bacs,lipd|lipd|||ISA|C0542549|Very long chain fatty acid|lipd|lipd|||SPEC|particularly|hexacosanoic acid|very long chain fatty acids (VLCFA)|152|165|115
16750542.ab.1|relation|C0064975|lignoceric acid|bacs,lipd|lipd|||ISA|C0542549|Very long chain fatty acid|lipd|lipd|||SPEC|particularly|tetracosanoic acid|very long chain fatty acids (VLCFA)|152|197|115


16750542.ab.2 Although patients affected by this disorder predominantly present central and peripheral demyelination as well as adrenal insufficiency, the mechanisms underlying the brain damage in X-ALD are poorly known.


16750542.ab.2|relation|C0012634|Disease|dsyn|dsyn|||AFFECTS|C0030705|Patients|podg,humn|humn|||VERB|affected|disorder|patients|18|35|9
16750542.ab.2|relation|C0270611|Brain Injuries|inpo|inpo|||COEXISTS_WITH|C0162309|Adrenoleukodystrophy|dsyn|dsyn|||PREP|in|brain damage|X-ALD|179|167|183
16750542.ab.2|relation|C0878575|Peripheral demyelination|patf|patf|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||VERB|present|peripheral demyelination|patients|58|78|9|NO_INDICATOR_RULE
16750542.ab.2|relation|C0001623|Adrenal gland hypofunction|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||VERB|present|adrenal insufficiency|patients|58|114|9|NO_INDICATOR_RULE

16750542.ab.8 Similarly, the antioxidant enzyme activities CAT, SOD and GPx were not altered in erythrocyte from X-ALD patients as compared to controls.


16750542.ab.8|relation|C0162309|Adrenoleukodystrophy|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||X-ALD|patients||99|105
16750542.ab.8|relation|C0014792|Erythrocytes|cell|cell|||PART_OF|C0030705|Patients|podg,humn|humn|||PREP|from|erythrocyte|patients|93|82|105
16750542.ab.8|relation|C0014792|Erythrocytes|cell|cell|||LOCATION_OF|C1148564|antioxidant activity|moft|moft|||PREP|in|erythrocyte|antioxidant enzyme activities|78|82|15

----- Citation 16751040 -----
16751040.ab.1 PURPOSE: To describe the ophthalmic findings in patients with Danon disease, an X-linked condition causing cardiomyopathy in males and females.


16751040.ab.1|relation|C0015411|Eye Manifestations|sosy|sosy|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|in|ophthalmic findings|patients|44|25|48
16751040.ab.1|relation|C0878677|Glycogen Storage Disease Type IIb|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|Danon disease|patients|56|62|48
16751040.ab.1|relation|C0878677|Glycogen Storage Disease Type IIb|dsyn|dsyn|||CAUSES|C0878544|Cardiomyopathies|dsyn|dsyn|||VERB|causing|Danon disease|cardiomyopathy|99|62|107|GERUND_INDICATOR
16751040.ab.1|relation|C0878544|Cardiomyopathies|dsyn|dsyn|||PROCESS_OF|C0086582|Males|popg,humn|humn|||PREP|in|cardiomyopathy|males|121|107|125
16751040.ab.1|relation|C0878544|Cardiomyopathies|dsyn|dsyn|||PROCESS_OF|C0086287|Females|popg,humn|humn|||PREP|in|cardiomyopathy|females|121|107|135

----- Citation 16752564 -----
16752564.ab.11 Experiment with a moving physical phantom was then carried out to demonstrate the accuracy of the proposed method and the increase of signal-to-noise ratio over three-dimensional PET.


16752564.ab.11|relation|C0681814|research study|resa|resa|||USES|C0282611|Phantoms, Imaging|medd|medd|||PREP|with|Experiment|phantom|10|0|34

----- Citation 16754935 -----
16754935.ab.1 PURPOSE: To address early and late treatment failures in older patients with diffuse large B-cell lymphoma (DLBCL), we designed a two-stage randomized trial of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) versus rituximab plus CHOP (R-CHOP), with a second random assignment to maintenance rituximab (MR) or observation in responding patients.


16754935.ab.1|relation|C0079744|Lymphoma, Large-Cell, Diffuse|neop|neop|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|diffuse large B-cell lymphoma|patients|71|77|63
16754935.ab.1|relation|C0163868|CHOP regimen|topp|topp|||compared_with|C1882519|R-CHOP regimen|topp|topp|||PREP|versus|CHOP|R-CHOP|225|220|254|UMLS_CONC_REPLACE_SUBJ,NEWER_UMLS_CONC_OBJ
16754935.ab.1|relation|C0393022|rituximab|aapp,imft,phsu|phsu|||TREATS|C0030705|Patients|humn|humn|||PREP|in|rituximab (MR)|patients|339|310|354

----- Citation 16757590 -----
16757590.ti.1 Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear array HPV genotyping test.


16757590.ti.1|relation|C0012854|DNA|bacs,nnon|nnon|||PART_OF|C0021344|Human Papillomavirus|virs|virs|||MOD/HEAD||DNA|human papillomavirus||60|33

16757590.ab.4 HPV DNA was detected in 433 (82.0%) and 458 (86.7%) samples with PGMY-LB and LA-HPV (P = 0.047), respectively, for an excellent agreement of 93.8% (kappa = 0.76).


16757590.ab.4|relation|C0012854|DNA|bacs,nnon|nnon|||PART_OF|C0021344|Human Papillomavirus|virs|virs|||MOD/HEAD||DNA|HPV||4|0

----- Citation 16758763 -----
16758763.ab.5 Foveolar sensitivity and foveolar sensitivity compared to the age have been evaluated.



----- Citation 16763070 -----
16763070.ab.3 However, the current study demonstrates that oral administration of dibutyl phthalate (DBP) to female Long Evans (LE) hooded rats from weaning, through puberty, mating, and gestation disrupts pregnancy maintenance at dose levels similar to those that affect testis function in male rats.


16763070.ab.3|relation|C0678881|testicular function|ortf|ortf|||PROCESS_OF|C0034721|Rattus|mamm|mamm|||PREP|in|testis function|rats|273|258|282
16763070.ab.3|relation|C0012052|Dibutyl Phthalate|orch,phsu|orch|||DISRUPTS|C0032971|Pregnancy Maintenance|orgf|orgf|||VERB|disrupts|dibutyl phthalate|pregnancy maintenance|183|68|192
16763070.ab.3|relation|C0012052|Dibutyl Phthalate|orch,phsu|orch|||ADMINISTERED_TO|C0324537|Rats, Long-Evans|mamm|mamm|||NOM|administration|dibutyl phthalate|Long Evans (LE) hooded rats|50|68|102|UMLS_CONC_REPLACE_OBJ
16763070.ab.3|relation|C0012052|Dibutyl Phthalate|orch,phsu|orch|||AFFECTS|C0678881|testicular function|ortf|ortf|||VERB|affect|dibutyl phthalate|testis function|251|68|258|ANAPHORA

16763070.ab.4 Administration of 500 and 1000 mg DBP/kg/day, but not 250 mg DBP/kg/day, to female LE rats induced midpregnancy abortions.


16763070.ab.4|relation|C0012052|Dibutyl Phthalate|orch,phsu|phsu|||ADMINISTERED_TO|C0324537|Rats, Long-Evans|mamm|mamm|||NOM|Administration|DBP|LE rats|0|34|83
16763070.ab.4|relation|C0012052|Dibutyl Phthalate|orch,phsu|phsu|||CAUSES|C0156543|Unspecified Abortion|fndg|fndg|||VERB|induced|DBP|abortions|91|34|112
16763070.ab.4|relation|C0012052|Dibutyl Phthalate|orch,phsu|phsu|||NEG_CAUSES|C0156543|Unspecified Abortion|fndg|fndg|||VERB|induced|DBP|abortions|91|61|112


----- Citation 16765853 -----
16765853.ti.1 Autogenic training for tension type headaches: a systematic review of controlled trials.


16765853.ti.1|relation|C0004361|Autogenic Training|topp|topp|||TREATS|C0033893|Tension Headache|dsyn|dsyn|||PREP|for|Autogenic training|tension type headaches|18|0|23

16765853.ab.10 Further studies should investigate the use of standard autogenic training in patients with moderate headache.


16765853.ab.10|relation|C0004361|Autogenic Training|topp|topp|||TREATS|C0030705|Patients|podg,humn|humn|||PREP|in|autogenic training|patients|73|55|77
16765853.ab.10|relation|C0018681|Headache|sosy|sosy|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|headache|patients|85|100|77
16765853.ab.10|relation|C0004361|Autogenic Training|topp|topp|||TREATS(INFER)|C0018681|Headache|sosy|sosy|||INFER||autogenic training|headache||55|100

----- Citation 16774846 -----
16774846.ab.12 Accordingly, our results may help in understanding the positive consequences of ketogenic or calorie-restricted diets in persons with seizures.


16774846.ab.12|relation|C0036572|Seizures|sosy|sosy|||PROCESS_OF|C0027361|Persons|popg,humn|humn|||PREP|with|seizures|persons|128|134|121
16774846.ab.12|relation|C1135809|Caloric Restriction|topp|topp|||TREATS|C0027361|Persons|popg,humn|humn|||PREP|in|calorie-restricted diets|persons|117|93|121
16774846.ab.12|relation|C1135809|Caloric Restriction|topp|topp|||TREATS(INFER)|C0036572|Seizures|sosy|sosy|||INFER||calorie-restricted diets|seizures||93|134

----- Citation 16776793 -----
16776793.ab.4 PARTICIPANTS: Seven practices (113 clinicians, 24,119 patients) were randomly assigned to receive age-specific prescribing alerts plus the academic detailing intervention; eight practices (126 clinicians, 26,805 patients) received alerts alone.



----- Citation 16781345 -----
16781345.ab.4 This clinical review article is intended to analyze the outcome of management of a group of 22 ACC patients, who were treated in our clinic.


16781345.ab.4|relation|C0010606|Adenoid Cystic Carcinoma|neop|neop|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||ACC|patients||95|99

16781345.ab.23 CONCLUSIONS: The most proper method of treatment for ACC seems to be radical resection combined with radiotherapy.


16781345.ab.23|relation|C0728940|Excision|topp|topp|||COEXISTS_WITH|C0034618|Radiation therapy|topp|topp|||PREP|with|resection|radiotherapy|95|77|101
16781345.ab.23|relation|C0728940|Excision|topp|topp|||ISA|C0087111|Therapeutic procedure|topp|topp|||SPEC|be|resection|treatment|66|77|39
16781345.ab.23|relation|C0087111|Therapeutic procedure|topp|topp|||TREATS|C0010606|Adenoid Cystic Carcinoma|neop|neop|||PREP|for|treatment|ACC|48|39|53
16781345.ab.23|relation|C0728940|Excision|topp|topp|||TREATS(SPEC)|C0010606|Adenoid Cystic Carcinoma|neop|neop|||INFER||resection|ACC||77|53

----- Citation 16787352 -----
16787352.ab.2 Straight chain alkanols such as 1-butanol, 1-pentanol and 1-hexanol in water at certain ratios were effective solvent systems.

16787352.ab.2|relation|C0089147|1-Butanol|lipd|lipd|||ISA|C1562418|Alkanol|orch|orch|||SPEC|such as|1-butanol|Straight chain alkanols|24|32|0|APPOSITIVE
16787352.ab.2|relation|C0044399|1-hexanol|phsu,orch|orch|||ISA|C1562418|Alkanol|orch|orch|||SPEC|such as|1-hexanol|Straight chain alkanols|24|58|0|UMLS_CONC_REPLACE_SUBJ,APPOSITIVE
16787352.ab.2|relation|C0068264|n-pentanol|irda,orch|orch|||ISA|C1562418|Alkanol|orch|orch|||SPEC|such as|1-pentanol|Straight chain alkanols|24|43|0|UMLS_CONC_REPLACE_SUBJ,APPOSITIVE

----- Citation 16798222 -----
16798222.ab.2 The aims of this study were to evaluate expression levels of NF-kappaB in nonsmall-cell lung cancer (NSCLC) and to elucidate its clinical significance and prognostic value for patients with NSCLC.


16798222.ab.2|relation|C0079904|NF-kappa B|aapp,imft|aapp|||ASSOCIATED_WITH|C0007131|Carcinoma, Non-Small-Cell Lung|neop|neop|||PREP|in|NF-kappaB|nonsmall-cell lung cancer|70|61|74
16798222.ab.2|relation|C0007131|Carcinoma, Non-Small-Cell Lung|neop|neop|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|NSCLC|patients|184|190|176

16798222.ab.12 Overexpression of NF-kappaB inhibits tumor cell apoptosis and indicates an unfavorable prognosis for overall survival in some patients with NSCLC.


16798222.ab.12|relation|C0079904|NF-kappa B|aapp,imft|aapp|||DISRUPTS|C0162638|Apoptosis|celf|celf|||VERB|inhibits|NF-kappaB|apoptosis|28|18|48|UMLS_CONC_REPLACE_SUBJ
16798222.ab.12|relation|C0007131|Carcinoma, Non-Small-Cell Lung|neop|neop|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|NSCLC|patients|134|140|126
SE|16798222|CONCLUSIONS|ab|12|relation|5|3|C0162638|Apoptosis|celf|celf|||apoptosis||||901|2104|2113|PREP|PROCESS_OF|C0597032|Neoplastic Cell|cell|||tumor cell|||

----- Citation 16801230 -----
16801230.ab.1 This laboratory experiment studied the effects of a thermal-insulating mouse pad on arm temperature and comfort during computer work.


16801230.ab.1|relation|C0022877|Laboratory|mnob,orgt|orgt|||LOCATION_OF|C0681814|research study|resa|resa|||MOD/HEAD||laboratory|experiment||5|16

16801230.ab.2 Fourteen subjects performed two 20-min computer tasks (a mouse task and a combined task alternating keyboard and mouse use), under three conditions, namely with: 1) a thermal-insulating pad; 2) a placebo pad; 3) no pad (desktop).



----- Citation 16809978 -----
16809978.ab.7 Multiple regression analysis revealed the duration of illness to be a risk factor for renal function deterioration in AN patients (r=0.580, p<0.001).


16809978.ab.7|relation|C0003125|Anorexia Nervosa|mobd|mobd|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||AN|patients||118|121
16809978.ab.7|relation|C0232807|Decreased renal function|fndg|fndg|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|in|renal function deterioration|patients|114|86|121|UMLS_CONC_REPLACE_SUBJ
16809978.ab.7|relation|C0232807|Decreased renal function|fndg|fndg|||COEXISTS_WITH(INFER)|C0003125|Anorexia Nervosa|mobd|mobd|||INFER||renal function deterioration|AN||86|118|INFERENCE

----- Citation 16815628 -----
16815628.ab.2 We determined if SNPs in haplotype block sub-regions C2 (SNPs C2-1, G/C(3436), C2-2, A/G(3944)) or C1 (C1-1, C/T(20965), C1-2, C/T(30056)) are associated with risk in an ultraviolet radiation (UVR)-dependent manner.



----- Citation 16823322 -----
16823322.ab.1 OBJECTIVE: We report a case of a choroid plexus vascular malformation of the cerebral aqueduct, third, and fourth ventricles of an adolescent female that was resected with endoscopic assistance.


16823322.ab.1|relation|C1280704|Entire choroid plexus|bpoc|bpoc|||LOCATION_OF|C0158570|Vascular anomaly|cgab|cgab|||MOD/HEAD||choroid plexus|vascular malformation||33|48
16823322.ab.1|relation|C0007769|Cerebral aqueduct|bsoj|bsoj|||LOCATION_OF|C0158570|Vascular anomaly|cgab|cgab|||PREP|of|cerebral aqueduct|vascular malformation|69|77|48
16823322.ab.1|relation|C0149556|Fourth ventricle structure|bsoj|bsoj|||LOCATION_OF|C0158570|Vascular anomaly|cgab|cgab|||PREP|of|fourth ventricles|vascular malformation|69|107|48
16823322.ab.1|relation|C0149555|Third ventricle structure|bsoj|bsoj|||LOCATION_OF|C0158570|Vascular anomaly|cgab|cgab|||PREP|of|third, and fourth ventricles|vascular malformation|69|96|48|UMLS_CONC_REPLACE_SUBJ,COORDINATION
16823322.ab.1|relation|C0007769|Cerebral aqueduct|bsoj|bsoj|||PART_OF|C0001588|Adolescents, Female|aggp,humn|humn|||PREP|of|cerebral aqueduct|adolescent female|124|77|131|UMLS_CONC_REPLACE_OBJ
16823322.ab.1|relation|C0149556|Fourth ventricle structure|bsoj|bsoj|||PART_OF|C0001588|Adolescents, Female|aggp,humn|humn|||PREP|of|fourth ventricles|adolescent female|124|107|131|UMLS_CONC_REPLACE_OBJ
16823322.ab.1|relation|C0149555|Third ventricle structure|bsoj|bsoj|||PART_OF|C0001588|Adolescents, Female|aggp,humn|humn|||PREP|of|third, and fourth ventricles|adolescent female|124|96|131|UMLS_CONC_REPLACE_OBJ


16823322.ab.4 Subsequent magnetic resonance imaging scans with and without contrast revealed an enhancing mass originating in the third ventricle, traversing the cerebral aqueduct, and terminating in the fourth ventricle.


16823322.ab.4|relation|C1268983|Entire third ventricle|bsoj|bsoj|||LOCATION_OF|C0577559|Mass of body structure|fndg|fndg|||VERB|originating|third ventricle|mass|97|116|92|UMLS_CONC_REPLACE_OBJ,WSD,NON_SEMNET_RELATION,NO_INDICATOR_RULE,GERUND_INDICATOR
16823322.ab.4|relation|C0007769|Cerebral aqueduct|bsoj|bsoj|||LOCATION_OF|C0577559|Mass of body structure|fndg|fndg|||VERB|traversing|cerebral aqueduct|mass|133|148|92|UMLS_CONC_REPLACE_OBJ,WSD,NON_SEMNET_RELATION,NO_INDICATOR_RULE,GERUND_INDICATOR
16823322.ab.4|relation|C1278832|Entire fourth ventricle|bsoj|bsoj|||LOCATION_OF|C0577559|Mass of body structure|fndg|fndg|||VERB|terminating|fourth ventricle|mass|171|190|92|UMLS_CONC_REPLACE_OBJ,WSD,NON_SEMNET_RELATION,NO_INDICATOR_RULE,GERUND_INDICATOR
16823322.ab.4|relation|C0024485|Magnetic Resonance Imaging|diap|diap|||DIAGNOSES|C0577559|Mass of body structure|fndg|fndg|||VERB|revealed|magnetic resonance imaging scans|mass|70|11|92|UMLS_CONC_REPLACE_OBJ,WSD
16823322.ab.4|relation|C0024485|Magnetic Resonance Imaging|diap|diap|||USES|C0009924|Contrast Media|irda|irda|||PREP|with|magnetic resonance imaging scans|contrast|43|11|61|COORDINATION, NON_SEMNET_RELATION
16823322.ab.4|relation|C0024485|Magnetic Resonance Imaging|diap|diap|||NEG_USES|C0009924|Contrast Media|irda|irda|||PREP|without|magnetic resonance imaging scans|contrast|52|11|61|COORDINATION, NON_SEMNET_RELATION

16823322.ab.8 CONCLUSION: Choroid plexus vascular malformations can exist intraventricularly and can be confused with a neoplasm.


16823322.ab.8|relation|C1280704|Entire choroid plexus|bpoc|bpoc|||LOCATION_OF|C0158570|Vascular anomaly|cgab|cgab|||MOD/HEAD||Choroid plexus|vascular malformations||12|27
16823322.ab.8|relation|C1517569|Intraventricular|blor|blor|||LOCATION_OF|C0158570|Vascular anomaly|cgab|cgab|||VERB|exist|intraventricularly|vascular malformations|54|60|27|NO_INDICATOR_RULE,NEW_UMLS_CONC_SUBJ

----- Citation 16842506 -----
16842506.ab.7 Many resident and immigrant inflammatory cells, including intraepithelial neutrophils, were IL-8 receptor A positive.


16842506.ab.7|relation|C1512942|intraepithelial|spco|spco|||LOCATION_OF|C0027950|neutrophil|cell|cell|||MOD/HEAD||intraepithelial|neutrophils||58|74|NON_SEMNET_RELATION
16842506.ab.7|relation|C0027950|neutrophil|cell|cell|||ISA|C0440752|Inflammatory cell|cell|cell|||SPEC|including|neutrophils|inflammatory cells|48|74|28|NOT_IN_HIERARCHY

16842506.ab.13 We suggest that this phenomenon, in contrast to chemotropism, is named chemophobia.



----- Citation 16850791 -----
16850791.ab.1 Posture disorders and morphofunctional defect were studied in 44 patients with cerebral insult using computer anthropometry.


16850791.ab.1|relation|C0012634|Disease|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|in|disorders|patients|58|8|65

----- Citation 16856002 -----
16856002.ti.1 Biphasic versus triphasic oral contraceptives for contraception.


16856002.ti.1|relation|C0700589|Contraceptive methods|topp|topp|||USES|C0009905|Contraceptives, Oral|phsu|phsu|||PREP|for|contraception|oral contraceptives|45|50|26

16856002.ab.2 A suggested disadvantage of biphasic compared to triphasic oral contraceptive pills is an increase in breakthrough bleeding.


16856002.ab.2|relation|C0009905|Contraceptives, Oral|phsu|phsu|||AUGMENTS|C0006140|Breakthrough Bleeding|fndg|fndg|||NOM|increase|oral contraceptive pills|breakthrough bleeding|90|59|102

16856002.ab.20 In contrast, cycle control with the biphasic pill was comparable to that of the triphasic containing the same progestin (norethindrone).


16856002.ab.20|relation|C0028356|Norethindrone|horm,phsu,strd|horm|||ISA|C0033306|Progestins|horm,phsu,strd|horm|||SPEC|(|norethindrone|progestin|120|121|110|APPOSITIVE

----- Citation 16856443 -----
16856443.ab.3 A retrospective study of prenatal, natal and postnatal data of pregnant women who had fetal echocardiography at Siriraj Hospital, Bangkok, Thailand, from January 1999 to July 2005 was conducted.


16856443.ab.3|relation|C0412564|Fetal echocardiography|diap|diap|||ADMINISTERED_TO|C0033011|Pregnant Women|popg,humn|humn|||AUX|had|fetal echocardiography|pregnant women|82|86|63
16856443.ab.3|relation|C0019994|Hospitals|hcro,mnob|hcro|||LOCATION_OF|C0412564|Fetal echocardiography|diap|diap|||PREP|at|Siriraj Hospital|fetal echocardiography|108|112|86

----- Citation 16875036 -----
16875036.ab.1 Pregnancies resulting from a spontaneous ovulation and fertilization are extremely rare in women with Turner syndrome.


16875036.ab.1|relation|C0041408|Turner's Syndrome|cgab,dsyn|dsyn|||PROCESS_OF|C0043210|Woman|popg,humn|humn|||PREP|with|Turner syndrome|women|96|102|91
16875036.ab.1|relation|C0029965|Ovulation|ortf|ortf|||CAUSES|C0032961|Pregnancy|orgf|orgf|||VERB|resulting|ovulation|Pregnancies|12|41|0|NON_SEMNET_RELATION,GERUND_INDICATOR
16875036.ab.1|relation|C0015914|Fertilization|orgf|orgf|||CAUSES|C0032961|Pregnancy|orgf|orgf|||VERB|resulting|ovulation|Pregnancies|12|41|0|NON_SEMNET_RELATION,GERUND_INDICATOR
16875036.ab.1|relation|C0032961|Pregnancy|orgf|orgf|||PROCESS_OF|C0043210|Woman|popg,humn|humn|||PREP|in|Pregnancies|women|87|0|91

----- Citation 16877310 -----
16877310.ti.1 The effectivity analysis of accumulation of liposomal, micellar, and water-soluble forms of diminazene in cells and in organs.


16877310.ti.1|relation|C0007634|Cells|cell|cell|||LOCATION_OF|C0012447|Diminazene|orch,phsu|orch|||PREP|in|cells|diminazene|102|106|92
16877310.ti.1|relation|C0178784|Organ|bpoc|bpoc|||LOCATION_OF|C0012447|Diminazene|orch,phsu|orch|||PREP|in|organs|diminazene|115|119|92

----- Citation 16877721 -----
16877721.ti.1 Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.


16877721.ti.1|relation|C0534628|Endostatins|aapp,phsu|aapp|||PART_OF|C0086418|Homo sapiens|grup,humn|humn|||MOD/HEAD||endostatin|human||36|30
16877721.ti.1|relation|C0534628|Endostatins|aapp,phsu|aapp|||TREATS|C0030705|Patients|podg,humn|humn|||PREP|in|endostatin|patients|46|36|50
16877721.ti.1|relation|C0206754|Neuroendocrine Tumors|neop|neop|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|neuroendocrine tumors|patients|58|73|50
16877721.ti.1|relation|C0534628|Endostatins|aapp,phsu|aapp|||TREATS(INFER)|C0206754|Neuroendocrine Tumors|neop|neop|||INFER||endostatin|neuroendocrine tumors||36|73

16877721.ab.4 PATIENTS AND METHODS: Forty-two patients with advanced pancreatic endocrine tumors or carcinoid tumors were treated with rhEndostatin administered as a bid subcutaneous injection at a starting dose of 60 mg/m2/d.


16877721.ab.4|relation|C0242363|Islet Cell Tumor|neop|neop|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|pancreatic endocrine tumors|patients|40|55|32
16877721.ab.4|relation|C0007095|Carcinoid Tumor|neop|neop|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|carcinoid tumors|patients|40|86|32
16877721.ab.4|relation|C1705207|Recombinant Human Endostatin|aapp,phsu|phsu|||TREATS|C0030705|Patients|podg,humn|humn|||VERB|treated|rhEndostatin|patients|108|121|32|NEWER_UMLS_CONC_SUBJ
16877721.ab.4|relation|C1705207|Recombinant Human Endostatin|aapp,phsu|phsu|||TREATS(INFER)|C0242363|Islet Cell Tumor|neop|neop|||INFER||rhEndostatin|pancreatic endocrine tumors||121|55|NEWER_UMLS_CONC_SUBJ
16877721.ab.4|relation|C1705207|Recombinant Human Endostatin|aapp,phsu|phsu|||TREATS(INFER)|C0007095|Carcinoid Tumor|neop|neop|||INFER||rhEndostatin|carcinoid tumors||121|86|NEWER_UMLS_CONC_SUBJ

----- Citation 16879324 -----
16879324.ab.1 We have recently shown that melatonin decreases the late (24 hr) increase in blood-brain barrier (BBB) permeability and the risk of tissue plasminogen activator-induced hemorrhagic transformation following ischemic stroke in mice.

16879324.ab.1|relation|C0025219|Melatonin|horm,nsba,phsu|horm|||AFFECTS|C1305865|Blood - brain barrier function|ortf|ortf|||COMPLEX|decreases the late (24 hr) increase in|melatonin|blood-brain barrier|38|28|77
16879324.ab.1|relation|C0025219|Melatonin|horm,nsba,phsu|horm|||AFFECTS(SPEC)|C0031164|Permeability|npop|npop|||COMPLEX|decreases the late (24 hr) increase in|melatonin|blood-brain barrier permeability|38|28|77
16879324.ab.1|relation|C0031164|Permeability|npop|npop|||PROCESS_OF|C0005854|Blood - brain barrier anatomy|bpoc|bpoc|||VERB|blood-brain barrier (BBB) permeability|38|28|77|
16879324.ab.1|relation|C0032143|Alteplase|aapp,enzy,phsu|aapp|||CAUSES|C1096400|Haemorrhagic transformation stroke|dsyn|dsyn|||ADJ|induced|tissue plasminogen activator|hemorrhagic transformation|161|132|169|UMLS_CONC_REPLACE_OBJ
16879324.ab.1|relation|C0948008|Ischemic stroke|dsyn|dsyn|||PRECEDES|C1096400|Haemorrhagic transformation stroke|dsyn|dsyn|||VERB|following|ischemic stroke|hemorrhagic transformation|196|206|169|GERUND_INDICATOR,UMLS_CONC_REPLACE_OBJ
16879324.ab.1|relation|C0948008|Ischemic stroke|dsyn|dsyn|||PROCESS_OF|C0026809|Mus|mamm|mamm|||PREP|in|ischemic stroke|mice|221|206|225

16879324.ab.2 In the study, we further explored whether melatonin would reduce postischemic neurovascular oxidative/nitrosative damage and, therefore, improve preservation of the early increase in the BBB permeability at 4 hr after transient focal cerebral ischemia for 60 min in mice.


16879324.ab.2|relation|C0025219|Melatonin|horm,nsba,phsu|horm|||PREVENTS|C0242606|Oxidative Stress|comd|comd|||VERB|reduce|melatonin|oxidative/nitrosative damage|58|42|92|UMLS_CONC_REPLACE_OBJ,COORDINATION
16879324.ab.2|relation|C0025219|Melatonin|horm,nsba,phsu|horm|||AUGMENTS|C0031164|Permeability|npop|npop|||VERB|improve|melatonin|permeability|137|42|191
16879324.ab.2|relation|C0917805|Transient Cerebral Ischemia|dsyn|dsyn|||PROCESS_OF|C0026809|Mus|mamm|mamm|||PREP|in|transient focal cerebral ischemia|mice|262|218|266

----- Citation 16887433 -----
16887433.ab.1 OBJECTIVE: To explore the hypothesis that high ghrelin levels contribute to obesity in Prader-Willi syndrome (PWS), we assessed whether the increased levels observed in older persons with PWS exist in very young children, before the onset of hyperphagia.


16887433.ab.1|relation|C0911014|ghrelin|aapp,bacs|aapp|||PREDISPOSES|C0028754|Obesity|dsyn|dsyn|||VERB|contribute|ghrelin|obesity|62|47|76
16887433.ab.1|relation|C0028754|Obesity|dsyn|dsyn|||COEXISTS_WITH|C0032897|Prader-Willi Syndrome|cgab|cgab|||PREP|in|obesity|Prader-Willi syndrome|83|76|87
16887433.ab.1|relation|C0032897|Prader-Willi Syndrome|cgab|cgab|||PROCESS_OF|C0001792|Elderly|aggp,humn|humn|||PREP|with|PWS|older persons|182|188|169|NEW_UMLS_CONC_OBJ

16887433.ab.4 PWS and control groups also had equivalent fasting levels of total ghrelin (787 +/- 242 vs 716 +/- 135 pg/mL, respectively; P = .24), bioactive ghrelin (102 +/- 35 vs 91 +/- 23 pg/mL; P = .45), insulin, and glucose.


16887433.ab.4|relation|C0009932|Control Groups|grup,humn|humn|||LOCATION_OF|C0911014|ghrelin|aapp,bacs|aapp|||AUX|had|control groups|ghrelin|28|8|67
16887433.ab.4|relation|C0009932|Control Groups|grup,humn|humn|||LOCATION_OF|C0911014|ghrelin|aapp,bacs|aapp|||AUX|had|control groups|ghrelin|28|8|144|COORDINATION
16887433.ab.4|relation|C0009932|Control Groups|grup,humn|humn|||LOCATION_OF|C0021641|Insulin|aapp,horm,phsu|aapp|||AUX|had|control groups|insulin|28|8|194|COORDINATION
16887433.ab.4|relation|C0009932|Control Groups|grup,humn|humn|||LOCATION_OF|C0017725|Glucose|bacs,carb,phsu|bacs|||AUX|had|control groups|glucose|28|8|207|COORDINATION

16887433.ab.6 CONCLUSIONS: Children <5 years of age with PWS, who had not yet developed hyperphagia or excessive obesity, had normal ghrelin levels, in contrast with the hyperghrelinemia of older, hyperphagic people with PWS.


16887433.ab.6|relation|C0032897|Prader-Willi Syndrome|cgab|cgab|||PART_OF|C0008059|Child|aggp,humn,inpr|humn|||PREP|with|PWS|Children|37|43|13
16887433.ab.6|relation|C0020505|Hyperphagia|mobd|mobd|||NEG_PROCESS_OF|C0008059|Child|aggp,humn,inpr|humn|||VERB|developed|hyperphagia|Children|64|74|13
16887433.ab.6|relation|C0028754|Obesity|dsyn|dsyn|||NEG_PROCESS_OF|C0008059|Child|aggp,humn,inpr|humn|||VERB|developed|obesity|Children|64|99|13
16887433.ab.6|relation|C0911014|ghrelin|aapp,bacs|aapp|||PART_OF|C0008059|Child|aggp,humn,inpr|humn|||AUX|had|ghrelin|Children|108|119|13
16887433.ab.6|relation|C0032897|Prader-Willi Syndrome|cgab|cgab|||PART_OF|C0027361|Persons|popg,humn|humn|||PREP|with|PWS|people|201|207|195
16887433.ab.6|relation|C0020505|Hyperphagia|mobd|mobd|||PROCESS_OF|C0027361|Persons|popg,humn|humn|||MOD/HEAD||hyperphagic|people||183|195

----- Citation 16890392 -----
16890392.ab.2 We report 4 cases of children presenting with a cerebral hydatid cyst (2 boys and 2 girls, mean age 9 years).


16890392.ab.2|relation|C0338436|Cerebral hydatid cyst|dsyn|dsyn|||PROCESS_OF|C0008059|Child|aggp,humn,inpr|humn|||VERB|presenting|cerebral hydatid cyst|children|30|48|21|GERUND_INDICATOR

----- Citation 16895685 -----
16895685.ab.1 Diffuse atherosclerosis entails a 15-30% risk of plaques on renal arteries (ARAS), with a correlation with coronary atherosclerosis.


16895685.ab.1|relation|C0035065|Structure of renal artery|bpoc|bpoc|||LOCATION_OF|C0332461|Plaque (lesion)|fndg|fndg|||PREP|on|renal arteries|plaques|56|60|49
16895685.ab.1|relation|C0017327|Generalized atherosclerosis|dsyn|dsyn|||PREDISPOSES|C0332461|Plaque (lesion)|fndg|fndg|||NOM|risk|Diffuse atherosclerosis|plaques|41|0|49|NON_SEMNET_RELATION, UMLS_CONC_REPLACE_SUBJ, UMLS_CONC_REPLACE_OBJ

16895685.ab.26 Skin or muscle biopsy are contributive in showing crystals and help avoid renal biopsy; 3) other localizations involve the mesenteric circulation and the central nervous system.



----- Citation 16899102 -----
16899102.ab.2 MATERIAL AND METHODS: Peri-implantitis was induced by ligature placement in five beagle dogs (n = 30 implants).


16899102.ab.2|relation|C0324306|Beagle|mamm|mamm|||ISA|C0012984|Canis familiaris|mamm|mamm|||SPEC||beagle|dogs||81|88
16899102.ab.2|relation|C0023692|Ligature|medd|medd|||CAUSES|C2936258|Peri-implantitis|dsyn|dsyn|||VERB|induced|ligature|Peri-implantitis|43|54|22|NEWER_UMLS_CONC_OBJ
16899102.ab.2|relation|C0023692|Ligature|medd|medd|||TREATS|C0012984|Canis familiaris|mamm|mamm|||PREP|in|ligature placement|beagle dogs|72|54|81
16899102.ab.2|relation|C0023692|Ligature|medd|medd|||TREATS(SPEC)|C0324306|Beagle|mamm|mamm|||INFER||ligature placement|beagle||54|81

----- Citation 16901783 -----
16901783.ti.1 Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis.


16901783.ti.1|relation|C1334147|ITGB4 gene|gngm|gngm|3691|ITGB4|STIMULATES|C0242957|ERBB2 gene|gngm|gngm|||VERB|amplifies|Beta 4 integrin|ErbB2|16|0|26|NO_INDICATOR_RULE
16901783.ti.1|relation|C1334147|ITGB4 gene|gngm|gngm|3691|ITGB4|PREDISPOSES|C1512981|Mammary Tumorigenesis|neop|neop|||VERB|promote|Beta 4 integrin|mammary tumorigenesis|45|0|53

----- Citation 16902165 -----
16902165.ab.3 Therefore, we investigated the effects of G-CSF administration on mobilization and functional activities of blood-derived EPC in patients with chronic ischemic heart disease (CIHD).


16902165.ab.3|relation|C0264694|Chronic ischemic heart disease NOS|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|chronic ischemic heart disease|patients|137|143|129
16902165.ab.3|relation|C0079459|Granulocyte Colony-Stimulating Factor|aapp,imft|aapp|||AFFECTS|C0038250|Stem cells|cell|cell|||NOM|effects|G-CSF|EPC|31|42|122
16902165.ab.3|relation|C0038250|Stem cells|cell|cell|||PART_OF|C0030705|Patients|podg,humn|humn|||PREP|in|EPC|patients|125|122|129|INDICATOR_RULE_COMMENTED_OUT

16902165.ab.4 METHODS AND RESULTS: Sixteen patients with CIHD received 10 microg/kg per day subcutaneous G-CSF injection for 5 days.


16902165.ab.4|relation|C0264694|Chronic ischemic heart disease NOS|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|CIHD|patients|37|43|29
16902165.ab.4|relation|C1533685|Injection procedure|topp|topp|||ADMINISTERED_TO|C0030705|Patients|podg,humn|humn|||VERB|received|injection|patients|48|97|29|UMLS_CONC_REPLACE_SUBJ
16902165.ab.4|relation|C1533685|Injection procedure|topp|topp|||USES|C0079459|Granulocyte Colony-Stimulating Factor|aapp,imft|aapp|||MOD/HEAD||injection|G-CSF||97|91|NON_SEMNET_RELATION
16902165.ab.4|relation|C0079459|Granulocyte Colony-Stimulating Factor|aapp,imft|aapp|||ADMINISTERED_TO(INFER)|C0030705|Patients|podg,humn|humn|||INFER||G-CSF|patients||91|29|INFERENCE

----- Citation 16903766 -----
16903766.ab.10 From this review, it appears that BTX-A injection into the detrusor muscle is a very effective method for treating urinary incontinence secondary to neurogenic detrusor overactivity (NDO), as well as urinary incontinence due to idiopathic overactive bladder (IDO).


16903766.ab.10|relation|C1533685|Injection procedure|topp|topp|||USES|C0006050|Botulinum Toxin Type A|hops,phsu|phsu|||MOD/HEAD||injection|BTX-A||40|34
16903766.ab.10|relation|C1533685|Injection procedure|topp|topp|||TREATS|C0042024|Urinary Incontinence|dsyn|dsyn|||VERB|treating|injection|urinary incontinence||106|40|115
16903766.ab.10|relation|C1533685|Injection procedure|topp|topp|||TREATS|C0042024|Urinary Incontinence|dsyn|dsyn|||VERB|treating|injection|urinary incontinence|106|40|200|COORDINATION, GERUND_INDICATOR
16903766.ab.10|relation|C0878773|Overactive Bladder|dsyn|dsyn|||CAUSES|C0042024|Urinary Incontinence|dsyn|dsyn|||ADJ|due to|overactive bladder|urinary incontinence|221|239|200
16903766.ab.10|relation|C1180419|Detrusor|bpoc|bpoc|||LOCATION_OF|C1536696|Overactivity|fndg|fndg|||MOD/HEAD||detrusor|overactivity||160|169
16903766.ab.10|relation|C1536696|Overactivity|fndg|fndg|||CAUSES|C0042024|Urinary Incontinence|dsyn|dsyn|||ADJ|secondary|overactivity|urinary incontinence|136|169|115
16903766.ab.10|relation|C0006050|Botulinum Toxin Type A|hops,phsu|phsu|||TREATS(INFER)|C0042024|Urinary Incontinence|dsyn|dsyn|||VERB|treating|injection|urinary incontinence

----- Citation 16912584 -----
16912584.ab.6 After adjustment for demographics and personal history of cardiovascular disease, strong familial risk was also significantly associated with diabetes, hypercholesterolemia, hypertension, and obesity.



16912584.ab.7 A risk assessment model that included familial risk, demographics, and personal history of diabetes, hypercholesterolemia, hypertension, and obesity was most optimal with an area under the curve statistic of 87.2% CONCLUSIONS: Familial risk assessment can stratify risk for early-onset coronary heart disease.



----- Citation 16913431 -----
16913431.ab.11 Professional treatment seeking was very low and may be related to specific pain behaviors and effective coping strategies in this ethnic group.


16913431.ab.11|relation|C0946267|Pain:behavior|inbe|inbe|||PROCESS_OF|C0015031|Ethnic group|popg,humn|humn|||PREP|in|pain behaviors|ethnic group|121|75|130
16913431.ab.11|relation|C0009967|Coping Behavior|inbe|inbe|||PROCESS_OF|C0015031|Ethnic group|popg,humn|humn|||PREP|in|coping|ethnic group|121|104|130|NEW_UMLS_CONC_SUBJ,DYSONYM

----- Citation 16914119 -----
16914119.ti.1 The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infection.


16914119.ti.1|relation|C0287269|WIN 55,212|orch,phsu|orch|||ISA|C0006864|Cannabinoids|orch|orch|||SPEC||WIN 55,212|cannabinoid||26|14
16914119.ti.1|relation|C0287269|WIN 55,212|orch,phsu|orch|||STIMULATES|C0387583|cyclooxygenase 2|aapp,enzy|aapp|||VERB|increases|WIN 55,212|COX-2|39|26|49
16914119.ti.1|relation|C0287269|WIN 55,212|orch,phsu|orch|||STIMULATES|C0012472|Dinoprostone|eico,horm,phsu|horm|||VERB|increases|WIN 55,212|PGE2|39|26|70
16914119.ti.1|relation|C0006104|Brain|bpoc|bpoc|||PART_OF|C0026809|Mus|mamm|mamm|||MOD/HEAD||brain|murine||93|86
16914119.ti.1|relation|C0225336|Endothelial Cells|cell|cell|||LOCATION_OF|C0387583|cyclooxygenase 2|aapp,enzy|aapp|||PREP|in|endothelial cells|COX-2|82|107|49
16914119.ti.1|relation|C0225336|Endothelial Cells|cell|cell|||LOCATION_OF|C0012472|Dinoprostone|eico,horm,phsu|horm|||PREP|in|endothelial cells|PGE2|82|107|70


16914119.ab.2 The fact that cyclooxygenase-2 (COX-2) expression in brain endothelium mediates a wide variety of actions during CNS inflammatory diseases such as MS, and that cannabinoids ameliorate the progression of TMEV-IDD, lead us to investigate the role of cannabinoids on COX-2 expression on murine brain endothelial cell cultures subjected or not to TMEV infection.


16914119.ab.2|relation|C0011304|Demyelination|patf|patf|||ISA|C0012634|Disease|dsyn|dsyn|||SPEC||IDD|IDD||208|208
16914119.ab.2|relation|C0026769|Multiple Sclerosis|dsyn|dsyn|||ISA|C0007682|CNS disorder|dsyn|dsyn|||SPEC|such as|MS|CNS inflammatory diseases|139|147|113
16914119.ab.2|relation|C0387583|cyclooxygenase 2|aapp,gngm,enzy|aapp|||PART_OF|C0014257|Endothelium|tisu|tisu|||PREP|in|cyclooxygenase-2|endothelium|49|14|59
16914119.ab.2|relation|C0014257|Endothelium|tisu|tisu|||PART_OF|C0006104|Brain|bpoc|bpoc|||MOD/HEAD||endothelium|brain||59|53
16914119.ab.2|relation|C0206425|Encephalomyelitis Virus, Murine, Theiler|virs|virs|||CAUSES|C0012634|Disease|dsyn|dsyn|||MOD/HEAD||TMEV|IDD||203|208
16914119.ab.2|relation|C0206425|Encephalomyelitis Virus, Murine, Theiler|virs|virs|||CAUSES|C0009450|Communicable Diseases|dsyn|dsyn|||MOD/HEAD||TMEV|infection||343|348
16914119.ab.2|relation|C0206425|Encephalomyelitis Virus, Murine, Theiler|virs|patf|||CAUSES(SPEC)|C0011304|Demyelination|patf|dsyn|||INFER||TMEV|IDD||203|208
16914119.ab.2|relation|C0006864|Cannabinoids|orch|orch|||TREATS|C0012634|Disease|dsyn|dsyn|||VERB|ameliorate|cannabinoids|IDD|173|160|208
16914119.ab.2|relation|C0006864|Cannabinoids|orch|orch|||TREATS(SPEC)|C0011304|Demyelination|patf|dsyn|||INFER||cannabinoids|IDD||160|208
16914119.ab.2|relation|C0006864|Cannabinoids|orch|orch|||INTERACTS_WITH|C0387583|cyclooxygenase 2|aapp,gngm,enzy|aapp|||NOM|role|cannabinoids|COX-2|240|248|264
16914119.ab.2|relation|C0006104|Brain|bpoc|bpoc|||PART_OF|C0026809|Mus|mamm|mamm|||MOD/HEAD||brain|murine||291|284
16914119.ab.2|relation|C0225336|Endothelial Cells|cell|cell|||PART_OF|C0006104|Brain|bpoc|bpoc|||MOD/HEAD||endothelial cell|brain||297|291|UMLS_CONC_REPLACE_SUBJ
16914119.ab.2|relation|C0007635|Cell, Cultured|cell|cell|||PART_OF|C0014257|Endothelium|tisu|tisu|||MOD/HEAD||cell cultures|endothelial||309|297|UMLS_CONC_REPLACE_SUBJ

16914119.ab.6 TMEV infection of murine brain endothelial cell cultures induced a significant increase of COX-2 expression at 8h, which was maintained even increased, at 20 and 32h post-infection.


16914119.ab.6|relation|C0021311|Infection|dsyn|dsyn|||PRODUCES|C0387583|cyclooxygenase 2|aapp,enzy|aapp|||COMPLEX|induced a significant increase|infection|COX-2|57|5|91
16914119.ab.6|relation|C0006104|Brain|bpoc|bpoc|||PART_OF|C0026809|Mus|mamm|mamm|||MOD/HEAD||brain|murine||25|18
16914119.ab.6|relation|C0225336|Endothelial Cells|cell|cell|||PART_OF|C0006104|Brain|bpoc|bpoc|||MOD/HEAD||endothelial cell|brain||31|25|UMLS_CONC_REPLACE_SUBJ
16914119.ab.6|relation|C0206425|Encephalomyelitis Virus, Murine, Theiler|virs|virs|||CAUSES|C0009450|Communicable Diseases|dsyn|dsyn|||MOD/HEAD||TMEV|infection|

----- Citation 16929605 -----
16929605.ab.3 Median operative time, body weight, prostate weight, pathologic stage, incidence of positive surgical margins, urinary continence, the need for post-operative analgesics, peri-operative complications, are the parameters we assessed.



16929605.ab.8 CONCLUSION: The results we obtained with the mini-laparotomic incision are comparable to previous reports of the standard incision, also by our group, though with a lower need for postoperative analgesia.


16929605.ab.8|relation|C0023038|Laparotomy|topp|topp|||ISA|C0184898|Surgical incisions|topp|topp|||SPEC||laparotomic|incision||50|62

----- Citation 16950193 -----
16950193.ab.3 The present study evaluated soluble plasma osteopontin in 32 patients with echocardiographically determined rheumatic mitral stenosis and compared the results to those of a control group of 22 healthy patients.


16950193.ab.3|relation|C0264766|Rheumatic mitral stenosis|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|rheumatic mitral stenosis|patients|69|108|61
16950193.ab.3|relation|C0013516|Echocardiography|diap|diap|||DIAGNOSES|C0264766|Rheumatic mitral stenosis|dsyn|dsyn|||ADJ|determined|echocardiographically|rheumatic mitral stenosis|97|75|108|NO_INDICATOR_RULE,NEW_UMLS_CONC_SUBJ
16950193.ab.3|relation|C0032105|Plasma|bdsu|bdsu|||LOCATION_OF|C0069676|osteopontin|aapp,bacs|aapp|||MOD/HEAD||plasma|osteopontin||36|43|NON_SEMNET_RELATION
16950193.ab.3|relation|C0030705|Patients|podg,humn|humn|||LOCATION_OF|C0069676|osteopontin|aapp,bacs|aapp|||PREP|in|patients|osteopontin|54|61|43

16950193.ab.10 Elevated levels of high-sensitivity C-reactive protein concentrations suggest the presence of ongoing inflammation in those patients.


16950193.ab.10|relation|C0021368|Inflammation|patf|patf|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|in|inflammation|patients|114|102|124


----- Citation 16979443 -----
16979443.ti.1 Selective Internal Radiation Therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma.


16979443.ti.1|relation|C1831994|selective internal radiation therapy|topp|topp|||TREATS|C0494165|Secondary malignant neoplasm of liver|neop|neop|||PREP|for|Selective Internal Radiation Therapy|liver metastases|43|0|48|NEWER_UMLS_CONC_SUBJ
16979443.ti.1|relation|C1319315|Adenocarcinoma of large intestine|neop|neop|||CAUSES|C0494165|Secondary malignant neoplasm of liver|neop|neop|||ADJ|secondary|colorectal adenocarcinoma|liver metastases|65|78|48|NO_INDICATOR_RULE

16979443.ab.2 It is FDA approved for liver metastases secondary to colorectal carcinoma and is under investigation for treatment of other liver malignancies, such as hepatocellular carcinoma and neuroendocrine malignancies.


16979443.ab.2|relation|C0019204|Primary carcinoma of the liver cells|neop|neop|||ISA|C0006826|Malignant Neoplasms|neop|neop|||SPEC|such as|hepatocellular carcinoma|malignancies|144|152|130
16979443.ab.2|relation|C0494165|Secondary malignant neoplasm of liver|neop|neop|||CAUSES|C0009402|Carcinoma of the Large Intestine|neop|neop|||ADJ|secondary|liver metastases|colorectal carcinoma|40|23|53
16979443.ab.2|relation|C0006826|Malignant Neoplasms|neop|neop|||PART_OF|C1278929|Entire liver|bpoc|bpoc|||MOD/HEAD||malignancies|liver||130|124
16979443.ab.2|relation|C0019204|Primary carcinoma of the liver cells|neop|neop|||PART_OF(SPEC)|C1278929|Entire liver|bpoc|bpoc|||INFER||hepatocellular carcinoma|liver||152|124
16979443.ab.2|relation|C0006826|Malignant Neoplasms|neop|neop|||PART_OF|C0027912|Neurosecretory Systems|bdsy|bdsy|||MOD/HEAD||malignancies|neuroendocrine||196|181

16979443.ab.6 Ex vivo analyses have shown that microspheres preferentially cluster around the periphery of tumor nodules with a high tumor:normal tissue ratio of up to 200:1.


16979443.ab.6|relation|C0028259|Nodule|acab|acab|||PART_OF|C0027651|Neoplasm|neop|neop|||MOD/HEAD||nodules|tumor||99|93

----- Citation 16986607 -----
16986607.ab.5 CONCLUSIONS: The high success rate of this treatment supports the tentative diagnosis of oviducal obstruction in these mares and indicates that blockage of the mare's oviducts may occur in the form of a moveable accumulation of debris rather than from permanent fibrous adhesions resulting from salpingitis.


16986607.ab.5|relation|C0015560|Mammalian Oviducts|bpoc|bpoc|||LOCATION_OF|C0028778|Obstruction|patf|patf|||MOD/HEAD||oviducal|obstruction||89|98
16986607.ab.5|relation|C0028778|Obstruction|patf|patf|||PROCESS_OF|C0324143|Mare|mamm|mamm|||PREP|in|obstruction|mares|109|98|119
16986607.ab.5|relation|C0036130|Salpingitis|dsyn|dsyn|||CAUSES|C0334156|Fibrous adhesion|acab|acab|||VERB|resulting|salpingitis|fibrous adhesions|280|295|262|NON_SEMNET_RELATION,GERUND_INDICATOR
16986607.ab.5|relation|C0015560|Mammalian Oviducts|bpoc|bpoc|||PART_OF|C0324143|Mare|mamm|mamm|||MOD/HEAD||oviducts|mare||167|160
16986607.ab.5|relation|C0015560|Mammalian Oviducts|bpoc|bpoc|||LOCATION_OF|C1706968|Blockage (obstruction - finding)|fndg|fndg|||PREP|of|mare's oviducts|blockage|152|160|144|NEWER_UMLS_CONC_OBJ, SEMNET_RELATION_ADDED_ALREADY?


----- Citation 17056862 -----
17056862.ab.14 This rule has the potential to improve and standardise the care of children presenting with head injuries.


17056862.ab.14|relation|C0018674|Craniocerebral Trauma|inpo|inpo|||PROCESS_OF|C0008059|Child|aggp,inpr|aggp|||VERB|presenting|head injuries|children|76|92|67|GERUND_INDICATOR

----- Citation 17131231 -----
17131231.ab.9 Dystonic reactions (mainly involving oculomotor cranial nerves and limbs) in operated patients (especially carriers of deep brain stimulation (DBS) devices) are increasingly being reported, constituting a new type of dystonia in patients with Parkinson's disease: dystonia linked to surgical treatment.


17131231.ab.9|relation|C0013421|Dystonia|sosy|sosy|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|in|dystonia|patients|225|217|229
17131231.ab.9|relation|C0030567|Parkinson Disease|dsyn|dsyn|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|Parkinson's disease|patients|237|243|229
17131231.ab.9|relation|C0013421|Dystonia|sosy|sosy|||COEXISTS_WITH(INFER)|C0030567|Parkinson Disease|dsyn|dsyn|||INFER||dystonia|Parkinson's disease||217|243
17131231.ab.9|relation|C0543467|Operative Surgical Procedures|topp|topp|||AFFECTS|C0013421|Dystonia|sosy|sosy|||PART|linked|surgical treatment|dystonia|273|283|264|NO_INDICATOR_RULE
17131231.ab.9|relation|C0028864|Oculomotor nerve structure|bpoc|bpoc|||PART_OF|C0037303|Bone structure of cranium|bpoc|bpoc|||MOD/HEAD||oculomotor cranial nerves|cranial||37|48
17131231.ab.9|relation|C0028864|Oculomotor nerve structure|bpoc|bpoc|||LOCATION_OF|C0541919|Dystonic reaction|fndg|fndg|||VERB|involving|oculomotor cranial nerves|Dystonic reactions|27|37|0|GERUND_INDICATOR
17131231.ab.9|relation|C0015385|Limb structure|bpoc|bpoc|||LOCATION_OF|C0541919|Dystonic reaction|fndg|fndg|||VERB|involving|limbs|Dystonic reactions|27|67|0|GERUND_INDICATOR
17131231.ab.9|relation|C0541919|Dystonic reaction|fndg|fndg|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||VERB|involving|Dystonic reactions|patients|27|0|86
17131231.ab.9|relation|C0543467|Operative Surgical Procedures|topp|topp|||TREATS|C0030705|Patients|podg,humn|humn|||MOD/HEAD||operated|patients||77|86|NEW_UMLS_CONC_SUBJ,NO_INDICATOR_RULE

----- Citation 17135279 -----
17135279.ab.9 Our result indicates that DYRK1A could be a key molecule bridging between beta-amyloid production and tau phosphorylation in AD.


17135279.ab.9|relation|C1414204|DYRK1A gene|aapp,gngm|gngm|1859|DYRK1A|ASSOCIATED_WITH|C0002395|Alzheimer's Disease|dsyn|dsyn|||PREP|in|DYRK1A|AD|121|26|125
17135279.ab.9|relation|C1414204|DYRK1A gene|gngm|gngm|||INTERACTS_WITH|C2700455|Microtubule-Associated Protein Tau|aapp|aapp|||VERB|bridging|DYRK1A|tau|57|26|102|NO_INDICATOR_RULE, UMLS_CONC_REPLACE_SUBJ, NEWER_UMLS_CONC_OBJ, GERUND_INDICATOR
17135279.ab.9|relation|C1414204|DYRK1A gene|gngm|gngm|||INTERACTS_WITH|C0611285|APP protein, human|aapp,gngm,bacs|aapp|||VERB|bridging|DYRK1A|beta-amyloid|57|26|74|NO_INDICATOR_RULE, UMLS_CONC_REPLACE_SUBJ, GERUND_INDICATOR

----- Citation 17182661 -----
17182661.ab.1 Lobular neoplasia is a relatively uncommon lesion, which is frequently diagnosed in biopsy specimens taken for other reasons.


17182661.ab.1|relation|C0861352|Lobular Neoplasia|neop|neop|||ISA|C0221198|Lesion|fndg|fndg|||SPEC|is|Lobular neoplasia|lesion|18|0|43
17182661.ab.1|relation|C0677862|Biopsy sample|tisu|tisu|||LOCATION_OF|C0861352|Lobular Neoplasia|neop|neop|||PREP|in|biopsy specimens|Lobular neoplasia|80|84|0

----- Citation 17191304 -----
17191304.ti.1 Cytokeratin autoantibodies: useful serologic markers for toluene diisocyanate-induced asthma.


17191304.ti.1|relation|C0205976|Tolylene Diisocyanate|hops,orch|hops|||CAUSES|C0004096|Asthma|dsyn|dsyn|||ADJ|induced|toluene diisocyanate|asthma|78|57|86
17191304.ti.1|relation|C0004358|Autoantibodies|aapp,imft|aapp|||PREDISPOSES|C0004096|Asthma|dsyn|dsyn|||NOM|markers|autoantibodies|asthma|45|12|86

----- Citation 17293230 -----
17293230.ab.2 METHODS AND MATERIALS: Nineteen patients with non-small-cell lung cancer who underwent imaging with positron emission tomography (PET) and CT were selected.


17293230.ab.2|relation|C0007131|Carcinoma, Non-Small-Cell Lung|neop|neop|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|non-small-cell lung cancer|patients|40|46|32
17293230.ab.2|relation|C0040405|X-Ray Computed Tomography|diap|diap|||ADMINISTERED_TO|C0030705|Patients|podg,humn|humn|||VERB|underwent|CT|patients|77|139|32
17293230.ab.2|relation|C0032743|Positron-Emission Tomography|diap|diap|||ADMINISTERED_TO|C0030705|Patients|podg,humn|humn|||VERB|underwent|positron emission tomography|patients|77|100|32

----- Citation 17663001 -----
17663001.ti.1 High MMP-1 mRNA expression is a risk factor for disease-free and overall survivals in patients with invasive breast carcinoma.


17663001.ti.1|relation|C0853879|Breast cancer invasive NOS|neop|neop|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||PREP|with|invasive breast carcinoma|patients|94|100|86

17663001.ab.3 MATERIALS AND METHODS: We assessed the prognostic value of MMP-1 mRNA expression in tumor tissue specimens from 85 breast carcinoma patients with a median follow-up time of 38 months (range, 2-48 months).


17663001.ab.3|relation|C0127082|Interstitial Collagenase|aapp,enzy|aapp|||PART_OF|C1292533|Tissue specimen|tisu|tisu|||PREP|in|MMP-1|tissue specimens|80|59|90
17663001.ab.3|relation|C1292533|Tissue specimen|tisu|tisu|||PART_OF|C0027651|Neoplasm|neop|neop|||MOD/HEAD||tissue specimens|tumor||90|84
17663001.ab.3|relation|C1292533|Tissue specimen|tisu|tisu|||PART_OF|C0030705|Patients|podg,humn|humn|||PREP|from|tissue specimens|patients|106|90|132
17663001.ab.3|relation|C0678222|Breast Carcinoma|neop|neop|||PROCESS_OF|C0030705|Patients|podg,humn|humn|||MOD/HEAD||breast carcinoma|patients||115|132
17663001.ab.3|relation|C1292533|Tissue specimen|tisu|tisu|||LOCATION_OF|C1515670|mRNA Expression|genf|genf|||PREP|in|tissue specimens|mRNA expression|80|90|65|RELATION_BLOCKED_IN_EXCEPTIONS.PL
17663001.ab.3|relation|C1515670|mRNA|genf|genf|||PRODUCES|C0127082|Interstitial Collagenase|aapp,enzy|enzy|||NOM|expression|MMP-1|mRNA expression|70|59|65|NO_INDICATOR_RULE



